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ABSTRACT 
The purpose of this study was to characterize blaCTX-M plasmids originating from bovine 
Escherichia coli and investigate their contribution to bacterial host fitness. 
In this study 52 bovine Escherichia coli strains collected between March and October 
2007 encoding blaCTX-M, an extended spectrum β-lactamase (ESBL) gene conferring 
resistance to 3rd generation cephalosporins, were characterized.  The majority of strains 
belonged to E. coli commensal phylogroups A and B1 expressing a multi-drug 
resistance (MDR) phenotype and harboured multiple plasmids of which 90% were 
transferred by conjugation. Transconjugants or transformants were made successfully 
from all 52 strains when selecting for resistance to cefotaxime. All plasmids were 
shown by PCR and sequence analysis to harbour blaCTX-M and nearly 80 % encoded 
multiple resistances. Plasmid sequence analysis of four plasmids encoding blaCTX-M-14b 
(IncI1-X1), -15 (IncFII-FIA-FIB) and -32 (IncX1 and IncB), identified genes necessary 
for stable plasmid maintenance and spread. 
Five representative plasmids encoding blaCTX-M-1, -15, -14b and -32 were assayed for their 
fitness impact upon the host. Efficiencies of β-lactam hydrolysis using whole cell 
extracts were determined in the same E. coli BL21 host strain with the most efficient 
encoded by blaCTX-M-14b and blaTEM-1 ESBL genes and least efficient encoded blaCTX-M-15 
only. A 160 kb plasmid encoding 13 resistance genes was grown in the presence of 380 
different metabolites and differences in metabolite utilisation between this and the 
plasmid-free BL21 strain determined. The plasmid-harbouring strain utilized less 
phosphor-sulphur compounds, suggesting the metabolic cost incurred by acquiring the 
plasmid may have implications of cellular utilization of alternative phosphate sources. 
There were no differences in growth was observed in nutrient rich media. The 
contribution of active efflux to resistance was investigated using L-phenylalanyl-L-
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arginyl-b-naphthylamide (PAβN) in combination with ampicillin, cefotaxime or 
ceftazidime. Minimum inhibitory concentration (MIC) values were found to decrease ≥ 
2 fold in the presence of the efflux pump inhibitor (EPI), in some cases becoming 
completely susceptible to ampicillin. This indicates that the possible use of EPIs in 
combination with previously failed antimicrobial drugs to potentially restore efficacy of 
treatment.
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1 INTRODUCTION 
1.1 Antibiotic Resistance: An Introductory Overview 
Antimicrobials are defined as substances with the ability to inhibit bacterial growth 
(bacteriostatic) or kill bacteria (bactericidal). Antimicrobials broadly refer to anti-
infective agents against bacteria, from microbial (termed antibiotics), synthetic, semi-
synthetic, plant and animal origin (Courvalin 2006). Antimicrobials target several 
mechanisms in bacteria, nucleotide synthesis (RNA, DNA), protein synthesis, cell wall 
synthesis, metabolic pathways and cell membrane disruption. 
Resistance to antimicrobial compounds can be mediated by intrinsic and acquired 
mechanisms. The former mechanisms referrers to bacteria of a particular species that 
are innately resistant to particular compounds, without prior exposure to the compound. 
Acquired resistance is where a bacterial population, initially susceptible to a given 
antimicrobial, become resistant, proliferate, and spread in a population upon selective 
pressure to the given antimicrobial. This clonal expansion of the resistant strain is 
known as vertical transmission of resistance. Another method of resistance is the 
transfer of resistance determinants by mobile genetic elements such as plasmids, 
transposons and bacteriophages. Collectively this method of transmission is known as 
horizontal gene transfer (HGT). 
Resistance can be achieved by several mechanisms including acquisition of genes that 
encode enzymes that inactivate the antimicrobial e.g. β-lactamases that cleave the amide 
bond of the β-lactam ring, efflux systems that enable the extrusion of the compound, 
acquisition of genes that encode proteins with altered drug resistant variants (e.g. sul 
genes that confer resistance to sulphonamides), or protect the target (tetO tetM 
ribosomal protection proteins that confer resistance to tetracycline). Alternatively 
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bacteria can acquire mutations in target molecules that render them less able to bind 
efficiently to the antimicrobial (gyrA mutations that confer resistance to 
fluoroquinolones), or may incur mutations in regulatory regions that could result in the 
overexpression of target proteins (e.g. in trimethoprim resistance), or resulting in down 
regulation of porin genes that would limit access of the antimicrobial into the cell 
(OmpF in E. coli) (see reviews; Normak et al., 2002). 
Acquired resistance poses a great threat to treatment of bacterial infections. The 
acquisition and spread of resistance has partially been linked to the transfer of resistance 
genes by HGT. Plasmids have been implicated in much of this spread, readily 
transferring by conjugation (Caratolli, 2009). The persistence of resistance to 
antimicrobials despite the cessation of prescription e.g. sulphonamides, supports the 
hypothesis that some bacteria may act as potential reservoirs of resistance. An example 
would be the Enterobacteriacieae and other gut microbes (Levy 1982; Osterblad, 
Leistevuo et al. 1995; Sunde and Sorum 1999). Previous studies have shown E. coli to 
be one of the most significant contributors to persistence of antimicrobial resistance in 
healthy humans, with a large number of resistance genes encoded on plasmids 
(Osterblad, Hakanen et al. 2000). E. coli, a commonly found commensal, can harbour 
multiple plasmids that may encode some resistances, including plasmids that harbour 
blaCTX-M, conferring resistance to third generation cephalosporins. This class of β-
lactam antimicrobials were commonly prescribed to treat a wide variety of infections. 
However due to the increased incidences of resistance, mediated by extended spectrum 
β-lactamases, such as CTX-M, treatment failure was quickly observed. This class of 
antimicrobial target membrane anchored enzymes involved in cell wall synthesis, 
preventing peptidoglycan crosslinking thus weakening the cell wall. The relative ease of 
accessing these enzymes (localised on the outer cell membrane), low production costs 
and high specificity, makes this an ideal anti-infective target. Therefore investing in 
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prolonging the efficacy of this drug is of great interest to public health. Understanding 
the mechanisms that govern resistance to these antimicrobial is the first step. This thesis 
aims to investigate in detail the genetic platform to which these ESBL enzymes are 
encoded on and the effect to the host. 
1.2 Pathogenic E. coli  
E. coli is one of the most abundant Gram-negative facultative anaerobes inhabiting the 
gastrointestinal (GI) tract, and its potential to act as a reservoir for resistance genes 
makes this an interesting organism to study. 
E. coli strains are largely non-pathogenic, however if the host becomes 
immunocompromised or suffers damage to the GI lining, then even these non-
pathogenic strains of  E. coli can mount an infection (Kaper et al., 2004). However, the 
acquisition of virulence factors which, like antibiotic resistance genes may be carried on 
a variety of MGEs, gives rise to E. coli pathotypes with the ability to cause disease in 
the host, leading to complications such as; sepsis, meningitis, urinary tract infections, 
diarrhoeal diseases, mastitis, enterotoxaemia, homolytic uremic syndrome (HUS) and 
hemorrhagic colitis (HC) (Erskine et al., 2002; Lanz et al., 2003; Nataro and Kaper, 
1998). These differ from their non-pathogenic counterparts, because of their ability to 
express virulence factors that aid colonisation of host surfaces and ensure survival 
within the host. 
Enteropathotypes of E. coli are classified into at least seven different classes based on 
their virulence mechanisms which include; (i) enterotoxigenic E. coli (ETEC), (ii) 
enteropathogenic E. coli (EPEC), (iii) enterohaemorrhagic E. coli (EHEC), (iv) 
enteroinvasive E. coli (EIEC), (v) enteroaggregative E. coli (EAEC), (vi) diffuse 
adherent E. coli (DAEC) and (vii) necrotoxigenic E. coli (NTEC) (Nataro and Kaper, 
1998). In addition to these intestinal pathogens, other clinically relevant E. coli 
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subspecies include; uropathogenic E. coli (UPEC), which causes urinary tract 
infections; and increasing cases of extraintestinal pathotypes of E. coli, found to be the 
causative agent in some cases of meningitis and sepsis, are collectively known as 
extraintestinal pathogenic E. coli (ExPEC) (Russo and Johnson, 2000). 
E. coli encode virulence factors not usually found in commensals, that enable 
pathogenic E. coli to overcome host defences e.g. enabling the bacterium to colonize a 
variety of different host cell surfaces (adhesins), to evade host immunity and survive 
within serum (bacterial capsule, endotoxins and exotoxins), to divide within and escape 
from macrophages, to cause damage to the host tissue, often mediated by toxins. These 
capabilities are achieved by possession and expression of multiple virulence genes 
carried by the bacterium of which many are also be found located on plasmids such as 
heat labile toxin genes in enterotoxigenic E. coli and fimbrial adhesins on many 
differing E. coli (ETEC, EHEC etc). These include the presence of fimbriae, toxins, 
siderophores (iron capture), intimate adherence and acid tolerance. These features are 
essential in ensuring survival of the bacterium in the host (Castanie-Cornet et al., 1999; 
Nataro and Kaper, 1998; Richard and Foster, 2003).  
 
The different pathotypes of E. coli can be classified by their ‘O’ antigens 
(lipooligosaccharides), ‘H’ (flagella) and ‘K’ (capsular) antigens. A combination of the 
O and H antigens defines a serotype (F. Kauffman 1946, Nataro and Kaper, 1998). To 
date there are over 100 different K groups, 180 O groups and over 60 H groups 
described, giving rise to approximately 700 different antigenic types (Robins-Browne 
and Hartland, 2002). Although still used today, serotyping methods are now 
supplemented by other molecular methods to distinguish between strains in addition to 
more traditional biochemical tests, Gram staining and colony morphology observation, 
summarized in table 1 below. 
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Table 1-1: Properties used to identify E. coli 
Test/observation Result 
Colony morphology Colonies appear round, smooth and shiny 
Gram stain Gram-negative rods 
Catalase positive Yes 
Oxidase positive No 
Indole production Yes 
Nitrate reduction Yes 
Methyl red Yes 
Glucose, lactose, sucrose, maltose and 
lactose fermentation 
Yes 
Raffinose fermenter  No 
Hemolysis Some yes, β-hemolysis 
Coagulase production Yes 
 
1.2.1 Molecular subtyping of E. coli strains  
Molecular typing/grouping methods to distinguish different E. coli species have 
provided a useful tool for monitoring E. coli strains that may be responsible for 
systematic outbreaks. Described below is a brief summary of some of the tools that may 
be used, some of which were employed in identification of the epidemic international E. 
coli clone ST131 O25:H24 
1.2.1.1 Pulse field gel electrophoresis  
Pulse gel electrophoresis (PFGE) is a molecular subtyping tool used to distinguish 
strains of E. coli based on their restriction digestion patterns. DNA fragment patterns 
are interpreted based on the PFGE pattern. The principle of this typing relies on random 
genetic changes that result in differential restriction pattern. Strains can be categorised 
based on their relatedness; 1) indistinguishable (part of an outbreak): which have an 
identical number and size of bands, 2) closely related (probably part of an outbreak): a 
difference of 2-3 DNA fragments, 3) possibly related (possibly part of an outbreak): a 
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difference of 4-6 bands and 4) unrelated (not part of the outbreak): a difference of ≥ 7 
(Tenover et al., 1998). PFGE has been employed in previous studies to type the ST131 
clones, however this method did not cluster these strains as part of an outbreak under 
the Tenover criteria, and often did not meet the ‘possibly related’ criteria. 
1.2.1.2 MLST 
Multi-locus sequence typing was developed in later studies and showed one E. coli 
known, now known commonly as sequence type (ST) 131, to belong to the same clone. 
This method is based on sequencing short nucleotide sequences (400-500bp) of 5-7 
housekeeping genes that have diversified resulting in polymorphisms within the genes 
to give sequence types. The method relies on the low mutation rates of the 
housekeeping genes, making it a suitable method for monitoring strain epidemiology 
(Enright et al., 1999). MLST transformed how molecular epidemiology data was 
analysed, whereas with PFGE, single nucleotide polymorphisms could results in 
changes to the digestion pattern and consequently migration. This would result in 
almost no information as to the clonality. Using housekeeping genes that are strongly 
conserved for typing in MLST enables information on the population biology and 
evolutionary history to be assimilated. 
1.2.1.3 Other typing methods 
As described above MLST offers a robust typing system when studying strain 
epidemiology. However due to the time consuming protocol and expensive, this method 
is rarely used for high throughput screening. Other methods such as random amplified 
polymorphic DNA (RAPD), Enterobacterial repetitive intragenic consensus sequences 
(ERIC) PCR and ribotyping provide information on strain relationships. 
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Other more broad identification tools include phage typing; based on the lytic patterns 
denoting resistance or sensitivity to bacteriophage infections and E. coli Phylogrouping. 
Phage typing is limited to E. coli O157:H7 and its susceptibility to 16 different 
bacteriophages, to which 88 different bacteriophages are used in combination to 
distinguish between E. coli strains (Ahmed et al., 1987; Woodward et al., 2002). 
Phylogrouping is a method used to type strains based on electrophoretic mobility 
(Multi-locus enzyme electrophoresis – MLEE) or more recently the PCR amplification 
of variable genes in different phylogroups of E. coli, of which there are four A, B1, B2 
and D. Later whole genome sequencing techniques found the non-
pathogenic/commensal group B1 to be further subdivided into phylogroup E and B1, a 
non-O157 EHEC pathogenic group and a commensal group respectively (Sims and Kim, 
2011). 
1.3 E. coli structure 
E. coli is a Gram-negative rod, typically measuring 2-6 µm, which inhabits both human 
and veterinary gastrointestinal tracts as part of the gut flora characteristic to the 
members of the Enterobacteriaceae family (Nataro and Kaper, 1998).  
The Gram-negative cell wall consists of an inner and outer membrane (Fig. 1-1), with 
multiple protein constituents. Adjacent to the inner membrane is the rigid peptidoglycan 
layer consisting of alternating residues of β-(1,4) linked N-acetylglucosamine and N-
acetylmuramic acid, liked by a peptide chain consisting of 3-5 amino acids (to be 
described in greater detail in section 1.9). Undecaprenyl phosphate sugars are essential 
in peptidoglycan synthesis they act as glucosyl carriers enabling the transfer of 
hydrophilic motifs across the cytoplasmic membrane (Bouhss et al., 2008). Membrane 
derived oligosaccharides (MDO); a class of β-glucans containing β-1-2 and β –1-6 
linked glucose subunits with substitutions of membrane derived moieties, in addition to 
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the peptidoglycan layer forms an extensive porous mesh-like polymer matrix (Lequette 
et al., 2008; van Golde, 1973). Between the peptidoglycan layer and the outer 
membrane lies the periplasmic space containing soluble proteins e.g. enzymes. The 
peptidoglycan layer is anchored to the outer membrane by lipoproteins. Embedded on 
the outer membrane are the outer membrane proteins also involved in transport e.g. 
porins and components of the bacterial secretion systems. Forming a monolayer 
covering the outer membrane are lipopolyssaccharides, which contribute to cellular 
integrity and provide protection from chemical attack. (Holtje, 1998; Robins-Browne 
and Hartland, 2002). 
The cell wall and membrane encases the cytoplasm, containing proteins, enzymes and 
the DNA. The genetic components of E. coli are discussed in the section that follows. 
 
 
Figure 1-1: Schematic representation of the structure of a gram-negative cell wall. In red are the 
phosphate heads of the phospholipids; yellow are the phosphatidylethanolamine phospholipids, yellow 
phospholipids; phosphatidylglycerol; green are Kdo; 3-deoxy-D-manno-octulosonic acid, black heptose 
consisting of L-glycero-D-manno-heptose, ‘n’ is a variable number of O-antigen repeats, Pink/purple are 
PPEtn; pyrophosphoethanolamine. Picture taken from Essentials of glycobiology (2nd Edition) 2008. 
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1.4 Genetics of E. coli 
The E. coli genome is made up of a single, circular double stranded DNA molecule 
about 4x106 base pairs (bp) in length, localised within the cytoplasm in a region termed 
the nucleoid. In the era of whole genomic sequencing the size of E. coli genomes can be 
variable due to core and accessory genes. In addition to the genophore (prokaryotic 
genome), E. coli can harbour plasmids; circular double stranded DNA molecules 
capable of autonomously replicating within the bacterial cell. These can vary in number 
(estimated to be up to 11 plasmids) and size (1kb to 200kb). These extrachromosomal 
DNA molecules have the capacity to encode a multitude of genes including 
antimicrobial and heavy metal resistance, antibiotic production, bacteriocins, toxins and 
various virulence factors. Of particular relevance to this thesis is the frequent but non-
exclusive carriage of antibiotic resistance genes on plasmids. 
 
1.5 Horizontal gene transfer  
Horizontal gene transfer (HGT) is the acquisition of genetic material from an exogenous 
source, within or outside a phylogenetic group or even between different organisms. 
HGT is a major driving force behind evolution and adaptation in bacteria especially in 
the development of antimicrobial resistance. HGT can be mediated by three primary 
mechanisms: a) conjugation, mediated by plasmids or conjugative transposons; b) 
transduction, mediated by bacteriophages; and c) transformation of cell-free DNA. 
These three mechanisms enable the transfer of DNA intercellularly and intracelluarly 
increasing the genetic diversity, collectively known as mobile genetic elements (MGE). 
MGEs are DNA molecules that are capable of movement either by transposition or 
homologous recombination. Other MGEs include insertion sequences (IS) or insertion 
elements (ISE), transposons, integrons and cassettes (Carattoli, 2003). Of all the 
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mechanisms, plasmid conjugation is currently regarded by many authors as the most 
common mechanism of transfer among prokaryotes (Bennett, 2008; Carattoli, 2001; 
Frost et al., 2005; Liebert et al., 1999; Mahillon et al., 1999; Sota, 2008). Irrespective of 
whether plasmids mediate most HGT, of importance to this thesis is not only the 
carriage but also the transmission of β-lactam resistances by plasmids. 
 
1.5.1 Transduction and Transformation 
The transfer of DNA between bacterial cells can occur by either of these mechanisms. 
Natural bacterial transformation can occur in natural environments, the contribution to 
HGT cannot be quantified, because the competency of the bacteria cannot be 
determined in the environment, however studies using naturally competent bacteria 
have demonstrated the ability of transformation to contribute to bacterial evolution 
(Rizzi et al., 2008). 
Transduction is mediated by bacteriophages and is generally limited to phages that 
accommodate large DNA segments 50-100kb genomes. Bacteriophages, which can lie 
dormant in the host bacterial chromosome as prophages, may switch to a virulent 
replication state and result in maturation of the virus particle, and packing of its own 
DNA (specialized transduction) or accidentally packaging host DNA (generalized 
transduction). The lysis of the cell and infection of another recipient cell, could result in 
recombination (Frost et al, 2005). 
 
1.5.2 Bacterial Plasmids 
Plasmids are extranuclear genetic elements capable of autonomous replication. Plasmids 
commonly exist as double stranded covalently closed circular molecules, but 
increasingly, linear plasmids have been found in some bacterial species (Hinnebusch 
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and Tilly, 1993). Plasmids can also be integrated into the bacterial chromosome; known 
as integrated conjugative elements (ICEs), increasing the diversity of the genome from 
laterally acquired DNA from distantly related sources (Andam et al., 2011; Burrus et al., 
2004). Plasmids encode a number of genes that control their replication and 
maintenance, in addition to genes that may confer some advantage to the host e.g. 
antimicrobial resistance, metabolic function or virulence genes. Bacterial plasmids can 
be self-transmissible by conjugation, often encoding these proteins necessary for 
conjugative transfer on the plasmids itself. Mobilizable plasmids do not encode these 
genes and consequently cannot transfer by conjugation unless with other larger 
conjugative plasmids or integrative conjugative elements (ICE) by a process known as 
mobilization. Other plasmids, like the cryptic plasmids, do not encode any genes that 
confer a known phenotype (Frost et al., 2005; Francia et al., 2004; Sota, 2008). With the 
advent of plasmid DNA sequencing, recent studies have reported the presence of 
extensive plasmid transfer genes that make up the large structures necessary for 
conjugative transfer, resistance and virulence. Woodford and colleagues reported three 
ESBL plasmids found in the ST131:O25 international E. coli clone (Woodford et al., 
2009).  
 
1.5.3 Transposons 
Transposons are part of the MGE family of transposable elements that move by two 
main mechanisms, conservative transposition and by replicative transposition. The 
conservative transposition mechanism simplistically is a “cut and paste” mechanism 
between donor and recipient DNA. Replicative transposition, involves a co-integrate 
intermediate between donor and recipient, after recognition of target DNA by 
recombination. The exchange of DNA is catalysed by a transposase (tnpA) and the 
cointegrate resolved by a resolvase (tnpR) (Derbyshire et al., 1986). There are two types 
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of transposons commonly found in Gram-negative bacteria, composite and complex. 
Composite transposons are characterised by the presence of insertion sequences (IS) 
either side of the intervening gene. Complex transposons are more diverse in nature and 
have been identified as the most prevalent class associated with antimicrobial resistance 
genes. Complex transposons transposase by replicative transposition. They are 
characterised by flanking 38bp inverted repeats (IR), tnpA and tnpR genes and a res site, 
at which resolvase acts. The Tn3 family of complex transposons consist of a family of 
transposons including the most widely studied member of this group Tn21 (Grinsted et 
al., 1990; Liebert et al., 1999) (Fig. 1-2). These transposons can encode a multitude of 
resistance genes, but can also carry other mobile genetic elements independent of the 
transposon; including integrons, gene cassettes (open reading frames), metabolic 
operons and ISEs (Hall and Collis, 1995; Liebert et al., 1999). Tn21 transposons have 
been found in association with β-lactamase genes; CTX-M-9 and CTX-M-2 and CTX-
M-15, thought to have influenced the spread of these genes (Novais et al., 2006, 
Sandergen et al., 2011; Valverde et al., 2006). 
 
1.5.4 Conjugative transposons 
Conjugative transposons are non-replicative self-transmissible integrative elements 
derived from bacteriophages, with the ability to trigger the transfer of other non-self 
transmissible elements and plasmids. Transfer of genetic material occurs via a 
covalently closed intermediate, integrating into the chromosome/DNA without 
duplicating the target site at the point of integration. Conjugative transposons cannot 
replicate independently and thus require a further recombination event once transfer to 
the recipient cell has taken place to ensure its maintenance. To date, no conjugative 
transposons have been found in E. coli (Hochhut and Waldor, 1999; Scott and 
Churchward, 1995; Waters, 1999). 
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1.5.5 Integrons 
Integrons are gene capture systems that employ site-specific recombination to integrate 
gene cassettes at specific insertion sites (attI) in addition to a secondary recombination 
site (attC) within the integron. Integration is mediated by a site-specific recombinase 
(intI), which encodes an integrase (Carattoli, 2001; Fluit and Schmitz, 2004; Recchia 
and Hall, 1995).  
Multiple gene cassettes can be integrated into one integron with expression driven from 
two integron specific promoters, Pc and P2 upstream of the gene cassettes (Hall and 
Collis, 1995;). The promoters are located on the 5’ conserved region of the intI gene and 
the attI. The secondary attC site, located at the 3’ end of the gene cassette mobilizes the 
gene, which integrates the gene cassette to an integron via the attI site (Fig. 1-2) (Jove et 
al., 2010; Mazel, 2006; O’Brien, 2002).  
There are four classes (1-4) of integrons, defined by the sequence identity of the 
integrase enzymes. Of the four, class 1 and 2 are the most prevalent among pathogenic 
bacteria (Carattoli, 2001). Integrons themselves are not mobile but aid the capture of 
genes, however they are sometimes found in association with part of the tni module, 
thought to encode transposition genes because of its similarity to tni genes of Tn5053 
and Tn402 (Fig. 1-2). These genes (tni) are thought to be part of the larger transposition 
module of related transposons such as Tn5053, but the loss of some of the tni genes 
classifies most clinical class 1 integrons as defective transposons (Betteridge et al., 
2011; Brown et al., 1996; Kholodii et al., 1995; O'Brien, 2002,). 
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Adapted from Carattoli, 2001 and Liebert et al., 1999 
Figure 1-2: Schematic diagram of a transposon, Tn21. The flanking inverted repeat (IR) sequences are 
represented by the blue line, a mer operon (genes encoding mercury resistance and its regulation) are in 
grey. The tnp region, which encodes the transposase gene (tnpA), the resolvase gene (tnpR) the putative 
transposon regulator (tnpM) and a resolution site (res) are in the blue-arrowed boxes. Also shown is a 
classic integron flanked with IR sequences (grey lines). The integron harbours a 5’ conserved segment 
(CS); which includes the integrase gene (intI1), an attI1 insertion site. Gene cassettes within the integron 
include the quaternary ammonium compound disinfectant resistance gene (qacEΔ1) and sulphonamide 
resistance gene (sul1), orf5 (unknown function) and the transposition (tni) module shaded in grey. Gene 
acquisition by recombination via the (attC) site is outlined (Carattoli, 2001; Liebert et al., 1999). Depicted 
by block arrows is the direction the genes are transcribed. 
 
1.5.6 Insertion elements 
Insertion elements (ISs) are major contributors to genetic plasticity in bacterial genomes. 
They are commonly associated with transposons and together cooperate in the 
mobilization of genes they encompass. IS elements have been found amongst bacterial 
chromosomes, pathogenicity islands and plasmids, found to assemble an array of genes 
of different functions including virulence, catabolic utilization and antimicrobial 
resistance (commonly associated with class II transposons like Tn3). Insertion elements 
are typically 0.5-2 kb in size, that encode a transposase (TnpA or InsAB fusion protein) 
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for transposition, recognising the terminal inverted repeats. These elements can however 
mobilise independently of the transposon. Their mobilization is catalysed by a DDE 
transposase characterized by the amino acid triad (aspartate-aspartate-glutamate) and 
can be mobilized by either the cut and paste mechanisms (described in section 1.5.2) or 
the rolling circle mechanism, which results in the circularisation of the IS elements 
bringing the IRs together, which contain the -35 or -10 box forming the promoter. A 
third mechanism involves a conintegrate intermediate (Shapiro intermediate) between 
the donor and recipient. Once resolved, two copies of the IS element exist, one in the 
donor and the other in the recipient (Bennet et al., 2004; Mahillon et al., 1999). 
 
1.6 Plasmid transfer and maintenance 
1.6.1 Conjugation in Gram-negative bacteria 
Bacterial conjugation is by far the most studied of the DNA translocation systems 
(Waters, 1999). Conjugation is fundamental in HGT, not only limited to genes that 
confer antimicrobial resistance but also includes genes that enable the bacterium to 
occupy a new niche e.g. hydrocarbon degradation, production of nitrogen fixing nodules 
and /or to exert virulence (Lamb et al., 1982; Lawley, 2004).  
Plasmid mediated bacterial conjugation is dependent on successful transfer of plasmids 
to the recipient. For this to occur, close contact between the donor cell and recipient 
must be achieved. The success of conjugative transfer relies on three essential proteins, 
(i) the transferosome: a multi-protein complex that forms the conjugative pilus via a 
type IV secretion system (T4SS), also known as the membrane pair formation (Mpf) 
complex, (ii) the relaxasome; a DNA/protein complex that is formed by the binding of 
transfer proteins to the origin of transfer (oriT), introducing single stranded nicks in the 
DNA and finally (iii) the coupling protein (CP); a cytoplasmic membrane protein that 
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links the two components together enabling transfer of DNA to the recipient  (Cascales 
and Christie, 2004; Gilmour M. W., 2000; Lawley, 2004; Waters, 1999). 
Initial contact of the donor and recipient cells can occur in two ways; random collision 
or be mediated by the conjugative pilus. The pilus mediates initial attachment 
recognising a carbohydrate receptor on the surface of the recipient cell and thus 
stabilizing the mating pair (Fig. 1-3). This triggers the rapid initiation of DNA transfer 
independent of prior transcription and translation events (Gilmour M. W., 2000; Lawley, 
2004; Waters, 1999). The relaxosome, mediated by a relaxase enzyme, cleaves the 
negatively supercoiled plasmid DNA at the oriT junction; an AT rich sequence 
comprised of tandem repeats that contains a nic site (the site at which DNA cleavage 
occurs). This results in the covalent attachment of the tyrosine residue from the relaxase 
enzyme to the 5' end of the nicked DNA (Pansegrau et al., 1990). Strand replacement 
synthesis occurs at the 3' end of the nicked DNA, catalyzed by DNA polymerase III via 
a rolling circle mechanism (Lawley, 2004; Pansegrau et al., 1990). Once transferred, 
both the donor nicked DNA and the newly synthesised single stranded DNA molecule 
in the recipient is re-circularized by the relaxase complex and conjugational transfer is 
halted (Becker and Meyer, 2000).  The 3' end then acts as a primer for synthesis of the 
replacement strand in the recipient (Becker and Meyer, 2000).  
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Figure 1-3: Bacterial conjugation in Gram-negative bacteria. (A): schematic diagram of the 
components of the type IV secretion system in A. tumefaciens. In green is the ATPase that provides 
energy for the translocation of molecules across to the recipient. (B): mating bridge formation between 
cells. (C): Mating aggregates; donor strains have an abundance of pili and flagella (black arrows) and 
recipients are ‘bald’ indicated by the white arrow. (D): schematic representation of rolling circle 
replication of plasmid DNA and translocation of genetic material. 
 
1.6.2 Pilus structure 
The T4SS is a complex of 13 core proteins that span the cell envelope facilitating the 
transfer of DNA or effector proteins through a pore to the recipient and even take up 
DNA during natural transformation (Chen and Dubnau, 2004; Hofreuuter et al., 2001; 
Lawley et al. 2003). The T4SS system is made up of core proteins; TraA (pilin), L, E, K, 
B, V, C and G and auxiliary proteins; TraF, G, H, N, U, W and TrbC. These proteins 
make up the pilus structure and proteins necessary for mating pair stabilization. 
Additional proteins, TraD (coupling protein) and TraI (relaxase), M and Y respectively, 
are necessary for binding to DNA and subsequent transfer.  
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Two types of pilus have been described in the conjugative systems: the F-like pili and 
the P-like pili. These pili differ in their structure, the F-like pili being long and flexible 
and the P-like pili short and rigid (Lawley et al. 2003; Schroder and Lanka, 2005). 
 
1.6.3 Plasmid establishment in the recipient cell 
The incoming plasmid DNA may experience a hostile environment upon entry to the 
new host. In order to exist symbiotically with the host, the plasmid must initially 
overcome any host defences for example activation of bacterial SOS systems that result 
in plasmid destruction or cell death, which can be triggered by the transient single 
stranded plasmid DNA molecule upon entry into the recipient (Baharoglu et al., 2010 ). 
Upon entry into the recipient cell, plasmid encoded ssb and psiB proteins are expressed. 
SSB is a DNA binding protein that binds to single stranded DNA during DNA 
replication amongst other metabolic processes. Previous studies showed that ssb was 
able to depress genes necessary for bacterial conjugation in bacteria that encoded a drd 
mutation; a gene required for the suppression of conjugation. PsiB is a protein that is 
involved in inhibition of the SOS response in E. coli, possibly by inhibiting the 
activation of the RecA protein; a protein involved in the activation of the E. coli SOS 
response (Althorpe et al., 1999). Some plasmids in addition to ssb and psiB possess an 
anti-restriction system encoded by the ardA gene. This gene when expressed protects 
the incoming plasmid from digestion by type I restriction enzymes, which recognise and 
digest unmethylated ‘exogenous’ DNA, allowing the unmodified plasmid DNA to 
evade restriction (Althorpe et al., 1999). All three genes (ardA, ssb and psiB) are 
transferred early during plasmid translocation to alleviate the hostile environment in the 
recipient cell.  
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1.6.4 Plasmid maintenance  
Once the plasmid has established a replication system in the recipient cells, ensuring its 
maintenance in the host is vital. Bacterial plasmids employ several mechanisms to 
ensure this, which include, postsegregational killing, partitioning systems and site-
specific recombination systems (Funnell, 2005). 
1.6.4.1 Postsegregational killing (PSK) 
This mechanism refers to the maintenance of a genetic element in a host, known as 
genetic addiction. It relies on the action of a toxin and antitoxin encoded on the plasmid, 
to which the activity of the toxin is inhibited by the antitoxin. The antitoxin can 
counteract the toxin in three ways, (i) by inhibiting expression of the toxin (ii) by 
inhibiting the toxin itself or (iii) or by protecting the cellular target. An imbalance or 
loss of the toxin/antitoxin system (due to plasmid loss) results in the rapid 
decomposition of the antitoxin due to its proteolytic activity, leaving the toxin to exert 
its action of the cellular target that subsequently leads to programmed cell death (Jaffe 
et al., 1985). 
There are three types of genetic addiction systems (or PSK) which include, a proteic 
system, a restriction modification system and an anti-sense RNA regulated system. 
Below is a brief overview of the above mechanisms involved in genetic addiction 
(Gerdes, 2000). 
1.6.4.1.1 Proteic system 
The proteic system is the classical toxin/antitoxin system where the antitoxin serves as 
the antidote to the toxin by binding and inhibiting its activity (Critchlow et al., 1997). 
An example of this system is the CcdB/CcdA: toxin/antitoxin protein set. The CcdB 
toxin binds to the DNA gyrase, specifically the GyrA subunit, forming a CcdB-GyrA 
complex which results in the formation of double stranded DNA breaks mediated by 
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DNA gyrase (Critchlow et al., 1997; Gerdes, 2000). Although the exact method of 
eventual cell death is unknown, it has been proposed that the CcdB-GyrA-DNA 
complex forms a lesion at the replication fork that blocks DNA replication much like 
the quinolones that block DNA replication. Blocking polymerase access inevitably 
affects downstream processes that are thought to lead to cell death (Critchlow et al., 
1997; Jaffe et al., 1985).   
1.6.4.1.2 The restriction modification system  
The toxin in this case is a restriction enzyme that recognises and cleaves specific DNA 
sequences (see REBASE for extensive study of these proteins; http://rebase.neb.com). 
The introduction of these breaks in the DNA in turn induces the bacterial SOS response 
that is signalled by DNA damage, consequently leading to cell death. The antitoxin 
negates the effect of the toxin by binding to the sequence specific regions and 
methylating the DNA, which prevents cleavage of the DNA. Loss of the gene results in 
dilution of the antitoxin and subsequent restriction enzyme mediated cleavage of 
chromosomal DNA and cell death. Although both the toxin and antitoxin are diluted at 
the same rate, the restriction enzyme need only cleave one site in the chromosome to 
induce cell death in contrast to the methyltransferase that requires methylation of all 
available sites to preserve cellular integrity (Kobayashi, 2001).  
1.6.4.1.3 Antisense-RNA regulated addiction systems 
The antisense-RNA regulated system relies on repression of toxin gene expression by 
its own antisense-RNA, encoded on the same locus. The antitoxin is an unstable 
antisense RNA molecule that binds to the leader region of the toxin gene and inhibits 
translation of the toxin gene (Blomberg et al., 1990). The RNA-RNA duplex is then 
cleaved by a ribonuclease III (RNAseIII) enzyme and prevents translation of the toxin 
protein. Loss of the gene results in the rapid decay of the RNA by the RNAse, and 
expression of the toxin is no longer repressed (Gerdes et al., 2000). 
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1.6.4.2 Partitioning systems 
Plasmid partitioning systems are positioning systems, but also confer some 
incompatibility. This differs from the classical replication mediated incompatibility 
system (see later), although it is loosely based on the same concept. That is to say, 
plasmids with the same partitioning system cannot coexist in the same cell. The Par 
proteins, ParA and ParB are encoded by the par gene. The ParB protein bind to a cis 
acting centromere-like partition site, multiple ParB proteins are recruited and bind to the 
DNA forming a nucleosome complex called the segrosome. This results in plasmid 
pairing of the newly replicated plasmid, and subsequently the recruitment of ParA, an 
ATPase that stimulates the separation of the plasmid pairings. By adhering to these 
strict subcellular localizations, plasmids ensure faithful segregation into daughter cells 
during cell division (Funnell, 2005). 
 
1.7 Plasmid incompatibility  
The success of genetic transfer between cells lies on the ability of the recipient cell to 
accept the donor plasmids. Plasmids are classified by incompatibility (Inc) grouping 
(Novick, 1987). This is defined as the inability for two plasmids to coexist in a cell in 
the absence of selection. That is to say, that if by conjugation (or transformation) a 
plasmid were to be introduced into a strain carrying an unknown Inc group and was 
eliminated in the progeny, the incoming plasmid would be termed incompatible, and 
assigned to the same Inc group (Carattoli, 2003; Datta and Hedges, 1971). This method 
of classification allows the identification and grouping of plasmids used to study the 
epidemiology of plasmids known to harbour antimicrobial resistance genes (Anderson 
et al., 1977). 
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Plasmid incompatibility stems from the need for plasmids to control their copy number 
within a host. Replication control is inversely proportional to the copy number i.e. a 
high copy number results in a low replication rate, therefore preventing plasmid loss 
due to low copy numbers in the cell. The alternative is the loss of replication control 
termed ‘runaway replication’, resulting in high copy numbers that eventually lead to cell 
death after about four generations (Brantl, 2004).  
Prior to the development of molecular Inc typing methods, plasmid grouping was based 
on the elimination of an incoming unknown plasmid from the recipient containing a 
plasmid of a known group (Datta and Hedges, 1971). Plasmids were then assigned an 
incompatibility group denoted by a letter in the alphabet. Using phenotypic methods 
such as plasmid elimination to group the plasmids proved difficult when trying to 
identify non-conjugative plasmids or plasmids that did not transfer across due to entry 
exclusion (surface exclusion), which arise from donor plasmid inhibiting an incoming 
plasmid, preventing redundant transfer of the same or related plasmid (Perumal and 
Minkley, 1984). 
In 1988, Couturier et al. developed a scheme to classify plasmids based on genetic 
similarities in their replication regions (replicons) using DNA hybridization techniques. 
This technique further propelled plasmid classification but could not discriminate 
between closely related plasmids leading to cross-hybridization reactions (Carattoli, 
2009; Couturier et al., 1988).   
In recent years the development of a PCR based replicon typing (PBRT) method for 
typing plasmids occurring in Enterobacteriaceae has enabled the rapid identification of 
plasmid groups (Carattoli et al., 2005). To date 26 Inc groups have been identified in 
Enterobacteriaceae by the plasmid section of the National Collection of Type Cultures 
(NCTC; London, United Kingdom). The PBRT technique uses 18 different primer 
pairs; 5 multiplex and 3 simplex reactions recognizing HI1, HI2, I1-γ, X, L/M, N, FIA, 
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FIB, FIC, W, Y, P, A/C, T, K, B/O, FrepB (which detects 20 of the 26 FII, FIII, FIV, 
FV and FVI variants) and FIIAs. However with every technique, limitations are 
expected and although the PBRT offers a high throughput screening of plasmid groups, 
identification of new and divergent variants require sequencing of the plasmids 
(Carattoli, 2009).  
1.8 Plasmid multi-locus sequence typing (MLST) 
Plasmid MLST is another typing scheme that is based on the amplification of several 
housekeeping genes and assigning plasmid types based on sequence variation, as in 
traditional MLST. To date plasmid typing schemes exist for IncI1, HI1, HI2, F and N 
plasmids. Sequences of alleles are input into the pMLST database (www.pubmlst.org) 
and sequence types assigned (Garcia-Fernandez et al., 2008; Garcia-Fernandez et al., 
2011; Villa et al., 2010). 
1.9 Plasmid sequencing 
Plasmid sequencing has proved to be an essential tool in understanding the structure of 
plasmids. Due to the ease of genetic exchange, typing systems may not account for the 
variability of the plasmid as a result of HGT. For example a plasmid may be typed as an 
IncI1 plasmid, but have a large amount of sequence from another plasmid group or may 
be a co-integrate of two plasmids. Plasmid sequencing is one way to obtain this 
information however, some challenges come with it. Firstly, extraction of large low 
copy plasmids, without genomic DNA contamination, and at high enough 
concentrations for sequencing to be performed has proved challenging. Nevertheless 
DNA extraction kits for bacterial artificial chromosomes have proved useful, but 
plasmids larger than 250 kb become more of a challenge to obtain using commercially 
available kits. Another challenge is the assembly. Assembly of whole genomic 
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sequencing (WGS) data uses a reference to assemble the sequencing reads into a 
scaffold. Due to the variability of the plasmid, aligning the contigs to a reference for 
assembly is not a viable option, instead de novo assembly methods are required. In 
addition, the presence of numerous repeat sequences as a result of IS elements or iterons 
(which control plasmid replication), are unable to be resolved by assembly programs. 
This will leave gaps in the sequence and primer walking is currently the only option to 
close gaps in the sequence (Frost et al., 2005). Despite the technical difficulties, a lot of 
information about the plasmids genetic content can be obtained. 
 
1.9.1 Antimicrobial chemotherapy and resistance 
Antimicrobials are defined as substances with the ability to inhibit bacterial growth 
(bacteriostatic) or even kill bacteria (referred to as bactericidal agents). This is a general 
term used to describe substances from microbial (termed antibiotics), synthetic, semi-
synthetic, plant and animal origin (Courvalin, 2006).  
As with most chemotherapeutic agents, antimicrobials target various structures and 
metabolic pathways, resulting in arrested bacterial growth (bacteriostatic) or cell death 
(bactericidal). These include substances that inhibit bacterial cell wall synthesis, protein 
synthesis, folic acid biosynthesis, DNA transcription and replication, all processes vital 
in ensuring growth and survival of the bacterium (Courvalin, 2006).  See Table 1-2 for a 
list of antimicrobials, their targets and mechanisms of resistance. 
 
Resistance can be mediated by six chief mechanisms; (i) altering the drug targets (e.g. 
fluoroquinolone resistance), (ii) mutations resulting in the over-expression of enzymes 
(e.g. resistance to sulphonamides and trimethoprim) and  (iii) acquisition of genes that 
encode enzymes that alter the drug (e.g. aminoglycosides, MLS antibiotics, 
tetracyclines and β-lactams), (iv) altered membrane permeability, (v) increased efflux 
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and (vi) expression of alternative proteins with reduced affinity for the drug (e.g. 
resistance to sulphonamides and trimethoprim) (Alekshun and Levy 2007).  
In addition, resistance to antimicrobials may be attributed to physiological changes 
including biofilm formation. Pseudomonas aeruginosa is an opportunistic bacterial 
pathogen that forms biofilms in lung infections of cystic fibrosis patients. These 
infections are notoriously difficult to treat because of the difficulty of the antimicrobial 
compound to penetrate the exopolysaccharide matrix (Drenkard et al., 2002). Another 
recent study by Llobert et al. 2011 found that Klebsiella pneumoniae strains exposed to 
polymixin, upregulated the expression of the capsule operon, causing an increase in 
capsule production. Polymixin is a cyclic lipopeptide that disrupts the LPS by 
displacing divalent cations that stabilise it. Resistance is thought to be mediated by 
decreased penetration of this compound through to the cell membrane (Llobert et al., 
2011). 
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Table 1-2: Antimicrobial drugs and modes of inactivation. 
Target mechanism Target Antimicrobial class Mechanism of action Mode of inactivation Reference 
DNA Toposiomerase IV/DNA 
gyrase 
Flouroquinolones Bind to topoisomerase-DNA complex, resulting in 
accumulation of double stranded breaks in DNA. 
Mutations in gyrA and parC . Qnr protection 
proteins; low-level resistance. Efflux (norA in 
S. aureus). 
Chen et al., 2003 36 
  Coumarins Competitive inhibitors of ATP for DNA gyrase and 
Topoisomerase IV. 
Mutations in target GyrB subunit of DNA 
gyrase. 
Gellart et al., 1976         
Hardy et al., 2003 
 RNA polymerase Rifamycins Binds beta subunit of RNAP thereby preventing trancription 
initiation. 
Mutations in target RNAP (rpoB).  Kohanski et al., 2010 
 DNA integrity Nitrofurans Double stranded DNA breaks mediated by free radicals. Nitrofuran reductase; structural and functional 
changes. Mediated by nsfA and nsfB. 
Whiteway et al., 1998 
 Folic acid synthesis Trimethoprim Competitive inhibitors of DHFR thus preventing folic acid 
synthesis. 
Mutations resulting in overproduction of 
DHFR. Mutations to decrease affinity of the 
drug. Expression of alternative DHFR 
enzymes. 
Huovinen et al., 1995 
  Sulfonamide Competitive inhibitors of DHPS thus preventing folic acid 
synthesis. 
Mutations resulting in overproduction of 
DHPS. Expression of alternative DHPS 
enzymes. 
Huovinen et al., 1995  
Protein synthesis 50S ribosomal subunit Macrolides Prevents peptide elongation. Esterification and phosphorylation. MLS 
resistance efflux (mefA) and erm 
methyltransferase. 
Leclercq et al., 1991 
  Lincosamides Bind to the 23S rRNA blocking both the 'A' and 'P' site and 
preventing peptide synthesis. 
Acetylation. MLS resistance efflux (mefA) and 
erm methyltransferase.. 
Leclercq et al., 1991 
  Streptogramins Streptogramin A binds the A site and prevent elongation of 
protein synthesis. Conformational changes allow Streptogramin 
B to bind and prevent peptide elongation and release of 
incomplete peptides. 
Streptogramin A; Acetylation and 
Streptogramin B; hydrolysis. MLS resistance 
efflux (mefA) and erm methyltransferase. 
Leclercq et al., 1991 
  Chloramphenicols Binds to the 'A' site of the ribosome, thus preventing binding of 
tRNA. 
Acetylation and efflux. Schawrz et al., 2004 
 30S ribosomal subunits Tetracylcins Binds to the 'A' site of the ribosome, thus preventing binding of 
tRNA and growing peptide. 
Reduction of drug, ribosomal protection 
proteins. Efflux mediated by PMF. 
Chopra et al., 2001 
  Aminoglycosides Reversibly bind to 16S rRNA resulting in incorporation of 
incorrect amino acids; misread. 
Acetylation, phosphorylation, 
nucleotidylation. Altered target. 
Kotra et al., 2000 
 
Abbreviations: ATP; adenosine triphosphate, MRSA; methicillin resistant S. aureus, DHFR; Dihydrofolate reductase, DHPS; Dihydropteroate synthase, MLS; Macrolide lincosamide, streptogramin. LPS; lipopolysaccharide. 
Ala; Alanine, Lac; Lactate, Ser; serine. RNA; ribonucleic acid, rRNA; ribosomal RNA, tRNA; transfer RNA. 
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Table 1-2: continued. 
Target mechanism Target Antimicrobial class Mechanism of action Mode of inactivation Reference 
Cell wall Peptidoglycan synthesis Beta-lactams Inhibiting transpeptidases therefore 
inhibiting crosslinking of peptidoglycan.  
Hydrolysis of beta-lactam ring by beta-
lactamases. Altered PBP. Porins (OmpF); 
reduced drug uptake. Target site duplication 
(MRSA). 
Mascaretti, 2003 
  Glycopeptides Bind to D-ala-D-ala terminus of nascent 
peptidoglycan chain and inhibit addition of 
new amino acid subunits. 
Alter chemical composition of target i.e. D-
ala-D-lac (-D-ser) pentapeptide instead. Drug 
trapping; thicker cell wall (S. aureus). 
Reynolds, 1989 
  Beta lactam inhibitors Co-administered with beta-lactams. 
Reversible/Irreversible inhibitor of beta-
lactamases. 
Over-expression of target beta-lactamase. 
Point mutations resulting in 
structural/functional changes. 
Bush, 1988 
Cell membrane Phospholipids Polymixins 
(Lipopeptide) 
Bind to LPS and eliminate disulphide 
bridges by displacing metal cations (Mg+ 
and Ca+). Physiochemical disruption of 
membrane.  
Efflux and target alteration. Zavascki et al., 2007 
    Bacitracins (cyclic 
polypeptide) 
Inhibits regeneration of isoprenyl 
phosphates (by inhibiting isoprenyl 
phosphatase), a lipid carrier involved in 
biosynthesis of the cell wall. 
Drug efflux (BcrABC). Stone et al., 1971 
 
Abbreviations: ATP; adenosine triphosphate, MRSA; methicillin resistant S. aureus, DHFR; Dihydrofolate reductase, DHPS; Dihydropteroate synthase, MLS; Macrolide lincosamide, streptogramin. LPS; lipopolysaccharide. 
Ala; Alanine, Lac; Lactate, Ser; serine. RNA; ribonucleic acid, rRNA; ribosomal RNA, tRNA; transfer RNA. 
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1.9.2 Disruption of DNA Synthesis 
There are two main classes of antimicrobials that target nucleic acid synthesis: the 
quinolones and coumarins that target nucleic acid synthesis; and rifamycins that target 
RNA synthesis. Quinolones target two tetrameric enzymes; DNA gyrase, made up of 
two GyrA and GyrB subunits or the topoisomerase IV subunits made up of two ParC 
and ParE subunits. DNA gyrase catalyses the negative supercoiling of DNA in an 
energy dependant reaction to relieve torsional stress and maintain DNA topology during 
replication and transcription. Topoisomerase, a homologue of DNA gyrase, decatenates 
interlinked daughter chromosomes after replication. Quinolones bind enzyme-bound 
DNA complexes and arrests the DNA bound enzymes where single stranded breaks 
have been made by the enzyme. Although the mechanisms of cell death is unknown, it 
has been suggested that cell death occurs as a result of activation of the SOS response 
due to the single stranded breaks. Mutations in the quinolone resistance determining 
region (QRDR) of these enzymes (GyrA and ParC) alter the structure thereby 
preventing binding of quinolones and thus confer reduced susceptibility to these 
compounds (Drlica et al., 2008, Hopkins et al., 2005). 
Coumarins are competitive inhibitors of ATP, binding to the ATP sites in the GyrB and 
ParE subunits of DNA gyrase and topoisomerase respectively, and inhibiting ATPase 
activity of these enzymes. Mutations that confer resistance come at the cost of losing 
enzymatic activity because of the close proximity of the ATP binding site and the 
coumarin binding site (which overlap). Consequently any changes to the tertiary 
structure to inhibit binding of the compound will also result in loss of ATP binding 
(Collin et al., 2011). 
Rifamycin inhibits transcription by binding to the β-subunit of RNA polymerase 
(RNAP), made up of 4 subunits (α, β, β’ and σ), forming a stable RNAP-drug complex. 
 43 
Missense mutations in the β-subunit of RNAP, encoded by rpoB confer resistance to 
rifamycins due to structural changes (Kohanski et al., 2010). 
1.9.3 Disruption of Proteins synthesis 
These antimicrobials target bacterial ribosomes, which are made up of two 
ribonucleoprotein subunits, 30S and 50S. Together, these form the 70S bacterial 
ribosome, which bind to the mRNA molecule to form the initiation complex, resulting 
in the addition of aminoacyl-tRNA subunits to nascent polypeptide. Antimicrobials that 
inhibit the 50S subunit include; macrolides-lincosamides-streptogramins (collectively 
MLS), chloramphenicol and oxazolidones. Antimicrobials that target 30S ribosomal 
subunit include tetracycline and aminoglycosides. 50S ribosomal inhibitors prevent 
translation initiation (oxazolidones) or peptide elongation. 30S ribosomal inhibitor bind 
to the A site of the ribosome, preventing binding of the aminoacyl-tRNA subunits. 
Resistance to these compounds involves the modification of the drug by; acetylation, 
phosphorylation and nucleotidylation resulting in chemically modified compounds 
unable to bind to the ribosomes. In addition, ribosomal protection proteins have been 
found to bind to ribosomes in proximal sites to elongation and dislodge the compounds 
from the binding site (Connell et al., 2003). 
1.9.4 Alterations to metabolism and expression of alternative drug targets 
Folic acid synthesis is the target for sulphonamides and trimethoprims, which act on 
two steps in the synthesis of tetrahydrofolic acid; a derivative of folic acid used in the 
production of thymine. Thymine is an essential precursor in the production of nucleic 
acid synthesis in bacteria, as bacteria cannot utilise exogenous sources of folic acid and 
must produce this compound. Dihydropteroic acid, a derivative of folic acid is produced 
from dihydropteroate diphosphate and p-aminobenzoic acid (PABA), catalysed by 
dihydropteroate synthase (DHPS). Tetrahydrofolic acid is produced from dihydrofolic 
acid. Dihydrofolic acid is produced from dihydropteroic acid catalysed by dihydrofolic 
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reductase (DHFR). Sulphonamides and trimethoprims inhibit DHPS and DHFR 
respectively. Resistance to these compounds is mediated by the production of drug 
resistant enzymes encoded by sul and dhfr genes, conferring resistance to 
sulphonamides and trimethorpims respectively. In addition, mutations in the promoter 
regions of dhfr have been found to increase the amount of DHFR produced. 
Trimethoprims act as competitive inhibitors for DHFR. By increasing the enzyme 
concentration, the number of enzyme active sites increase and the effect of the inhibitor 
is reduced as the enzyme active sites are no longer saturated with the antimicrobial 
compound, subsequently leading to reduced susceptibility (Huovinen et al., 2001). 
In addition to overexpression of the target, resistance to sulphonamides can be mediated 
by the presence of naturally drug insensitive variants of the DHPS enzyme, commonly 
borne on plasmids (Huovinen et al., 2001). 
1.9.5 Decreased intracellular drug concentration or increased efflux 
Decreased antibiotic influx in an important mechanism of resistance in Gram-negative 
bacteria. The hydrophobic lipid bilayer and porins of Gram-negative bacteria act like a 
selective barrier enabling the selective diffusion or transport of molecules into the cell. 
Hydrophobic molecules such as macrolides easily diffuse through the lipid bilayer and 
small hydrophilic molecules are transported via porins. Resistance mediated by altered 
LPS has been reported in polymixin resistant E. coli, K. pneumoniae and Salmonella 
strains, resulting in the reduced binding of antimicrobial peptides such as polymixins. 
These strains were found to have higher levels of 4-aminoarabinose and 
phosphoethanolamine effectively reducing the charge in the LPS layer (Delcour, 2009, 
Llobert et al., 2011). Other mechanism of resistance mediated by decreased influx is the 
decreased expression of porins. In E. coli the main channels are OmpF, OmpE and 
PhoE, made up of a trimer of 16-strand β-barrels making a pore. Changes to Omp 
expression can be triggered by exposure to antimicrobials. The multiple-antibiotic-
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resistance (Mar) phenotype has been shown to be a result of exposure to antimicrobial 
treatment, resulting in insensitivity to drugs, mediated by expression of global 
regulators such as micF, a small RNA that control the expression of ompF. The Mar 
phenotype has also been responsible for the increased expression of the efflux proteins 
including the acrAB locus (Alekshun and Levy, 1997). Other efflux mechanisms 
thought to contribute to resistance include ErmAB-TolC (E. coli), MexAB-OprM (P. 
aeroguinosa) and VexAB (Vibrio spp.) (Li and Nikaido, 2009). 
1.9.6 Alterations to the cell membrane 
Antimicrobials such as polymixin B, colistin (polymixin E) and daptomycin target the 
cell membrane. These are cationic polypeptides that target the anionic phospholipids in 
the cell membrane and are thought to destabilise the LPS by displacing the divalent 
cations. This leads to increased permeability and leakage, eventually leading to cell 
death. Resistance to these compounds is thought to be mediated by alterations to 
structure and level of LPS production, outer membrane proteins, Mg2+ and Ca2+ content, 
and expression of the capsular polysaccharide (Falagas et al., 2005).  
1.9.7 Disruption of cell wall synthesis 
The bacterial cell wall is reinforced with a layer of covalently cross-linked glycan 
matrix known as the peptidoglycan layer (murein). The peptidoglycan layer is made up 
of alternating sugar units of N-acetyl muramic acid (NAM) and N-acetylglucosamine 
linked via a β-(1,4) glycosidic bond. These carbohydrate moieties are crosslinked by a 
peptide chain consisting of 3 to 5 amino acids namely, D-alanine, D-glutamine, 
mesodiaminopimelic acid (Gram-negative) or L-lysine (Gram-positive), and two 
terminal D-alanine residues. The crosslinking of the glycan chains are catalysed by 
transpeptidase enzymes, which first cleaves the terminal D-alanine in the precursor 
linking peptide, then utilizes a serine residue in the active site that acylates the serine 
residue forming an acyl-enzyme intermediate. The subsequent de-acylation step results 
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in regeneration of the enzyme and formation of the peptide bond, crosslinking the 
peptide to the peptidoglyan layer (Fig. 1-4) (Mascaretti, 2003; Wilke et al., 2005). 
 
 
. 
 
Figure 1-4: Transpeptidation reaction resulting in the crosslinking of the peptidoglycan layer. The 
molecule on the left depicts the D-ala-D-ala terminal residues, the substrates of PBP (transpeptidase) in 
the peptidoglycan crosslinking reaction, depicted as the incoming enzyme. The ‘R’ group representes D-
alanine-D-glutamine-mesodiaminopimelic acid polypeptide. The transpeptidase enzyme cleaves the 
terminal D-ala residue forming an acyl-enzyme intermediate (middle complex). The enzyme catalyses a 
further de-acylation step with an adjacent peptide chain, resulting in the formation of a peptide bond and 
regeneration of the enzyme. From Biochemistry (5th Edition) W.H Freeman and Co. 
 
Vancomycin and β-lactams both target the transpeptidase enzyme involved in 
peptidoglycan synthesis. β-Lactams inhibit transpeptidation (crosslinking) of the 
peptidoglycan layer by binding to the active site and inhibiting the transpeptidases (also 
known as penicillin-binding proteins or PBP) that catalyse this reaction. Vancomycin 
covalently binds to the D-ala-D-ala subunits of transpeptidation and prevents access to 
the active site by steric hindrance. Resistance to these compounds is mediated by the 
expression of altered PBP with lower affinity for the compounds or production of 
enzymes that hydrolyse the active compounds. 
1.10 Beta-lactams 
Beta-lactam antibiotics are a broad class of antibiotics that include penicillin and its 
derivatives: cephalosporins, monobactams, carbapenems, and β-lactamase inhibitors. 
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Their chemical structure includes a four membered cyclic amide known as the β-lactam 
ring. β-Lactam inhibitors are usually co-administered with β-lactam antibiotics and 
function as competitive inhibitors for β-lactamases that bind irreversibly to the enzyme 
active site and forming an acyl-enzyme complex consequently inactivating the enzyme 
(Drawz et al., 2010). β-Lactams target membrane anchored bacterial enzymes known as 
transpeptidases, which are involved in synthesis of the peptidoglycan layer. The relative 
ease of accessing these enzymes (localised on the outer cell membrane), low production 
costs and its specificity (no functional or structural homologues in humans) makes this 
an ideal chemotherapeutic. Therefore investing in prolonging its efficacy is of great 
interest to healthcare workers and patients alike (Mascaretti, 2003; Wilke et al., 2005).  
Beta lactams mimic the D-ala-D-ala substrate, enabling efficient binding to the 
transpeptidase enzymes or PBP. The β-lactam antibiotics bind irreversibly to the PBPs 
forming a covalent penicilloyl-enzyme complex unable to catalyse transpeptidation 
reactions. β-Lactams bind to the enzymes active site, where a serine residue present in 
the active site, forms an ester bond with the carbonyl carbon of the β-lactam ring, 
resulting in the formation of a stable penicilloyl-enzyme complex (Fig. 1-3). As a 
consequence the acyl group cannot be transferred to the amino group of the nascent 
polymer. As the transpeptidase enzymes lay inactive, the constitutive autolysis and 
recycling of the peptidoglycan layer results in weakening of the cell wall polymer. The 
fragile cell wall coupled to the high osmotic internal pressure results in lysis of the 
bacterial cell (Mascaretti, 2003; Drawz et al., 2010). 
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Figure 1-5: Action of penicillin antimicrobial and the target (transpeptidase) molecule. It is 
proposed that an enzyme (yellow) mediated lysine molecule abstracts a proton from the active site serine 
molecule (OH-Ser), enabling a nucleophilic reaction to occur between the now electron rich moiety and 
the carbonyl group (red line), consequently forming an irreversible penicilloyl-enzyme complex (depicted 
in the picture on the right). From Biochemistry (5th Edition) W.H Freeman and Co. 
 
1.10.1 Resistance to β-lactams 
There are three mechanisms by which bacteria acquire resistance to β-lactams; (i) 
altering the permeability, (ii) altering the target molecule (PBPs) and (iii) inactivation 
by enzymes (Wilke et al., 2005). 
Mutations in the active site of the target molecule (PBPs) render the β-lactam inactive, 
as it is less able to bind to and inhibit transpeptidation (Wilke et al., 2005). In 
methicillin resistant S. aureus the mecA gene encodes a PBP2a transpeptidase with a 
lower affinity for methicillin (Lowy et al., 2003).  
Resistance to β-lactams can also be conferred by the production of β-lactamases. These 
enzymes are secreted into the periplasmic space where they hydrolyze the amide bond 
within the β-lactam ring rendering it inactive and are unable to bind to the enzyme 
active sites due to steric hindrance. There are over 470 β-lactamases known to date 
classed into four different groups (A to D) based on amino sequence similarity; known 
as the ambler classification system (Bradford, 2001; Paterson, 2006; Ambler, 1980). 
The class B enzymes are metallo-β-lactamases, harbouring a zinc ion coordinated to the 
enzyme. The remainder (A, C and D) are all serine β-lactamases. The class A enzymes 
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are the most frequently observed in clinical isolates, commonly associated with 
transferable plasmids. The first plasmid mediated β-lactamase gene described in E. coli 
was TEM-1 in the 1960’s. This gene was originally isolated in Greece, but was later 
found to have spread to other parts of the world and in different species of bacteria. The 
cause was attributed to its location within mobile genetic elements. New β-lactam 
antimicrobials were developed in an effort to resist inactivation by β-lactamases with a 
broader spectrum of activity targeting an array of β-lactamase enzymes. However 
resistance quickly developed which saw the emergence of extended spectrum β-
lactamases (ESBLs). ESBLs have an increased spectrum of activity against oxyimino-
cephalosporins and monobactams but not cephamycins or carbapenems. To date there 
are over 200 ESBLs described in a range of Enterobacteriaceae (Patterson and Bonomo, 
2005).  
 
Surveillance studies of the late 1980’s saw the emergence of isolates conferring higher 
MICs against cefotaxime and ceftazidime (Bonnet, 2004). This non-TEM, non-SHV 
ESBL was designated CTX-M-1, thought to be a derivative of chromosomal β-
lactamases from Kluvyera spp. The early 1990s saw a rapid rise in E. coli strains with 
ESBL phenotypes of presumptive CTX-M production and by the mid 2000’s it was 
reported in countries all over the world (Fig 1-6). Nucleotide sequencing of these 
enzymes (circa 1996) revealed variants of these enzymes to exist, grouped according to 
their amino acid sequence (Bonnet, 2004; Livermore and Woodford, 2006). 
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 Picture taken from Rafael Canton and Teresa M Coque (2006). Current opinion in microbiology. 
Figure 1-6: Global distribution of CTX-M β-lactamases. CTX-M enzymes are a heterogeneous group 
of enzymes found to have spread globally. Predominant enzymes include the CTX-M-1, -2, -8 and -9 
variants. The rapid spread of CTX-M producing isolates has been attributed to the association of these 
enzymes with mobile genetic elements such as plasmids and insertion elements.  
 
1.10.2 CTX-M enzymes 
Cefotaximases (blaCTX-M) are Ambler class A β-lactamases that hydrolyze extended 
spectrum cephalosporins and monobactams, but are inactive against cephamycins and 
carbapenems. In the recent years they have been the most prevalent β-lactamases found 
in animal isolates (Ewers et al., 2012). CTX β-lactamases hydrolyze cefotaxime, but 
also provide a high level resistance to penicillins, narrow-spectrum cephalosporins and 
third generation cephalosporins.  
CTX-M enzymes can be classed into five different classes based on their amino acid 
sequence identity, CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25 (see Fig 
1-7). To date over 50 allelic variants of CTX-M genes have been identified, but the 
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CTX-M-14 (CTX-M group 9) and -15 (CTX-M group 1) variants are by far the most 
clinically (and veterinary) relevant (Canton et al., 2012). The prevalence of CTX-M 
enzymes has been attributed to their effective cleavage of cefotaxime in addition to 
other narrow, broad and extended spectrum β-lactams. However, the activity between 
the different variants of CTX-M is heterogeneous (Rossolini et al., 2008, Patterson, 
2006). 
CTX-M enzymes are folded into two domains, the α-helical domain and five β-strands 
surrounding the α-helical domain. The active site is located between the two domains, 
with the B3 β-strand forming part of the active site. The bottom of the enzyme is 
denoted the Ω Loop. Mutations in the B3 and Ω loop regions results in increased 
flexibility and accommodation of compounds with bulkier side chains of the extended 
spectrum β-lactams, such as cefotaxime, in comparison to the broad-spectrum 
compounds such as ampicillin. Mutations in the B3 strand at position 240 from 
aspartate to a neutral glycine is thought to improve flexibility and increase access of the 
substrate to the active site. Mutations in the Ω-loop region (Pro167Ser) are thought to 
increase flexibility further enabling hydrolysis of larger side chains like ceftazidime. 
Although these CTX-M enzymes harbour the same mutations, their kinetic activity is 
variable, due to additional mutational variants that may enhance/decrease hydrolysis of 
certain substrates or differential expression of the variants (Chen et al., 2005). 
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Figure 1-7: Phylogenetic tree of the five CTX-
M clusters identified by amino acid sequence 
variation. The most prevalent enzymes found in 
clinical and veterinary samples today are the 
CTX-M-14 and CTX-M-15 enzymes belonging 
to CTX-M group 9 and 1 respectively. Picture 
taken from Canton et al., 2012 (Frontiers in 
Microbiology). 
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1.11 Mobile genetic elements and blaCTX-M genes 
CTX-M enzymes are thought to have originated from Kluyvera species harbouring klu 
enzymes. They are thought to have been mobilised from the Kluyvera chromosome by 
insertion elements, namely ISEcp1. ISEcp1 has also now been associated with 
mobilising CTX-M group 1 and 9 variants (Toleman and Walsh, 2011). ISEcp1 
elements are found upstream of the genes they mobilise and transpose the adjacent gene.  
In addition ISEcp1 encodes -35 and -10 promoter sequences and is thought to drive 
expression of downstream genes. This quality is thought to be exploited when genetic 
transfer occurs from one bacterial species to another, to drive expression in the new 
species (Poirel et al., 2003). 
CTX-M group 2 and 9 enzymes have been associated with insertion sequence common 
region 1 (ISCR1) upstream of the CTX-M gene. This insertion element mobilises genes 
via a rolling circle mechanism enabling transposition of large segments of DNA. ISCR1 
elements recognise their own terminal sequences, resulting in transposition to more 
genetically diverse regions and contributing further to their dissemination (Canton et al., 
2012; Toleman and Walsh, 2011). However attempts to monitor this transfer in vitro has 
been unsuccessful, but the potential for transfer of large sections of DNA may become a 
future concern in the dissemination of resistance genes. 
The spread of CTX-M variants has been highly attributed to their presence on plasmids 
(Carattoli, 2009). CTX-M variants have been associated with plasmids of particular 
incompatibility groups. For example the CTX-M-15 enzyme has been commonly found 
in association with the IncFII plasmid group. This particular plasmid has been very 
successful in the spread of this variant due to its presence on the conjugative (self-
transmissible) IncFII plasmid, and is commonly found in an E. coli clone ST131 that 
appears to have co-evolved with the plasmids, further aiding the spread of this CTX-M 
variant (and plasmid) (Canton et al., 2012; Coque et al., 2008; Woodford et al., 2011). 
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This is usually a large, low copy plasmid, but has evolved multiple mechanisms to 
ensure maintenance in the host, including multiple addition systems. This plasmid has 
been found to have undergone multiple recombination events resulting in the acquisition 
of multiple replication origins in addition to multiple drug resistance genes including; 
other β-lactamases such as blaTEM and blaOXA and genes that confer resistance to 
aminoglycosides, chloramphenicols, sulphonamides, trimethoprims and tetracyclines 
(Woodford et al., 2009). However, IncF plasmids are narrow host range plasmids 
limited to the Enterobacteriaceae family. Other broad host range plasmids associated 
with CTX-M enzymes include the IncN, IncL/M and IncI1, commonly found in 
Salmonella spp. and E. coli commonly isolated in food producing animals, thought to be 
reservoirs of resistance (Carattoli, 2011). 
1.12 Multi-drug resistance  
Altering membrane permeability is more commonly found in Gram-negative bacteria, 
making them more resistant to a larger repertoire of antibiotics. Multidrug transporters 
have been found to be responsible for conferring resistance or reducing susceptibility to 
antifungals, antiprotozoal and antimicrobials (Lomovskaya et al., 2007). Multidrug 
transporters in bacteria are classified into five families based on sequence similarity. 
These families are; the major facilitator (MFS), resistance-nodulation-cell division 
(RND), small multidrug resistance (SMR), multidrug and toxic compound extrusion 
(MATE), and ATP-binding cassette (ABC) families (Piddock et al., 2006). Many 
putative and proven drug transporters of all five families exist in the E. coli genome, 
and a large fraction of them are multidrug transporters. The RND efflux system plays a 
major role in drug resistance in Gram-negative bacteria by allowing the direct extrusion 
of a wide spectrum of lipophilic and amphiphilic substrates, including several classes of 
 55 
antimicrobials, antiseptic compounds, dyes and detergents into the extracellular space 
(Nikaido, 1996).  
In Gram-negative bacteria, transport of β-lactams into the periplasm occurs via outer 
membrane porins (Nikaido et al., 1983). The combination of reduced drug uptake (via 
porins) increased efflux and inactivation by periplasmic β-lactamase enzymes can 
effectively contribute to reduced susceptibility to these compounds (Wilke et al., 2005). 
With such broad specificity offered by MDR efflux pumps, reduced susceptibility and 
in some cases increased resistance is inevitable in Gram-negative bacteria (Nikaido and 
Normak, 1987; Nagano and Nikaido, 2009; Sawai et al., 1988). One of the most studied 
efflux systems is the AcrAB-TolC tripartite efflux protein in E. coli (Nikaido and 
Takatsuka, 2009). AcrB is the inner membrane protein, the AcrA protein is located in 
the periplasmic space and the TolC protein forms the outer membrane protein channel 
(Fig 1-8). Efflux is driven by an electrochemical potential gradient of H+. The substrate 
binds to the AcrB protein, where it is translocated through the TolC pore to the 
extracellular space bypassing the cell membrane and periplasmic space. Substrates for 
the AcrAB-TolC system include a number of antimicrobial classes including β-lactams 
(Yu et al., 2003).  
Clinically relevant Gram-negative organisms such as P. aeruginosa, S. enterica, C. 
jejuni, K. pneumoniae, H. pylori have all been described as having homologues of the 
AcrAB-TolC efflux systems or other known RND transporters that contribute to 
intrinsic resistance, challenging efficacy of current therapies (Piddock, 2006). The broad 
spectrum of antimicrobials that may be extruded by efflux transporters have made 
efflux proteins an attractive drug target. Efflux pump inhibitors (EPIs) target the 
substrate-binding region of the transporter (Lomovskaya et al., 2001). This however 
limits the type of the antimicrobial compounds inhibited, as the EPI either acts as a 
competitive inhibitor, preventing binding of substrates or cooperatively acts to prevent 
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disassociation of the antimicrobial substrates resulting in blocking of the channel. 
Consequently the rates of efflux inhibition depend on the type of EPI used 
(Lomovskaya et al., 2001; 6, Lomovskaya et al., 2007). 
 
Figure 1-8: Simplified ICM model of the tripartite AcrAB-TolC efflux transporter, part of the RND 
(resistance nodulation division) transporters. The substrate is guided to the efflux transporter by the 
AcrB inner membrane protein, and then it is translocated through the TolC transmembrane protein to the 
extracellular space by a H+ antiport system. Taken from Lomovskaya et al. 2007. Nature. 
1.13 The fitness cost of antibiotic resistance 
Resistance is thought to come at a cost, namely bacterial fitness, which is strictly 
defined as the capability of a genotype to survive and reproduce (Andersson and 
Hughes, 2010). The acquisition of resistance, through chromosomal mutation or HGT is 
thought to reduce bacterial fitness, but this cost can be alleviated through counteracting 
this cost by increasing fitness e.g. compensatory mutations or survival in a limiting 
condition such as an antibiotic environment where the bacterium encodes the resistance 
gene, resulting in survival and out-competition of strains that lack these traits. The 
relative fitness of a bacterial species can me be measured in different ways including in 
vitro and in vivo. In vitro fitness measurements can be detected by phenotypic markers, 
such as the expression of resistant variants including rpsL and rpoB mutations as a 
result of exposure to streptomycin and rifampicin respectively. In vivo measurements 
include competition assays with mutant and wild-type strains, and detection of the 
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ratio’s of the two strains after several days of infection and bioluminescent tags may be 
used to monitor the infection (Andersson and Hughes, 2010). Bacterial growth 
experiments have also been used to measure fitness, either in pairwise competition 
assays or measuring exponential growth rates of the two strains, these techniques have 
been used to measure fitness costs of plasmid acquisition to host strains (Humphrey et 
al., 2012, Lim et a., 2010, Platt et al., 2011).  
1.14 Antimicrobial resistance and its application to livestock 
Resistance to antimicrobials can be observed in an array of bacterial species, pathogenic 
and non-pathogenic, in human and animal populations. Monitoring resistance is 
therefore of great interest to researchers and clinicians alike. In doing so, resistance 
patterns can be identified for prevalence studies, in addition to detecting emerging 
resistance genes and providing suitable treatment courses (McEwen, 2006). 
Bacteria resistant to currently used antimicrobials can easily spread amongst livestock. 
Establishing a surveillance system allows the monitoring of common zoonotic 
pathogens like Enterobacteriaceae e.g. Salmonella, Campylobacter and in some cases 
Yersinia for the carriage of resistance phenotypes. Monitoring commensal bacteria such 
as E. coli, Enterococcus faecium and Enterococcus faecalis is crucial when studying 
resistance acquisition, as these bacteria can colonize the gastrointestinal tract of a range 
of animal species and even serve as a reservoir for these genes (McEwen, 2006). This 
may lead to contamination of food for human consumption. The array of bacterial 
species that can be found in the gut dramatically increases the probability of resistance 
gene acquisition (through various methods described earlier) both intra and interspecies. 
And now with the ever-increasing movement of animals across borders, the problem of 
resistance is not only a domestic but also an international one (O'Brien, 1997). 
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1.15 Surveillance of antimicrobial resistance 
Monitoring and surveillance systems track and record emerging resistance patterns 
provide early detection of outbreaks, improving treatment managements and guide 
policy for current and future prescription practices (www.who.int). Surveillance 
methods involve sampling, identifying the bacterial species, antimicrobial susceptibility 
profiling, data collection and analysis. The data is collated and presented through 
networks like the European Antimicrobial Resistance Surveillance Network (EARS-
Net) and European Surveillance of Antimicrobial Consumption (ESAC). These data are 
collected in various laboratories in their respective countries, producing yearly reports 
on resistance and antimicrobial usage patterns. Therefore it is crucial to maintain the 
same sampling techniques and lab practices to compare the data. The set up of councils 
such as the British Society of Antimicrobial Chemotherapy (BSAC) and Clinical and 
Laboratory Standards Institute (CLSI) ensure laboratory interpretations for laboratory 
tests such as minimum inhibitory concentration (MIC) determination and antimicrobial 
disc diffusion assays are comparable between labs, but no high throughput routine 
method of assaying the genetic determinants of resistance is used. In recent years, the 
development of PCR-based techniques and miniature microarray technology enabled 
high throughput screening of strains, providing clinically relevant information e.g. 
genes encoding virulence and antibiotic resistance clinically relevant information 
including genes encoding virulence and antibiotic resistance (Anjum et al., 2007; 
Anjum et al., 2011). 
1.16 CTX-M encoding plasmids in the UK 
The most frequently detected CTX-M enzyme in the UK in human E. coli isolates is 
CTX-M-15 and -3, however in animals, CTX-M-14 has been found to be the most 
prevalent (Livermore and Hawkey, 2005, Randall et al., 2011, Stokes et al., 2012). The 
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detection of this enzyme was first reported in 2004 (Teale et al., 2005). These genes are 
commonly associated with multi-drug resistant plasmids, capable of transferring by 
conjugation, which may aid the persistence and dissemination of these resistance genes 
(Randall et al., 2011). In recent reports however, an epidemic plasmid, pCT, encoding 
the CTX-M-14 varaint in E. coli, was not found associated with any other resistance 
genes suggesting the drive for persistence could be driven solely by the presence of β-
lactam compounds (Cotell et al., 2011). Sequence analysis of this plasmid revealed 
multiple addition and conjugative systems that may explain the apparent spread of this 
plasmid worldwide (Cotell et al., 2011). This further expresses the need to study the 
horizontal spread of MDR plasmids as they may impact the clinical strategies used to 
combat disease. 
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1.17 Aims 
The increasing isolation of blaCTX-M encoding plasmids from zoonotic pathogens and 
commensal E. coli strains suggests the genetic platform in which these enzymes exists 
are a significant contributing factor to the dissemination and persistence of CTX-M 
enzymes.  
The aim of this study was to characterize blaCTX-M encoding plasmids and investigate 
those aspects of these plasmids that may contribute to their global spread. The 
prevalence of particular CTX-M variants suggests that some variants of these enzymes 
may favor particular plasmids, which in turn contribute to their dissemination.  
The working testable hypothesis is that, in the absence of selection, blaCTX-M variants 
harbored within a plasmid solely define the prevalence of that blaCTX-M variant observed 
globally. However, it is recognized that the plasmid itself may play a contributing role 
and alternatively it could be a combination of the genetic platform to which blaCTX-M is 
found that stabilizes the gene and the plasmid harboring the gene within a population. 
The stability or success of the gene; defined by the ability to spread amongst a 
population, would depend on the plasmid it is located on, but in the presence of 
selection the genes including CTX-M enzymes would provide an advantage. This thesis 
aims to explore the contribution, if any, of plasmids harboring CTX-M enzymes to 
overall fitness in the presence and absence of selection and whether they are linked to 
particular plasmid incompatibility groups or the CTX-M variant. In addition the genetic 
structure of these plasmids will be explored through plasmid sequencing to identify 
potential genetic traits that may enable the plasmid to persist within a population. 
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The specific aims are as follows: 
- To characterize field isolates from bovine E. coli species, collected from regions 
across the United Kingdom, conferring the ESBL phenotype. 
- To characterize the plasmids possessing blaCTX-M genes to identify their 
transferability, drug resistance phenotype and genotype and any linkage to 
plasmids isolated from other regions. 
- To identify the genetic structure of plasmids encoding the CTX-M variants. 
- To investigate the cost of acquiring the plasmid to host fitness.  
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2 MATERIALS AND METHODS 
2.1  Bacteriological techniques 
2.1.1 Initial screening of bacterial isolates 
Fifty-two E. coli isolates were selected from samples collected from farm visits received 
from regional laboratories in England and Wales in 2007. All 52 isolates had already 
been screened by colleagues at the AHVLA (bacteriology) for resistance to cefotaxime 
by plating onto Chromagar™ ECC supplemented with 2 and 8 mg/L of cefotaxime (ctx) 
(Randall, Kirchner et al. 2009). Chromagar ECC™ is a chromogenic media that enables 
identification of E. coli (blue colonies) and other coliforms (mauve/red colonies). Each 
positive colony (blue in colour) was selected and plated onto Chromagar ECC™, and 
analysed further by real time PCR to detect blaCTX-M genes. 
2.1.2 Bacterial Cultivation 
All bacterial strains were stored at -80 °C in Luria Bertani (LB) Broth containing 25 % 
glycerol (v/v). Strains were routinely grown from frozen stocks on LB agar plates (or 
Broth) at 37 °C for 16-18 hours. Liquid cultures were incubated aerobically shaking at 
150- 200 rpm at 37 °C for 16-18 hours. 
2.1.3 Bacterial enumeration  
Colony forming units (CFUs) per ml were determined by the Miles and Misra method 
used for surface variable counts (Miles & Misra, 1938). Ten-fold serial dilutions of a 
bacterial suspension in 0.1 M phosphate buffered saline (PBS) at pH 7.2, was used to 
spot three 20 µl droplets onto dry LB agar plates and allowed to soak into the agar. The 
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plates were incubated at 37 ˚C for 16-18 hours and colonies were counted at the 
appropriate dilution factor. 
2.1.4 E. coli identification 
All the isolates were plated onto Brilliant Green Agar (BGA) to confirm the isolates 
were not contaminated during storage. BGA is a selective media used to select for 
lactose and/or sucrose fermenters including Salmonella and E. coli. Brilliant Green 
included in the medium inhibits growth of Gram-positive bacteria and most Gram-
negative bacteria. The agar also includes a phenol red indictor, which discolours in the 
presence of lactose/sucrose fermentation. E. coli ferments lactose and sucrose producing 
yellow/green colonies, non-fermenters, including Salmonella, produces red/pink 
colonies surrounded by bright red medium.  
Isolates were recovered from frozen stocks as outlined above. Overnight colonies were 
streaked onto BGA plates to single colonies and incubated for 16-18 hours at 37°C. 
Included, were a positive and negative control: S. Nottingham (NCTC 7832) and E. 
coli (NCTC 10418) respectively. 
2.1.5 Preparation of competent cells 
Competent cells were prepared by three different methods, two chemically competent 
methods (Sambrook et al.1989) using Calcium chloride (CaCl2) and Rubidium Chloride 
(RbCl2), and an electrical competent procedure (Sheng et al., 1995). These cells were 
used in the transformation of blaCTX-M plasmids for subsequent phenotypic studies and 
are detailed below. 
2.1.5.1 CaCl2 Chemically competent cells 
A fresh overnight culture (LB broth) was diluted 1:150 for growth in pre-warmed LB 
broth. Cells were grown at 37 ˚C with shaking at 250 rpm to an OD600 of 0.4 and 
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thereafter immediately placed on ice for 20 minutes. Cells were harvested by spinning 
the culture for 10 minutes at 1250 g (4 ˚C) and re-suspended in 12 ml ice cold 0.1 M 
CaCl2, then incubated on ice for 30 minutes. The cells were pelleted by centrifuging at 
1250 g at 4 ˚C for 10 minutes. After decanting the supernatant, the cells were re-
suspended in ice cold 0.1 M CaCl2 containing 15 % glycerol (v/v) and aliquoted into 
pre-chilled microcentrifuge tubes to be stored at -80 ˚C in 100-200 µl aliquots. 
2.1.5.2 RbCl2 Chemically competent cells 
To prepare RbCl2 competent cells, a fresh overnight culture was diluted 1:100 with 
fresh pre-warmed LB broth supplemented with the following: 5 mM glucose, 10 mM 
MgSO4, 10mM MgCl2, and incubated in a shaking incubator (250 rpm) at 37 ˚C to an 
OD600 of 0.4. The culture was immediately placed on ice for 20 minutes, and then 
centrifuged for 10 minutes at 1250 g at 4 ˚C. The cells were re-suspended with 50 ml 
ice cold 0.1 M CaCl2 and pelleted again as above. Cells were re-suspended in 5ml 
transformation buffer (100 mM CaCl2, 50 mM MgCl2, 50 mM MnCl2, 50 mM RbCl2) 
and incubated on ice for 1 hour. The chemically competent cells were stored in 100 - 
200 µl aliquots at -80 ˚C in 10 % glycerol (v/v). 
2.1.5.3 Electrically competent cells 
Electrically competent cells were prepared as described previously by Sheng et al. 1995, 
with a modification to the centrifuging speeds and an additional 20 minute incubation 
step on ice following growth. An overnight culture was diluted 1:1000 in LB broth to an 
OD600 of 0.4. Cells were placed on ice for 20 minutes harvested by centrifuging at 2500 
g for 10 minutes at 4 ˚C. Cells were re-suspended in 10 % glycerol (v/v), equal to the 
original culture volume and spun at 2500 g for 10 minutes (4 ˚C) to pellet cells. This 
washing and pelleting step was then repeated again using 10 % glycerol (v/v), equal in 
volume to the original culture. Once decanted, the cells were re-suspended in 60 ml of 
 65 
10 % glycerol (v/v) and pelleted once more. The cells were re-suspended in 2 ml of 
10 % glycerol (v/v) per litre of initial culture volume and stored in 100 µl aliquots at -80 
˚C. 
2.1.5.4 Competent cell lines 
Table 2-1: Listed in the table below are the competent cell lines used in this study. 
Competent 
Cell 
Supplier Competency type Genotype 
E. coli 
DH10B™ 
Invitrogen   Chemical (Cat. No. 
18297-010) and 
electrocompetent (Cat. 
No. 18297-015)  
F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 endA1 
araD139 Δ(ara leu) 7697 galU galK rpsL 
nupG λ– 
E. coli BL21 Novagen Chemical (Cat. No 
69449-3) F– ompT hsdSB (rB- mB-) gal dcm lon 
E. coli 
BL21KAMR 
Prof. Nikaido 
UC Berkley 
Made Chemical and 
electrocompetent 
BL21 _acrAB _mdtABC _(srl-
recA)306::Tn10(Tcr) (Kim et al. 2010) 
E. coli K12 
(20R764) 
AHVLA Made chemical and 
electrocompetent 
F–  lac+ rif+ 
 
 Molecular Methods 2.2
2.2.1 Standard PCR 
Polymerase chain reaction (PCR) was performed in a GeneAmp® PCR system (9600) 
cycler machine (Applied biosystems).  
Thermostable DNA Taq polymerse (Promega; Cat. No. M186B or Qiagen; Cat. No. 
201203) was used in all standard PCR reactions according to the manufacturer’s 
instructions, unless otherwise stated. Unless stated the following PCR reaction mixtures 
and conditions were used; 5 µl 10 x reaction buffer, 1 U of Taq polymerase, 10 µM of 
each primer, 10 mM of each deoxynucleoside triphosphate (dNTP), 1-2 µl of and made 
up to 50 µl with nuclease free water. PCR cycling conditions were as follows; 5 minutes 
at 94 ˚C, 30 cycles of 94 ˚C for 1 minute, 60 ˚C for 30 seconds, 72 ˚C for 1 seconds and 
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a final extension at 72 ˚C for 5 minutes. Primers used in this study can be found in 
appendix B. 
2.2.2 Gel electrophoresis 
DNA was run on a 0.8 – 2 % agarose gel. The gels were stained in 0.8 µg/ml ethidium 
bromide and visualized under ultraviolet light using the AlphaImager™ system (Alpha 
Innotech). 
 
2.2.3 Colony PCR 
A single colony was re-suspended directly into the PCR mixture. This crude lysate 
method was employed for screening for blaCTX-M PCR, however was not used in the 
instance of multiplex PCR’s due to the low sensitivity of the reaction that may result in 
non-specific products. 
 
2.2.4 DNA extraction 
Different DNA extraction methods were employed. Below are details of the methods 
used. 
2.2.4.1  Cell lysates 
From a fresh overnight culture, 3 to 5 five single colonies were picked and re-suspended 
in 100 µl of nuclease free water. This was heated to 95 ˚C for 15 minutes, and then 
chilled on ice for a further 1 minute before 3-5 µl was used in subsequent PCR reactions. 
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2.2.4.2 Alkaline lysis 
Bacteria from a fresh overnight culture (plate or broth) were pelleted and re-suspended 
in a tris base buffer, with a detergent (SDS or Sarcosyl) and adjusted to pH 8.0. The 
suspension was incubated at temperatures ranging from 54- 60 ˚C as per indicated by 
the subsequent method i.e. PFGE, DNA microarray genotyping or Plasmid DNA 
extraction. 
2.2.4.3 Plasmid DNA extraction 
Two methods were used to extract plasmids; a) phenol chloroform extraction for 
plasmid content analysis by gel electrophoresis, and b) plasmid midi prep extraction 
(QIAGEN Cat. 12143); for subsequent transformation, PCR and sequencing procedures. 
2.2.4.3.1 Phenol Chloroform extraction 
Plasmid DNA was extracted from 1 ml of a fresh overnight culture grown in LB broth. 
Cells were pelleted by centrifuging at maximum speed for 5 minutes and supernatant 
discarded. The pellet was re-suspended in 200 µl alkaline lysing solution (3 % SDS, 50 
mM trizma base (Sigma Cat. 93349), and 30 mM NaOH) and incubated at 55 ˚C for 30 
minutes. 200 µl of phenol:chloroform:isoamyl alcohol mix 25:24:1 (Sigma Cat. P3803) 
was added and the suspension was mixed by inverting five to six times. This was 
centrifuged at maximum speed for 10-15 minutes to separate the top aqueous phase 
(containing the nucleic acids) and the bottom organic phase (contains mainly proteins 
and chloroform). The aqueous phase was carefully aspirated and stored at -20 ˚C. 
2.2.4.3.2 Plasmid Midi prep 
Plasmid DNA was prepared as per manufacturers instructions; unless otherwise stated, 
using the Qiagen plasmid midi kit (Cat. No. 12142) or the HiSpeed plasmid midi kit 
(Cat. No. 12662). A higher initial culture volume was used and all subsequent buffer 
volumes were adjusted accordingly. Briefly, 50 ml of an overnight culture was pelleted 
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and re-suspended in 8 ml buffer P1. 8ml of buffer P2 and pre-chilled buffer P3 were 
added separately and mixed by gently inverting 4-6 times between buffers. The mixture 
was centrifuged at maximum speed for 30 minutes (4 ˚C), decanted, and then spun 
again at maximum speed for 15 minutes (4 ˚C). The supernatant was applied to a 
column, previously equilibrated with 8 ml buffer QBT and allowed to empty by gravity 
flow. The column was washed twice with 20 ml buffer QC and eluted with buffer QF. 
DNA was concentrated by one of the methods described below.  
2.2.5 Concentrating plasmid DNA 
2.2.5.1 Ethanol precipitation 
The eluate from the plasmid extraction was precipitated either by adding 0.7 volumes of 
room temperature 100 % isopropanol then incubated at room temperature for 15 
minutes, or 2.2 volumes 100 % ethanol and placed at -80 ˚C for 30-60 minutes. The 
mixture was centrifuged at 15,000 g for 60 minutes (4 ˚C). The isopropanol/ethanol 
mixture was carefully decanted and the DNA pellet was washed with 0.4 volumes of the 
original sample volume with 70 % ethanol (v/v). This was incubated at -80 ˚C for 30 
minutes and then centrifuged at 15,000 g for 60 minutes (4 ˚C). The pellet was re-
suspended in an appropriate volume with nuclease free water. 
2.2.5.2 Sodium acetate precipitation 
Sodium acetate was added to a final concentration of 0.3 M. To that, 2.2 volumes of 
100 % ethanol was added and placed at -80 ˚C for 30-60 minutes. The mixture was 
washed, pelleted and re-suspended as above.  
2.2.6 Bacterial plasmid transformation 
Two methods were employed to introduce plasmids to host plasmids; chemical 
transformation and electroporation. The latter of the two methods was employed when 
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transformation was unsuccessful, which was the case for some of the large plasmids 
(>90 kb).  
2.2.6.1 Chemical transformation 
Approximately 100-500 ng of DNA (1-2 µl) was mixed with 30 µl of E. coli chemically 
competent cells prepared as previously described (section 2.1.5.1) and incubated on ice 
for 30 minutes. Cells were heat shocked at 42 ˚C for 30 seconds and placed on ice for 2 
minutes. 250 µl of room temperature S.O.C media (super optimal broth with catabolite 
repression media) was added and incubated for 1 hour at 37 ˚C. This was plated onto 
dried LB agar plates supplemented with 3 mg/L cefotaxime for selection of strains 
harbouring blaCTX-M encoding plasmids. Strains were confirmed to harbour blaCTX-M by 
colony PCR. 
2.2.6.2 Bacterial electroporation 
100 - 500ng DNA was mixed with 30-50 µl of competent cells and incubated on ice for 
10 minutes. The mixture was transferred to a 0.1 cm cuvette (BioRad Cat. No 165-
2089). Electroporation parameters were as follows; 1.25 kV (12.5 kV/cm), 25 µF and 
100Ω. The cells were recovered in 500 µl of S.O.C media for 1 hour and plated on 
selective media LB agar plates as above. Strains harbouring blaCTX-M encoding plasmids 
were screened by PCR. 
 Bacterial conjugation 2.3
Plasmid transferability for all the strains was determined by in vitro conjugation, using a 
rifampicin resistant E. coli K12 (20R764) strain as the recipient. Isolates were plated on 
LB agar and incubated for 16-18 hours at 37 °C and three representative colonies were 
used to inoculate LB broths. These were incubated for 16-18 hours in a shaking 
incubator at 37 °C. 
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Optical density readings (OD600) of the overnight liquid cultures were taken and 
appropriate volumes were calculated to result in a 1:10 ratio of donor strains to recipient 
strain (E. coli K12 - 20R764) in a final volume of 3 ml. 200 µl of the resulting 
donor/recipient mixture was dispensed onto a 0.2 µm membrane filter (Millipore 
GTTP02500) and incubated at 37 °C for 1 hour. The same was repeated on the donor 
only and recipient only cultures as positive and negative controls for the selective plates 
(see below).  The reaction was stopped by placing the filter into a 15 ml falcon tube 
containing 5 ml of ice cold 0.1 M PBS (pH 7.2) and placed on ice. The filters were 
washed by gentle vortexing and cells pelleted by centrifuging at 3200 g for 10 minutes, 
then re-suspended in 1 ml 0.1 M PBS (pH 7.2). The cells were then further diluted in 
0.1 M PBS (pH 7.2) and spread onto a selective LB media containing 1 mg/L 
cefotaxime and 150 mg/L rifampicin. These were incubated for 16-18 hours at 37 °C. 
As controls, the recipient cultures were spread onto selective LB media containing 1 
mg/L cefotaxime and 150 mg/L rifampicin, and recipients were spread onto LB media 
containing150 mg/L rifampicin, to quantify any spontaneous mutants. 
 
The recipient overnight cultures were also plated on LB plates (minus selection) for 
enumeration of initial viability counts using the Miles & Misra method described above 
(section 2.1.3).  
Three transconjugants were picked and plated to single colonies on selective plates and 
incubated for 16-18 hours at 37 °C.  The presence of blaCTX-M was analysed by PCR to 
confirm successful transfer of blaCTX-M plasmids to the recipient strain. Plasmid transfer 
rates (frequency of transfer) were determined as the number of transconjugants 
(CFU/ml) per initial recipient (CFU/ml) (Fernandez-Astorga, Muela et al. 1992). 
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 Molecular subtyping methods 2.4
2.4.1 E. coli phylogrouping PCR 
E. coli phylogenetic characteristics were determined by PCR using a multiplex PCR 
reaction devised by Clermont et al. 2000. Three primers pairs; ChuA.1/2, YjaA.1/2 and 
TscpE4C2.1/2 (see appendix B for primer sequences) were used in a triplex reaction 
with 2 µl 10 x reaction buffer, 2.5 U of Taq polymerase, 20 µM of each primer, 2 µM of 
each deoxynucleoside triphosphate (dNTP), 3 µl of crude lysates (recovered in selective 
media form frozen stocks) and made up to 20 µl with nuclease free water. PCR cycling 
conditions were as follows; 5 minutes at 94 ˚C, 30 cycles of 94 ˚C for 30 seconds, 55 ˚C 
for 30 seconds, 72 ˚C for 30 seconds and a final extension at 72 ˚C for 7 minutes. 
Fragments were run on a 2 % gel and visualised under UV light subsequent to ethidium 
bromide staining. Phylogroups were assigned according to the dichotomous key 
approach described by Clermont and colleagues (Clermont et al., 2000). Controls 
included E. coli K12 20R764 (phylogroup A) and an E. coli ST131 strain (phylogroup 
B2; AHVLA, Dr. G. Wu). 
2.4.2 Pulse field gel electrophoresis  
Pulse field gel electrophoresis (PFGE) was used to further subtype the E. coli strains 
used in this study. Isolates were subjected to genomic DNA XbaI restriction digest 
according to the PulseNet protocol for subtyping E. coli 0157 (Centre of Disease 
Control, Atlanta) (CDC 2008). In brief, the isolates were suspended in a buffer 
containing 1 M tris and 0.5 M EDTA at pH 8.0. The cell suspension was adjusted to 
OD610 1.3-1.4. Agarose plugs were prepared containing a 1:1 (v/v ratio) mixture of the 
bacterial suspension and melted 1 % SeaKem Gold agarose containing 1 % SDS and 0.5 
mg/ml Proteinase K. 
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The plugs were lysed in 5 ml lysis buffer containing: 50 mM Tris, 50 mM EDTA pH 
8.0, 1 % sarcosyl and Proteinase K to a final concentration of 0.1 mg/ml. The plugs 
were incubated at 54°C (150 rpm) for 2 h. After cell lysis, plugs were washed with 
preheated (50°C) 10 ml HPLC (high performance liquid chromatography) water twice, 
followed by four washes with 10 ml preheated (50°C) TE buffer (10 mM Tris, 1 mM 
EDTA pH 8.0). Each wash was incubated for 10 minutes in a shaking incubator (150 
rpm).  
Plugs were digested with 50 U (per sample) of XbaI for 2 hours at 37 ˚C, and reaction 
stopped by adding an equal volume (200 µl) of 0.5 x Tris-Borate EDTA buffer (TBE). 
The samples were run on a 1 % agarose gel in 0.5 x TBE buffer, a 0.5 x TBE running 
buffer (2.2 L) containing 1 ml thiourea (8 mg/ml). Electrophoresis was performed with 
a CHEF DR-II apparatus (Bio-Rad) with the following settings; an initial switch time of 
2.2 seconds with final switch time of 54.2 seconds, 6 V, 120˚ included angle for 18 
hours at 14 ˚C. The gels were stained with 0.8 µg/ml ethidium bromide and visualized 
under ultraviolet light using the AlphaImager™ system (Alpha Innotech).  
Salmonella Ser. Braenderup H9812 standards were used to estimate the band sizes 
(Hunter, Vauterin et al. 2005) and gel images were analysed using the BioNumerics 
software (Applied Maths, Sint-Martens-Latem, Belgium). Macro-restriction profiles 
were used to construct a Dice coefficient-based similarity dendogram using the 
BioNumerics program, Applied Maths, Sint-Martens-Latem, Belgium (Carrico, Pinto et 
al. 2005; Hunter, Vauterin et al. 2005; Karlowsky, Kasloff et al. 2007). 
2.4.3 Antimicrobial resistance array 
All 52 isolates were analysed using an oligonucleotide array tube, used to detect 
antimicrobial resistant genes in Gram-negative bacteria. The array platform 
(ArrayTube™ AMR05) is mounted at the bottom of a 1.5 ml microcentrifuge tube, with 
68 different probes printed in triplicate. These include 56 different oligonucleotide 
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probes for genes conferring resistance to aminoglycosides, β-lactams, chloramphenicols, 
macrolides, tetracyclines, quinolones, sulphonamides and trimethorpims, in addition to 
two integrase genes associated with class 1 and 2 integrons. Certain gene probes e.g. 
blaCTX-M, are represented by more than one probe to account for allelic variants (Anjum 
et al., 2011). 
2.4.3.1 Crude lysis  
The method was carried out as previously described (Anjum et al., 2011). Briefly, 
samples were plated onto nutrient agar plates and grown overnight at 37˚C. A 10 µl 
loopfull of bacteria was re-suspended in 400 µl of bacterial lysis buffer (0.1 M Tris-HCl 
pH 8.0, 0.05 % Tween 20, 240 mg/L proteinase K). Bacteria were lysed by incubating 
the suspension at 60˚C for 2 hours in a lysis buffer, followed by incubating the sample 
at 95 ˚C for 15 minutes. The lysates were centrifuged at 15000 g for 5 minutes and 6.55 
µl (1-2 µg) of the supernatant (crude extract) was used in subsequent linear multiplex 
DNA amplification reactions. 
2.4.3.2 DNA labelling 
The crude extract (6.55 µl) containing genomic DNA was added to a mix containing: 1 
µl dNTPs (1 mM dA/C/GTP and 0.65 mM dTTP; GE Healthcare), 0.1 µl Therminator 
DNA polymerase (2000 units/ml, NEB), 1 µl Therminator 10 x reaction buffer (NEB), 
0.35 µl Biotin-16-dUTP (1 mM, Roche), 1 µl primer mix (Indentibac) to a final volume 
of 10 µl for linear multiplex amplification. The amplification cycling conditions were as 
follows; 96 ˚C for 5 minutes, followed by 40 cycles of; 62 ˚C for 20 seconds, 72 ˚C for 
40 seconds and 96 ˚C for 60 seconds. 
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2.4.3.3 Hybridisation 
The hybridisation step was carried out as per the manufacturer’s instructions 
(www.identibac.com). Briefly; the array tube was initially preconditioned using 500 µl 
of water for 5 minutes at room temperature on an agitating thermomixer set at 550 rpm. 
This was followed by another 500 µl wash with a hybridisation buffer containing 1 M 
NaPOi, 20 % SDS, 0.5 M EDTA, 20 x SSC (0.3 M sodium chloride and 0.03 M sodium 
citrate) made up in water. 10 µl of the biotin labelled amplicon was added to 90 µl of 
the hybridisation buffer, which was heated for 1 minute at 95˚C and placed on ice for a 
further minute. The mixture was added to the array tube and incubated at 55˚C for one 
hour at 550 rpm. 
The array tube was washed with a low stringent wash containing 2 x SSC and 0.01 % 
Triton and placed in the thermomixer for 5 minutes at 40 ˚C (550 rpm). The tube was 
washed a further two times with buffers containing 2 x SSC and 0.2 x SSC incubated at 
40˚C and 30˚C respectively (550 rpm). 100 µl of freshly prepared 2 % blocking 
solution; 0.02 g of milk powder dissolved in 1 ml of 6 x SSPE (0.9 M saline, 0.06 M 
sodium phosphate and 0.06 M EDTA)/0.005 % triton buffer was added to the array tube 
and incubated for 15 minutes at 30 ˚C (550 rpm).  
2.4.3.4 Staining, detection and analysis 
Horseradish peroxidase conjugated to streptavidin was used to stain the hybridised 
biotin-labelled DNA. Staining is mediated by an enzyme catalysed reaction producing a 
coloured precipitate upon addition of the substrate Trimethylbenzene (TMB). 100 µl of 
freshly prepared poly-HRP streptavidin was prepared by diluting a 1.5 mg/ml stock of 
Streptavidin in a 1: 50 v/v ratio with 6 x SSPE/0.005 % Triton buffer to obtain a final 
concentration of 0.2 µg/ml. This was incubated at 30 ˚C at 550 rpm for 15 minutes. The 
array tube was washed as before in 2 x SSC/0.01 % Triton, 2 x SSC and 0.2 x SSC 
incubated at 30 ˚C and 20 ˚C for the latter two washes at 550 rpm. 
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To detect the bound DNA, 100µl of the peroxidise substrate TMB Seramun grϋn,  
(Diagnostica GmbH) was added to the chip, incubated for 10 minutes at room 
temperature. The images were captured and visualised using the ArrayMate™ 
(www.identibac.com). Figure 2-1 shows an example of the image generated from the 
array tube.  Signal intensity values were measured using the Iconoclust imaging 
software (www.identibac.com). Data was normalised against the signal intensity value 
of the ihfA positive control probe and the median values (signal substance) for each 
triplicate gene probe was used in subsequent analysis. 
From previously published data (Batchelor et al., 2008), normalised intensity values for 
the corresponding gene probes of value ≥ 0.4, were considered present whilst those < 
0.2 were considered absent. Values between 0.4 and 0.2 were considered as ambiguous. 
The purpose of normalization was to limit the sources of systematic variation that may 
affect signal intensity values e.g. non-specific binding to the probes. 
Normalised data was analysed using Genespring GX v7.3.1 (Agilent technologies) to 
cluster the results using the Pearson correlation coefficient.  
 
Figure 2-1: An example of the image generated using the ArrayMate™ imaging software. The cells 
were lysed and DNA amplified by linear multiplex PCR labelled with biotin. The amplicons were 
hybridized to the arrays and the signal intensity measured using the Iconoclust imaging software. There 
are 6 biotinylated spots (indicated by arrows) on the AMR05 chip, which serve as marker spots for array 
chip validation, 4 control genes: ihfA, gapA, dnaE and hemL. The ihfA gene probe was used to normalise 
signal intensity values, 56 antimicrobial resistance genes and 2 integrase associated genes. 
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2.4.4 Validation of array data by PCR 
PCR was used to validate the array results that conflicted with phenotypic data (see 
section 2.2 above). 5 µl of template DNA was added to a PCR reaction mixture 
containing 10 x PCR buffer (Promega M186B) containing 2 mM or 3 mM MgCl2 
depending on primer pair used to improve stringency, 2.5 Units of Taq polymerase 
(Promega M186B; 2500 Units), 10 mM of each dNTP, 20 µM of the forward and 
reverse primer and adjusted to a 50 µl reaction volume with nuclease free water. 
PCR cycling conditions for the validation PCR were as follows:  94 °C for 3 minutes, 
followed by 30 cycles of 95 °C for 30 seconds, annealing for 1 minute (annealing 
temperatures between 50 °C and 64 °C were used for the different PCR primers 
corresponding each antimicrobial resistance genes present on the probes), 72 °C for 1 
minute; and a final extension at 72 °C for 5 minutes. Fragments were run on a 1 % 
agarose gel, stained in 0.8 µg/ml ethidium bromide and visualized under ultraviolet light 
using the AlphaImager™ system (Alpha Innotech). 
 
2.4.5 PCR subtyping of blaCTX-M  
The strains were confirmed to harbour blaCTX-M by multiplex PCR, devised by 
Woodford et al., 2005 to identify the alleles as previously described. For the sequencing 
PCRs blaCTX-M group 9 (Sabate, Navarro et al. 2002) and group 1 specific primers 
(Carattoli, Garcia-Fernandez et al. 2008) or blaCTX-M universal primers (Batchelor et al., 
2005) were used to amplify the genes.  A 30 cycle program (for blaCTX-M group 1 and 9 
primers) or 35 cycle (blaCTX-M universal primers) with a 60°C annealing temperature 
was used to amplify amplicons with sizes: 849 bp (group 1), 836 bp (group 9) and 585 
bp (universal). The fragments were visualised on an agarose gel stained with ethidium 
bromide, extracted and purified using the Qiagen PCR purification kit (Cat. No. 28104) 
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as per the manufacturers instructions. Gene products were sequenced using the ABI 
PRISM sequence analyser (3700) and analysed using DNAStar LaserGene v 9 EditSeq. 
2.4.6 Genetic environment surrounding blaCTX-M genes 
Commonly associated with blaCTX-M genes is the insertion element, ISEcp1. Primers 
described by (Poirel, Gniadkowski et al. 2002) were used to amplify the ISEcp1 element 
upstream of blaCTX-M  group 1 encoding strains. Reverse primers described in (Sabate, 
Navarro et al. 2002) were used in conjunction with forward primers described by (Poirel, 
Gniadkowski et al. 2002) to amplify the ISEcp1 element upstream of  blaCTX-M group 9 
genes (see appendix for a list of primer sequences).  Briefly the PCR was performed as 
follows: 8 µl of crude lysates or 3 µl of purified DNA was used in a 50 µl reaction 
consisting of 5 µl 10 x reaction buffer (containing 15mM MgCl2), 10 mM of each dNTP, 
10 µM of each primer and 1 U of Taq polymerase. PCR conditions were as follows; 
94 °C for 5 minutes, 30 cycles of 94 °C for 25 seconds, 52 °C for 40 seconds, 72 °C for 
70 seconds and a final extension at 72 °C for 6 minutes. Fragments were run on a 1 % 
agarose gel, stained in 0.8 µg/ml ethidium bromide and visualized under ultraviolet light 
using the AlphaImager™ system (Alpha Innotech). 
2.4.7 Plasmid content analysis  
Plasmid DNA was isolated by alkaline lysis and phenol chloroform extraction as 
described above (Kado and Liu 1981). Plasmid DNA was run on a 0.8 % agarose gel in 
TBE buffer at 21°C (maintained using a BioRad cooling module) for 6 hours at 150 V. 
Plasmid DNA was visualised by staining with 0.8 µg/ml ethidium bromide and 
visualised under UV light. 
Plasmid sizes were estimated using E. coli 39R 861 (Threlfall, Rowe et al. 1986) and a 
DNA supercoiled ladder (2-16Kb, Sigma) as markers. Approximate plasmid sizes were 
calculated using the Rochelle method (Rochelle et al., 1986), which uses a multiple 
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linear regression of the molecular weight (kb log10), against the relative mobility (mm 
log10) and the reciprocal square root of the relative mobility (mm). Statistical analysis 
was carried out using the ANOVA (analysis of variance) tool in Excel, which separates 
the sum of squares (ss) into their components. The resulting table gives the regression 
coefficients, which were used to estimate the plasmid sizes using the quadratic equation 
below: 
Log10 Mr = a + b1 (log10 r) + b2 (1/r 1/2) 
Where Mr is the estimated molecular weight (kb), ‘r’ is the distance migrated (mm). ‘a’, ‘b1’ and ‘b2’ are the regression coefficients 
obtained from running the ANOVA statistical tool. 
2.4.8 S1 PFGE to size plasmids 
S1 nuclease PFGE is a method used to size plasmid DNA by linearizing the circular 
covalently closed macromolecules by introducing ‘nicks’ in the DNA. This method was 
used to screen transconjugants for strains harbouring single plasmids encoding blaCTX-M. 
Transconjugants that harboured more than a single plasmid were transformed into 
DH10B™ (Invitrogen) and/or E. coli K12 20R764 competent cells (prepared as 
described in section 2.2.6) and S1 PFGE repeated to confirm the presence of a single 
plasmid.  
The method of S1 nuclease digestion followed by PFGE was performed as described 
previously (Barton et al., 1995; Dierikx et al., 2010). Whole genomic DNA extraction 
was performed essentially as described by the standard PFGE protocol (PulseNet; 
section 2.4.2). Any modifications to the protocol are described. Bacterial suspensions 
were adjusted to OD610 1.6-1.7. Subsequent to bacterial lysis and washes, the plugs 
were equilibrated in 200 µl S1 buffer (0.5M sodium acetate (pH4.5), 2.8M NaCl, 45mM 
ZnSO4) for 15 minutes at room temperature. S1 nuclease (Promega Cat. No. M5761-
E576B) was diluted with fresh S1 buffer to a final volume of 100 µl, and this enzyme-
buffer mix was added to the plug already equilibrated in 200 µl of buffer to a final 
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volume of 300 µl and a final enzyme concentration of 8 U/plug. This reaction was 
incubated at 37 °C for 45 minutes exactly, when the reaction was stopped by adding 100 
µl of 1 x TBE buffer. Electrophoresis was conducted in a CHEF DR-II system using the 
following conditions: initial and final switch times; 1 and 25 seconds respectively, 
voltage 6 V, included angle 120 ° for 17 hours at 14 °C. Plasmids were sized using a 
low range PFGE marker (NEB Cat. No. N0350S). 
2.4.9 Plasmid incompatibility group typing  
Plasmid incompatibility (Inc) groups were determined of all isolates by a PCR-based 
replicon typing (PBRT) method described by Carattoli et al., 2005. This method was 
also applied to plasmids transferred by conjugation. Plasmids that were unable to 
conjugate, or transferred more than one plasmid were transformed into DH10B™ 
and/or E. coli K12 20R764 chemically competent cells (Invitrogen/ this study) 
according to the manufacturers’ specifications; and subsequently typed by PBRT. The 
method employed 3 simplex and 5 multiplex PCR reactions recognising FIA, FIB, FIC, 
HI1, HI2, I1-Ig, L/M, N, P, W, T, A/C, K, B/O, X, Y, F, and FIIA, the major 
incompatibility groups among Enterobacteriaceae (Carattoli et al., 2005). Briefly, 2 µl 
of DNA extract (plasmid or whole genome) or 5 µl of crude lysates were added to a 
PCR reaction containing 2.5 µl 10 x reaction buffer (with 15 mM MgCl2), 10mM of 
each dNTP, 50 µM of each primer pair (see appendix for a list of the primers), 0.5 U of 
Taq polymerase and made up to 25 µl with nuclease free water. All PCR amplifications 
were performed under the following conditions; 94 °C for 5 minutes, 30 cycles of 94 °C 
for 1 minute, annealing at 60 °C (52 °C for F simplex PCR) for 30 seconds, 72 °C for 1 
minute and a final extension step at 72 °C for 5 minutes. Products were run on a 2 % 
agarose gel and visualised under UV light. Positive controls used in this study were a 
gift from Dr. Alessandra Carattoli (ISS Rome, IT). 
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2.4.10 pMLST of IncI1 group 
Plasmids belonging to the IncI1 incompatibility group were further typed by multi-locus 
sequence typing (pMLST) methods described by (Garcia-Fernandez, Chiaretto et al. 
2008). Six plasmid genes involved in plasmid maintenance and replication were 
identified as markers for typing plasmids by pMLST; pill (254 bp), sogS (254 bp), ardA 
(342 bp), repI1 (104 bp) and trbA-pndC (812 bp). Crude lysates from field strains 
known to harbour an IncI1 plasmid were typed by this method. Briefly; 2 µl of DNA 
extract (plasmid or whole genome) or 5 µl of crude lysates were added to a PCR 
reaction containing 5 µl 10 x reaction buffer (with 15 mM MgCl2), 10mM of each 
dNTP, 50 µM of each primer pair (see appendix B for a list of the primers), 0.5 U of 
Taq polymerase and made up to 50 µl with nuclease free water. PCRs were performed 
as follows; 1 cycle at 94 °C for 5 minutes, 30 cycles of 94 °C for 30 seconds, 60 °C for 
30 seconds, 72 °C for 1 minute and a final extension at 72 °C for 5 minutes. Amplicons 
were purified using the QIAquick PCR purification kit according to the manufacturer’s 
instructions (Qiagen Cat. No. 28104). Using the online pMLST database 
(http://pubmlst.org/plasmid) alleles were assigned to sequence types (ST) based on the 
sequencing data (Jolley, Chan et al. 2004). 
2.4.11 Next Generation plasmid sequencing and annotation 
Plasmid DNA was extracted as previously described using a Qiagen large construct kit 
that uses a larger initial culture volume (500 ml) (Qiagen Cat. No. 12462). Plasmid 
DNA (5 µg DNA) was sent to the AHVLA Central Sequencing Unit for 454 Next 
Generation Sequencing using the GS FLX Titanium series, (Roche). The reads were 
assembled into contigs using the Newbler assembler software.  
All contigs generated from the 454 sequencing data were joined into a pseudomolecule 
with a linker sequence (NNNNNCACACACTTAATTAATTAAGTGTGTGNNNNN) 
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that puts stop codons in all six reading frames (J. C Venter institute). The contigs were 
annotated using RAST (Rapid Annotation using subsystems Technology), which 
predicted the open reading frames (ORFs) in addition to using the SEED framework to 
provide further functional annotation (www.rastdb.com). The sequences were annotated 
further using the BLAST non-redundant database from NCBI 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) against other published plasmid sequences and 
the annotation results compared to that generated from RAST. 
 Phenotypic methodology 2.5
2.5.1 Antimicrobial resistance phenotype 
Antimicrobial resistance phenotypes for all 52 isolates was determined using the disc 
diffusion assay (Davis and Stout 1971). Briefly, E. coli cultures were plated onto Iso-
sensitest agar  (Oxoid) and incubated overnight at 37 ˚C in the presence of the following 
antimicrobials: amikacin (AK, 30 µg), amoxycillin/clavulanic acid (AMC, 30 µg), 
ampicillin (AMP, 10 µg), ampramycin (APR, 15 µg), cefotaxime (CTX, 30 µg), 
ceftazidime (CAZ, 30 µg), ciprofloxacin (CIP, 1 µg), chloramphenecol (C, 10 µg), 
furazolidone (FR, 15 µg), gentamacin (CN, 10 µg), nalidixic Acid (NA, 30 µg), 
neomycin (N, 10 µg), streptomycin (S, 25 µg), sulphamethoxazole/trimethoprim (SXT, 
25 µg), compound sulphonamides (S3, 300 µg), tetracycline (TE, 10 µg). Zone sizes 
were interpreted using a ProtoZONE (Don Whitley Scientific) automated reader and 
resistance phenotypes assigned using breakpoints set by the British society of 
Antimicrobial Chemotherapy (BSAC) (Andrews 2001). 
2.5.2 Susceptibility testing 
Minimum inhibitory concentrations (MIC’s) of three β-lactams; ampicillin (amp), 
cefotaxime (ctx) and ceftazidime (caz), were determined using the agar dilution method 
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(Andrews 2001). Briefly, serial double dilutions of the selected β-lactams were prepared 
in distilled water. The range of antimicrobial dilutions was determined using the BSAC 
MIC breakpoints for Enterobacteriaciae as a guideline. The ranges used were as 
follows; amp: 1 - 1024 mg/L (BSAC breakpoint ≥16), caz: 0.5 - 512 mg/L (BSAC 
breakpoint ≥2), ctx 0.5 - 512 mg/L (BSAC breakpoint ≥2). Antimicrobials were 
reconstituted in distilled water, filter sterilised using 0.2 µM filters then serially diluted 
to make a series of eleven double dilution stocks used to determine MIC. Control plates 
did not contain any antimicrobial agents. Agar dilution plates were then prepared by 
mixing 10 ml antimicrobial stocks (double strength) with 10 ml of molten double 
strength Iso-senitest agar. 
The inoculum was prepared from an overnight culture (approximately 109 CFU/ml) 
grown for 16-18 hours in a 37 °C shaking incubator (200 rpm) and adjusted to 104 
CFU/ml by diluting with 0.1 M PBS (phosphate buffered saline) pH 7.2. A standard 104 
CFU (colony forming units) per spot was delivered using a multipoint inoculator. A 
control plate (with no antibiotic) and E. coli control strain NCTC 10418 was included in 
every MIC determination. All the plates were incubated for 18 hours at 37 °C and the 
MIC interpreted according to BSAC guidelines. 
2.5.3 Bacterial growth kinetics 
Bacterial growth kinetics was determined using FLUOstar OPTIMA plate reader (BMG 
LABTECH). Liquid cultures grown in 3 ml LB broth were re-suspended at 0.1 % (v/v) 
in minimal media (1 x MOPS; 1 M 3-N-morpholinopropanesulfonic acid, 0.132 mM 
K2HPO4, 0.4 % glucose) or LB broth and incubated in the FLUOstar OPTIMA at 37 °C 
for 24 h. In some instances the media was supplemented with antimicrobials to measure 
growth kinetics in the presence of ctx, caz or amp. Control media (no bacteria) was also 
present in triplicate as were three technical repeats for each strain. Absorbance was 
measured every 15 minutes at OD600. At least two biological repeats were performed for 
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each strain. Bacterial viability counts expressed as CFU/ml were taken at timed 
intervals (0, 2.5, 5 and 24 h) as previously described (see section 2.1.3). The area under 
the curve was calculated and a two-tailed T-test carried out to assess statistical 
significance.  
2.5.4 Plasmid system enzyme kinetics 
2.5.4.1 Cell lysis by osmotic shock 
E. coli BL21 competent cells were transformed with blaCTX-M harbouring plasmids as 
described previously. Overnight liquid cultures grown at 37 °C were harvested by 
centrifuging at 10,000 x g for 30 minutes at 4 °C. Cells were washed once in an equal 
volume of sodium phosphate buffer (0.01M NaPO4 pH 7) then pelleted at 10,000 x g for 
30 minutes at 4 °C (Hedberg et al., 1995).  
Cells were lysed by osmotic shock (Berg JO, 1981) by re-suspending the cells in 1/10 
original volume of 0.02 M TrisHCl buffer (pH 8.0) containing 20 % (w/v) sucrose and 
incubated for 10 minutes at room temperature. Cells were then subjected to a freeze 
thaw cycle to improve recovery of protein by incubating at -80 °C and thawed in a 
37 °C water bath, this process was repeated once more. Cells were centrifuged at 10,000 
x g for 30 minutes at 4 °C and the supernatant fraction was collected and stored at -
20 °C. 
2.5.4.2 Measuring protein concentration  
The total protein content [T.prot] was measured using the BCA protein assay kit 
(Thermoscientific), using BSA as a standard. 
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2.5.4.3 Determining the extinction coefficient of hydrolysed nitrocefin at 492nm 
The molar extinction coefficient (absorption coefficient) measures the amount of light 
absorbed by a substance at a given wavelength. Previously reported molar extinction 
coefficients of nitrocefin at various experimental conditions included 20 500 M-1cm-1 at 
492 nm (Heras, 2008; 370) and 15 000 M-1cm-1 at 482 nm (Perez-Llarena 1997; 179).  
The aforementioned molar extinction coefficients were determined at conditions that 
differ from this study. For this study the molar extinction coefficient was determined 
from fully hydrolysed nitrocefin in a final volume of 200 µl.Hydrolysis of nitrocefin 
(100 µM) was monitored at 492 nm over 10 minutes using Beckman Coulter's 
PARADIGM™ detection platform. Absorbance was monitored using a flatbottom 
microplate (IWAKI®; 3860-096), using a path length defined by the volume of liquid in 
the well. The pathlength (0.53 cm) was determined mathematically using the following 
formula:
Equation 1     V = πr2h 
 
r; radius (cm), h; pathlength, V; sample volume(cm3) 
 
The change in absorbance per minute was used to calculate the extinction coefficient of 
fully hydrolysed nitrocefin using the Beer Lambert Law (equation 2). The Beer-
Lambert law states that the absorbance is proportional to the concentration of a given 
substance dissolved in a given solution at a given wavelength: 
 
Equation 2     Aλ = εcl 
 
Aλ; absorbance, ε; molar extinction coefficient, c; molar concentration of substance, l; length of 
light path. 
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The molar extinction coefficient for nitrocefin was calculated to be 20 469 M-1cm-1 
under these conditions at 492nm, 25 °C ± 0.5 °C, 50 mM sodium phosphate buffer pH 
7.0. 
2.5.4.4 Determining β-lactamase activity 
β-Lactamase activity of the supernatant fraction was assayed spectrophotmetrically (λ= 
492 nm) in the presence of 100 µM nitrocefin (Calbiochem Cat. No. 484400) in 50 mM 
NaPO4 buffer (pH 7.0) (Hedberg et al., 1995).  The extracts were diluted appropriately 
to a measurable rate, typically 90 µl of protein extract was added to 10 µl of 100 µM 
nitrocefin in 50 mM sodium phosphate buffer (pH 7.0) to a final volume of 100 µl 
(Hedberg 1995; 39). All determinations were carried out in triplicate over a period of 10 
minutes (25°C) using a Beckman Coulter's PARADIGM™ detection platform.   
The β-lactamase activity of the crude extracts were measured as units of activity, where 
one Unit of β-lactamase is the amount of product formed per min in 1 ml of reaction at 
25 °C ± 0.5 °C, 50 mM sodium phosphate buffer pH 7.0(Bisswanger, 2004).  
The reduction of nitrocefin was monitored over 10 minutes and changes in absorbance 
at 492nm were plotted against time (in minutes). The gradient of the linear portion of 
the curve (OD/min) was used to calculate the enzyme activity per minute (or Units min-
1). The Beer-Lambert equation (equation 2) was used to calculate the Units of enzyme 
per minute using the determined molar absorption coefficient of nitrocefin, ε492=20 469 
M-1cm-1 (section 2.5.5.3), a path length of 0.27 cm; corresponding to the volume of 
liquid in the well was used and the OD/min. 
2.5.4.5 Determining the total enzyme concentration; [E]T 
The amount of enzyme (mg) produced in one millilitre was calculated by dividing the 
total enzyme activity (µmol min-1) by the specific activity (µmol min-1 mg-1) (Campbell 
and Farrell, 2006). The total enzyme activity and the total specific enzyme activity were 
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expressed as a measure in a 1ml reaction therefore the amount of enzyme could be 
expressed as mg ml-1. Molecular weights were estimated from amino acid sequences 
using the ExPASy PI/Mw computation tool, Swiss-Prot (http://web.expasy.org). The 
enzyme concentration (mol L-1) was calculated by dividing the concentration of enzyme 
(mg ml-1) by the molecular weight (g mol-1).  
 
2.5.4.6 Kinetic parameters of β-lactamase enzymes 
Crude lysates were used to assay for enzyme activity (Hedberg et al., 1995; Ocallaghan 
et al., 1972). Each well contained a total volume of 100 µl and the change in optical 
density at λ = 492 nm was measured at timed intervals for up to 15 minutes with a plate 
photometer (Paradigm Beckman Coultier). All determinations were carried out in 
triplicate. 
The reaction was started by addition of 90µl of 1U of β-lactamase (crude lysate) with a 
multichannel pipette. The initial rates of hydrolysis (v0) were determined over a range of 
nitrocefin concentrations (10 µM to 400 µM) in 50 mM NaPO4 buffer (pH 7.0, 25 ± 
2 °C) (see Fig. 2-). 
 
Figure 2-2: Layout of plate used to determine kinetic parameters of β-lactamase in the presence of 
nitrocefin. The β-lactamase activity was monitored following the reduction of nitrocefin at varying 
concentrations (10 – 400µM) measured at λ = 492nm in a 100 µl volumetric reaction. The reaction was 
measured at timed intervals for up to 15 minutes with a plate photometer. BL21_TF denotes the crude 
extracts of BL21 bacteria harbouring the CTX-M producing plasmids. 
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The initial velocity was determined by plotting absorbance readings (A492) determined 
by monitoring the reduction of nitrocefin (see above) against time (s). The gradient of 
the linear portion of the curve gave the rate in abs min-1 (see Fig. 6-4). The mean rate, 
from three technical replicates, (abs min-1) at each concentration of substrate (10µM to 
400µM) was used to calculate initial velocity (v0) using the Beer-Lambert Law 
[Equation 2] and molar absorption coefficient (20 469 M-1cm-1) obtained from fully 
hydrolysed nitrocefin. 
Initial velocity values were plotted against substrate concentration and a Lineweaver-
Burk double reciprocal plot was used to estimate KM and VMAX values. KM and VMAX 
values were calculated for the plasmid free E. coli BL21 host strain to obtain residual 
enzyme efficiencies, which were subtracted from the KM and VMAX values of the strains 
harbouring blaCTX-M plasmids. The enzyme turnover or catalytic constant (KCAT) was 
calculated as a measure of the efficiency of the enzyme by dividing the VMAX by the 
total enzyme concentration [E]T .  
2.5.5 Biolog™ Phenotypic microarray 
The phenotypic microarray (Biolog, Inc.) assay was used to assess phenotypic effects of 
plasmid acquisition. Single colonies grown on LB agar plates were re-suspended in 
inoculating fluid (IF-0A; Biolog) containing a redox dye, supplemented with 20 mM 
sodium succinate, 2 mM ferric citrate and 2.5 mg/ml thiamine. The turbidity was 
adjusted to 85 % using a turbidity standard (Cat. No. 3431). The Biolog™ plates were 
inoculated with 100 µl/ well of the inoculum for each strain. Bacterial growth was 
monitored by a colourimetric assay monitoring the reduction of a tetrazolium dye 
(colourless) to formazan (purple) by the cellular respiration process. Plates were 
incubated at 37°C for 96 hours and growth or cellular respiration was measured every 
15 minutes using the OmniLog® reader by capturing a digital image, where the image 
pixilation was used to measuring the intensity of formazan (purple) dye present and 
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convert it to arbitrary units. Kinetic data (time versus OmniLog® signal) was analysed 
with the OmniLog-PM software and area under the curve (AUC) was calculated to 
assess substrate utilisation for each strain using the OmniLog® software. Wells without 
substrate (colourless) were used as negative controls for each plate.  
The AUC of the test wells was divided by the AUC negative controls wells (A1) to give 
a fold change relative to the negative control of each strain. The fold change from the 
plasmid free strains was subtracted from the strains harbouring the plasmid to give 
relative changes in metabolism between the two strains. The results were reported as 
differences in fold change relative to the plasmid free strain.  
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3 RESULTS CHAPTER 3: Characterisation of E. coli field isolates 
conferring resistance to 3rd generation cephalosporin’s 
3.1 Introduction 
The rapid rise in strains conferring resistance to new classes of antimicrobials has 
increased the need for monitoring and surveillance of antimicrobial resistance. 
Acquiring and managing information on the emergence and trends of resistance in 
bacteria of human and animal origin is vital in improving our understanding of 
resistance with respect to the use of antimicrobials in humans and animals. By 
monitoring the persistence and spread of resistance, intervention and policies regarding 
the prudent use of antimicrobials in treatment strategies may be applied to circumvent 
the further spread of resistance (McEwen S. A. 2006). 
In this chapter, the aim is to characterise field isolates from the United Kingdom, known 
to be ESBL producers, by determining the clonality of the E. coli strains harbouring 
blaCTX-M genes, identifying the associated antimicrobial resistance genes and mobile 
genetic elements that may contribute to the prevalence of these ESBL producing E. coli 
strains in cattle and through the food chain.  
3.2 Results 
3.2.1 Study isolates 
The isolates in this study were part of an enhanced surveillance programme conducted 
in England and Wales in 2007. The programme was introduced to monitor veterinary 
bacteria for the presence of ESBLs, as part of a larger surveillance strategy to detect, 
assess and respond to new and re-emerging animal related threats.  
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Prior to the studies to be reported in this thesis the ESBL field isolates had already been 
collected and characterised as containing blaCTX-M. The following section details the 
steps involved.  Samples were collected over regular time periods, sampled from 
individual animals (floor faeces) or environmental samples (unidentified faeces, slurry, 
water/feed troughs, rodent/bird droppings, collecting yard and driveways. Samples were 
tested against a panel of cephalosporins including; cefotaxime, ceftazidime cefoxitin, 
cefepime, ceftiofur, cefoperazone, cephalexin and imipenem, only the floor faeces (from 
Cattle) were found to confer resistance to at least on of these compounds.  
Susceptibilities were determined for these isolates and interpreted using the BSAC 
guidelines (www.bsac.org.uk). Isolates found to be resistant to one or more of these 
compounds at the AHVLA reference laboratories were selected for further analysis as 
part of the enhanced surveillance programme. The samples were subsequently screened 
for ESBL production at the Animal Health and Veterinary Laboratories Agency 
(AHVLA). This work was performed by colleagues at the AHVLA whom I am grateful 
to acknowledge here. 
 
Fifty-two E. coli isolates from the enhanced surveillance project, mainly from cattle 
faeces, with presumptive ESBL phenotypes were selected for this study. They represent 
a cross-section of isolates made from 3 specific farm visits in Pembrokeshire (n = 9), 
Dorset (n = 7) and Shropshire (n = 22), and from routine submissions made to the 
AHVLA regional laboratory network in Hertfordshire (n = 6) and Bedfordshire (n = 8) 
(see Table 3-1 for details). 
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3.2.2 Confirmatory identification of E. coli  
The isolates were plated onto brilliant green agar (BGA), containing phenol red 
indicator. The colonies appeared yellow/green in colour indicating the presence of 
lactose and sucrose fermentation, indicative of the E. coli species.  
 
Table 3-1: Details of isolates used in the study including; origin, sampling and host 
species. 
 
Isolate Origin species Animal group  Sample Location 
I1-21 Bovine Adult cows Field faeces Farm visit, Pembrokeshire 
I1-22 Bovine Adult cows Field faeces Farm visit, Pembrokeshire 
I1-23 Bovine Adult cows Field faeces Farm visit, Pembrokeshire 
I1-24 Bovine Adult cows Field faeces Farm visit, Pembrokeshire 
I1-25 Bovine Adult cows Field faeces Farm visit, Pembrokeshire 
I1-26 Bovine Adult cows Field faeces Farm visit, Pembrokeshire 
I1-27 Bovine Adult cows Field faeces Farm visit, Pembrokeshire 
I1-28 Bovine Adult cows Field faeces Farm visit, Pembrokeshire 
I1-29 Bovine Calf Floor faeces Farm visit, Pembrokeshire 
I1-30 Bovine Calf Faecal sample RVC labs, Hertfordshire 
I1-31 Bovine Calf Faecal sample RVC labs, Hertfordshire 
I1-32 Bovine Calf Faecal sample RVC labs, Hertfordshire 
I1-33 Bovine Calf Faecal sample RVC labs, Hertfordshire 
I1-34 Bovine Calf Faecal sample RVC labs, Hertfordshire 
I1-35 Bovine Calf Faecal sample RVC labs, Hertfordshire 
I1-36 Bovine Calf Floor faeces Regional labs, Bedfordshire 
I1-37 Bovine Calf Floor faeces Regional labs, Bedfordshire 
I1-38 Bovine Calf Floor faeces Regional labs, Bedfordshire 
I1-39 Bovine n/a Floor faeces Regional labs, Bedfordshire 
I1-40 Bovine Calf Floor faeces Regional labs, Bedfordshire 
I1-41 Bovine Calf Floor faeces Regional labs, Bedfordshire 
I1-42 Bovine n/a Floor faeces Regional labs, Bedfordshire 
I1-43 Bovine Calf Floor faeces Regional labs, Bedfordshire 
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Table 3-1: continued. 
 
Isolate Origin species Animal group  Sample Location 
I2-37 Bovine Milking cows Floor faeces Farm visit, Dorset 
I2-38 Bovine Milking cows Floor faeces Farm visit, Dorset 
I2-39 Bovine Milking cows Floor faeces Farm visit, Dorset 
I2-40 Bovine Milking cows Floor faeces Farm visit, Dorset 
I2-42 Bovine Milking cows Floor faeces Farm visit, Dorset 
I2-43 Bovine Collecting yard Environmental swab Farm visit, Dorset 
I2-45 Bovine Driveway Environmental swab Farm visit, Dorset 
I2-46 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-47 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-48 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-49 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-50 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-51 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-52 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-53 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-54 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-55 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-56 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-57 Bovine Weaned calves Floor faeces Farm visit, Shropshire 
I2-58 Porcine Pig Floor faeces Farm visit, Shropshire 
I2-59 Bovine Milking cows Floor faeces Farm visit, Shropshire 
I2-60 Bovine Milking cows Floor faeces Farm visit, Shropshire 
I2-61 Bovine Milking cows Floor faeces Farm visit, Shropshire 
I2-62 Bovine Milking cows Floor faeces Farm visit, Shropshire 
I2-63 Bovine Milking cows Floor faeces Farm visit, Shropshire 
I2-64 Bovine Milking cows Floor faeces Farm visit, Shropshire 
I2-65 Bovine Milking cows Floor faeces Farm visit, Shropshire 
I2-66 Bovine Milking cows Floor faeces Farm visit, Shropshire 
I2-67 Bovine Milking cows Floor faeces Farm visit, Shropshire 
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3.2.3 E. coli phylogrouping 
The phylogenetic background of each isolate was determined by a triplex PCR assay 
devised by Clermont et al., 2000. This classification method is based on sequence 
specific genes or DNA fragments thought to be specific to a phylogenetic group and 
uses a subtractive library from two E. coli strains to assign phylogenetic groups based 
on amplification of two genes; chuA, a gene required for heame transport in 
enteroheamorhagic O157:H7 E. coli (Torres and Payne 1997), yjaA; a gene involved in 
the cellular response to hydrogen peroxide and acid stress (Lee, Hiibel et al. 2010) and 
TSPE4.C2, a DNA fragment of unknown function identified from the subtractive library 
(Bonacorsi, Clermont et al. 2000). 
Based on the PCR amplicons identified, E. coli phylogenetic groups were assigned to 
the panel of 52 isolates. They belonged to all four phylogenetic groups with the most 
abundant phylogenetic group being group B1, with 46 % (n = 24) of isolates; 33 % (n = 
17) of strains belonged to group A, 11 % (n = 6) belonged to group D and finally 10 % 
(n = 5) of the isolates belonged to group B2. 
Figure 3-1 below describes the abundance of these groups relative to the region of 
isolation. Isolates from the Shropshire farm (n = 22) were largely represented by 
phylogroup B1 (n = 18) and the remaining four isolates from phylogroup A. Six of 
isolates from the Pembrokeshire farm (n = 9) belonged to phylogroup A, two from 
phylogroup B1 and one isolate belonging to phylogroup D. Isolates from the Dorset 
farm (n = 7) demonstrate the largest diversity of the three farms, with three of the four 
phylogroups represented; phylogroup D (n = 2), phylogroup B2 (n = 3) and lastly 
phylogroup A (n = 2). Isolates from the Hertfordshire region belonged to phylogroups 
A (n = 3), B1 (n = 2) and B2 (n = 1). All four phylogroups were represented in isolates 
from the Bedfordshire region with a quarter of the isolates (n = 2) belonging to group A 
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and B1, and three isolates belonging to phylogroup D and a single isolate from 
phylogroup B2.  
 
Figure 3-1: Map showing the regions to which the study isolates (n = 52) originated from and their 
respective phylogroups. The method of phylogenetic analysis was carried out as described by Clermont 
et al., 2000 using a triplex PCR to group the E. coli isolates into four main groups; A (blue), B1 (red), B2 
(green) and D (purple). 
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3.2.4 Molecular subtyping of E. coli isolates 
All 52 isolates used in this study were analysed by pulse field gel electrophoresis 
(PFGE), a molecular method used to cluster food borne disease pathogens for 
identification of common source for outbreaks. The isolates used in this study were 
subjected to XbaI PFGE analysis. Strain relatedness was calculated using the Dice 
coefficient (BioNumerics). Strains with the threshold linkage value at ≥ 81 %, were 
assigned the same type or subtype (denoted as numbers). Two strains were said to be of 
the same ‘subtype’ if they have identical banding patterns or of the same ‘type’ with up 
to six banding differences (Carrico, Pinto et al. 2005). Strain clusters were assigned 
letters (A-E), as shown in Fig. 3-2. Table 3-2 also shows the PFGE groups assigned 
using the Dice coefficient threshold.   
 
The highest similarity (≥ 81 % similarity threshold) belonged to isolates from the 
Shropshire farm (designated ‘S’), with 59 % (13/22) of the isolates assigned to this 
cluster (cluster E). Four other isolates from this region showed 60 % similarity to cluster 
‘E’ isolates. Clustering of the remaining isolates from this region (n = 5) demonstrated 
≤ 40 % similarity to the other isolates from this farm. Two of these isolates (I2-46 and 
I2-49) demonstrated approximately 85 % similarity to each other but with only 40 % 
similarity to cluster E isolates. Another isolate; I2-47 demonstrated a 35 % similarity to 
cluster ‘E’ Shropshire isolates, but with a higher similarity percentage (60 %) to I1-35, 
an isolate from the Hertfordshire region. Isolate I2-50 appeared to have undergone 
incomplete digestion, therefore clustering of this isolate could not be determined.  
 
Of the seven strains isolated from the Dorset farm (designated ‘D’); five were found to 
have 50 % similarity. The remaining two isolates, I2-40 and I2-37 were 40 % and 30 % 
similar to other isolates from this farm respectively (cluster D).  
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Isolates form the Pembrokeshire farm (designated ‘P’) were more variable with only two 
sets of isolates, I1-24 and I1-27 (cluster B) and I1-28 and I1-29 (cluster D), clustering 
together with 90 % and 95 % similarity respectively, suggesting a clonal origin. The 
remaining isolates from this region were found to have between 35 % and 40 % 
similarity to each other. 
 
Isolates from the Bedfordshire regional laboratories (designated ‘B’) were also variable 
with only two isolates clustered within the dice coefficient threshold (≥ 81 %), I1-42 
and I1-43 (cluster A). These demonstrated a 95 % similarity suggesting possible 
clonality. Two isolates, I1-38 and I1-40 (cluster B) demonstrated 80 % similarity. These 
stains fall outside the Dice coefficient criteria but can be designated as ‘possibly related’ 
strains (Tenover, Arbeit et al. 1995). The isolates from this region, when compared to 
each other, were found to have 35-40 % similarity with each other. 
 
Only two strains of the seven strains from the Hertfordshire regional laboratories 
(designated ‘H’) fulfilled the Dice coefficient criteria, I1-31 and I1-32 with 95 % 
similarity, suggesting possible clonality. The remainder of the strains belong to clusters 
B, C and D with only 30 – 50 % similarity with strains from this region. 
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Figure 3-2: PFGE macrorestriction profiles. Isolates were digested with XbaI and analysed by agarose 
gel electrophoresis. The dendogram shows sequence similarity from 20 % to 100 %. Superscripts adjacent 
to the isolate name denote farm locations; ‘P’; Pembrokeshire farm, ‘H’; Hertfordshire regional labs, ‘B’; 
Bedfordshire regional labs, ‘D’; Dorset farm, ‘S’; Shropshire farm. DNA relatedness was calculated using 
the Dice coefficient (BioNumerics). The dotted vertical line represents ≥ 81 % similarity threshold. 
Separated by the red dotted line, are Clusters A to E. The largest clusters of genetically related isolates are 
indicated by the box (solid line), from the Shropshire (80 % similarity) and Dorset (50 % similarity) 
farms. 
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3.2.5 Antimicrobial susceptibility 
Antimicrobial resistance phenotypes for all 52 isolates were determined by the disk 
diffusion assay. Susceptibility testing showed all isolates to be resistant to β-lactams, 
ampicillin (amp), cefotaxime (ctx) and ceftazidime (caz). Antimicrobial resistance 
phenotypic patterns varied greatly within isolates from the same farm; however isolates 
found to be epidemiologically indistinguishable (identical number of bands) by PFGE 
displayed the same phenotypic makers in most cases. This was true for isolates; I1-28 
and I1-29 (Pembrokeshire), I1-38 and I1-40, I1-42 and I1-43, from the Bedfordshire 
region and the E1 clusters of the Shropshire farm isolates, suggesting the clonal 
expansion of these strains within these regions (see table 3-2). 
Two isolates from the Hertfordshire region; I1-31 and I1-32, which were found to have  
95 % similarity, were found to have the same phenotypic markers indicative of their 
close genetic relation  
70 % (n = 15) of the isolates from the Shropshire farm had the same phenotypic markers 
of resistance characterised by a Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip profile (see 
table 3-2). These isolates were found to have ≥ 81 % similarity from their 
macrorestriction profile (Fig. 3-2), suggesting a possible clonal amplification of a strain 
harbouring these strains, however these strains were not identical.  
All but one isolate from the Dorset farm (cluster D) were found to harbour the same 
phenotypic markers  (amp, caz and ctx), however these strains were found to be related 
with ≤ 50 % similarity, suggesting that they may harbour the same mobile genetic 
element. Isolates from different regions; I1-21/26/24 (Pembrokeshire) and I1-30 
(Hertfordshire) and I1-28/29 (Pembrokeshire) and I1-33 (Hertfordshire), demonstrated 
similar phenotypic markers of resistance, but these strains were unrelated 
geographically, with the two regions lying in the West and East of the United Kingdom. 
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Table 3-2: Detailed results of E. coli phylogrouping, PFGE grouping and 
antimicrobial susceptibility assay on the isolates used in this study. 
!
Isolate Phylogenetic group PFGE type Associated antibiotic resistance markers 
Pembrokeshire Farm 
I1-21 B1 nd Te, Amp, Caz, S, Ctx 
I1-22 A B5 Na, Te, Amp, Caz, Sxt, S3, Ctx, Cip 
I1-23 D C1 Na, Te, N, Amp, Caz, Sxt, C, S, S3, Ctx 
I1-24 A B7 Te, Amp, Caz, S, Ctx 
I1-25 B1 A2 Amp, Caz, S, Ctx 
I1-26 A D10 Te, Amp, Caz, S, Ctx 
I1-27 A B7 Na, Te, Amp, Caz, Sxt, S, S3, Ctx, Cip 
I1-28 A D1 Amp, Caz, Ctx 
I1-29 A D1 Amp, Caz, Ctx 
Hertfordshire regional labs 
I1-30 B2 C2 Te, Amp, Caz, S, Ctx 
I1-31 A B3 Na, Te, Amp, Caz, C, S, S3, Ctx, Cip 
I1-32 A B4 Na, Te, Amp, Caz, C, S, S3, Ctx, Cip 
I1-33 B1 D8 Amp, Caz, Ctx 
I1-34 A B6 Na, Te, Amp, Fr, Caz, Stx, C, Cn, S, S3, Ctx, Cip 
I1-35 B1 C3 Te, N, Amp, Caz, S, S3, Ctx 
Bedfordshire regional labs 
I1-36 B1 B8 Te, Amp, Caz, Stx, S, S3, Ctx 
I1-37 B1 D9 Te, N, Amp, Caz, Stx, C, AmC, S, S3, Ctx 
I1-38 B2 B1 Te, Amp, Caz, Stx, S, S3, Ctx 
I1-39 D B2 Te, N, Amp, Caz, Sxt, S, S3, Ctx 
I1-40 D B1 Te, Amp, Caz, Sxt, S, S3, Ctx 
I1-41 D B9 Te, N, Amp, Caz, Sxt, C, S, S3, Ctx,  
I1-42 A A1 Na, Te, Amp, Caz, Sxt, C, AmC, S, S3, Ctx, Cip 
I1-43 A A1 Na, Te, Amp, Caz, Sxt, C, AmC, S, S3, Ctx, Cip 
Abbreviations:- Am;- Amoxycillin/clavulanic- acid,- Amp;- Ampicillin,- Ctx;- Cefotaxime,- Caz;- Ceftazidime,- Cip;- Ciprofloxacin,- C;-
Chloramphenicol,-Fr;-Furizolidone,-N;-neomycin,- -Na;-Nalidixic-acid,-Te;-Tetracyclin,-S;-Streptomycin,-Sxt;- sulphamethoxazole,-
S3;-compound-sulphonamide.-nd;-not-determined.-Phylogenetic-groups-include-A,-B1,-B2-and-D.-PFGE-clustering-is-indicated-by-a-
letter-(A-to-E)-followed-by-a-number-(1N10).$
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Table 3-2: continued:  
Isolate Phylogenetic group PFGE type Associated antibiotic resistance markers 
Dorset farm isolates 
I2-37 A A4 Amp, Caz, Cn, Ctx,  
I2-38 D D6 Amp, Caz, Ctx,  
I2-39 B2 D4 Amp, Caz, Ctx 
I2-40 B2 D2 Amp, Caz, Ctx 
I2-42 D D6 Amp, Caz, Ctx 
I2-43 B2 D4 Amp, Caz, Ctx 
I2-45 A D5 Amp, Caz, Ctx 
Shropshire farm isolates 
I2-46 B1 D3 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-47 A C4 Te, N, Amp, Caz, Sxt, C, AmC, S, S3, Ctx 
I2-48 B1 D7 Amp, Caz, Ctx 
I2-49 B1 D3 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-50 A nd Te, N, Amp, Caz, Sxt, C, AmC, S, S3, Ctx 
I2-51 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-52 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-53 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-54 B1 E2 Amp, Caz, Sxt, C, S3, Ctx 
I2-55 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-56 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-57 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-58 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-59 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-60 A E4 Te, N, Amp, Caz, Sxt, C, AmC, S, S3, Ctx 
I2-61 A E4 Te, N, Amp, Caz, Sxt, C, AmC, S, S3, Ctx 
I2-62 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-63 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-64 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-65 B1 E3 Amp, Caz, Ctx 
I2-66 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
I2-67 B1 E1 Na, Te, N, Amp, Caz, Sxt, C, S3, Ctx, Cip 
Abbreviations:- Am;- Amoxycillin/clavulanic- acid,- Amp;- Ampicillin,- Ctx;- Cefotaxime,- Caz;- Ceftazidime,- Cip;- Ciprofloxacin,- C;-
Chloramphenicol,-Fr;-Furizolidone,-N;-neomycin,- -Na;-Nalidixic-acid,-Te;-Tetracyclin,-S;-Streptomycin,-Sxt;- sulphamethoxazole,-
S3;-compound-sulphonamide.-nd;-not-determined.-Phylogenetic-groups-include-A,-B1,-B2-and-D.-PFGE-clustering-is-indicated-by-a-
letter-(A-to-E)-followed-by-a-number-(1N10).-
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3.2.6 Resistance gene profiles; characterisation of β-lactam encoding genes 
All 52 isolates were analysed using an oligonucleotide array tube, used to detect 
antimicrobial resistant genes in Gram-negative bacteria. The array consists of 68 
antimicrobial resistance genes. DNA microarray data confirmed the presence of one or 
more ESBL genes to be present in all the isolates, conferring resistance to β-lactams 
(blaCTX-M groups 1, 2, 8, 9 and 26); which reflected the susceptibility profiles observed 
in the disc diffusion assay (see Fig. 3-3 below).  
 
The Dorset farm isolates, previously found to harbour the same antimicrobial resistance 
markers (see table 3-2), were found to harbour blaCTX-M group 1 genes conferring 
resistance to β-lactams. 
Sixteen out of twenty-two isolates from the Shropshire region were found to encode 
blaCTX-M group 1 genes, with 13 of these isolates belonging to the E1 PFGE cluster. The 
remaining six isolates from this farm harboured blaCTX-M group 9 genes, four of which 
also harboured an additional β-lactamase gene, blaOXA-1. 
Pembrokeshire isolates were all found to harbour blaCTX-M group 1 genes, with all but 
one isolate harbouring additional β-lactamase genes; blaTEM-1 or blaOXA-1. Isolates from 
the Hertfordshire regional labs, also harboured blaCTX-M group 1 genes in addition to 
blaTEM-1 or blaOXA-1 in all but one of the isolates. 
Four of the eight isolates from the Bedfordshire regional labs harboured blaCTX-M group 
9 genes, three with additional blaTEM-1 genes (I1-36, I1-40 and I1-41) and I1-39 having 
both blaTEM-1 and blaOXA-1 genes. Only one isolate harboured a blaCTX-M group 1 gene 
with additional blaTEM-1 and blaOXA-1 genes. The remaining three isolates from this 
region; I1-38, I1-42 and I1-43, all harboured both blaCTX-M group 1 and group 9 genes in 
addition to a blaTEM-1 gene. 
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3.2.7 Resistance gene profiles; characterisation of non-β-lactam encoding genes 
Non-β-lactam genes included on the array platform confer resistance to 
aminoglycosides (aac, aad and strA/B), chloramphenicol/florfenicol (cat and floR), 
sulphonamides (sul), tetracycline (tet) and trimethoprims (dhfr). 75 % of the isolates 
were found to encode at least two or more non-β-lactam resistance genes. Interestingly 
none of the isolates from the Dorset farm harboured any non-β-lactam resistance genes 
(see Fig. 3-3 below).  
Often isolates found to have differing PFGE macrorestriciton profiles of ≤ 50 %, 
classified as unrelated, were found to have the same antimicrobial resistance genes. This 
was observed in isolates from the Shropshire region, namely D3 and E1 clusters (see 
table 3-3) suggesting non-clonal relationship. This was also observed in isolates I2-47, 
I2-50, I2-60 and I2-61, which all had differing macrorestriction profiles with similarities 
between 35 – 75 % (clusters C4 and E4) but with the same antimicrobial genes (see 
table 3-3). 
Interestingly, isolates from two different regions; Hertfordshire (I1-30) and 
Pembrokeshire (I1-21 and I1-24), also had the same antimicrobial genes: blaCTX-M-1, 
strB, blaTEM-1, tetA. These strains were isolated from the East (Hertfordshire) and West 
(Pembrokeshire) of the UK, with only 35 % similarity between them. Under the genetic 
relatedness scheme described by Tenover et al., 1995 these strains would be described 
as unrelated, further suggesting the transfer of these resistance markers by mechanisms 
other than clonal spread. 
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Figure 3-3: Antimicrobial resistant genes identified using miniaturized DNA microarray 
technology. Data was analysed with GeneSpring GX v7.3.1(Agilent technologies) and clustered using 
Pearson correlation coefficient. Red/yellow denotes genes present, blue denotes absent genes. All the 
isolates were found to encode either CTX-M group 1 (blaCTX-M-1, -15 and -32) or CTX-M group 9 
(blaCTX-M-14 and -14b) variants, with three isolates encoding both blaCTX-M-14 and -15 genes. 
Majority of the isolates also encoded other antimicrobial resistance determinants commonly found in 
multiple drug resistant bacteria. Abbreviations: aac6lb, aadA1, aadA2, aadA4, strA and strB confer 
resistance to aminoglycosides. catA1, catB3 and cmlA confer resistance to chloramphenicols. floR confers 
resistance to chloramphenicol/florfenicol. ctxM1, ctxM9, tem1 and oxa1 confer resistance to β-lactams. 
dfrA7, dfrA14, dfrA17 and dfrA19 confer resistance to trimethoprims. sul1, sul2 and sul3 confer resistance 
to sulphonamides. tetA and tetB confer resistance to tetracylcines. Int1 and Int2 are integrons (mobile 
genetic elements) commonly associated with antimicrobial resistance genes. 
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3.3 Phenotypic and genotypic correlation between antimicrobial resistance 
markers and phenotype represented using the disc diffusion assay. 
The antimicrobial susceptibility phenotype (determined by the disc diffusion assay) and 
genotype (determined by the array) were compared for all the isolates (see table 3-3). 
The phenotypic markers of resistance were grouped into the general class the 
antimicrobials fall into (aminoglycosides, β-lactams, chloramphenicols/florfenicols, 
sulphonamides, tetracyclines, trimethoprims and quinolones). The genotypic markers 
were also grouped into the antimicrobial class that the genes conferred resistance to: β-
lactams (blaCTX-M, blaTEM-1 and blaOXA-1), aminoglycosides (aac, aad and strA/B), 
chloramphenicols/florfenicols (cat and floR), sulphonamides (sul), tetracyclines (tet), 
trimethoprims (dhfr) and quinolones (qnr).  
Genotypic and phenotypic correlation with each antimicrobial group from the DNA 
array and susceptibility profiles of the field isolates was assessed using kappa statistics. 
Sulphonamides, trimethoprims and β-lactams scored kappa coefficients of 1, denoting 
‘perfect’ correlation. Aminoglycosides, chloramphenicols/florfenicols and tetracyclines 
showed very good correlation (≥ 0.8). Quinolones scored ‘poor’ correlation. This was 
investigated further (see below).  
Genes that were identified using the array but were absent for the phenotypic marker 
were amplified by PCR to confirm the presence of these genes. This is because some 
alleles were unable to be resolved by the array, possibly due to polymorphic differences 
in the genes, but the presence or absence could be confirmed by PCR. The confirmed 
genotypic profiles were used to construct table 3-3. 
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Table 3-3: Genotypic and phenotypic correlation of donor isolates 
 
Antimicrobial class Phenotype Genotype Kappa 
β-lactams 52 52 1 
Choramphenicol/Florfenicols 26 29 0.885 
Sulphonamides 32 35 0.875 
Trimethoprims 28 30 0.922 
Aminoglycosides 37 39 0.902 
Tetracylines 35 37 0.910 
Quinolones* 23 0 0 
 
The-kappa-coefficient-was-used-to-assess-the-correlation-between-phenotypic-and-genotypic-data-prior-to-validation-of-the-DNA-
array-genes-by-PCR.-Scores-of-1;-denote-complete-agreement-and-0-indicates-very-poor-correlation.-Scores-<-0.2-were-interpreted-
as-poor,-0.21-to-0.4;-fair,-0.41-to-0.6;-moderate,-0.61-to-0.8;-good-and-0.81-to-1;-very-good-correlation.-
 
3.3.1 Quinolone resistance 
The twenty-three isolates conferring resistance to quinolones (nalidixic and 
ciprofloxacin) did not harbour any plasmid mediated qnr resistance markers included on 
the DNA array (qnrA, -B and -S). These isolates were screened for mutations that give 
rise to quinolone resistance in the DNA gyrase (gyrA) and topoisomerase (parC) genes 
of the quinolone resistance determining region (QRDR) (Fig. 3-4 and 3-5). Single point 
mutations in the QRDR region gives rise to quinolone resistant strains, however this 
difference between wild type and mutant strains cannot be resolved by the array, as it 
cannot identify single base pair changes reliably. In cases where there was no 
correlation between the quinolone resistance susceptibility and array data, nucleotide 
sequencing was employed. All isolates except one, I1-27, were found to encode 
mutations within QRDR region of gyrA and parC. This strain was found to harbour the 
aac(6)lb aminoglycoside resistance gene that confers low level cross-resistance to 
fluoroquinolones in addition to its acetyl-transferase activity (Robicsek, Strahilevitz et 
al. 2006).  
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  AAC68570.1     GDVIGKYHPHGDSAVYDTIVRMAQPFSLRYMLVDGQGNFGSIDGDSAAAM 120  
 I1-27          --------------------------------------------------  
 I1-42          ------------L---N---------------------------------  
 I1-43          ------------L---N---------------------------------  
 I1-22          ------------L---N---------------------------------  
 I1-31          ------------L---N---------------------------------  
 I1-32          ------------L---N---------------------------------  
 I1-34          ------------L---N---------------------------------  
 I2-46          ------------L---N---------------------------------  
 I2-49          ------------L---N---------------------------------  
 I2-51          ------------L---N---------------------------------  
 I2-52          ------------L---N--------------------------------- 
 I2-53          ------------L---N---------------------------------  
 I2-55          ------------L---N---------------------------------  
 I2-56          ------------L---N---------------------------------  
 I2-57          ------------L---N---------------------------------  
 I2-58          ------------L---N---------------------------------  
 I2-59          ------------L---N---------------------------------  
 I2-62          ------------L---N---------------------------------  
 I2-63          ------------L---N---------------------------------  
 I2-64          ------------L---N--------------------------------- 
 I2-66          ------------L---N---------------------------------  
 I2-67          ------------L---N---------------------------------  
                                      
Figure 3-4: Sequence alignment of the GyrA gene that confers resistance to quinolones. 
Quinolone resistance determining regions were amplified by PCR and sequenced using the primers 
described in Rodriguez-Martinez et al., 2006. The QRDR substitution S83L (shaded black) confers 
resistance to quinolones. D87N (shaded grey) of the QRDR region, confers low level resistance to 
fluoroquinolones (Chen and Lo 2003; Kim, Park et al. 2009). This amino substitution does not alter the 
steriochemical structure greatly and is therefore unlikely to confer resistance to quinolones on its own. 
The GyrA reference sequence was obtained from the NCBI BLAST database; accession number 
AAC68570.1. 
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 ACI78115.1     FKKSARTVGDVLGKYHPHGDSACYEAMVLMAQPFSYRYPLVDGQGNWGAPDDPKSF 115 
 I1-27          -------------------------------------------------------- 
 I1-42          ------------------------K------------------------------- 
 I1-43          ------------------------K------------------------------- 
 I1-22          --------------------I----------------------------------- 
 I1-31          --------------------I----------------------------------- 
 I1-32          --------------------I----------------------------------- 
 I1-34          --------------------I-----------------------------------  
  I2-46          --------------------I-----------------------------------                
  I2-49          --------------------I----------------------------------- 
  I2-51          --------------------I----------------------------------- 
  I2-52          --------------------I----------------------------------- 
  I2-53          --------------------I----------------------------------- 
  I2-55          --------------------I----------------------------------- 
  I2-56          --------------------I-----------------------------------  
  I2-57          --------------------I-----------------------------------  
  I2-58          --------------------I-----------------------------------  
  I2-59          --------------------I-----------------------------------  
  I2-62          --------------------I----------------------------------- 
  I2-63          --------------------I-----------------------------------   
  I2-64          --------------------I-----------------------------------  
  I2-66          --------------------I-----------------------------------  
  I2-67          --------------------I-----------------------------------  
 
Figure 3-5: Sequence alignment of the ParC gene that confers resistance to quinolones. 
Quinolone resistance determining regions were amplified by PCR and sequenced using the primers 
described in Rodriguez-Martinez et al., 2006. 
The S80I substitution (shaded black) is an accessory QRDR substitution that gives rise to quinolone 
resistance. The E84K substitution (shaded grey) results in a positively charged amino acid from an 
otherwise negative charge (wild type), thought to decrease affinity to ciprofloxacin. The ParC reference 
sequence was obtained from the NCBI BLAST database; accession number ACI78115.1.  
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3.3.2 Plasmid content analysis 
Plasmid profiles were determined using gel electrophoresis (an example can be found in 
Fig. 3-6 overleaf). Plasmid sizes were calculated according to the method described by 
Rochelle et al.  
The results showed that all the isolates harboured at least one large plasmid (60-150 kb) 
(see table 3-4), with 65 % (34/52) of the strains harbouring two or more plasmids. The 
large plasmids are characteristic of multidrug resistant (MDR) plasmids, and further 
sequencing of selected plasmids was performed to gain insight into the mobile elements 
present on these plasmids (see Chapter 5). 
 
Plasmid size calculation: 
    Log10 Mr = a + b1 (log10 r) + b2 (1/r1/2) 
Where Mr is the estimated molecular weight, r is the distance migrated (mm) and a, b1 and b2 are the regression coefficients obtained 
from running the ANOVA statistical tool. 
 
 
3.3.3 Plasmid typing 
Plasmid incompatibility groups were determined by a PCR-based replicon typing 
method (PBRT) (Carattoli, Bertini et al. 2005). About half the isolates (n = 25) were 
found to harbour multiple replicons (two or more) with IncF plasmids (FrepB, IncFIA, 
IncFIB) being present in 54 % of the isolates; in addition to IncN, IncB/O, IncI1, IncK 
and IncP plasmids (see table 3-4). Fourteen isolates from the Shropshire farm (n = 22) 
were untypeable (14/22) using the PBRT scheme.  Isolates from the Dorset farm, that 
had indicated a single plasmid carriage correlated these findings by harbouring a single 
incompatibility group, IncN. 
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Figure 3-6: Representative gel picture of the plasmid profile used to estimate plasmid sizes of field 
isolates. A supercoiled ladder and plasmids from E. coli were used to estimate plasmid sizes.
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Table 3-4: Results of the plasmid profile analysis and PCR based replicon typing of 
the project isolates. 
Region isolated Isolate 
No. of 
plasmids Estimated plasmid Size (kb) PBRT 
Pembrokeshire 
Farm 
I1-21 2 80, 50 N, Y 
I1-22 3 150, 6, 4.5 F, FIA, FIB 
I1-23 4 140, 60, 10, 7 B/O, F, FIB, P 
I1-24 1 50 F, N 
I1-25 1 100 F, I1 
I1-26 1 55 N 
I1-27 1 50 F, FIA, FIB, N  
I1-28 2 100, 5.5 F 
I1-29 2 100, 5.5 F  
Hertfordshire 
regional labs 
I1-30 3 100, 50, 14 FIA, FIB, N 
I1-31 6 150, 50, 30, 6, 4.5, 3 F, FIA, FIB, N   
I1-32 6 150, 100, 50, 6, 4.5, 3 F, FIA, FIB, I1, N  
I1-33 2 80, 30 F, K 
I1-34 3 150, 50, 6 F, FIB, K, N  
I1-35 2 150, 80 F, FIA, FIB 
Bedfordshire 
regional labs 
 
I1-36 3 140, 80, 4 F  
I1-37 3 150, 100, 80 F, FIA, FIB, I1 
I1-38 5 150, 80, 58, 5.5, 3.8 F, FIA, FIB, I1, K   
I1-39 2 100, 80 B/O, F, FIB, P, Y 
I1-40 3 140, 80, 4 F, FIB 
I1-41 7 150, 140, 100, 80, 58, 5.5, 4.5 F, FIA, FIB, P 
I1-42 5 100, 80, 50, 5.5, 3.8 F, FIA, FIB 
I1-43 5 140, 100, 80, 5.5, 3.8 F, FIA, FIB 
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Table 3-4: continued. 
Region  Isolate 
No. of 
plasmids 
Estimated plasmid Size 
(kb) PBRT 
Dorset Farm I2-37 2 50, 4.5 N  
I2-38 1 60 N  
I2-39 1 60 N  
I2-40 1 60 N 
I2-42 1 60 N 
I2-43 1 60 N 
I2-45 1 60 N 
Shropshire Farm I2-46 1 70 - 
I2-47 6 120, 80, 60, 7, 5.5, 4.5 F, FIA, FIB, I1  
I2-48 2 100, 80 F, FIA, FIB 
I2-49 2 100, 60 - 
I2-50 5 100, 80, 7, 5.5, 4.5 F, FIA, FIB, I1 
I2-51 2 100, 60 - 
I2-52 2 100, 60 B/O 
I2-53 1 100 - 
I2-54 1 70 F 
I2-55 1 60 - 
I2-56 1 60 - 
I2-57 2 100, 60 - 
I2-58 2 100, 60 - 
I2-59 1 60 - 
I2-60 2 100, 80 F, FIA, FIB 
I2-61 5 100, 80, 7, 5.5, 4.5 F, FIA, FIB, I1 
I2-62 2 100, 60 - 
I2-63 2 100, 60 - 
I2-64 2 100, 60 - 
I2-65 1 80 F, FIB, I1 
I2-66 1 60 - 
I2-67 1 60 - 
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3.3.4 Sequence analysis of blaCTX-M variants and genetic environment 
surrounding blaCTX-M  
DNA microarray analysis detects five groups of CTX β-lactamases; groups 1, 2, 8, 9 
and 26. With over 80 allelic variants of CTX-M enzymes sequencing these genes was 
necessary to identify the variants represented within the isolates. blaCTX-M genes were 
amplified by PCR and sequenced. DNA sequences were compared against the BLAST 
non-redundant database from NCBI (www.ncbi.nlm.nih.gov/) and blaCTX-M variants 
subsequently assigned. As identified by the DNA array results, only two variants of the 
CTX-M enzymes were present; groups 1 and 9 (see table 3-5). The CTX-M group 1 
enzymes included variants: CTX-M-1, -15 and -32.  CTX-M group 9 enzymes included 
CTX-M-14 and a closely related variant CTX-M-14b, differing by only one amino acid 
substitution (A231V) (Navarro, Mesa et al. 2007). 
 
All the isolates from the Pembrokeshire farm and Hertfordshire regional labs were 
found to encode blaCTX-M-15 variants.  Half of the isolates from the Bedfordshire regional 
labs harboured blaCTX-M-14, a single isolate encoded blaCTX-M-15 and three isolates 
harboured both a blaCTX-M-14 and blaCTX-M-15 variants. All the Dorset isolates harboured 
blaCTX-M-1 variants. Unlike the other farm isolated strains (Dorset and Pembrokeshire), 
isolates from the Shropshire farm were found to harbour four types of CTX-M enzymes 
including: blaCTX-M-1 (n =1), -14 (n =1), -14b (n =5) and -32 (n =15). Interestingly, all the 
isolates in the E1 PFGE cluster and two from the D3 cluster encoded blaCTX-M-32.  
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3.3.5 Analysis of the additional mobile genetic elements harboured within the 
isolates 
3.3.5.1 ISEcp1 
The genetic environment surrounding the β-lactamase gene was analysed by PCR and 
67 % of the strains (n=35) were found to harbour the ISEcp1 insertion sequence element 
upstream of the β-lactamase gene (see table 3-5). Three of the isolates encoding both 
blaCTX-M-14 and blaCTX-M-15 genes were found to harbour the ISEcp1 element upstream of 
both β-lactamase genes. These elements may be on separate plasmids, as these strains 
were found to harbour multiple plasmids. 
3.3.5.2 Integrons 
Integron associated genes IntI1 and IntI2, part of the mobile genetic element (MGE) 
family, were also present in 52 % (n=27) of the isolates of which 20 of these were in 
isolates from region 5 (see table 3-5). IntI1 has been previously associated with 
sulphonamide resistance gene; sul1. This common association of sul genes with 
integrons is thought to contribute to the spread and persistence of sulphonamide 
resistance, despite restricted use of this drug class (Perreten and Boerlin 2003). 
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Table 3-5: Mobile genetic elements identified in the field isolates and associated resistance genes identified by micro-array analysis. 
Region isolated Strain CTX-M type ISEcp1  Integrons Associated antimicrobial genes identified by microarray analysis 
Pembrokeshire Farm I1-21 CTX-M-15 + - blaCTX-M-1, strB, blaTEM-1, tetA 
 I1-22 CTX-M-15 + intI1 aac(6')lb, aadA4, catB3, blaCTX-M-1, dfrA17, blaOXA-1, strA, strB, sul1, sul2, tetB 
 I1-23 CTX-M-15 + - catA1, blaCTX-M-1, dfrA7, dfrA17, strA, strB, sul2, blaTEM-1, tetA 
 I1-24 CTX-M-15 + - blaCTX-M-1, strB, blaTEM-1, tetA 
 I1-25 CTX-M-15 + - blaCTX-M-1, strB, blaTEM-1 
 I1-26 CTX-M-15 + - blaCTX-M-1, strB, blaTEM-1, tetB 
 I1-27 CTX-M-15 + - blaCTX-M-1, dfrA17, strB, blaTEM-1, tetA, tetB 
 I1-28 CTX-M-15 + - blaCTX-M-1, blaTEM-1 
  I1-29 CTX-M-15 + - blaCTX-M-1, blaTEM-1 
Hertfordshire regional labs I1-30 CTX-M-15 + - blaCTX-M-1, strB, blaTEM-1, tetA 
 I1-31 CTX-M-15 + - aac(6')lb, blaCTX-M-1, floR, blaOXA-1, strB, sul2, tetB 
 I1-32 CTX-M-15 + - aac(6')lb, catB3, blaCTX-M-1, floR, blaOXA-1, strA, strB, sul2, tetB 
 I1-33 CTX-M-15 + - blaCTX-M-1 
 I1-34 CTX-M-15 + - aadA4, blaCTX-M-9, dfrA17, strB, sul1, sul2, blaTEM-1, tetA 
  I1-35 CTX-M-15 + - blaCTX-M-1, strB, sul2, blaTEM-1, tetB 
Bedfordshire regional labs I1-36 CTX-M-14 + intI2 aadA1, aadA4, blaCTX-M-9, dfrA7, dfrA19, sul1, blaTEM-1, tetB 
 I1-37 CTX-M-15 + intI1 aadA1, blaCTX-M-1, floR, blaOXA-1, strB, sul1, sul2, blaTEM-1, tetB 
 I1-38 CTX-M-14 and 15 + + - aadA1, aadA4, blaCTX-M-1, blaCTX-M-9, dfrA1, dfrA17, sul1, sul2, blaTEM-1, tetB 
 I1-39 CTX-M-14 + intI1 aac(6')lb, aadA4, blaCTX-M-1, dfrA17, dfrA19, blaOXA-1, sul1, sul2, strA, strB, blaTEM-1 
 I1-40 CTX-M-14 + intI2 aadA1, aadA4, blaCTX-M-9, dfrA17, sul1, blaTEM-1, tetB 
 I1-41 CTX-M-14 + - catA1, blaCTX-M-9, dfrA17, dfrA19, strB, sul1, sul2, blaTEM-1, tetA  
 I1-42 CTX-M-14 and 15 + + intI2 aadA1, aadA4, blaCTX-M-1, blaCTX-M-9, dfrA1, dfrA17, floR, strB, sul1, sul2, blaTEM-1, tetB 
  I1-43 CTX-M-14 and 15 + + intI2 aadA1, aadA4, blaCTX-M-1, blaCTX-M-9, dfrA1, dfrA17, floR, strB, sul1, sul2, blaTEM-1, tetB 
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Table 3-5: continued 
 
Region  Strain CTX-M type ISEcp1  Integrons Associated antimicrobial genes identified by microarray analysis 
Dorset Farm I2-37 CTX-M-1 + - blaCTX-M-1 
I2-38 CTX-M-1 + - blaCTX-M-1 
I2-39 CTX-M-1 + - blaCTX-M-1 
I2-40 CTX-M-1 + - blaCTX-M-1 
I2-42 CTX-M-1 + - blaCTX-M-1 
I2-43 CTX-M-1 + - blaCTX-M-1 
I2-45 CTX-M-1 + - blaCTX-M-1 
Shropshire Farm I2-46 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-47 CTX-M-14b - intI1 aadA1, blaCTX-M-9, floR, blaOXA-1, strB, sul1, sul2, tetB 
I2-48 CTX-M-14 + - blaCTX-M-9 
I2-49 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-50 CTX-M-14b + intI1 aadA1, blaCTX-M-9, floR, blaOXA-1, strB, sul1, sul2, tetB 
I2-51 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-52 CTX-M-32 - intI1 aadA1, cmlA1, blaCTX-M-1, dfrA12, dfrA14, strB, sul3, blaTEM-1, tetA 
I2-53 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-54 CTX-M-1 - intI1 aadA1, blaCTX-M-9, dfrA1, floR, sul1 
I2-55 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-56 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-57 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-58 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-59 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-60 CTX-M-14b + intI1 aadA1, blaCTX-M-9, floR, blaOXA-1, strB, sul1, sul2, tetB 
I2-61 CTX-M-14b + intI1 aadA1, blaCTX-M-9, floR, blaOXA-1, strB, sul1, sul2, tetB 
I2-62 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-63 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-64 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-65 CTX-M-14b + - blaCTX-M-9 
I2-66 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
I2-67 CTX-M-32 - intI1 aadA1, aadA2, cmlA1, blaCTX-M-1, dfrA12, sul3, tetA 
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3.3.6 Analysis of β-lactam susceptibility 
The MICs were determined for all the strains against three β-lactams; ampicillin, 
cefotaxime and ceftazidime. The susceptibility profiles were compared for the strains 
producing the five CTX-M variants; CTX-M-1, -14, -14b, -15 and -32. In addition 
susceptibility profiles were compared for the three strains producing both the CTX-M-
14 and -15 enzymes.  Median MIC values were taken from each CTX-M variant 
producing strain and results presented in the graph below (see Fig. 3-7).  
The results indicate that all the CTX-M variants were equally resistant to ampicillin 
(MIC ≥ 1014 mg/L).  
CTX-M-14 producing isolates were found to have the lowest MIC values against 
cefotaxime (MIC 128 mg/L). CTX-M-1, -14b, -15 and -32 were shown to have higher 
cefotaxime MIC values at 256 mg/L, however the highest cefotaxime MIC values (512 
mg/L) were observed with the three strains harbouring both blaCTX-M-14 and blaCTX-M-15 
variants. 
CTX-M group 1 variants; CTX-M-15 and -32 were found to have the highest MIC 
values for ceftazidime at 512 mg/L and 256 mg/L respectively. However CTX-M-1 
producing strains, a member of the same CTX-M group had lower MIC values at 64 
mg/L. Strains harbouring CTX-M-14 and strains harbouring both CTX-M-14 and -15 
variants also gave MIC median values at 64 mg/L. 
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Figure 3-7: Detailed analysis of β-lactam susceptibility and CTX-M producing strains. MIC values 
were interpreted using the BSAC plate dilution method.  
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3.4 Discussion 
The isolates presented in this study were part of a collection from the enhanced 
surveillance study from two farms and submissions from 3 regional laboratories. 
Phylogenetic analysis of these isolates demonstrated the representation of all four major 
groups; A, B1, B2 and D (Herzer, Inouye et al. 1990). These isolates were not collected 
as a result of an outbreak and therefore it was not surprising that a majority (79 %) of 
the strains belonged to the commensal phylogenetic group A and B1. The B1 
phylogenetic group is unique because it is further divided into two subgroups; B1c and 
B1e. B1c falls into the commensal phylogroup A subtype and the subgroup B1e falls 
into the phylogroup E, a cluster of non-O157 EHEC, EAEC and ETEC pathogenic 
strains (Sims et al., 2011).  
Only 21 % of the isolates were found to belong to the pathogenic E. coli phylogroups D 
and B2, which typically harbour EPEC, UPEC, APEC and ExPEC strains (Sims et al., 
2011). These pathogenic strains can successfully colonize the gastrointestinal tract in as 
early as two week old calves (China et al., 1998). These pathogenic strains of E. coli are 
non-pathogenic to adult cattle; however EHEC (China et al., 1998; Mainil et al., 1987) 
and ETEC (Acres et al., 1977; Nagy and Fekete, 1999) strains have been identified as 
one of the major causes of neonatal calf diarrhoea, which can lead to high calf 
morbidity and mortality rates (Svensson et al., 2003).  
 
Through consumption of contaminated feed, water or other environmental sources, 
persistence of E. coli 0157:H7 in healthy adult cattle suggests a potential reservoir for 
these species (Besser et al., 2001; Brown et al., 2001; Carlson et al., 2009). Brown et al., 
2001 found that persistent colonisation of particular E. coli strains led to the increased 
efficiency in attachment to the endothelial cells (Carlson et al., 2009). This coupled to 
persistent shedding of the E. coli strains may lead to clonal expansion of a particular 
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subtype of E. coli, pathogenic or commensal (Carlson et al., 2009; Robinson et al., 
2009), which may be a reason for the abundance of some clones from the Shropshire 
and Dorset farms.  
 
Antimicrobial susceptibility profiles of these isolates revealed the presence of multiple 
antimicrobial resistance genes, both in the commensal and pathogenic strains. The 
successful dissemination of these E. coli strains within the farm by clonal expansion, as 
suggested by the PFGE profiles, consequently increases the incidence of spread of 
antimicrobial resistance through vertical transmission, this was observed in the strains 
isolated from the Shropshire and Dorset farms (Petersen, Christensen et al. 2006; 
Carlson, Nightingale et al. 2009; Johnson, Menard et al. 2009; Johnson, Johnston et al. 
2010; Woodford, Turton et al. 2011).  
 
Vertical transmission (clonal expansion) of strains harbouring antimicrobial resistance 
genes is viewed as an efficient vehicle of dissemination because of the already 
established niche, the ability to transfer (vertically) any associated mobile genetic 
element to daughter cells and thirdly the ability to act as a donor in the transfer of these 
mobile genetic elements through horizontal gene transfer (Carlson, Nightingale et al. 
2009; Woodford, Turton et al. 2011). 
 
Resistance to quinolones can be mediated by four chief mechanisms; 1) chromosomal 
mutations that occur in the quinolone resistance determining region (QRDR), 2) 
reduction in accumulation by active efflux, 3) acquired resistance collectively known as 
plasmid mediated quinolone resistance (PMQR) and 4) decreased uptake or increased 
efflux of quinolones, thought to be associated with the multiple-antimicrobial resistance 
(MAR) phenotype or other efflux systems such as AcrAB efflux pump or the plasmid-
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mediated quinolones efflux pumps, OqxAB and Qep. Expression of MarA, encoded 
within the mar operon, controls expression of over 60 chromosomal genes including 
genes that are involved in decreased influx (down-regulation of OmpF) or increased 
efflux (Hopkins, Davies et al. 2005, Kern et al., 2000, Nordman et al., 2008). The qnr 
genes confer the PMQR phenotype, although these resistance genes are though to confer 
a low-level resistance phenotype (Rodriguez-Martinez et al., 2003). Qnr proteins is a 
218 amino acid protein of the pentapeptide family that typically interacts with other 
proteins, binding to DNA gyrase and preventing the action of quinolones (Tran and 
Jacoby 2002). For the isolates examined in this study, none of the twenty-three isolates 
conferring resistance to quinolones (nalidixic and ciprofloxacin) were found to harbour 
the qnr gene from DNA microarray analysis (qnrA, B and S).  
 
Sequence analysis of the QRDR of the 23 isolates determined these isolates (n = 22) to 
harbour single point mutations in the target genes; gyrA and parC. The gene products, 
DNA gyrase and topoisomerase IV respectively, are targets for quinolones. DNA gyrase 
and topoisomerase IV are thought to be homologues of each other, with high amino acid 
sequence similarity in the QRDR region at the N-terminus (Peng and Marians 1993). 
Mutations in the QRDR region prevent binding of the quinolones to these enzymes, thus 
conferring resistance (Ouabdesselam, Hooper et al. 1995; Vila, Ruiz et al. 1996). 
 
A single isolate (I1-27) did not harbour any QRDR mutations, despite conferring 
resistance to quinolones. This strain was found to harbour an aminoglycoside resistance 
gene; aac(6’)-lb-cr by PCR analysis. This encodes an acetyl transferase enzyme that 
alters the drug by acetylation, thereby resulting in reduced binding to the ribosomes. 
However, Robicsek et al. described the ability for AAC(6’)-lb-cr to confer low level 
resistance to floroquinolones by acetylating the amino group in the piperzinyl group of 
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ciprofloxacin and is a plasmid mediated quinolone resistance (PMQR) trait (Robicsek, 
Strahilevitz et al. 2006).  
Antimicrobial resistance genes located on plasmids can be transferred efficiently from 
one host to another by horizontal gene transfer (HGT) and is thought to be a major 
contributor to the persistent dissemination of antimicrobial genes (Grohmann, Muth et 
al. 2003; Fluit 2005; Andam, Fournier et al. 2011). Multidrug resistance phenotypes 
have been associated with complex mobile genetic elements that enable their efficient 
transmission (Liebert, Hall et al. 1999). It is widely accepted that the rapid 
dissemination and consequently the prevalence of CTX-M β-lactamases is attributed to 
their association with mobile platforms including plasmids, integrons, and insertion (IS) 
elements (Canton and Coque 2006; Novais, Canton et al. 2006; Valverde, Canton et al. 
2006; Novais, Canton et al. 2007; Poirel, Naas et al. 2008; Vinue, Lantero et al. 2008; 
Woodford, Carattoli et al. 2009).   
 
Twenty-seven (52 %) of the isolates were found to harbour integrase genes (int1 and 
int2) found within class 1 and class 2 integrons respectively. Often located on plasmids, 
these gene capture systems incorporate open reading frames (gene cassettes) within 
them, facilitating expression of these genes (Hall and Collis 1998). Multiple 
antimicrobial resistance (AMR) genes can be found in tandem within integrons, making 
them vital contributors to multidrug resistance phenotypes (Hall and Collis 1998). 
Fifteen of the 27 int1 harbouring strains were found to have four AMR genes (dfrA12, 
aadA2, sul3 and cmlA1) recently identified in a class 1 integron (Sunde, Solheim et al. 
2008). This association of the sul3 and cmlA genes with class 1 integrons is thought to 
contribute to its rapid spread in the former case (Perreten and Boerlin 2003) and 
persistence of resistance to chloramphenicol’s in the latter case despite the cessation of 
use in food producing animals in 1988 (Gilmore 1986; de Jong, Thomas et al. 2012). 
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Previous studies have found blaCTX-M genes associated with complex sul1 harbouring 
class 1 integrons (Sabate, Navarro et al. 2002; Novais, Canton et al. 2006; Riano, 
Moreno et al. 2006; Vinue, Lantero et al. 2008). The genetic platform surrounding these 
blaCTX-M genes is thought to be a major factor in the dissemination of blaCTX-M genes 
(Canton and Coque 2006). 63 % of the isolates were found to harbour the IS element 
ISEcp1uspstream of blaCTX-M, including the strains harbouring two variants of blaCTX-M. 
ISEcp1-blaCTX-M genes have been associated with transposons and this is thought to be a 
means of gene acquisition by transposable events including conjugative transposition 
and by site specific homologous recombination, enabling inter and intra-cellular 
transfer of genetic material (Liebert, Hall et al. 1999; Poirel, Decousser et al. 2003; 
Canton and Coque 2006).  
The association of IS elements, integrons and transposons with plasmids is thought to 
be a major contributor to the evolution and spread of plasmids and the genes they carry. 
The strains in this study were found to harbour ISEcp1 elements upstream of blaCTX-M 
genes, in addition to integrons, capable of capturing antimicrobial gene cassettes and 
plasmids.  
Plasmids are commonly found to harbour multiple drug resistance genes (Watanabe 
1963). These are typically large plasmids (60kb to 400kb) conferring resistance to 
multiple drug classes (Boyd, Tyler et al. 2004; Garcia, Navarro et al. 2007; Welch, 
Fricke et al. 2007; Woodford, Carattoli et al. 2009). All the isolates in thus study were 
found to harbour at least one plasmid and showed a MDR phenotype. Plasmids have 
previously been found to harbour CTX-M β-lactamase genes, which are have been 
attributed with the rapid dissemination of these genes. CTX-M-9, -14, -15 and 32 are 
such β-lactamases thought to be associated with epidemic plasmids, which include 
narrow host range plasmids IncF, IncI, IncB/O and IncHI2 and broad host range 
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plasmids IncK, IncN and IncP (Cottell et al., 2011, Boyd, Tyler et al. 2004, Lavollay, 
Mamlouk et al. 2006; Novais, Canton et al. 2006, Valverde et al., 2009). The isolates 
included in this study were found to harbour multiple replicon types including both 
narrow (IncF, IncI, IncB/O) and broad host range (IncN and IncP) plasmids mentioned 
above, with the potential to transfer genetic material across different bacterial species. 
 
E. coli 0157:H7 strains which are pathogenic for humans have been found in mature 
cattle that show no obvious symptoms (Whipp, Rasmussen et al. 1994; Armstrong, 
Hollingsworth et al. 1996) are thought to be reservoirs of these pathogenic organisms 
(Armstrong, Hollingsworth et al. 1996). Similarly, in the panel of isolates chosen 32 % 
of the strains harbouring a multidrug resistance phenotype were found to belong to 
phylogroup A and another 46 % belonging to phylogroup B1; both groups have been 
associated with pathogenic E. coli. Non-pathogenic E. coli strains of bovine origin are 
thought to be able to colonize the human gut, if only temporarily, thereby increasing the 
chance of horizontal gene transfer resistance determinants (Marshall, Petrowski et al. 
1990; Oppegaard, Steinum et al. 2001). The ability for these non-pathogenic and 
pathogenic strains to harbour multiple drug resistance, adapt to new hosts and stabilise 
in the absence of selection are all factors that contribute to the persistence of resistance 
(Salyers and Amabile-Cuevas 1997; Blake, Hillman et al. 2003), make them potentially 
difficult to treat when human infection occurs.  
 
These results suggest the possible association of these resistance determinants on 
mobile platforms such as plasmids, thus enabling efficient horizontal transfer of 
resistance to other strains, in addition to vertical transfer by clonal expansion. 
Furthermore, the detection of these MDR phenotypes in both pathogenic and non-
pathogenic E. coli species, suggests the ability of E. coli to act as a reservoir of 
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resistance genes. In addition the presence of CTX-M-15 producing isolates, a variant 
commonly associated with human infections was observed in these isolates. This may 
have implications in the transfer of CTX-M-15 harbouring strains between humans and 
animals in close contact to these animals further aiding the dissemination of these ESBL 
producing strains. 
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4 RESULTS CHAPTER 4: Molecular characterisation of blaCTX-M 
encoding plasmids 
4.1 Introduction 
Work from the previous chapter has shown that the E. coli field isolates chosen for this 
study harbour a multidrug resistance phenotype, containing in most cases more than one 
antimicrobial resistance gene. In addition, these isolates were found to harbour multiple 
plasmids up to 150 kb in size.  
In this chapter the characteristics of blaCTX-M plasmids identified in the first chapter will 
be investigated. The plasmids were transferred to the same E. coli K12 host by 
conjugation or transformation in cases where conjugation was unsuccessful or in 
instances where multiple plasmids transferred across. Plasmid sizes were estimated 
using S1 nuclease PFGE and resistance profiles of the subsequent transconjugant or 
transformant was investigated using antimicrobial disc diffusion assays and miniature 
DNA microarray analysis.  
 
4.2 Results 
4.2.1 Identifying IncI1 plasmid phylogenetic relationship by plasmid multi-locus 
sequence typing 
In the previous chapter, the isolates were found to be a mixture of all four phylogenetic 
groups including commensal E. coli strains harbouring multiple plasmids. The field 
isolates were typed by the PCR based replicon typing (PBRT) method. Isolates that 
harboured IncI1 plasmids (see table 3.4) were typed by plasmid MLST (pMLST) to 
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determine the possible extent of evolution of the IncI1 plasmid harboured within the 
field isolates, which at the time this work was done only the IncI1 and IncH plasmid 
typing system were available (http://pubmlst.org/plasmid).  
Seven of the ten field isolates harbouring IncI1 plasmids were picked  for pMLST 
studies. These include; I1-25 (Pembrokeshire), I1-37, I1-42, I1-43 (Bedfordshire), I2-47, 
I2-50 and I2-61 (Shropshire).  Briefly, the pMLST method involved PCR amplifying 
and sequencing genes required for replication and maintenance, which include: pill, a 
gene within the pil locus involved in pilus biogenesis; sogS, a primase involved in 
discontinuous plasmid DNA replication; ardA, encodes a type-I restriction enzyme, 
repI1, the RNAI antisense regulating system in the IncI1 replication system and the 
intragenic trbA- pndC region involved in maintenance and plasmid transfer respectively 
(Garcia, Navarro et al. 2007). Amplicons were compared with known allelic variants 
and sequence types (ST) assigned using the pMLST database 
(http://pubmlst.org/plasmid) (see table 4.1). 
The I1-25 field isolate harbouring both blaTEM-1 and blaCTX-M-15 β-lactamases was 
assigned to ST 24, with additional resistance markers conferring resistance to 
sulphonamides. I1-37, assigned to ST 48, harboured three β-lactamase genes; blaCTX-M-
15, blaTEM-1 and blaOXA-1 but with no additional resistance markers apart from those 
conferring resistance to β-lactams; ampicillin (amp), ceftazidime (caz) and cefotaxime 
(ctx). I1-42 and I1-43 harboured two CTX-M enzymes; blaCTX-M-14 and blaCTX-M-15 in 
addition to blaTEM-1 were assigned to ST 31 of clonal complex (cc) 31; denoting the 
number of nucleotide differences between alleles and groups of isolates genetically 
related clusters differing by one or two loci respectively. I2-47, I2-50 and I2-61 isolates 
from the same farm were assigned to ST 38 of the cc-3 clonal complex. These strains 
harboured only the blaCTX-M-15 β-lactamase gene which conferred resistance to 
ampicillin, ceftazidime and cefotaxime. 
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Table 4-1: pMLST results of IncI1 harbouring of E. coli field isolates. 
 
Region Isolate Phylogroup Resistance 
markers 
β-lactamase pMLST 
Pembrokeshire 
farm 
I1-25 B1 Amp, Caz, S, 
Ctx 
blaCTX-M-15, blaTEM-1 ST 24 
Bedfordshire 
regional labs 
I1-37 B1 Amp, Caz, Ctx blaCTX-M-15, blaTEM-1, 
blaOXA-1 
ST 48 
Bedfordshire 
regional labs 
I1-42 A Amp, Caz, Ctx blaCTX-M-14, blaCTX-M-15, 
blaTEM-1 
ST 31 CC-
31 
Bedfordshire 
regional labs 
I1-43 A Amp, Caz, Ctx blaCTX-M-14, blaCTX-M-15, 
blaTEM-1 
ST 31 CC-
31 
Shropshire farm I2-47 A Amp, Caz, Ctx blaCTX-M-14b ST 38 CC-3 
Shropshire farm I2-50 A Amp, Caz, Ctx blaCTX-M-14b ST 38 CC-3 
Shropshire farm I2-61 A Amp, Caz, Ctx blaCTX-M-14b ST 38 CC-3 
 
Abbreviations: E. coli phylogroups were designated using the method described by Clermont et al., 2000 (see chapter 3, 3.2.3). 
pMLST (plasmid multi-locus sequence tying). Amp; ampicillin, Caz; ceftazidime, Ctx; cefotaxime. Sequence types (ST) assigned 
using http://pubmlst.org/plasmid database. Genetically related plasmids are given as clonal complex (cc). 
 
4.2.2 Plasmid characterisation 
Conjugation experiments were performed on all 52 isolates to determine if the CTX-M 
producing isolates harboured these and other antimicrobial resistance genes on plasmids 
and to what extent these were transferable. Plasmid transferability for all the strains was 
determined by in vitro conjugation experiments using a rifampicin (rif) resistant E. coli 
K12 (20R764) strain as a recipient. Transconjugants were selected on the basis of 
rifampicin and cefotaxime resistance. Of 52 donors, transfer was achieved with 49  and 
in these the presence of blaCTX-M genes confirmed by PCR amplification. Based on the 
initial donor and transconjugants counts, frequency of transfer rates were determined 
(see chapter 2; 2.2.6 for methodology). 
 
All 49 plasmids were able to transfer blaCTX-M harbouring plasmids by conjugation. The 
frequency of transfer rates; measured as the number of transconjugants (cfu/ml) per 
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initial recipient (cfu/ml) ranged between 1.02 x 10-2 (i.e. approximately 1 
transconjugant per 100 initial recipients) to 9.23x10-9 (approximately 1 transconjugant 
per 100 million initial recipients), see table 4-4 for the individual transfer rates. 
 
The plasmid content for each of the 49 resulting transconjugants was determined by the 
alkaline lysis method of Kado and Liu (1981) for estimating plasmid sizes (section 
2.3.1). The alkaline lysis method extracts plasmids predominantly in their covalently 
closed form, however, estimating plasmid sizes by this method is limited due to the 
different conformations of the plasmid that migrate at different speeds within the 
electrophoresis gel i.e. nicked open circular, covalently closed DNA, linear, supercoiled 
and denatured supercoiled DNA.  By this method 11 of the 49 transconjugants were 
identified as having multiple plasmids. These plasmids were later transformed into E. 
coli K12 (20R764), selected with cefotaxime and rifampicin. Transformants were 
obtained for all 11 of transconjugants that harboured multiple plasmids. In addition the 
three plasmids that could not conjugate were subjected to transformation into E. coli 
K12 and transformants selected in the presence of cefotaxime and rifampicin. All the 
resulting transconjugants (n = 38) and transformants (n = 14), representing blaCTX-M 
harbouring plasmids from the isolates were resized using S1 nuclease PFGE (method 
described in chapter 2; 2.3.8) (Dierikx, van Essen-Zandbergen et al. 2010). S1 nuclease 
linearizes the plasmid DNA by introducing ‘nicks’ in the DNA, thus enabling a more 
accurate method of sizing the plasmid using a linear DNA marker. A standard curve of 
the linear DNA marker sizes (kb) was plotted against the distance migrated (mm) and 
plasmid sizes were approximated from the resulting quadratic equation of the 
polynomial curve. Plasmids ranged in size from 28 kb (IncN) to 175 kb (IncF). The 
plasmids were grouped based on their Inc type and the average sizes of plasmids 
belonging to a particular Inc group was calculated (see Fig. 4-1). 
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Having ensured that each ESBL plasmid was in the same host background without other 
plasmids, it was now possible to type them by PBRT (PBRT) (Carattoli, Bertini et al. 
2005). Plasmid transfer rates were grouped according to their Inc group; IncF (including 
FIA and FIB) IncN, IncI, IncB/O, ‘untypeable’ (untypeable by this method) and co-
transfer plasmids (see Fig. 4-1).  
 
The non-conjugable plasmids (I1-39TF, I2-55TF and I2-66TF) from strains I1-39, I2-55 
and I2-66 were transformed into E. coli K12 (20R764). Two of the three non-
conjugable plasmids (I2-55TF and I2-66TF) could not be typed using the PBRT method 
and the third plasmid (I1-39TF) was found to harbour an IncF replicon (see table 4-4 for 
detailed results).  
 
IncF plasmids were found to have the highest transfer rates averaging at 8.00x10-4 with 
an average plasmid size of 80 kb. IncN (45 kb) and IncI1 (86 kb) averaged at frequency 
of transfer rates of 1.14x10-4 and 9.71x10-5, approximately eight times less efficient in 
transfer than plasmids of the IncF group. For plasmids from the Shropshire farm 14 of 
the 22 isolates were untypeable by the PBRT method.  Seven of the transconjugants 
from this region were found to have more than one plasmid and thus grouped under the 
co-transfer plasmids with a mean transfer rate of 2.83x10-8. The remaining seven with 
plasmid sizes averaging 61 kb, were found to have mean transfer rates of 4.48x10-6. 
Only one transconjugant was identified as harbouring the IncB/O (151 kb) group with 
the lowest transfer rates (4.62x10-8). 
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Thirteen transconjugants from different regions were found to harbour more than one 
plasmid suggesting that mobilisation of the ESBL plasmid may have been dependent 
upon characteristics of the plasmid itself. These varied in size, usually with one smaller 
plasmid and were not limited to particular Inc types (see table 4-3 for details). To 
calculate the average transfer rate of co-transferred plasmids, the sizes were arbitrarily 
separated into large (ranging from 86-175 kb) and small (ranging from 28-45 kb) and 
mean sizes determined to be 118 and 36 kb respectively. The transfer rate for co-
transferred plasmids was 2.83x10-8, approximately 30, 000 times less efficient than the 
IncF plasmids. 
0 2.0×10-4 4.0×10-4 6.0×10-4 8.0×10-4 1.0×10-3
IncF
IncN
IncI
Untypable
IncB/O
Co-transfer
4.48x10-6
2.83x10-8
4.62x10-8
9.71x10-5
1.14x10-4
8.00x10-4
151 kb
36 kb 118 kb
61 kb
86 kb
45 kb
80 kb
Frequency of transfer
In
co
m
pa
tib
ili
ty
 g
ro
up
in
g
 
Figure 4-1: Graphical representation of plasmid transferability rates and their respective plasmid 
incompatibility groups and their average plasmid sizes. Frequency of transfer rates were calculated as 
the number of transconjugants (cfu/ml) per initial donor (cfu/ml). Plasmids were typed by PBRT. Plasmid 
sizes were approximated using S1 nuclease PFGE and the mean values calculated for all the plasmids 
belonging to the particular Inc group. IncF (n =13) plasmids were found to be the highest frequency of 
transfer rates, followed by conjugative plasmids IncN (n =12) and IncI1 (n =3). Fourteen plasmids from 
the Shropshire region were untypeable by the PBRT method. Thirteen transconjugants were found to 
harbour more than one plasmid, these were grouped as co-transferred plasmids (see table 4-2 for details). 
Three plasmids were unable to conjugate and were not included in this data analysis. 
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4.2.3 Transferable phenotypic antimicrobial resistance markers 
To determine the overall co-transfer of resistance markers with the ESBL producing 
plasmids, resistance profiles of the field isolates were compared between the 
transconjugants/transformants harbouring blaCTX-M encoding plasmids (selected with 
cefotaxime) and the field isolates. For this the antimicrobial resistance profiles for all 49 
transconjugants and the three transformants that were unable to conjugate, were 
determined using the disc diffusion assay against a panel of 16 antimicrobials (see 
methodology section 2.4.1).  
The percentage of co-transferred resistance markers was calculated as the number of 
antimicrobial class markers (i.e. β-lactams, aminoglycosides, chloramphenicols, 
trimethoprims, sulphonamides, quinolones and nitrofurans) present in each 
transconjugant/transformant (recipient) divided by the number present in their donor; 
72 % of the markers were found to co-transfer with the ESBL phenotypic markers (amp, 
ctx and caz), irrespective of plasmid Inc group (Fig. 4-2). 
 
All the isolates were found to have markers of β-lactam resistance, conferring resistance 
to ampicillin and cefotaxime (table 4-2). Interestingly only 35 % (n = 18) of the 
transconjugants were found to be no longer resistant to ceftazidime. Resistance to the 
aminoglycosides (amikacin, apramycin, gentamacin, neomycin and streptomycin) was 
the most abundant resistance phenotype, present in 75 % (n = 39) of the field isolates 
but of these 62 % of these markers (n = 24) were present in the resulting 
transconjugant/transformant derivatives. Interestingly resistance to this class of drugs 
was limited to markers conferring resistance to streptomycin only (n = 10), neomycin 
only (n = 13) and gentamicin and streptomycin (n = 1). 
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Thirty-two field strains conferred co-resistance to sulfamethoxazole/trimethoprim (SxtR) 
and compound sulphonamide (S3S), a marker for resistance to both sulphonamides and 
trimethoprims; 66 % (n = 21) of these resistance makers were transferred to the 
resulting transconjugant/transformants. 
 
Tetracycline resistance was the third most common resistance maker in the field isolates, 
with 73 % (n = 38) of the strains conferring resistance to tetracycline (TetR); 53 % of 
plasmids transferred this resistance phenotype (n = 20), associated with the IncN, IncF 
and untypeable plasmid groups.  
 
Chloramphenicol resistance (CR) markers were present in 54 % (n = 28) of the isolates. 
Only half (n = 14) of these markers of resistance were present in the 
transconjugant/transformant derivatives.  
 
Twenty-three donor field strains (44 %) were found to harbour markers that confer 
resistance to quinolones. Interestingly, four strains were able to transfer resistance to 
quinolones; nalidixic acid and ciprofloxacin (see table 4-4). This was unusual because 
resistance to quinolones were previously found to be a result of chromosomal mutations 
(chapter 3), however these were transferred into an E. coli K12 background and no 
known plasmid mediated quinolone resistance genes were identified by the DNA 
microarray analysis (see section 4.2.4).  
Only one field isolate was resistant to the nitrofuran; furazolidone (Fr). This resistance 
marker was transferred to the transconjugant (I1-34TC); which incidentally had 
multiple plasmids. When the ESBL was transformed into E. coli K12 (I1-34TF), this 
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resistance phenotype marker was not transferred. Collectively these data suggest the two 
markers, ESBL and Fur were not on the same replicon. 
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Figure 4-2: Schematic representation of transferable antimicrobial resistance markers determined by disc diffusion. Represented are phenotypic profiles for the donor 
isolates, transconjugants (TC) and transformants (TF) of plasmids that transferred multiple plasmids during conjugation. Abbreviations: Sulf/Trimeth: 
Sulfamethoxazole/trimethoprim. ND: not done. 72 % of the resistance markers were found to be transferable. 
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Figure 4-2: continued.  
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4.2.4  Transferable genes of resistance  
In order to define the genetic basis of the resistances that were in the donor field isolates 
and those associated with the ESBL, DNA microarrays were carried out (see Fig. 4-4). 
All the plasmid-harbouring derivatives were found to harbour blaCTX-M group 1 or 9 
genes. Seventeen (32 %) of the CTX-M producing plasmids had no additional resistance 
markers aside from blaCTX-M, in agreement with the phenotypic data. Additional genes 
that confer resistance to β-lactams; blaTEM-1 and blaOXA-1 were present in 34 % (n = 18) 
and 6 % (n = 3) of the transferred plasmids respectively. 
Fifty-eight percent of blaCTX-M plasmids transferred had additional multidrug resistance 
gene profiles and this was to be anticipated given the data arising from the phenotypic 
assays described above. Other antimicrobial resistance genes include markers that 
associated with aminoglycoside resistance; aadA2 (27 %), strB (13 %), aadA4 (12 %), 
strA (8 %) and aac(6)’lb  (8 %). Frequently detected sulphonamide and trimethoprim 
resistance genes included: sul3 (27 %), sul1 (13 %), sul2 (2%) and dfrA12 (23 %), 
dfrA17 (13 %) and dfrA14 (2 %) respectively. Genes associated with resistance to 
tetracyclines included; tetA (35 %) and tetB (4 %). Markers for 
chloramphenicol/florfenicol resistance included cmlA1 (27 %) and catA1 (2 %).  
Only sixteen (45 %) of the plasmids were found to harbour the integrase associated 
gene (int1), 7 % less than the donor field isolates. A majority (n = 14) were harboured 
within the plasmids from a single farm (Shropshire region). Interestingly, no int2 
integrase associated genes were observed in blaCTX-M encoding plasmids. 
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Figure 4-3: Antimicrobial resistant genes identified in the transferred plasmids using miniaturized 
DNA microarray technology. Data was analysed with GeneSpring GX v7.3.1(Agilent technologies) and 
clustered using Pearson correlation coefficient. Red/yellow denotes genes present, blue denotes absent 
genes. The plasmids were grouped into 7 groups based on Pearson coefficient clustering. All the plasmid 
harboured either blaCTX-M group 1 or 9 genes. 
Abbreviations: aac6lb, aadA1, aadA2, aadA4, strA and strB confer resistance to aminoglycosides. catA1, 
catB3 and cmlA confer resistance to chloramphenicols. floR confers resistance to 
chloramphenicol/florfenicol. ctxM1, ctxM9, tem1 and oxa1 confer resistance to β-lactams. dfrA7, dfrA14, 
dfrA17 and dfrA19 confer resistance to trimethoprims. sul1, sul2 and sul3 confer resistance to 
sulphonamides. tetA and tetB confer resistance to tetracylcines. Int1 and Int2 are integrons (mobile 
genetic elements) commonly associated with antimicrobial resistance genes.  
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4.2.5 Gene clustering 
Seven major gene clusters were identified in blaCTX-M encoding plasmids, clustered 
using the Pearson correlation coefficient (see Fig. 4-4). 
Group 1: This group included nine plasmids (IncI1, F and N) harbouring the blaCTX-M-1 
gene only and included plasmids from donor isolates from three different regions, 
Bedfordshire, Hertfordshire and Dorset. Interestingly, only the Dorset field isolates 
clustered together when analysing the donor strains (see chapter 3).  
Group 2: Eight plasmids (IncI1, F and untypeable) clustered together harbouring only 
blaCTX-M-9 gene only and were from donor field isolates from the Shropshire farm. These 
plasmids were previously clustered together in the donor field strains although 
additional resistance genes were present but clearly not associated with the blaCTX-M-9 
gene. 
Group 3: Six plasmids (IncF and N) were clustered together in this group harbouring 
blaCTX-M-1 and blaTEM-1. The plasmids in this cluster were primarily from the 
Pembrokeshire field isolates and one plasmid was from the Dorset farm. Interestingly 
the Pembrokeshire field isolates from this group were clustered with other donor field 
isolates from this farm, but after transformation/conjugation, now clustered in group 4, 
encoding strB and tetA genes in addition to the ESBL genes transferred by plasmids.  
Group 4: This group included six plasmids (IncF and N) harbouring the ESBL gene, 
blaCTX-M-1 in addition to blaTEM-1, strA, strB and tetA. These plasmids were from strains 
isolated from Pembrokeshire (n = 6) and Hertfordshire (n = 1). 
Group 5: Five plasmids (all IncF), all from donor field strains isolated in the 
Bedfordshire region, harboured blaCTX-M-9, blaTEM-1, aadA4, dfrA17 and sul1 multi-drug 
resistance genes. These plasmids also clustered together when the genes for the donor 
field isolates were analysed. 
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Group 6: Four plasmids (IncFIA-FIB and N) were clustered in this group; three 
plasmids from the Pembrokeshire (n = 1) and Hertfordshire (n = 3) field isolates. Genes 
included, blaCTX-M-1 and blaOXA-1 in addition to the aminoglycoside- quinolone cross-
resistance gene aac(6)’lb. I1-34TF and I1-22TF harboured additional resistance markers 
aadA4, dfrA17, sul1, tetB and intI. The I1-34TF plasmid encoded three additional 
resistance genes, catA1 and blaTEM-1. These plasmids also clustered together in the DNA 
array analysis for the field isolates, but upon transfer lost all lost strA, strB and sul2 
genes between them.  
Group 7: The largest cluster of plasmids (n = 14) was derived from the Shropshire farm 
isolates. These plasmids, one IncB/O and the remaining unytypeable, encoded several 
multi-resistance genes including; aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA and 
int1. The I2-52TC plasmid harboured four additional resistance genes including, dfrA14, 
strB, sul2, and blaTEM-1. All plasmids found to cluster together from this farm in the 
transconjugants/transformants, were also grouped together in the analysis of genes of 
the donor field isolates, found with the same resistance genes, suggesting the same 
plasmid may be responsible for the transfer of resistance genes in this farm. 
 
4.2.6 Genotypic and phenotypic correlation  
Genotypic and phenotypic correlation with each antimicrobial group from the DNA 
array and susceptibility profiles of the transconjugants/transformants was assessed using 
kappa statistics. Sulphonamides, trimethoprims and β-lactams scored kappa coefficients 
of 1, denoting ‘perfect’ correlation. Aminoglycosides, chloramphenicols/florfenicols 
and tetracyclines showed very good correlation (≥ 0.8). Quinolones scored ‘poor’ 
correlation because of resistance due to mutations in topoisomerase genes rather than 
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qnr genes, which were present on the array; however four plasmids (all transconjugants) 
conferred resistance to quinolones.  
Genes that were identified using the array but were absent for the phenotypic marker 
were PCR amplified to confirm the presence of these genes on the plasmids. This is 
because some alleles were unable to be resolved by the array, but presence/absence 
could be confirmed by PCR. The confirmed genotypic profiles were used to construct 
table 4-4. 
 
Table 4-2: Genotypic and phenotypic correlation between transferred plasmids 
 
Antimicrobial class Phenotype Genotype Kappa 
β-lactams 52 52 1 
Choramphenicol/florfenicols 15 18 0.867 
Sulphonamides 21 21 1 
Trimethoprims 21 21 1 
Aminoglycosides 24 28 0.885 
Tetracylines 20 22 0.92 
Quinolones* 4 0 0 
 
The kappa coefficient was used to assess the correlation between phenotypic and genotypic data prior to validation of the DNA 
array genes by PCR. Scores of 1; denote complete agreement and 0 indicates very poor correlation. Scores < 0.2 were interpreted as 
poor, 0.21 to 0.4; fair, 0.41 to 0.6; moderate, 0.61 to 0.8; good and 0.81 to 1; very good correlation. 
 
4.2.7 Co-transfer plasmids 
Eleven plasmids were co-transferred during the original conjugations with selection for 
the transfer of the ESBL phenotype. Multiple plasmids present in these transconjugants 
were identified and sizes estimated by the alkaline lysis method described by Kado and 
Liu (1981). All 11 plasmids were transformed and the antimicrobial gene profiles of the 
resulting blaCTX-M plasmids assessed (see table 4-3).  
Eight plasmids that harboured quinolone resistance markers (CipR and NaR) became 
susceptible to these antimicrobials once transformed into their E. coli hosts (K12 or 
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DH10). This suggests, the resistance determinant may have been encoded on the other 
plasmids co-transferred with the transformed blaCTX-M plasmid. These could include 
allelic variants of the qnr genes not included on the AMR05 DNA array chip e.g. qnrC  
and qnrD.  
Three donor strains (I2-47, I2-46 and I2-64) transferred two plasmids, a single ‘large’ (> 
60kb) and a smaller plasmid (< 60kb). I2-47TC harboured an 86 kb IncI1 plasmid and a 
35 kb plasmid untypeable by the PBRT method. DNA array analysis of the 
antimicrobial genes of the transconjugants (harbouring both plasmids) and the 
transformant (harbouring the 35 kb plasmid) revealed both plasmids to encode only 
blaCTX-M group 9 genes and no other resistance genes. Two transconjugants; I2-46TC 
and I2-64TC, each harboured two plasmids; 111 kb, 45 kb and 90 kb, 40kb respectively, 
all untypeable by the PBRT scheme. These plasmids harboured the same resistance 
genes, however their phenotypic profiles showed I2-46TC to confer resistance to 
nalidixic acid (Na) and ciprofloxacin (Cip). blaCTX-M genes were found to be encoded on 
the smaller 45 kb (I2-46TC) and 40kb (I2-64TC) plasmids respectively. 
 
I1-40TC was found to harbour two large plasmids; 156 kb and 122 kb, both belonging 
to the IncF group. The plasmids were subjected to S1 nuclease digest and run on a 
PFGE and bands corresponding to the two plasmids extracted. PCR amplification of 
blaCTX-M group 9 genes suggested that both plasmids harboured this gene. The 
transformant and transconjugant were found to have the same susceptibility profile and 
belonged to the same Inc group (IncF), suggesting these may be the same plasmid 
migrating at different speeds, as an artefact of agarose gel separation. This would 
explain the existence of these similar plasmids, of the same Inc group, in the same cell, 
which by definition would be unable to co-exist in the same cell.  
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Two transconjugants, I2-62TC and I2-52TC were found to harbour a 58 kb IncF and a 
151 kb IncB/O plasmid respectively. The larger IncB/O plasmid (I2-52TC) harboured a 
multi-resistance gene profile determined by DNA microarray analysis, harbouring an 
integrase associated gene intI and genes conferring resistance to aminoglycosides 
(mediated by aadA1, aadA2 and strB), chloramphenicols (cmlA1), trimethoprims 
(dfrA12 and dfrA14), tetracycline (tetA), sulphonamides (sul2 and sul3) and two β-
lactam genes (blaCTX-M-1 and blaTEM-1) conferring resistance to β-lactams determined by 
antimicrobial susceptibility assays (disc diffusion). Plasmid extraction was carried out 
on the original parent field isolate (donor; I2-52) and transformed into E. coli DH10. 
Plasmid characterisation of the resulting transformant (I2-52TF) derivative revealed a 
40 kb plasmid untypeable by the PBRT scheme. This plasmid was found to have fewer 
resistance genes, however still conferring resistance to the same group of antimicrobials 
as the transconjugant derivative. This smaller plasmid still harboured the integrase 
associated gene intI and interestingly had the same resistance gene profile as the 
plasmids from this region also harbouring untypeable 40-50 kb plasmids (see table 4-3). 
The IncF harbouring I2-62TC plasmid was also extracted (from the original donor; I2-
62) and transformed into E. coli DH10. The resulting transformed plasmid (I2-62TF) 
was found to be a 40 kb plasmid, 12 kb smaller than the transconjugant I2-62TC. This 
40 kb plasmid was untypeable by the PBRT scheme, similar to other plasmids from this 
farm (see table 4-4). The IncF plasmid (I2-62TC; 58 kb) harboured only the blaCTX-M-9 
variant of the CTX-M β-lactamase. The smaller 40 kb plasmid (I2-62TF) was found to 
harbour several resistance genes conferring resistance to aminoglycosides (aadA1, 
aadA2), chloramphenicols (cmlA1), trimethoprims (dfrA12), tetracycline (tetA), 
sulphonamides (sul3) and β-lactams (blaCTX-M-1), a profile identical to the other 
plasmids also from this region encoding a CTX-M group 1 variant (see table 4-4). 
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Table 4-3: Summary of co-transfer plasmids identified. 
 
Plasmid 
Recipient E. 
coli strain 
Estimated plasmid size 
(kb) Associated antimicrobial resistance markers Antimicrobial resistance genes Int PBRT 
I1-22TCb E. coli K12 150, 6, 4.5c Amp, Caz, Ctx, Cip, Na, S3, Sxt, Te ND ND F, FIA, FIB 
I1-22TF E. coli DH10 171 Amp, Caz, Ctx, Sxt, S, S3, Te aac6lb, aadA4, blaCTX-M-1, dfrA17, blaOXA-1, sul1, tetB int1 F, FIA, FIB 
I1-31TCb E. coli K12 150, 6c Amp, Ctx, S3, Sxt ND ND F, FIB, N 
I1-31TF E. coli DH10 28 Amp, Caz, Ctx aac6lb, blaCTX-M-1, blaOXA-1   N 
I1-32TCb E. coli K12 150, 100, 4.5c Amp, Caz, Ctx, Na ND ND F, FIB 
I1-32TF E. coli DH10 151 Amp, Caz, Ctx, S aac6lb, blaCTX-M-1, blaOXA-1  F, FIA, FIB 
I1-34TCb E. coli K12 50, 6c Amp, Caz, Ctx, Cip, C, Cn, Fr, Na, S, S3, Stx, Te ND ND F, FIA, FIB, N 
I1-34TF E. coli DH10 175 Amp, Caz, Ctx, C, Cn, S, S3, Stx, Te aac6lb, aadA4, catA1, blaCTX-M-1, dfrA17, blaOXA-1, sul1, blaTEM-1, tetB int1 F, FIA, FIB 
I1-40TCa E. coli K12 156, 122 Amp, Ctx, S3, Sxt aadA4, blaCTX-M-9, dfrA17, sul1, blaTEM-1  F 
I1-40TF E. coli DH10 ND ND aadA4, blaCTX-M-9, dfrA17, sul1, blaTEM-1  F 
I2-46TCa E. coli K12 111, 45 Amp, Caz, Ctx, Cip, C, Na, N, S3, Stx, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 - 
I2-47TCa E. coli K12 86, 35 Amp, Ctx blaCTX-M-9  I1 
I2-47TF E. coli K12 35 ND blaCTX-M-9  - 
I2-49TCb E. coli K12 100, 60c Amp, Ctx, Cip, C, Na, N, S3, Sxt, Te ND ND - 
I2-49TF E. coli K12 40 Amp, Caz, Ctx, C, N, S3, Sxt aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3 int1 - 
I2-50TCb E. coli K12 100, 80, 60,  7, 5.5, 4.5c Amp, Ctx, C, N, Sxt, Te ND ND F, FIB, I1 
I2-50TF E. coli K12 40 Amp, Caz, Ctx blaCTX-M-9  - 
I2-51TCb E. coli K12 100, 60c Amp, Caz, Ctx, Cip, C, Na, N, S3, Sxt, Te ND ND - 
I2-51TF E. coli K12 40 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 - 
I2-58TCb E. coli K12 100, 60c Amp, Caz, Ctx, Cip, C, Na, N, S3, Sxt, Te ND ND - 
I2-58TF E. coli K12 40 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 - 
I2-61TCb E. coli K12 100c Amp, Ctx blaCTX-M-9  I1 
I2-61TF E. coli K12 40 Amp, Ctx blaCTX-M-9  - 
I2-62TC* E. coli K12 58 Amp, Ctx blaCTX-M-9 ND F 
I2-62TF* E. coli DH10 40 ND aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 - 
I2-63TCb E. coli K12 100, 60c Amp, Caz, Ctx, Cip, C, Na, N, S3, Sxt,Te ND ND - 
I2-63TF E. coli K12 40 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 - 
I2-64TCa E. coli K12 92, 40 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 - 
I2-52-TC* E. coli K12 151 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, dfrA14, strB, sul2, sul3, blaTEM-1, tetA int1 B/O 
I2-52TF* E. coli DH10 40 ND aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12,, sul2, tetA int1 - 
*; These plasmids were found to transfer two different plasmids by the two methods employed conjugation and transformation. Both plasmids were typed by PBRT, sized by S1 PFGE and resistance gene profiles determined by 
miniaturized DNA micro-array analysis. a; These plasmids transferred as multiple plasmids to the recipient E. coli K12 strains. The plasmids were extracted from these transconjugants and transformed into E. coli K12 and used 
in subsequent plasmid characterization studies. b; Transconjugants found to harbour multiple plasmids by plasmid profile were transformed into E. coli K12 and resulting transformants were used in subsequent disc diffusion 
assays, DNA array analysis and plasmid sizing by PFGE. c; These plasmids were sized by the alkaline lysis method. Abbreviations:Amp; Ampicillin, Ctx; Cefotaxime, Caz; Ceftazidime, Cip; Ciprofloxacin, C; Chloramphenicol, 
N; neomycin,  Na; Nalidixic acid, Te; Tetracycline, S; Streptomycin, Sxt; sulfamethoxazole, S3; compound sulphonamide, aac6lb, aadA1, aadA2, aadA4, strA and strB confer resistance to aminoglycosides. catA1 and cmlA 
confer resistance to chloramphenicols. ctxM1, ctxM9, tem1 and oxa1 confer resistance to β-lactams. dfr12, dfrA14 and dfrA17 confer resistance to trimethoprims. sul1, sul2 and sul3 confer resistance to sulphonamides. tetA and 
tetB confer resistance to tetracylcines. Int1 and Int2 are integrons (mobile genetic elements) commonly associated with antimicrobial resistance genes. ND: not done. 
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4.2.8 Changes to β-lactam susceptibility upon plasmid transfer  
In order to investigate if the susceptibility to β-lactams varied between the donors and 
transconjugant/transformant derivatives, MICs were determined against ampicillin, 
cefotaxime and ceftazidime. The susceptibility profiles were compared for the plasmids 
producing blaCTX-M-1 variants; CTX-M-1, CTX-M-15, CTX-M-32 and blaCTX-M-9 
variants; CTX-M-14 and CTX-M-14b. Median MIC values were taken from each CTX-
M variant producing transconjugants/transformants and comparisons between the CTX-
M variants and the parent strains were made. The results can be found in the bar chart 
below (Fig. 4-5).  
The results indicate that all the CTX-M variants were equally resistant to ampicillin 
(MIC ≥ 1024 mg/L). High MIC values were also observed in the donor isolates (see 
table 4-4 for details).  
CTX-M group 1 variants (CTX-M-32 and CTX-M-15) had the highest median MIC 
values against ceftazidime (MIC ≥ 32 mg/L and ≥ 64 mg/L respectively); eight and 
four-fold lower than the donor field strains (MIC ≥256 mg/L) respectively (Fig. 4-5). 
CTX-M-14 producing plasmids followed with median MIC values of 32 mg/L, the 
same as in the donor strains. CTX-M-1 and CTX-M-14b producing plasmids had the 
lowest median MIC values with ceftazidime; ≥12 mg/L and ≥8 mg/L respectively, these 
were 5 (64 mg/L) and 4 (32 mg/L) times lower than the donor strains. 
Susceptibility to cefotaxime dropped only 2-fold in the transconjugants/transformants 
encoding the CTX-M-32 and -15 (MIC ≥ 128 mg/L) variants compared to the donor 
strains (MIC ≥ 256 mg/L). The remaining MIC values for variants; CTX-M-1 (MIC ≥ 
32 mg/L), CTX-M-14 (MIC ≥ 64 mg/L) and CTX-M-14b (MIC ≥ 64 mg/L) decreased 
four-fold from their field isolate donors. 
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Figure 4-4: Analysis of β-lactam susceptibility testing on CTX-M producing transformants (TF) 
and transconjugants (TF) in comparison to donor strains. MIC values were interpreted using the 
BSAC plate dilution method. Results show all the CTX-M variants (donor strains and plasmid 
derivatives) were resistant to ampicillin (MIC ≥ 1024 mg/L) (data not shown). MIC values dropped 2-8 
fold in the presence of ceftazidime (top) and cefotaxime (bottom) between the donor field isolates and 
transconjugant (TC) and transformants (TF). 
 
 146 
Table 4-4: Summary of blaCTX-M harbouring plasmids isolated from bovine E. coli in the UK in 2007. (See legend on pg. 149) 
        MIC (mg/L) 
Region isolated Plasmid 
Frequency of 
transfer PBRT 
Plasmid size 
(kb) 
Associated antibiotic 
resistance markers Antimicrobial resistance genes Integron Caz Ctx Amp 
Hertfordshire I1-33TC 2.35 x 10-5 F 60 Amp, Caz, Ctx blaCTX-M-1  64 128 > 1024 
Hertfordshire I1-35TC 1.07 x 10-4 F 60 Amp, Caz, Ctx blaCTX-M-1  64 128 > 1024 
Dorset I2-38TC 1.43 x 10-5 N 45 Amp, Ctx blaCTX-M-1  32 32 > 1024 
Dorset I2-39TC 5.25 x 10-6 N 45 Amp, Ctx blaCTX-M-1  8 32 > 1024 
Dorset I2-40TC 1.15 x 10-5 N 45 Amp, Ctx blaCTX-M-1  8 64 > 1024 
Dorset I2-42TC 3.86 x 10-5 N 45 Amp, Ctx blaCTX-M-1  16 32 1024 
Dorset I2-43TC 2.10 x 10-5 N 45 Amp, Ctx blaCTX-M-1  8 32 > 1024 
Dorset I2-45TC 6.00 x 10-6 N 45 Amp, Ctx blaCTX-M-1  8 32 > 1024 
Bedfordshire I1-43TC 2.18 x 10-6 I1 86 Amp, Caz, Ctx blaCTX-M-1   32 64 > 1024 
Shropshire I2-48TC 1.10 x 10-7 F 70 Amp, Ctx blaCTX-M-9  32 16 1024 
Shropshire I2-65TC 1.93 x 10-5 - 35 Amp, Ctx blaCTX-M-9  8 64 > 1024 
Shropshire I2-60TC 1.19 x 10-5 - 35 Amp, Ctx blaCTX-M-9  8 128 > 1024 
Shropshire I2-61TF 8.57 x 10-9 - 35 Amp, Ctx blaCTX-M-9  8 64 > 1024 
Shropshire I2-50TF 1.00 x 10-8 - 40 Amp, Caz, Ctx blaCTX-M-9  8 128 > 1024 
Shropshire I2-47TC 6.60 x 10-8 I1 86, 35 Amp, Ctx blaCTX-M-9  8 64 > 1024 
 I2-47TF - - 35 ND blaCTX-M-9  ND ND ND 
Shropshire I2-54TC 1.50 x 10-6 F 75 Amp, Ctx blaCTX-M-9  16 64 1024 
Shropshire I2-62TC 6.67 x 10-7 F 58 Amp, Ctx blaCTX-M-9  8 32 1024 
  I2-62TF - - 40 ND aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 ND ND ND 
Dorset I2-37TC 1.25 x 10-3 N 45 Amp, Ctx blaCTX-M-1, blaTEM-1  32 64 > 1024 
Pembrokeshire I1-28TC 9.88 x 10-6 F 60 Amp, Caz, Ctx blaCTX-M-1, blaTEM-1  64 128 > 1024 
Pembrokeshire I1-29TC 5.37 x 10-6 F 60 Amp, Caz, Ctx blaCTX-M-1, blaTEM-1  64 128 > 1024 
Bedfordshire I1-37TC 2.85 x 10-4 I1 86 Amp, Caz, Ctx blaCTX-M-1, blaTEM-1  32 64 > 1024 
Bedfordshire I1-42TC 4.00 x 10-6 F, I1 86 Amp, Caz, Ctx blaCTX-M-1, blaTEM-1  32 64 > 1024 
Pembrokeshire I1-25TF 2.10 x 10-5 F 70 Amp, Caz, Ctx, S blaCTX-M-1, blaTEM-1   32 128 > 1024 
Pembrokeshire  I1-23TC 1.02 x 10-2 F 54 Amp, Caz, Ctx, S blaCTX-M-1, strA, strB, blaTEM-1  64 128 > 1024 
Pembrokeshire I1-26TC 3.88 x 10-6 N 45 Amp, Caz, Ctx, S, Te blaCTX-M-1, strB, blaTEM-1, tetA  32 128 > 1024 
Hertfordshire I1-30TC 4.25 x 10-6 N 45 Amp, Caz, Ctx, S, Te blaCTX-M-1, strB, blaTEM-1, tetA  64 128 > 1024 
Pembrokeshire I1-24TC 1.33 x 10-5 N 45 Amp, Caz, Ctx, S, Te blaCTX-M-1, strA, strB, blaTEM-1, tetA  256 128 > 1024 
Pembrokeshire I1-21TC 1.71 x 10-6 N 45 Amp, Caz, Ctx, S, Te blaCTX-M-1, strA, strB, blaTEM-1, tetA  64 128 > 1024 
Pembrokeshire I1-27TC 4.29 x 10-8 N 45 Amp, Caz, Ctx, S, Te blaCTX-M-1, strA, strB, blaTEM-1, tetA   128 128 > 1024 
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Table 4-4 continued. 
 
        MIC (mg/L) 
Region isolated Strain 
Frequency 
of transfer PBRT 
Plasmid 
size (kb) 
Associated antibiotic resistance 
markers Antimicrobial resistance genes Integron Caz Ctx Amp 
Bedfordshire I1-41TC 3.20 x 10-5 F 86 Amp, Ctx, Sxt, S3 blaCTX-M-9, dfrA17, sul1, blaTEM-1  32 64 > 1024 
Bedfordshire I1-36TC 1.60 x 10-7 F 122 Amp, Ctx, Sxt, S3 aadA4, blaCTX-M-9, dfrA17, sul1, blaTEM-1  16 64 > 1024 
Bedfordshire I1-38TC 1.09 x 10-7 F 122 Amp, Ctx, Sxt, S3 aadA4, blaCTX-M-9, dfrA17, sul1, blaTEM-1  64 128 > 1024 
Bedfordshire I1-40TC 1.58 x 10-6 F 156, 122 Amp, Ctx, Sxt, S3 aadA4, blaCTX-M-9, dfrA17, sul1, blaTEM-1  16 128 > 1024 
 I1-40TF - F  ND aadA4, blaCTX-M-9, dfrA17, sul1, blaTEM-1  ND ND ND 
Bedfordshire I1-39TF ≥0 F 86 Amp, Caz, Ctx, S, Sxt, S3 aadA4, blaCTX-M-9, dfrA17, sul1, blaTEM-1  16 64 > 1024 
Hertfordshire I1-32TF 7.02 x 10-8 FIA-FIB 151 Amp, Caz, Ctx, S aac6lb, blaCTX-M-1, blaOXA-1  64 32 > 1024 
Hertfordshire I1-31TF 1.20 x 10-7 N 28 Amp, Caz, Ctx aac6lb, blaCTX-M-1, blaOXA-1  16 32 1024 
Pembrokeshire I1-22TF 1.00 x 10-8 FIA-FIB 171 Amp, Caz, Ctx, S, S3, Sxt, Te aac6lb, aadA4, blaCTX-M-1, dfrA17, blaOXA-1, sul1, tetB int1 64 128 > 1024 
Hertfordshire I1-34TF 4.00 x 10-9 FIA-FIB 175 Amp, Caz, Ctx, C, Cn, S, S3, Sxt, Te aac6lb, aadA4, catA1, blaCTX-M-1, dfrA17, blaOXA-1, sul1, blaTEM-1, tetB int1 >512 256 > 1024 
Shropshire I2-49TF 1.71 x 10-8 - 40 Amp, Caz, Ctx, C, N, S3, Sxt aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3 int1 32 32 > 1024 
Shropshire I2-46TC 6.67 x 10-9 - 111, 45 Amp, Caz, Ctx, Cip, C, Na, N, S3, Stx, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 32 128 1024 
Shropshire I2-56TC 4.50 x 10-8 - 51 Amp, Caz, Ctx, Cip, C, Na, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 32 128 > 1024 
Shropshire I2-59TC 4.80 x 10-8 - 40 Amp, Caz, Ctx, Cip, C, Na, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 64 64 > 1024 
Shropshire I2-53TC 1.50 x 10-8 - 40 Amp, Caz, Ctx, Cip, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 32 64 > 1024 
Shropshire I2-66TF ≥0 - 40 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 32 128 > 1024 
Shropshire I2-55TF ≥0 - 51 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 32 64 > 1024 
Shropshire I2-67TC 5.14 x 10-9 - 125 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 32 64 > 1024 
Shropshire I2-51TF 7.50 x 10-8 - 40 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 64 128 > 1024 
Shropshire I2-57TC 1.20 x 10-8 - 100 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 64 128 > 1024 
Shropshire I2-58TF 3.60 x 10-8 - 40 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 64 128 > 1024 
Shropshire I2-63TF 9.23 x 10-9 - 40 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 128 128 > 1024 
Shropshire I2-64TC 4.36 x 10-8 - 92, 40 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, sul3, tetA int1 64 128 > 1024 
Shropshire I2-52TC 4.62 x 10-8 B/O 151 Amp, Caz, Ctx, C, N, S3, Sxt, Te aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12, dfrA14, strB, sul2, sul3, blaTEM-1, tetA int1 32 128 > 1024 
  I2-52TF - - 40 ND aadA1, aadA2, cmlA1, blaCTX-M-1, dfr12,, sul3, tetA int1 ND ND ND 
See legend below. 
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Table 4-4: Summary of blaCTX-M harbouring plasmids isolated from bovine E. coli in the UK in 2007. 
The table shows transconjugant (TC) and transformant (TF) derivatives of the field isolates and the frequency of transfer rates of the TCs and plasmid sizes of the resulting CTX-M 
harbouring plasmids. Transconjugants that harboured multiple plasmids were screened for blaCTX-M and these highlighted in bold. The plasmids were typed by PBRT, untypeable 
plasmids by this method were denoted by a dash (-). Antimicrobial resistance markers were determined by disc diffusion (phenotype) and DNA microarray analysis (genotype). 
Abbreviations:Amp; Ampicillin, Ctx; Cefotaxime, Caz; Ceftazidime, Cip; Ciprofloxacin, C; Chloramphenicol, N; neomycin,  Na; Nalidixic acid, Te; Tetracycline, S; Streptomycin, 
Sxt; sulfamethoxazole, S3; compound sulphonamide, aac6lb, aadA1, aadA2, aadA4, strA and strB confer resistance to aminoglycosides. catA1 and cmlA confer resistance to 
chloramphenicols. blaCTX-M-1, blaCTX-M-9, blaTEM-1 and blaOXA-1 confer resistance to β-lactams. dfr12, dfrA14 and dfrA17 confer resistance to trimethoprims. sul1, sul2 and 
sul3 confer resistance to sulphonamides. tetA and tetB confer resistance to tetracylcines. Int1 and Int2 are integrons (mobile genetic elements) commonly associated with 
antimicrobial resistance genes. ND: not done. 
 
 149 
4.3 Discussion 
The donor field isolates were found to confer a multi-drug resistance phenotype and 
harboured plasmids, a not unexpected result given the significance of plasmid mediated 
resistance in E. coli as outlined in the introductory chapter to this thesis. The plasmids 
were typed by PBRT and in some isolates found to harbour multiple replicon types, as a 
result of multiple plasmids. Ten field strains were found to harbour the IncI1 replicon. 
Seven of these plasmids were typed by plasmid multi-locus sequence typing (Garcia-
Fernandez et al., 2008). These plasmids were found to belong to groups ST24, ST31 
(CC-31) and ST38 (CC-3). ST24 has been previously identified in an E. coli isolate in 
the Netherlands in 2004 (pST-24). This plasmid however was not recorded as 
harbouring any β-lactamases genes (http://pubmlst.org). 
The clonal complex (CC) 3 ST38 plasmid type has previously been identified in a 
plasmid from the UK isolated from a human E. coli strain harbouring a blaCMY-2 AmpC-
like β-lactamase, but no CTX-M enzymes were identified. CMY-2 encoding plasmids 
were first reported in 1990 and have since spread globally in multiple 
Enterobacteriaceae species (Bauernfeind et al., 1990; Bauernfeind et al., 1996; Navarro 
et al., 2001). These plasmids have been associated with blaTEM-1 β-lactamases in 
addition to other multidrug resistance phenotypes and mobile genetic elements such as 
ISEcp1 upstream of the blaCMY-2 (Navarro et al., 2001). The ST38 plasmid was also 
found to harbour an ISEcp1 upstream of the blaCTX-M-15 gene, which was present in an 
IncF plasmid. This isolate also harboured a plasmid bearing an IncI1 gene. The 
association of the β-lactamase genes with a mobile genetic element in the IncF plasmid, 
would enable mobilisation of adjacent genes (Poirel et al., 2003) and thus serve as an 
ideal platform for genetic recombination events that could result in the acquisition of 
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blaCTX-M genes to another plasmid in close proximity such as the ST38 IncI1 bearing 
plasmid that was identified.  
The ST31 CC 31 plasmid (found in strains I1-42 and I1-43), has previously been 
identified in S. sonnei and E. coli strains (http://pubmlst.org/plasmid). These blaCTX-M-15 
harbouring plasmids have been found in different geographical regions including 
Belgium, Germany, France, the Netherlands, UK and USA. These strains have been 
isolated from several species including horses, humans and cattle. Interestingly, one 
ST31 plasmid previously identified (Folster et al., 2010) harboured a 90 kb plasmid 
encoding blaCTX-M-15 and blaTEM β-lactamases. This plasmid also displayed a multi-drug 
resistance phenotype conferring resistance to ampicillin, sulfamethoxazole, nalidixic 
acid, streptomycin and tetracycline (Folster, Pecic et al. 2010). The two ST31 plasmids 
identified in this study also harboured these β-lactamase genes and observed a similar 
antimicrobial resistance profile. These pMLST results demonstrate the widespread 
nature of these plasmids, not least in their isolation from multiple Enterobacteriaceae 
species and from multiple hosts.  
 
Plasmid typing of the field isolates found 73 % of the isolates harboured known 
conjugative plasmids including narrow host range plasmids; IncB/O, IncF (IncFIB and 
IncFIA), IncI1 and broad host range plasmid IncN. These plasmid Inc types are amongst 
those most commonly found to be associated with large multi-drug resistance plasmids 
(Boyd et al., 2004; Couturier et al., 1998; Lavollay et al., 2006, Waters, 1999). 
Conjugation frequency studies were employed to determine the extent horizontal gene 
transfer play in the dissemination of blaCTX-M harbouring plasmids identified in this 
study.  
IncF plasmids were found to have the highest transfer rates followed by IncN, IncI1 and 
the least efficient IncB/O. The conjugation experiments highlighted the transfer rate of 
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particular Inc groups irrespective of size, as these varied in each group; with IncF 
plasmids ranging from 54 to 175 kb, IncI1 plasmids from 86 kb and the IncB/O plasmid 
at approximately 151 kb. No plasmids smaller than 28 kb were shown using the S1 
nuclease method, unlike the plasmid profile gel (Fig. 3-6) where plasmids as small as 
3.8 kb were detected. This could be a limitation of the PFGE gel, which in the time 
period (16hrs) could have excluded the smaller plasmids from the gel. This experiment 
was performed at 37 °C, an optimal temperature of IncF and IncF like plasmids. At this 
temperature, DNA transfer is thought to occur at an approximate rate of 45 kb per 
minute (Lawley et al., 2004). IncF and IncI1 plasmids have been also been shown to 
harbour adhesins at the tip of the pilus, thereby mediating efficient donor-recipient 
contact through higher incidence of cell-cell contact (Lawley et al., 2004). The IncB/O 
plasmid frequency transfer rates were low, although these plasmids have the same pilus 
structure as the IncI1 plasmids (Waters, 1999). This suggests that the plasmid itself may 
limit the transfer by conjugation. Plasmids such as the IncH plasmids are known to 
transfer at higher rates at lower temperatures (22 - 30°C) (Lawley et al., 2004). In the 
first instance, this experiment could be repeated at varying temperatures to determine if 
the frequency of transfer is affected.  
 
Three IncF plasmids (I1-22TF, I1-32TF and I1-34TF) bearing blaCTX-M-15 (CTX-M 
group 1), harboured FIA-FIB replicons. These multi-replicon plasmids have previously 
been associated with blaCTX-M-15 genes (Carattoli et al., 2009). The FIA-FIB is 
commonly found in enteric bacteria and it is thought that in such instances where 
multiple replicons are available, one replicon remains highly conserved, leaving the 
other able to mutate and possibly alter the compatibility group (Carattoli et al., 2008).  
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All the plasmids included in this study were found to harbour at least one gene 
conferring resistance to β-lactams. Seventeen plasmids (33 %) were found to only 
harbour genes that conferred resistance to β-lactams mainly from blaCTX-M group 1 and 
9. Sequence of blaCTX-M genes present in the donor strains, indicated that these were 
most likely to be the CTX-M-1, -15 (group 1) and CTX-M-14 and 14b (group 9) 
variants that had been transferred in the recipients.   
The remainder of the plasmids (56 %; n = 35) all harboured a multi-drug resistance 
(MDR) phenotype. This was reflected from the transfer of multiple genes between 
donor and recipient strains, as identified from DNA microarray analysis. It must be 
noted that the transfer of the plasmids from possible clonal donor strains (e.g. isolates 
from the Shropshire Farm, see Fig.3-2) may skew the frequency of these resistance 
genes observed and impact the resistance reporting of this data. Nineteen of these MDR 
plasmids encoded additional blaTEM-1 genes, and eleven of these were IncF plasmids. 
Previous studies have found blaTEM-1 genes to co-exist with blaCTX-M-15 variants due to 
the association of blaTEM-1 with Tn3 transposons. It is hypothesised that IncF plasmids 
can acquire CTX-M β-lactamases via an integration mediated Tn3::blaTEM transposition 
event with the ISEcp1 containing blaCTX-M-15 and blaCTX-M-14 variants (Boyd et al., 2004; 
Carattoli, 2009; Marcade et al., 2009). 
Also commonly found in association with blaCTX-M-15 genes are blaOXA-1 and aac’(6)lb 
genes, which are thought to have originated from a gene cassette (Boyd et al., 2004). 
This is a common feature of IncF plasmids (Carattoli, 2009), as was demonstrated in the 
results with three plasmids (I1-22TF, I1-32TF and I1-34TF), which harboured these 
resistance genes. Interestingly, an IncN plasmid (I1-31TF) was grouped with these 
plasmids found to harbour the blaOXA-1 and aac’(6)lb resistance genes (see table 4-4).  
Seven plasmids, from the same farm (Dorset) harboured IncN plasmids encoding the 
blaCTX-M-1 variant. Previous studies have demonstrated the successful transfer of a 
 153 
blaCTX-M-1 encoding IncN plasmid between farm workers and pigs on an unrelated farm, 
and like the IncN plasmids observed in this study, the majority had no additional 
resistance genes (Moodley et al., 2009). 
Two plasmids were found to harbour the IncI1 incompatibility group encoding blaCTX-M-
14b, and blaCTX-M-15 variants. Although not largely represented in this panel of strains, 
IncI1 plasmids are widely distributed amongst Enterobacteriaceae (Carattoli, 2009). 
Smet et al., 2010 sequenced a 92 kb IncI1 plasmid encoding only blaCTX-M-15 and 
blaTEM-1 resistance genes, showing similar gene profiles to the three IncI1 plasmids 
identified in this study which also harbour the same CTX-M variants and an additional 
TEM-1 β-lactamase in one of the plasmids (I1-37TC) (Smet et al., 2010). Their 
sequenced plasmid was also found to have an extensive number of genes required for 
conjugation, in addition to a gene cluster encoding the type-IV pili, required for 
adhesion and invasion of Shigatoxigenic E. coli (Smet et al., 2010). The association of 
resistance determinants with this effective conjugative platform and virulence factors 
are factor for the successful dissemination of this plasmid family (Carattoli, 2009).  
Plasmids harbouring blaCTX-M-32 genes from the Shropshire region were found to confer 
a distinct resistance profile, conferring resistance to multiple antimicrobials including 
aminoglycosides, β-lactams, chloramphenicols, sulphonamides, trimethoprims and 
tetracyclines. These plasmids were identified as possessing the intI integrase marker, 
associated with class 1 integrons (Hall and Collins, 1998).  Resistance determinants 
(aadA1, aadA2, cmlA1, dfr12, sul3) in these plasmids have been commonly found 
amongst class 1 integrons (Mazel, 2006; Sunde et al., 2008).  
Class 1 integrons (InS21, In35, In116 and In60) have been found to harbour blaCTX-M 
genes within them; these include blaCTX-M-1, -2, -3, -9 (Arduino et al., 2002; Di Conza et al., 
2005; Eckert et al., 2006; Novais et al., 2006; Power et al., 2005; Riano et al., 2006; 
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Sabate et al., 2002; Vinue et al., 2008), however no blaCTX-M-32 genes have been 
described amongst these.  
Previous studies analysing the genetic environment surrounding the blaCTX-M-32 variant 
have found these genes to be associated more commonly with the insertion elements IS1, 
IS5 and ISEcp1 (Cartelle et al., 2004; Farnandez et al., 2007). The plasmids in this 
study did not harbour the ISEcp1 element upstream of the blaCTX-M-32 gene. However 
Fernandez and colleagues have found a partially truncated ISEcp1element, with 
insertions of IS1 and IS5 elements upstream of the blaCTX-M-32 gene (Farnandez et al., 
2007). The primers used to detect the ISEcp1 in this study were located at the 3’ end of 
the ISEcp1 element (Poirel et al., 2002) and the 3’ end of blaCTX-M (Carttoli et al., 2008). 
If the IS1 and IS5 insertions were present, the resulting amplicon would be ~ 3 kb 
instead of the estimated 1 kb fragment. The resulting large PCR amplicon may not have 
been amplifiable using the conditions used in this study and explain the negative results 
obtained during ISEcp1 screening. 
The blaCTX-M-32 plasmids harbouring these uniform resistance genes from the Shropshire 
farm were untypeable by the PBRT scheme. This may be due to genetic changes in the 
replicon region making them unyteable by the PBRT scheme. Previous studies have 
observed a 35 kb ‘untypeable’ plasmid harbouring an IncX-like backbone (pJIE143), 
with conjugative machinery that enables the transfer of this plasmid by conjugation 
(Partridge et al., 2011). This type of genetic changes may explain the characteristics of 
the similarly sized plasmids observed in the Shropshire region. The same group 
identified another ‘untypeable’ plasmid belonging to the IncN family of plasmids. 
Unlike the pJIE143 plasmid, pJIE137 harboured class 1 integrons (intI) in addition to 
aadA2, dfrA12 and sul1 integron associated gene cassettes (Partridge et al., 2012), 
which were also observed in the plasmids of the Shropshire region. Plasmid pJIE137 
also harboured genes encoding conjugation machinery similar to the Tra proteins of 
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R46 IncN plasmid (Partridge et al., 2012). The pJIE137 plasmid from this study was 
also found to harbour an ISCR1 element; a complex IS91-like insertion element 
commonly associated with class 1 integrons (Toleman et al., 2006). This unique mobile 
genetic element may offer a secondary horizontal gene transfer mechanism to classical 
conjugation, by way of a rolling-circle mechanism of self-transposition (Toleman et al., 
2006). This element has also been associated with other blaCTX-M variants including 
blaCTX-M-2, -9, -14 (Bae et al., 2007; Toleman et al., 2006). 
Characteristics found in the pJIE137 and pJIE143 plasmids demonstrate the importance 
of understanding the genetic environment of blaCTX-M genes. Although ISCR1 elements 
have not been found in conjunction with blaCTX-M-32 genes, further work on the 
untypeable plasmids from the Shropshire farm will be required to ascertain the exact 
nature of transfer of these plasmids by conjugation or the unique rolling-circle 
mechanism of the ISCR1 element. Determining the plasmid backbone will also further 
our understanding of how the plasmid had spread across the farm. 
 
Eleven transconjugants (21 %) transferred multiple plasmids during conjugation. Upon 
transformation 26 % of their resistance determinants were lost, most frequently 
quinolone resistance markers (Na and Cip). The loss in quinolone resistance is most 
likely due to the chromosomal mutations found in the QRDR, although this does need 
verification. 
Furthermore, due to the limitations of plasmid sizing of supercoiled plasmids, 
estimating the sizes did not take into account migration of the different conformations 
of the plasmid. Transconjugants that presented multiple plasmids of varying sizes may 
have been a result of the different forms of plasmid migrating at different rates on the 
plasmid profile gel. These plasmids often harboured the same plasmid Inc groups, and 
by definition, plasmids with the same Inc group cannot co-exist in the same cell (Datta 
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and Hedges, 1971). It is likely that the multiple plasmids in these instances were merely 
different forms of the plasmid. DNA micro-array and S1- nuclease PFGE analysis on 
the transconjugants would have to be performed to confirm this postulation.  
Two transconjugants (I2-46TC and I2-64TC), were found to have co-transferred 
untypeable plasmids. These plasmids would need to be sequenced to identify the 
replicon types or any possible recombination events that may have taken place in vitro 
to give rise to the larger plasmids observed in the transconjugant derivatives. 
 
As shown in this chapter, all resistance to ampicillin and cefotaxime was transferred, 
although only 67 % of ceftazidime resistance was transferred. Susceptibility to these 
three antimicrobials was determined in recipients’ after transfer and in the donor strains. 
MIC levels for all the donor strains and plasmid derivatives (transconjugants or 
transformants) to ampicillin were ≥ 1024 mg/L. Very high levels of resistance to 
aminopenicillins (ampicillin and amoxicillin) have previously been observed with CTX-
M enzymes (Bonnet, 2004).  However, the MIC values for the plasmid derivatives were 
in general lower than the donor field strains for ceftazidime and cefotaxime. Genotypic 
results showed 100 % transfer of blaCTX-M genes and 95 % and 57 % transfer of 
additional β-lactamase genes; TEM-1 and OXA-1 respectively. Therefore this reduction 
in MIC levels despite the transfer of the CTX-M enzymes suggests other elements 
present in the donor strains account for the differences including possibly 
chromosomally located resistance genes and multidrug resistance efflux systems.  
At least 2 fold lower ceftazidime MIC values were seen with all the CTX-M variants 
compared to cefotaxime MIC values. CTX-M enzymes are generally more active 
against cefotaxime than ceftazidime (Barthelemy et al., 1992). This is because CTX-M 
enzymes have more flexibility within the β3 strand and Ω-loop due to amino acid 
substitutions in this region, enabling access of larger side chains such as the 
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cephalosporins. In addition amino acid substitutions including; Asn-104, Ser-237, Asp-
240 and Arg-276 in the CTX-M enzymes are thought to increase substrate specificity 
enabling the efficient hydrolysis of oxyimino-cephalosporinas including ceftazidime 
and cefotaxime, unlike the earlier ESBL enzymes TEM and SHV which poorly 
hydrolyse these compounds (Bonnet, 2004). 
Differences between the group 1 enzymes, CTX-M-1, -15 and -32 was observed, with 
CTX-M-1 having the lowest MIC against cefotaxime (median MIC 32 mg/L) and the 
second lowest against ceftazidime (median MIC 12 mg/L). CTX-M-1 is described as the 
least efficient blaCTX-M group1 enzyme in comparison to CTX-M-15 and -32. This is 
because it lacks the D240G mutation in the omega loop; a mutation thought to increase 
the flexibility of the β-strand thus rendering the active site more accessible to bulkier 
side chains such as that of ceftazidime (Novais, Canton et al. 2008; Rossolini, D'Andrea 
et al. 2008; Novais, Comas et al. 2010).  
CTX-M-15 and -32 had the same median MIC values against cefotaxime (median MIC 
128 mg/L); however the median MIC value for ceftazidime was two-fold less for CTX-
M-32 in comparison to CTX-M-15. Previous studies have demonstrated CTX-M-32 
enzymes as the most efficient inactivator of oxyimino-cephalosporins with respect to 
the five variants (CTX-M-1, -14, -14b, -15 and -32) represented in this data set, thought 
to be because of its ability to efficiently inactivate cefotaxime and ceftazidime (Novais, 
Comas et al. 2010). However, the MIC data shows that the CTX-M-32 enzyme is 
similar, if not less efficient than CTX-M-15, owing to the lower MIC values of CTX-M-
32 against ceftazidime (Novais, Comas et al. 2010). The presence of other β-lactamase 
genes on blaCTX-M-15 encoding strains may account for their higher levels of resistance to 
ceftazidime. Although ceftazidime is a poor substrate for the TEM-1 enzyme; previous 
studies have shown that mutations in the omega loop, results in increased hydrolytic 
activity towards ceftazidime (Petrosino and Palzkill 1996). 
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CTX-M-14 and 14b producing strains, both CTX-M group 9 variants, had lower 
cefotaxime and ceftazidime MIC values than their group 1 counterparts (CTX-M-1, -15 
and -32). This decrease in MIC between the different group 9 and 1 enzymes has 
previously been observed (Bonnet, 2004). These two enzyme variants differ in substrate 
specificity due to the active site substitution D240G. CTX-M group 1 enzymes (CTX-
M-15 and -32) encode a glycine residue at position 240 (Ambler numbering), an 
uncharged residue thought to negate any steric hindrance in binding of the 
cephalosporins. The charged aspartate residue present in the group 9 enzymes (CTX-M-
14 and14b) may restrict binding of the bulkier side chains of cephalosporins, especially 
ceftazidime (Bonnet, 2004). This difference in substrate accommodation may explain 
the lower MIC values obtained for these group 9 enzymes. 
Four fold differences were observed in CTX-M-14 and -14 b ceftazidime MIC values. 
CTX-M-14b enzymes are thought to have evolved from the CTX-M-9 variant, with only 
one base pair difference (GCA→GTA) resulting in an A231V substitution (numbering 
of Ambler et al., 1980). Whilst, CTX-M-14 harbours two base pair substitutions with 
respect to the CTX-M-9 variant (GCA→GTG), coding for the same amino acid as the 
CTX-M-14b enzyme, A231V (Sabate, Tarrago et al. 2000; Poirel, Naas et al. 2001; 
Navarro, Mesa et al. 2007). The CTX-M-14 enzymes encode two additional silent base 
pair mutations, not present in CTX-M-14b and CTX-M-9. CTX-M-14 and -14b 
enzymes have the same tertiary structure and therefore there should be no difference in 
their substrate specificity (Chen et al., 2005), although four-fold differences in 
ceftazidime MIC values were observed in this study. Interestingly all the CTX-M-14 
enzymes were encoded within IncF plasmids and the CTX-M-14b enzymes were 
encoded within the ‘untypeable’ plasmids. These IncF plasmids harboured additional 
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TEM-1 enzymes, which as previously postulated for CTX-M-15, may have resulted in 
increased specificity to the ceftazidime substrate (Petrosino and Palzkill, 1996). 
The differences in MIC values between the different CTX-M enzymes may give some 
insight to the reason for the prevalence observed of CTX-M 15 enzymes in recent years 
in clinical E. coli samples in Europe (Livermore et al., 2007). That is to say, that CTX-
M-15 enzymes should, in theory be the most abundant of the β-lactamase variants due 
to its relative tolerance to β-lactam agents, making it a more efficient enzyme and a 
possible criterion for positive selection under Darwinian theory of evolution (Gillespie 
2004). The relative efficiency of the other CTX-M variants in this study in susceptibility 
to cefotaxime and ceftazidime suggests other factors may influence drug susceptibility 
in the plasmid system, including the presence of other, albeit less, efficient B-
lactamases, whose activity has an additive effect. 
In the next chapter, further analysis of the role of CTX-M variants and plasmids in the 
relative fitness of the strain will be investigated. 
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5 RESULTS CHAPTER 5: Nucleotide sequencing of blaCTX-M-14b, -15 
and -32 encoding multidrug resistance plasmids from E. coli  
5.1 Introduction 
The rapid spread of antimicrobial resistance determinants has been attributed to the ease 
of transfer of plasmid encoding these genes (Salyers et al., 1997). As discussed in 
chapter one, transfer is mediated by a complex conjugation system usually encoded on 
the plasmid by a cluster of co-ordinately regulated genes, the so-called tra genes, along 
with other genes for pilus assembly (pil) and plasmid establishment in the host cell (ssb 
and psiB). Rates of transfer vary between plasmids as we have seen in previous chapters 
(see section 4.2.2). Also, transfer is limited by the competence of the recipient 
bacterium to receive the plasmid, as also discussed in chapter one, such factors as 
surface exclusion and incompatibility play a role in limiting plasmid transfer. Once 
transferred to a new host bacterium, the plasmid usually becomes established and 
maintained more or less irreversibly. To achieve this state of ‘successful maintenance’ 
in a new host background, the plasmid encodes genes that counter mechanisms that 
would result in random plasmid loss during cell division. These maintenance processes, 
that are thought to impart a fitness cost to the host, include plasmid partitioning systems, 
that ensure plasmid segregation during replication and cell division, site specific 
recombinases that resolve plasmid multimers during replication and recombination and 
post-segregational killing systems (PSK), also known as addiction systems that ensure 
survival of only bacteria which retain the plasmid (Gerdes, 2000 in; Slater et al., 2008).  
In addition, for those plasmids encoding a selectable trait such as antibiotic resistance, 
the presence of selection will provide a selective advantage over their plasmid free 
strains. Often encoded on plasmids, are genes conferring resistance to multiple drug 
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classes. These genes can be found adjacent to each other owed to by the arrangement of 
gene cassettes within an integron (Recchia and Hall, 1995). Other contributors to 
genetic diversity include the association of resistance genes with insertion elements 
(ISEs), Integrons and ISEs have been found to drive expression of genes they 
encompass and play an important role in host adaptability (Hall and Collins, 1995; 
Poirel et al., 2003). Collectively these elements provide a source of genetic diversity. By 
providing a selective advantage, metabolic or physical, HGT enables the organism to 
adapt to a new ecological niche (Andam et al., 2011).  
In this chapter, the aim is to sequence a number of ESBL plasmids to gain a complete 
understanding of the biology of the encoding plasmids. The sequence data will enable 
interrogation of plasmid transfer and maintenance systems, define the MDR regions 
within its genetic context, discover other factors associated with the plasmids that the 
studies in chapters 3 and 4 have not revealed and perhaps gain insights into plasmid 
evolution. 
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5.2 Results and Discussion 
5.3 Plasmid sequence analysis 
Four plasmids were selected for sequencing harbouring the blaCTX-M-32, -15 and -14 
variants from the transformant or transconjugant derivatives of the field isolates 
collected from various regions in the UK, characterised in the previous chapter. Two 
plasmids harboured narrow host range conjugative replicons IncI1 (pI2-47TC), IncB/O 
(pI2-52TC) and a multireplicon plasmid harboured IncF-FIA-FIB (pI1-34TF), identified 
using the PCR based replicon typing (PBRT) scheme. The fourth plasmid (pI2-53TF) 
was one of the 17 plasmids from the Shropshire farm that could not be typed by this 
scheme and was representative of these untypeable plasmids (see Table 5.1). 
Sequencing of this plasmid would help determine its replication control mechanism and 
possibly ascertain its conjugative or mobilisation system. These four plasmids harbour 
the blaCTX-M-32, -15, and -14 variants, which have previously been reported in isolates from 
both human and animal origin (Boyd et al., 2004; Cartelle et al., 2004; Cottell et al., 
2011; Ma et al., 2002; Smet et al., 2010; Woodford et al., 2009). Sequence analysis of 
these plasmids originating from bovine E. coli strains presenting blaCTX-M variants 
commonly found in human as well as animal origins, will enhance our understanding as 
to the mechanisms that enable efficient dissemination and persistence in different 
species. The plasmid contigs arising from sequence data were concatenated and 
compared with other fully sequenced plasmids for any similarities in gene arrangements 
within the concatenated plasmid sequence, which may give insight into the possible 
mechanisms of plasmid evolution. 
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Table 5-1: Summary of blaCTX-M plasmids selected for sequencing. 
      
Plasmid PBRT 
Plasmid 
size (kb) 
Associated resistance 
profile Antimicrobial resistance genes Int 
pI1-34TF F, FIA, FIB 175 
Amp, Caz, Ctx, C, Cn, S, 
S3, Sxt, Te 
aac6lb, aadA4, catA1, blaCTX-M-15, 
dfrA17, blaOXA-1, sul1, blaTEM-1, 
tetB 
intI1 
pI2-47TC I1 86, 35 Amp, Ctx blaCTX-M-14b  
pI2-52TC B/O 151 Amp, Caz, Ctx, C, N, S3, Sxt, Te 
aadA1, aadA2, cmlA1, blaCTX-M-
32, dfr12, dfrA14, strB, sul2, sul3, 
blaTEM-1, tetA 
intI1 
pI2-53TF - 40 Amp, Caz, Ctx, Cip, C, N, S3, Sxt, Te 
aadA1, aadA2, cmlA1, blaCTX-M-
32, dfr12, sul3, tetA 
intI1 
 
The four plasmids were selected from the available 52 strains analysed in the previous chapter based on their blaCTX-M variant, 
plasmid Inc group and antimicrobial resistance gene profiles (phenotype/genotype) and sequenced including: pI1-34TF, pI2-47TC 
(the 35 kb plasmid in bold), pI2-52TC and pI2-53TF. Shown are the Inc groups (determined by PBRT), plasmid sizes (determined 
by S1-nculease PFGE), phenotypic and genotypic resistance genes determined by disc diffusion and miniaturized DNA microarray 
(see chapter 4). Abbreviations: Amp; Ampicillin, Ctx; Cefotaxime, Caz; Ceftazidime, Cip; Ciprofloxacin, C; Chloramphenicol, N; 
neomycin, Na; Nalidixic acid, Te; Tetracycline, S; Streptomycin, Sxt; sulfamethoxazole, S3; compound sulphonamide, aac6lb, 
aadA1, aadA2, aadA4, strA and strB confer resistance to aminoglycosides. The catA1 and cmlA confer resistance to 
chloramphenicols. The blaCTX-M-1, blaCTX-M-9, blaTEM-1 and blaOXA-1 genes confer resistance to β-lactams. The dfr12, dfrA14 and 
dfrA17 genes confer resistance to trimethoprims. Sulphonamide resistance genes include; sul1, sul2 and sul3. Tetracycline resistance 
genes included; tetA and tetB. The integron class 1 associated integrase gene is denoted as intI1 and is commonly associated with 
multidrug resistance gene cassettes. ND: not done. 
 
5.3.1 Analysis of pI1-34TF 
This plasmid was identified as a ~175 kb IncFIA-FIB fusion replicon plasmid, isolated 
from the I1-34 field stain. Nucleotide sequence analysis (see chapter 2, section 2.4.11) 
revealed this plasmid to harbour a blaCTX-M-15 ESBL variant. This plasmid was selected 
for sequence analysis due to the multiple drug resistance genes identified by DNA 
microarray analysis in the transformant pI1-34TF. This plasmid was found to harbour 
resistance genes to six classes of drugs including, aminoglycosides, β-lactams, 
chloramphenicols, sulphonamides, tetracyclines and trimethoprims, with a total of 10 
antimicrobial resistance genes (see table 5-1).  
 
5.3.1.1 Plasmid scaffold 
Plasmid pI1-34TF was found to have an overall 57 % nucleotide identity to pIP1206; a 
multidrug resistance E. coli IncFII-FIA-FIB plasmid isolated from bovine faeces 
(GenBank AM886293.1) (Perichon et al., 2008) (see Fig. 5-1A). This plasmid 
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harboured 217 predicted open reading frames (ORFs, see table 5-2). Regions of 
homology included the tra and trb conjugative systems, antimicrobial resistance genes 
conferring resistance to chloramphenicol (catA1), tetracycline (tetB) and quinolones 
(qepA) (Lawley et al., 2003). Plasmid pI1-34TF was found to encode the repE gene of 
the FIA replicon, repA of FIB and the regulators of FII replicon (repA1-A4 and A6). 
Plasmid pIP1206 however did not encode a blaCTX-M gene.  
The blaCTX-M-15 gene and surrounding regions of pI1-34TF was found to be similar to 
two plasmids, pEK499 (GenBank EU935739) (Woodfoord et al., 2009) (Fig. 5-1B) and 
pEC-L8 (GenBank GU371928) (Smet et al., 2010) (Fig. 5-1C), with 39 % (66 kb) and 
37 % (62 kb) overall nucleotide identity respectively to pI1-34TF encoding mainly the 
transfer genes (tra), resistance genes (aac(6)lb, blaOXA-1, blaCTX-M-15, blaTEM-1) and post-
segregational killing (PSK) systems (ccdA/ccdB, hok/mok). Both of these plasmids 
harboured fusion replicons IncFII-FIA and were previously found to have 75 % 
homology to each other (Smet et al., 2010).  
  
 165 
 
 
 
Figure 5-1: Sequence alignments of pI1-34TF with (A) pIP1206 and (B) pEK499 using WebACT 
(www.webact.org) with a cut-off of 1000 bp. (A) Plasmid pI1-34TF was found to have 57 % nucleotide 
identity to pIP1206, an IncFIA-FIB-FII plasmid. pIP206 did not encode any blaCTX-M genes. (B) Plasmid 
pI1-34TF was found to have 39 % nucleotide identity to IncFII-FIA blaCTX-M-15 plasmid pEK499. (C) 
Plasmid pI1-34TF was found to have 37 % nucleotide identity to IncFII-FIA blaCTX-M-15 pEC-L8 plasmid.  
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Table 5-2: Predicted open reading frames identified in pI1-34TF. 
 
Continued on the following page. 
 
Contig Function Start Stop Strand
1 Aerobactin siderophore receptor IutA @ TonB-dependent siderophore receptor 2672 471 -
1 L-lysine 6-monooxygenase [NADPH] (EC 1.14.13.59), aerobactin biosynthesis protein IucD 4031 2754 -
1 Citrate:6-N-acetyl-6-N-hydroxy-L-lysine ligase, alpha subunit (EC 6.3.2.27), aerobactin biosynthesis protein IucA 5770 4028 -
1 N6-hydroxylysine O-acetyltransferase (EC 2.3.1.102), aerobactin biosynthesis protein IucB 6717 5770 -
1 Citrate:6-N-acetyl-6-N-hydroxy-L-lysine ligase, alpha subunit (EC 6.3.2.27), aerobactin biosynthesis protein IucA 8442 6718 -
1 hypothetical protein 8578 9771 +
1 hypothetical protein 9835 9978 +
1 Enolase (EC 4.2.1.11) 11306 10872 -
1 Manganese ABC transporter, inner membrane permease protein SitD 12328 11774 -
1 Manganese ABC transporter, inner membrane permease protein SitD 12630 12310 -
1 Manganese ABC transporter, inner membrane permease protein SitC 13484 12627 -
1 Manganese ABC transporter, ATP-binding protein SitB 14308 13481 -
1 Manganese ABC transporter, periplasmic-binding protein SitA 15222 14308 -
2 COG2963: Transposase and inactivated derivatives 99 455 +
2 unknown in ISEc8 452 802 +
2 COG3436: Transposase and inactivated derivatives 833 1054 +
2 COG3436: Transposase and inactivated derivatives 1162 1347 +
2 Arginine pathway regulatory protein ArgR, repressor of arg regulon 1890 1411 -
2 Arginine/ornithine antiporter ArcD 3374 1971 -
2 Ornithine carbamoyltransferase (EC 2.1.3.3) 4426 3422 -
2 Carbamate kinase (EC 2.7.2.2) 5422 4511 -
2 Arginine deiminase (EC 3.5.3.6) 6653 5433 -
2 hypothetical protein 7459 7313 -
2 Hemolysin 7494 7739 +
2 FIG00244926: hypothetical protein 7742 7861 +
2 RepA1 8419 7967 -
2 Replication regulatory protein repA2 8979 8722 -
2 hypothetical protein 9159 9281 +
2 SrnB 9412 9263 -
2 hypothetical protein 9838 9656 -
3 hypothetical protein 2061 2381 +
3 FIG00641101: hypothetical protein 2563 2420 -
3 IncF plasmid conjugative transfer protein TraR 2738 2517 -
3 IncF plasmid conjugative transfer pilus assembly protein TraV 3388 2873 -
3 IncF plasmid conjugative transfer protein TrbG 3636 3385 -
3 IncF plasmid conjugative transfer protein TrbD 3845 3648 -
3 IncF plasmid conjugative transfer protein TraP 4422 3832 -
3 IncF plasmid conjugative transfer pilus assembly protein TraB 5839 4412 -
3 IncF plasmid conjugative transfer pilus assembly protein TraK 6567 5839 -
3 IncF plasmid conjugative transfer pilus assembly protein TraE 7120 6554 -
3 IncF plasmid conjugative transfer pilus assembly protein TraL 7453 7142 -
3 IncF plasmid conjugative transfer pilin protein TraA 7833 7468 -
3 IncF plasmid conjugative transfer regulator TraY 8261 7866 -
3 IncF plasmid conjugative transfer regulator TraJ 9049 8360 -
3 IncF plasmid conjugative transfer mating signal transduction protein TraM 9619 9236 -
3 X polypeptide 9949 10542 +
3 putative ORF 10702 10568 -
3 unnamed protein product 11767 10838 -
3 FIG00638017: hypothetical protein 12064 11777 -
3 hypothetical protein 12128 12364 +
3 hypothetical protein 12420 12698 +
3 hypothetical protein 12860 12705 -
3 F leading maintenance 13143 12985 -
3 hypothetical protein 14094 13243 -
3 Transposase 14375 14091 -
3 Protein sok 14669 14857 +
3 PsiA protein 15588 14869 -
3 PsiB protein 16019 15585 -
3 Probable chromosome partitioning protein parB 16208 16074 -
3 Putative cytoplasmic protein 16532 16299 -
3 Single-stranded DNA-binding protein 17052 16600 -
3 Retron-type reverse transcriptase 19148 17247 -
3 hypothetical protein 19890 20093 +
3 hypothetical protein 20424 20272 -
3 FIG00643413: hypothetical protein 20654 20442 -
3 Plasmid pO157 DNA, complete sequence 20916 20680 -
3 FIG00638607: hypothetical protein 21245 20889 -
3 hypothetical plasmid protein 22654 21293 -
3 YdaB 22936 22706 -
3 FIG00639443: hypothetical protein 23168 23028 -
3 hypothetical protein 23283 23155 -
3 hypothetical protein 23482 23763 +
3 hypothetical protein 24159 23968 -
3 Orf52 protein 24578 24156 -
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Table 5-2: continued. 
 
 
Continued on the following page. 
Contig Function Start Stop Strand
3 Putative antirestriction protein 25050 24625 -
3 hypothetical protein 25206 25346 +
3 FIG00638373: hypothetical protein 26234 25464 -
3 YcgB 26713 26279 -
3 putative cytoplasmic protein 26948 26727 -
3 Adenine-specific methyltransferase (EC 2.1.1.72) 27632 26949 -
3 FIG00637984: hypothetical protein 27740 27865 +
3 Plasmid PO157 DNA, complete sequence 28943 28017 -
3 Chromosome (plasmid) partitioning protein ParB 30628 29657 -
3 Chromosome (plasmid) partitioning protein ParA 31785 30628 -
3 FIG00639997: hypothetical protein 31750 31902 +
3 Replication initiation protein RepE 33137 32382 -
3 FIG00638134: hypothetical protein 33665 33546 -
3 Resolvase 34665 33859 -
3 CcdB toxin protein 34971 34666 -
3 CcdA protein (antitoxin to CcdB) 35191 34973 -
3 hypothetical protein 35633 35436 -
3 Virulence-associated protein vagC 35751 35981 +
3 VagD 35978 36394 +
3 FIG131328: Predicted ATP-dependent endonuclease of the OLD family 36469 38034 +
3 FIG116849: hypothetical protein 38019 39041 +
3 hypothetical protein 39261 39097 -
4 aminoglycoside-(3)-N-acetyltransferase 36 896 +
4 hypothetical protein 2124 1933 -
4 hypothetical protein 2130 2375 +
4 hypothetical protein 2977 2861 -
5 Transposon modulator protein 349 149 -
5 Integron integrase IntI1 1715 702 -
5 Dihydrofolate reductase (EC 1.5.1.3) 1873 2346 +
5 Streptomycin 3''-O-adenylyltransferase (EC 2.7.7.47) 2477 3265 +
5 Ethidium bromide-methyl viologen resistance protein EmrE 3471 3818 +
5 Dihydropteroate synthase (EC 2.5.1.15) 3812 4651 +
5 similar to puromycin N-acetyltransferase 4779 4982 +
5 Chromate transport protein ChrA 5138 6343 +
5 Transcriptional regulator, PadR family 6354 6659 +
5 FIG00643008: hypothetical protein 6798 6685 -
5 Transposase 6886 7650 +
5 Repressor protein MphR(A) 8619 8143 -
5 major facilitator superfamily MFS_1 9965 8727 -
5 Macrolide 2'-phosphotransferase I 10219 9962 -
5 unnamed protein product 10253 10888 +
6 Beta-lactamase (EC 3.5.2.6)-blaOXA-1 1457 582 -
7 orf; Unknown function (Insertion Sequence Associated) 1518 1171 -
7 Insertion Sequence Associated 1919 1515 -
7 IncF plasmid conjugative transfer pilus assembly protein TraC 1918 2280 +
7 IncF plasmid conjugative transfer protein TrbI 2277 2663 +
7 IncF plasmid conjugative transfer pilus assembly protein TraW 2660 3292 +
7 IncF plasmid conjugative transfer pilus assembly protein TraU 3289 4281 +
7 IncF plasmid conjugative transfer protein TrbC 4290 4928 +
7 IncF plasmid conjugative transfer protein TraN 4925 6733 +
7 IncF plasmid conjugative transfer protein TrbE 6760 7017 +
7 IncF plasmid conjugative transfer pilus assembly protein TraF 7010 7753 +
7 IncF plasmid conjugative transfer protein TrbA 7767 8108 +
7 hypothetical protein 8424 8089 -
7 IncF plasmid conjugative transfer protein TraQ 8505 8789 +
7 IncF plasmid conjugative transfer protein TrbB 8776 9330 +
7 IncF plasmid conjugative transfer protein TrbJ 9320 9634 +
7 IncF plasmid conjugative transfer protein TrbF 9588 9980 +
7 IncF plasmid conjugative transfer pilus assembly protein TraH 9967 11340 +
7 IncF plasmid conjugative transfer protein TraG 11337 14162 +
7 IncF plasmid conjugative transfer surface exclusion protein TraS 14159 14668 +
7 IncF plasmid conjugative transfer surface exclusion protein TraT 14682 15413 +
7 hypothetical protein 15623 15501 -
7 IncF plasmid conjugative transfer protein TraD 15665 15805 +
7 IncF plasmid conjugative transfer protein TraD 15826 17862 +
7 IncF plasmid conjugative transfer DNA-nicking and unwinding protein TraI 17862 22982 +
7 IncF plasmid conjugative transfer pilin acetylase TraX 23002 23748 +
7 IncF plasmid conjugative transfer fertility inhibition protein FinO 23752 24363 +
7 FIG00640595: hypothetical protein 24497 24709 +
7 putative nuclease 24894 25016 +
7 hypothetical protein 25177 25010 -
7 Insertion Sequence Associated 25184 25831 +
7 orf, conserved hypothetical protein 25831 26178 +
7 Transposase 26198 27769 +
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Table 5-2: continued. 
 
Contig Function Start Stop Strand
8 FIG00640301: hypothetical protein 97 216 +
8 insertion sequence IS100, ATP-binding protein 1039 260 -
8 Transposase 2061 1039 -
8 Transposase 2833 2075 -
8 Transposase 3092 2835 -
8 hypothetical protein 3434 3141 -
9 transposase TnpA 755 51 -
10 Transposase 436 41 -
11 Right origin-binding protein 670 254 -
11 transposon tn10 tetc protein 758 1351 +
11 Tetracycline efflux protein TetA 2687 1464 -
11 Transcriptional regulator, ArsR family 3897 3352 -
11 IS1 ORF2 5062 4685 -
11 Insertion element protein 5382 5107 -
11 Chloramphenicol acetyltransferase (EC 2.3.1.28) 5661 6320 +
11 YbjA protein 6898 6521 -
11 TnpA transposase 9931 6965 -
11 resolvase 10308 9934 -
12 Beta-lactamase (EC 3.5.2.6)-blaTEM-1 181 1041 +
12 InsA protein (Fragment) 1318 1136 -
12 hypothetical protein 2628 1318 -
12 Programmed cell death toxin PemK 3245 2913 -
12 Programmed cell death antitoxin PemI 3504 3247 -
12 microcin M activity protein McmM 4250 3597 -
12 hypothetical protein 4369 4247 -
12 hypothetical protein 4488 4348 -
12 RepA1 6046 5189 -
12 Replication regulatory protein repA2 (Protein copB) 6605 6348 -
12 COG3547: Transposase and inactivated derivatives 7010 8032 +
12 hypothetical protein 8504 8857 +
12 COG1112: Superfamily I DNA and RNA helicases and helicase subunits 9770 9270 -
13 Transposase 23 268 +
13 stable plasmid inheritance protein 270 446 +
13 Error-prone, lesion bypass DNA polymerase V (UmuC) 837 448 -
13 Transposase 1451 1095 -
13 hypothetical protein 1897 1673 -
13 hypothetical protein 2034 2204 +
13 RepFIB replication protein A 2197 3174 +
13 FIG00243898: hypothetical protein 3369 3250 -
13 RepFIB associated resolvase 4199 3459 -
13 hypothetical protein 4356 4475 +
13 hypothetical protein 4559 4699 +
13 FIG00642198: hypothetical protein 5033 6043 +
13 FIG00643263: hypothetical protein 6259 6372 +
13 FIG00641477: hypothetical protein 7493 7377 -
13 Transposase insC for insertion element IS2A/D/F/H/I/K 8121 7756 -
13 Colicin I receptor precursor 8487 10373 +
13 FIG00640645: hypothetical protein 10380 11171 +
14 hypothetical protein 257 376 +
14 TnpA transposase 90 2411 +
14 Glucose-1-phosphatase (EC 3.1.3.10) 3331 2588 -
14 hypothetical protein 3475 3353 -
14 hypothetical protein 3938 3453 -
14 Putative thioredoxin precursor 4448 3963 -
14 ABC transporter, ATP-binding subunit precursor 5130 4435 -
14 membrane protein 6265 5135 -
14 Similar to ABC transporter: eg YBJZ_ECOLI hypothetical ABC transporter 7538 6255 -
14 Putative membrane protein 8920 7541 -
14 Periplasmic protein p19 involved in high-affinity Fe2+ transport 9551 9024 -
14 Putative high-affinity iron permease 11532 9592 -
14 FIG00640820: hypothetical protein 11593 11751 +
14 Na(+)-translocating NADH-quinone reductase subunit C (EC 1.6.5.-) 12586 11825 -
14 Membrane protein, suppressor for copper-sensitivity ScsD 13329 12823 -
14 Secreted protein, suppressor for copper-sensitivity ScsC 13477 13319 -
14 hypothetical protein 13758 13627 -
15 Tryptophan synthase beta chain like (EC 4.2.1.20) 2321 2593 +
15 Beta-lactamase (EC 3.5.2.6)-blaCTX-M-15 3515 2640 -
15 hypothetical protein 3790 3668 -
15 transposase InsC3 for insertion sequence ISEc9 5033 3771 -
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5.3.1.2 Plasmid transfer, establishment and maintenance 
Plasmid pI1-34TF was found to harbour three replication systems of the IncFIA, FIB 
and FII group. Multiple replicons have been identified previously on plasmids 
harbouring the blaCTX-M-15 gene isolated from human samples in America, Australia, 
Europe and India (Carattoli, 2009). Multireplicon plasmids are thought to be 
advantageous due to the ability of the plasmid to drive replication from any of the 
available replication origins. If a plasmid with the same replicon were to be introduced 
into the same host, provided the resident plasmid is driving expression from one of its 
alternative replicons, the incoming plasmid will be able to replicate, because in this 
instance they would be compatible (Villa et al., 2010). Furthermore, the replicon that is 
not involved in replication initiation can undergo mutational changes resulting in 
divergent replicons that will enable other IncF plasmids to be acquired, thus breaking 
the incompatibility barrier.  
Plasmid pI1-34TF was found to encode tra and trb conjugative genes, which code for 
the F-pilus, which accounted for at least 16 % of the genes identified. Plasmid 
maintenance systems identified on this plasmid included four toxin-antitoxin genes 
(ccdB/ccdA, hok/mok, pemK/pemI and vagD/vagC) and partitioning systems 
(sopA/sopB). These PSK systems were also identified in pEK499 carrying a total of five 
killing systems and plasmid pIP1206 carrying three of the four toxin-antitoxin genes 
identified on this plasmid (Perichon et al., 2008; Woodford et al., 2009). These systems 
are thought to ensure plasmid inheritance in the absence of antimicrobial selection. 
5.3.1.3 Mobile genetic elements 
Eighteen percent of the genes identified from the draft plasmid genome were associated 
with horizontal gene transfer including transposases and resolvases, which include 
genes associated with transposons Tn21, and Tn3 and IS elements: IS1, IS2, IS26, 
IS6100, and ISEcp1B. Also identified were class 1 integron associated genes tnpM 
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(transposase) and intI1 (integrase). The integron associated genes were found in one 
contig encoding a Tn21 modulator protein (tnpM), and two transposase genes (tnpA); 
one of which was associated with IS6100, an integrase gene (intI1), a putative chromate 
transporter (chrA) and four resistance genes (dfrA7, aadA4, sulI, mphA). This region 
showed 99 % similarity to a homologous region in pEK499 (Woodford et al., 2009), but 
unlike pEK499, which was flanked by an IS26 transposase, the blaCTX-M-15 gene of pI1-
34TF harboured an ISEcp1- blaCTX-M-15-orf477Δ transposon unit similar to a blaCTX-M-15 
harbouring IncFII plasmid pEK516 (GenBank EU935738) (Woodford et al., 2009) (see 
Fig. 5-2). 
 
Figure 5-2: A schematic diagram of the genetic organisation surrounding the blaCTX-M-15 gene. 
This region was found to be similar (100 % homology) to an IncFII plasmid pEK516 (GenBank 
EU935738). The arrows indicate the orientation of each of the genes identified, which encoded the 
ISEcp1 transposase upstream of the blaCTX-M-15 gene and downstream was the hypothetical protein 
orf477Δ (amb).  
 
5.3.1.1 Drug resistance 
Ten antimicrobial resistance genes were identified by sequencing conferring resistance 
to aminoglycosides (aac(6’)lb and aadA4), chloramphenicol (catA1), trimethoprims 
(dfrA17), sulphonamides (sul1), a macrolide inactivation cluster (mphR-mrx-mphA) and 
ESBL genes blaTEM-1, blaOXA-1 and blaCTX-M-15. Genes conferring resistance to 
tetracycline included tetR (repressor), tetC, tetD and tetA(B) (efflux pumps). The 
nanoarray results identified this plasmid as encoding the tetB gene, however, the 
sequencing results identified the tetA(B) gene. The tetA(B) gene encoded on this 
plasmid was found to have 100 % nucleotide identity to tetA(B) of pIP1206 (GenBank 
CAP07771), a gene highly similar (99 % amino acid alignment) to tetB of Haemophilus 
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parasuis (GenBank YP_195816.1), but only 44 % similar (amino acid alignment) to E. 
coli tetA (GenBank ACQ42041) (Perichon et al., 2008) (see Fig. 5-3). These results 
suggest that the array is capable of detecting this variant of tet gene. Both proteins 
belong to the major facilitator superfamily involved in tetracycline efflux in an 
electrochemical proton gradient depended process (Kimura et al., 1998; Saraceni-
Richards and Levy, 2000; Speer et al., 1992). 
Other genes conferring resistance to various compounds included resistance to 
chromates (chrA), quaternary ammonium compounds (qacE) and copper (scsS/scsD).  
Also identified were ATP-binding cassette (ABC) proteins, permeases and major 
facilitator (MFS) transporters predicted to be involved in iron/manganese transport 
(sitABCD). The role of these transporters in virulence and plasmid maintenance have 
not been confirmed, although the plasmid mediated iron transporters are thought to 
contribute to the virulence of pathogenic bacteria harbouring these plasmids, by 
enabling iron capture in the low iron environment, such as in the humans and animal 
hosts (Janakiraman and Slauch, 2000; Szczepanowski, et al., 2005). 
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tetAB_CAP07771        ---------------------------MNSSTKIALVITLLDAMGIGLIMPVLPTLLREF 33 
tetB_YP_195816.1      MNCEFKLIYC----ILKIRKVKIEKSEMNSSTKIALVITLFDAMGIGLIMPVLPTLLREF 56 
tetA_ACQ42041         MSTNLSVIKNPRVQSDQRRLVRRPDVKPNRPLIVILSTVALDAVGIGLIMPVLPGLLRDL 60 
                                                  * .  : *  . :**:********** ***:: 
 
tetAB_CAP07771        IASEDIANHFGVLLALYALMQVIFAPWLGKMSDRFGRRPVLLLSLIGASLDYLLLAFSSA 93 
tetB_YP_195816.1      IASEDIANHFGVLLALYALMQVIFAPWLGKMSDRFGRRPVLLLSLIGASLDYLLLAFSSA 116 
tetA_ACQ42041         VHSNDVTAHYGILLALYALMQFACAPVLGALSDRFGRRPVLLVSLAGAAVDYAIMATAPF 120 
                      : *:*:: *:*:*********.  ** ** :***********:** **::** ::* :.  
 
tetAB_CAP07771        LWMLYLGRLLSGITGATGAVAASVIADTTSASQRVKWFGWLGASFGLGLIAGPIIGGFAG 153 
tetB_YP_195816.1      LWMLYLGRLLSGITGATGAVAASVIADTTSASQRVKWFGWLGASFGLGLIAGPIIGGFAG 176 
tetA_ACQ42041         LWVLYIGRIVAGITGATGAVAGAYIADITDGDERARHFGFMSACFGFGMVAGPVLGGLMG 180 
                      **:**:**:::**********.: *** *...:*.: **::.*.**:*::***::**: * 
 
tetAB_CAP07771        EISPHSPFFIAALLNIVAFLVVMFWFRETKNTRDNTDTEVGVETQSNSVYITLFKTMPIL 213 
tetB_YP_195816.1      EISPHSPFFIAALLNIVTFLVVMFWFRETKNTRDNTDTEVGVETQSNSVYITLFKTMPIL 236 
tetA_ACQ42041         GFSPHAPFFAAAALNGLNFLTGCFLLPESHKGERRPLRREALNPLASFRWARGMTVVAAL 240 
                       :***:*** ** ** : **.  * : *::: . ..  . .::. :.  :   :..:. * 
 
tetAB_CAP07771        LIIYFSAQLIGQIPATVWVLFTENRFGWNSMMVGFSLAGLGLLHSVFQAFVAGRIATKWG 273 
tetB_YP_195816.1      LIIYFSAQLIGQIPTTVWVLFTENRFGWNSMMVGFSLAGLGLLHSVFQAFVAGRIATKWG 296 
tetA_ACQ42041         MAVFFIMQLVGQVPAALWVIFGEDRFHWDATTIGISLAAFGILHSLAQAMITGPVAARLG 300 
                      : ::*  **:**:*:::**:* *:** *::  :*:***.:*:***: **:::* :*:: * 
 
tetAB_CAP07771        EKTAVLLGFIADSSAFAFLAFISEGWLVFPVLILLAGGGIALPALQGVMSIQTKSHQQGA 333 
tetB_YP_195816.1      EKTAVLLGFIADSSAFAFLAFISEGWLVFPVLILLAGGGIALPALQGVMSIQTKSHQQGA 356 
tetA_ACQ42041         ERRALMLGMIADGTGYILLAFATRGWMAFPIMVLLASGGIGMPALQAMLSRQVDEERQGQ 360 
                      *: *::**:***.:.: :*** :.**:.**:::***.***.:****.::* *....:**  
 
tetAB_CAP07771        LQGLLVSLTNATGVIGPLLFAVIYNHSLPIWDGWIWIIGLAFYCIIILLSMTFMLTPQAQ 393 
tetB_YP_195816.1      LQGLLVSLTNATGVIGPLLFAVIYNHSLPIWDGWIWIIGLAFYCIIILLSMTFMLTPQAQ 416 
tetA_ACQ42041         LQGSLAALTSLTSIVGPLLFTAIYAASITTWNGWAWIAGAALY----LLCLPALRRGLWS 416 
                      *** *.:**. *.::*****:.**  *:. *:** ** * *:*    **.:. :     . 
 
tetAB_CAP07771        GSKQETSA 401 
tetB_YP_195816.1      GSKQETSA 424 
tetA_ACQ42041         GAGQRADR 424 
                      *: *.:. 
 
Figure 5-3: Amino acid alignment of TetA(B) of pI1-34TF, which has 100 % nucleotide identity to 
TetA(B) of  pIP1206 (GenBank CAP07771). This protein was found to have 99 % homology to TetB of 
Haemophilus parasuis (GenBank YP_195816.1) but only 44 % homologous to E. coli TetA (GenBank 
ACQ42041). Alignments were performed using the web based ClustalW algorithm (ww.ebi.ac.uk).  Key: 
“*”; identical,  “:” (colon) and “.” (dot/full stop) are conserved and semiconserved substitutions 
respectively. 
 173 
5.3.1.2 Hypothesis of plasmid evolution 
Plasmid pI1-34TF was found to harbour three replicons FIA, FIB and FII. The plasmid 
scaffold was a mosaic of different plasmids, in that only about 60 % of the plasmid was 
homologous to pIP1206; previously identified as harbouring the IncFIA-FIB-FII 
multiple replicon and only about 45-50 % similarity to pEK499 and pEC-L8 harbouring 
the blaCTX-M-15 gene on an IncFII-FIA fusion plasmid. The ability of the plasmid to 
switch replication to a different replicon (IncFIA, FIB or FII) could enable the 
acquisition of an additional plasmid harbouring an IncF replication system to replicate 
in the same cell. The coexistence with other IncF-like plasmids may enable 
recombination between other incoming (but not limited to) IncF plasmids resulting in 
the variability observed between this plasmid and other IncF mutlireplicon plasmids.  
Furthermore, the parent strain was found to harbour multiple plasmids leading to the 
possibility of recombination events occurring between the pI1-34TF plasmid and other 
plasmids harboured within the strain, further expanding the genetic pool available to 
contribute to genetic plasticity of the plasmid. The mosaic nature of pI1-34TF plasmid 
scaffold is most likely the result of multiple recombination or transposition events that 
have occurred mediated by regions of homology (site specific or homologous 
recombination).   
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5.3.2 Analysis of pI2-47TC 
Replicon typing identified this plasmid as belonging to the IncI1 group and it was found 
to be ~ 86 kb in size. This plasmid co-transferred along with a smaller ~35 kb plasmid 
(pI2-47TF) found to be untypeable using the PBRT scheme (table 5-1). DNA was 
extracted from the transconjugant derivative of this plasmid (pI2-47TC) and introduced 
into E. coli DH10B by transformation. This plasmid was selected for sequencing 
because of the nature of the co-transfer of the two plasmids. The resulting sequenced 
plasmid pI2-47TC was found to be approximately 127 kb in size. Sequence analysis of 
this plasmid and the possible hypothesis of the evolution of this plasmid are discussed 
below. 
5.3.2.1 Plasmid scaffold 
The sequence pI2-47TC was found to have 59 % similarity (75 kb) to a 93 kb IncI1 
plasmid; pEK204 (GenBank EU935740) isolated in E. coli encoding the blaCTX-M-3 
variant (Woodford et al., 2009) (see Fig. 5-4A). This plasmid harboured 175 predicted 
ORFs (see table 5-3). Regions of similarity included; extensive conjugative transfer 
genes tra (~ 25 kb), trb (~ 5 kb) and pil (~ 11 kb) loci; plasmid maintenance proteins 
encoded by psiB and ssb; and the IncI1 repZ replicase gene. The repZ gene and type IV 
pili are characteristics of IncI1 plasmids (Woodford et al., 2009).  
In addition to the IncI1-like conjugative systems identified, pI2-47TC was found to 
encode genes showing 99-100% identity to taxABC and pilX genes and a π replication 
protein (pir). These are conjugative systems characteristic of IncX plasmids (Chu et al., 
2008; Nunez et al., 1997; Norman et al., 2008; Partridge et al., 2011). Plasmid pI2-
47TC was found to have 25 % (31 kb) overall similarity to a 34.3 kb IncX1 plasmid 
pJIE143 (GenBank JN194214), isolated in E. coli encoding the blaCTX-M-15 variant 
(Partridge et al., 2011) (see Fig. 5-4B).  
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Figure 5-4: Sequence alignments of (A) pI2-47TC with pEK204 and (B) pJIE143 using WebACT 
(www.webact.org) with a cut-off of 1000 bp. A) Plasmid pEK204 (GenBank EU935740) was found to 
have 59 % similarity to pI2-47TC. B) Plasmid pJIE143, an IncX1 plasmid was found to have 25 % 
similarity to pI2-47TC. C) Homology of a ~ 3kb region encoding the ISEcp1 mobile element (100 % 
similarity) and blaCTX-M gene (99 %) was observed between the pJIE143 (blaCTX-M-15) and pEK204 blaCTX-
M-3, which only differ by one amino acid base change (D240G). The ISEcp1 region homology was shared 
with pI2-47TC but this plasmid was found to harbour a blaCTX-M-14b gene. 
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Table 5-3: Predicted open reading frames identified in pI2-47TC. 
 
Continued on the following page. 
 
Contig Function Start Stop Strand
1 Shufflon-specific DNA recombinase 33 1220 +
1 IncI1 plasmid conjugative transfer protein TraE 1371 2195 +
1 IncI1 plasmid conjugative transfer protein TraF 2281 3483 +
1 IncI1 plasmid conjugative transfer protein TraG 3543 4127 +
1 hypothetical protein 4290 4141 -
1 IncI1 plasmid conjugative transfer protein TraH 4522 4980 +
1 IncI1 plasmid conjugative transfer protein TraI 4977 5795 +
1 IncI1 plasmid conjugative transfer protein TraJ, related to pilus biogenesis/retracton protein 5792 6940 +
1 IncI1 plasmid conjugative transfer protein TraK 6937 7227 +
1 Plasmid conjugative transfer endonuclease 7242 7793 +
1 IncI1 plasmid conjugative transfer DNA primase 7883 11650 +
1 IncI1 plasmid conjugative transfer protein TraL 11668 12015 +
1 IncI1 plasmid conjugative transfer protein TraM 12012 12704 +
1 IncI1 plasmid conjugative transfer protein TraN 12715 13698 +
1 IncI1 plasmid conjugative transfer protein TraO 13701 14990 +
1 IncI1 plasmid conjugative transfer protein TraP 14990 15694 +
1 IncI1 plasmid conjugative transfer protein TraQ 15694 16221 +
1 IncI1 plasmid conjugative transfer protein TraR 16272 16676 +
1 IncI1 plasmid conjugative transfer protein TraS 16740 16928 +
1 IncI1 plasmid conjugative transfer protein TraT 16912 17712 +
1 IncI1 plasmid conjugative transfer protein TraU 17709 20846 +
1 IncI1 plasmid conjugative transfer protein TraV 20846 21460 +
1 IncI1 plasmid conjugative transfer protein TraW 21427 22629 +
1 IncI1 plasmid conjugative transfer protein TraX 22658 23242 +
1 IncI1 plasmid conjugative transfer integral membrane protein TraY 23270 25507 +
1 surface exclusion protein 25581 26231 +
1 hypothetical protein 26512 26303 -
1 hypothetical protein 26747 26875 +
1 FIG00641806: hypothetical protein 26903 27079 +
1 hypothetical protein 27695 27567 -
1 FIG01047462: hypothetical protein 27738 27989 +
1 post-segregation killing protein 28216 28061 -
1 TrbA 28505 29713 +
1 TrbB protein 29732 30802 +
1 FIG00640314: hypothetical protein 30795 33086 +
1 involved in conjugative DNA transfer 35822 33123 -
1 Nickel ABC transporter, periplasmic nickel-binding protein NikA (TC 3.A.1.5.3) 36165 35833 -
1 hypothetical protein 36293 36409 +
1 hypothetical protein 36399 36734 +
1 YdiA 37668 36820 -
1 hypothetical protein 37874 37710 -
1 hypothetical protein 37900 38013 +
1 hypothetical protein 38017 38214 +
1 FIG00642528: hypothetical protein 38248 38499 +
1 FIG00639209: hypothetical protein 38727 38530 -
1 Transposase 39454 38750 -
1 hypothetical protein 39684 39568 -
1 Mobile element protein 39686 41221 +
1 Mobile element protein 41238 41993 +
1 YDFB protein 42639 42373 -
1 FIG01046738: hypothetical protein 43167 42733 -
1 hypothetical protein 43166 43360 +
1 hypothetical protein 43353 43475 +
1 hypothetical protein 43912 43769 -
1 Antirestriction protein ArdA 44575 43896 -
1 hypothetical protein 45454 44858 -
1 PsiA protein 46170 45451 -
1 PsiB protein 46604 46167 -
1 FIG01047988: hypothetical protein 48614 46656 -
1 UPF0401 protein yubL 48906 48673 -
1 Single-stranded DNA-binding protein 49491 48964 -
1 hypothetical protein 50189 49875 -
1 FIG00638431: hypothetical protein 50451 50260 -
1 FIG01047188: hypothetical protein 50870 50448 -
1 Putative antirestriction protein 51342 50917 -
1 hypothetical protein 51637 51308 -
1 unknown; orf44 51752 51591 -
1 FIG00638373: hypothetical protein 52531 51755 -
1 YcgB 53011 52577 -
1 putative cytoplasmic protein 53246 53025 -
1 Adenine-specific methyltransferase (EC 2.1.1.72) 53930 53247 -
1 FIG00637984: hypothetical protein 54037 54162 +
1 FIG01048508: hypothetical protein 55216 54314 -
1 hypothetical protein 55258 55371 +
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Contig Function Start Stop Strand
1 hypothetical protein 55473 55882 +
1 Error-prone repair protein UmuD 55879 56316 +
1 Error-prone, lesion bypass DNA polymerase V (UmuC) 56316 57590 +
1 stable plasmid inheritance protein 58008 57592 -
1 Putative stability/partitioning protein encoded within prophage CP-933T-stbB 59023 58001 -
1 ybiA 59702 59394 -
1 FIG01048970: hypothetical protein 60466 59789 -
1 Resolvase 61392 60613 -
1 FIG00642857: hypothetical protein 61807 61394 -
1 Virulence-associated protein vagC 62381 62611 +
1 VagD 62608 63024 +
1 Beta-lactamase (EC 3.5.2.6) 64082 63222 -
1 Resolvase/integrase Bin 64822 64265 -
1 transposase 64986 67991 +
1 hypothetical protein 69218 69367 +
1 FIG00644632: hypothetical protein 69684 70286 +
1 FIG00643565: hypothetical protein 70303 70836 +
1 hypothetical protein 71054 71203 +
1 stability (stb) locus of IncFII plasmid NR1; similar to SwissProt accession number P11907 71575 71297 -
1 FIG01069112: hypothetical protein 71956 71681 -
1 hypothetical protein 72234 71956 -
1 hypothetical protein 72676 72792 +
1 replication initiation protein 74224 73148 -
1 hypothetical protein 74155 74475 +
1 hypothetical protein 75333 75620 +
1 hypothetical protein 75934 76056 +
1 IncI1 plasmid conjugative transfer NusG-type transcription antiterminator TraB 76062 76595 +
1 hypothetical protein 76745 76629 -
1 IncI1 plasmid conjugative transfer protein TraC 76794 77531 +
1 hypothetical protein 77704 78255 +
1 IncI1 plasmid conjugative transfer protein PilI 78417 78671 +
1 hypothetical protein 79040 78777 -
1 IncI1 plasmid conjugative transfer protein PilK 79431 79724 +
1 IncI1 plasmid conjugative transfer protein PilL 80053 81120 +
1 IncI1 plasmid conjugative transfer protein PilM 81120 81557 +
1 IncI1 plasmid conjugative transfer lipoprotein PilN 81571 83253 +
1 IncI1 plasmid pilus assembly protein PilO 83246 84541 +
1 IncI1 plasmid pilus assembly protein PilP 84528 84980 +
1 IncI1 plasmid conjugative transfer ATPase PilQ 84991 86544 +
1 IncI1 plasmid conjugative transfer inner membrane protein PilR 86557 87642 +
1 IncI1 plasmid conjugative transfer prepilin PilS 87659 88273 +
1 IncI1 plasmid conjugative transfer putative membrane protein PilT 88589 88843 +
1 Type-IV sectretion leader peptidase/N-methyltransferase 88828 89484 +
1 hypothetical protein 435 560 +
2 hypothetical protein 920 804 -
2 PI protein (Replication initiation protein) 1009 1881 +
2 hypothetical protein 1936 2298 +
2 hypothetical protein 2433 2960 +
2 hypothetical protein 3304 3444 +
2 FIG01069805: hypothetical protein 3795 3544 -
2 FIG01069787: hypothetical protein 4133 3831 -
2 Chromosome (plasmid) partitioning protein ParA 4886 4227 -
2 Resolvase 5857 4991 -
2 hypothetical protein 6349 6155 -
2 hypothetical protein 7365 6709 -
2 DNA-binding protein H-NS 7933 7469 -
2 Haemolysin expression modulating protein 8155 7949 -
2 DNA topoisomerase III (EC 5.99.1.2) 10305 8152 -
2 hypothetical protein 10894 10310 -
2 Exodeoxyribonuclease V beta chain (EC 3.1.11.5) 11395 10991 -
2 hypothetical protein 11905 11411 -
2 hypothetical protein 12210 11902 -
2 hypothetical protein 12567 12313 -
2 IncN plasmid KikA protein 12860 12573 -
2 hypothetical protein 13281 12862 -
2 Type IV secretion system protein VirD4 15155 13293 -
2 ATPase provides energy for both assembly of type IV secretion complex and secretion of T-DNA complex (VirB11)16170 15142 -
2 Inner membrane protein forms channel for type IV secretion of T-DNA complex (VirB10) 17290 16172 -
2 Forms the bulk of type IV secretion complex that spans outer membrane and periplasm (VirB9) 18188 17283 -
2 Inner membrane protein forms channel for type IV secretion of T-DNA complex (VirB8) 18874 18188 -
2 hypothetical protein 18995 18867 -
2 hypothetical protein 19383 19213 -
2 Inner membrane protein of type IV secretion of T-DNA complex, VirB6 20483 19389 -
2 Minor pilin of type IV secretion complex (VirB5) 21211 20495 -
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Contig Function Start Stop Strand
2 ATPase provides energy for both assembly of type IV secretion complex and secretion of T-DNA complex (VirB4)23970 21223 -
2 FIG01068513: hypothetical protein 24315 23989 -
2 Bores hole in peptidoglycan layer allowing type IV secretion complex assembly to occur (VirB1) 24948 24376 -
2 hypothetical protein 25127 24951 -
2 IncQ plasmid conjugative transfer protein TraG 25520 25305 -
2 ORF2 25810 25517 -
2 IncQ plasmid conjugative transfer DNA nicking endonuclease TraR (pTi VirD2 homolog) 27116 25887 -
2 ORF8 27623 27120 -
2 hypothetical protein 27846 27971 +
2 COG4226: Uncharacterized protein encoded in hypervariable junctions of pilus gene clusters 28331 27984 -
2 HicA 28576 28328 -
2 Mobile element protein 28860 30122 +
2 hypothetical protein 30103 30225 +
2 hypothetical protein 30392 30270 -
2 Beta-lactamase (EC 3.5.2.6) 30396 31247 +
2 S-methylmethionine permease 31897 31649 -
2 hypothetical protein 32046 31909 -
2 hypothetical protein 32472 32122 -
2 hypothetical protein 32557 32432 -
2 hypothetical protein 32781 32563 -
2 hypothetical protein 283 56 -
3 FIG00643296: hypothetical protein 521 270 -
3 FIG00643553: hypothetical protein 1060 518 -
3 COG2214: DnaJ-class molecular chaperone 1680 1165 -
3 IncI1 plasmid conjugative transfer pilus-tip adhesin protein PilV 88 336 +
4 hypothetical protein 17 223 +
5 hypothetical protein 191 18 -
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5.3.2.2 Plasmid transfer, establishment and maintenance 
Like the IncI1 pEK204 plasmid (Woodford et al., 2009), pI2-47TC encoded genes 
associated with IncI1 plasmids including the type IV pilus (pil prepilin genes); thin pili 
required for liquid mating and the RepZ replicase gene (Kim and Komano, 1997; 
Woodford et al., 2009).  In addition to the F-like pili encoded by the pil genes (part of 
the type IV secretion system), this plasmid also encoded the tra genes that make up the 
rigid pili of IncI1 plasmids (Komano et al., 1990). The conjugal transfer associated 
proteins; exc (surface exclusion protein), traE-Y (F-pilus), trbABC (putative transfer 
proteins), sogS/sogL (DNA primase and regulatory protein), and nikAB (relaxase and 
regulatory protein) were found make up 22 % of the total number of predicted genes in 
pI2-47TC.  
Interestingly this plasmid also encoded Pilx/Tax conjugation proteins previously 
identified in IncX plasmids (Norman et al., 2008; Nunez et al., 1997; Partridge et al., 
2011).  Plasmid pJIE143 was found to (GenBank JN194214) have 25 % similarity to 
pI2-47TC, and found to encode a π-like replication protein encoded by pir. Also 
identified, were the seven oriV-γ iterons, which provide binding sites for the π protein 
(Germino and Bastia, 1983). This protein has been studied extensively in the archetypal 
IncX2 plasmid R6K and is known to be involved in the replication and copy number 
control of this plasmid (Filutowicz et al., 1986; Nunez et al., 1997; Partridge et al., 
2011).  
The plasmid encoded two toxin-antitoxin genes: pndA/pndC and hicA/hicB, identified in 
pEK204 and pJIE143 respectively (Partridge et al., 2011; Woodford et al., 2009). Other 
plasmid establishment and maintenance systems included the Psi, SsB; involved in 
conjugation and HHA; a histone-like protein found on IncX1 pJIE143 (Partridge et al., 
2011). 
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5.3.2.3 Mobile genetic elements 
A Tn3 resolvase (tnpR), transposase (tnpA) and a 38bp inverted repeat were identified 
adjacent to the blaTEM-1 gene, all genes essential for Tn3 transposition (Kostriken et al., 
1981).  
The ISEcp1 element was identified 42 base pairs upstream of blaCTX-M-14b. The ISEcp1 
element is commonly associated with blaCTX-M genes and has been implicated in driving 
expression of downstream genes in addition to mobilising blaCTX-M (Poirel et al., 2003; 
Poirel et al., 2005). 
5.3.2.4 Drug resistance 
This plasmid was found by sequencing to harbour two resistance genes namely, blaCTX-
M-14b and blaTEM-1. The blaTEM-1 gene was not identified using the array (table 5-1). This 
anomaly was not acknowledged because the phenotype conferring resistance to 
ampicillin, ceftazidime and cefotaxime, denoted the presence of at least one ESBL to 
which blaCTX-M was attributed to give rise to the resulting phenotype. This reveals a 
greater accuracy of plasmid sequencing in detecting additional genes that may not be 
detected during phenotypic and high-throughput screening methods. 
Although the blaCTX-M-14b gene was not identified in either pEK204 (IncI1, blaCTX-M-3) or 
pJIE143 (IncX1, blaCTX-M-15), the genetic environment surrounding blaCTX-M genes was 
similar to that of pI2-47TC. All three plasmids harboured the ISEcp1element upstream 
blaCTX-M (99 % similarity); encoding the IRL (left inverted repeat), ISEcp1 associated 
transposase (tnpA) and the IRR (right inverted repeat) (Partridge et al., 2011; Woodford 
et al., 2009).  
The blaCTX-M-14b gene and associated ISEcp1 element was found to be 100 % similar to 
the genetic platform of plasmid pCT (GenBank FN868832); an epidemic IncK blaCTX-M-
14b plasmid from E. coli, which was isolated from a calf on a dairy farm in the UK 
(Cottell et al., 2011) (Fig. 5-5A). Interestingly, in pCT the region encoding the ISEcp1 
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element and associated transposase had 100 % nucleotide identity to pEK204 and 
pJIE143 and was also inverted as in pI2-47TC (Fig. 5-5B). Analysis of this region 
suggests possible acquisition of the blaCTX-M-14b gene via an ISEcp1 associated 
transposition event recognising the 14 bp inverted repeat sequences flanking these genes 
(Poirel et al., 2003; Poirel et al., 2005).  This could explain the presence of the blaCTX-M-
14b variant encoded by pI2-47TC within a scaffold similar to pEK204 and pJIE143, 
encoding blaCTX-M-3 and blaCTX-M-15variants, respectively.  
 
 
Figure 5-5: Genetic platform surrounding the blaCTX-M-14b gene. The genetic environment surrounding 
the blaCTX-M-14b gene was found to have 99 % nucleotide identity to pCT a blaCTX-M-14b harbouring IncK 
plasmid. The ISEcp1 element was also identified in the pJIE143 (blaCTX-M-15) plasmid. The presence of 
both elements could result in possible recombination events leading to the mobilisation of blaCTX-M 
downstream. 
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5.3.2.5 Hypothesis of plasmid co-integration 
The blaCTX-M-14b gene was identified on a single contig, which also harboured the pilX, 
tax and pir genes with 92 % nucleotide identity to pJIE143. This suggests that the 
IncX1 pJIE143-like scaffold harbours the ISEcp1-blaCTX-M-14 region and the IncX 
conjugative elements, but also has association with an IncI1-like plasmid scaffold, 
encoding IncI1 conjugative proteins.  
The identification of two replication control systems; IncX1 and IncI1, could be the 
result of a fusion of the two replicons (IncX1 and IncI1). This phenomenon has been 
observed previously in IncFII-FIA plasmids (Perichon et al., 2008; Szczepanowski et 
al., 2005; Woodford et al., 2009). Another possibility is the recombination of the two 
plasmids in vivo during conjugation, leading to the formation of a con-integrate 
resulting in a larger sequenced plasmid, a phenomenon that has been described 
previously in IncFII-HI2 co-integrate plasmid (Bradley et al., 1986). Evidence that 
supports this theory includes results from the initial plasmid sizing of the transconjugant 
by S1 nuclease PFGE (linear DNA), which identified two distinct plasmids 
approximately 86 kb and 35 kb in size (Fig. 5-6B). The resulting plasmid sequenced 
(pI2-47TC) was found to be ~ 130 kb, which is approximately the sum of both these 
plasmids. In addition, when IncI1-pEK204 and IncX-pJIE143 were merged into a 
pseudomolecule and compared with the pI2-47TC pseudomolecule, the alignments 
showed two distinct plasmid scaffolds of the IncI1 and IncX1 plasmids within the co-
integrate (Fig. 5-6A) 
These plasmids could to be sequenced individually (pre-integration) to determine any 
regions of homology that may have facilitated the co-integration events between an 
IncX1 and IncI1 plasmid, by homologous recombination to form pI2-47TC. 
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Figure 5-6: Hypothesis of pI1-47TC co-integration of a smaller mobilizable plasmid and larger 
conjugative plasmid. A) Sequence alignment of pI2-47TC pseudomolecule with pEK204 and pJIE143 
pseudomolecule depicts the hypothesis of proposed plasmid co-integration. Plasmid pI2-47TC was found 
to harbour both IncI1 and IncX1 replication systems, most similar to IncI1 pEK204 (blaCTX-M-3) and 
IncX1 pJIE143 (blaCTX-M-15). B) S1 nuclease-PFGE gel image showing the two ~35 kb and ~86 kb 
plasmids in the transconjugant I2-47TC (lane 5) in addition to other plasmids untypeable (by PBRT) 
plasmids of similar size to the smaller 35 kb plasmid isolated from the same farm (lane 1-4). 
5.3.3 Analysis of pI2-52TC 
Plasmid pI2-52TC was isolated from a strain from the same farm as pI2-47TC and pI2-
53TF. This plasmid was transferable by in vitro conjugation and was identified as 
belonging to the IncB/O group by PBRT. S1 nuclease PFGE estimated the size of this 
plasmid at 151 kb. The resistance gene profile of plasmid pI2-52TC differed from other 
plasmids of this region with profiles similar to pI2-53TF encoding: aadA1, aadA2, 
cmlA1, blaCTX-M-32, dfr12, sul3 and tetA. However, plasmid pI2-52TC was found to 
harbour four additional resistance genes: dfrA14, sul2, strB and blaTEM-1. To investigate 
whether this donor field isolate also harboured a plasmid with a similar resistance gene 
profile and a plasmid of similar size to other plasmids (untypeable 30-40 kb plasmids) 
isolated from the same farm.  DNA extracted from the field strain (I2-52, see chapter 3), 
and transformed into E. coli DH10B and plasmid sizing and DNA array experiments 
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performed (see chapter 2 for details). The resulting plasmid sizes and resistance gene 
profile of the transformant was found to be similar to other untypeable ~30 – 40 kb 
plasmids from this farm e.g. pI2-53TF (see table 5-1). The isolation of two plasmids 
encoding blaCTX-M group 1 genes from the donor strain by two different methods 
(conjugation and transformation) gave two plasmids; pI2-52TC (~150 kb) and pI2-52TF 
(~40 kb). These plasmids were found to have similar resistance gene profiles.. To 
investigate the relationship of the larger conjugative plasmid encoding similar resistance 
genes and other untypeable plasmids of this farm, the genetic composition of the ~150 
kb pI2-52TC plasmid was analysed, and discussed later is the sequence analysis of the 
smaller 40 kb plasmid pI2-53TF. 
5.3.3.1 Plasmid Scaffold 
This plasmid was found to have 67 % similarity to a 110 kb IncB plasmid (pR3521: 
GenBank GU256641) from E. coli isolated from a hospitalised patient in Greece 
(Papagiannitsis et al., 2011) (Fig. 5-7A). However, pR3521 did not encode a blaCTX-M 
gene. The genetic organisation surrounding blaCTX-M was found to be similar to a 
blaCTX-M-32 E. coli strain ECO39 (GenBank EU921825) (Fig. 5-9) (Lee et al., 2009). 
ECO39 plasmid was found to encode a Pir (initiator RepB) replication protein, toxin-
antitoxin system (StbED), plasmid partition protein (ParA) and resolvase (TnpR) 
similar to an IncX1 plasmid (pOU1114, GenBank DQ115387) isolated from E. coli 
(Chu et al., 2008) (Fig. 5-8). This plasmid harboured 186 predicted ORFs (see table 5-4). 
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Figure 5-7: Plasmid scaffold of pI2-52TC. A) Plasmid pI2-52TC was found to have 67 % similarity (89 
kb) to an IncB plasmid isolated from E. coli (pR3521: GU256641). B) The similarity regions harboured 
the tra and pil conjugative transfer genes and antimicrobial resistance genes blaTEM-1, strA and sul2. C) 
The integron 1 associated multi-resistance gene region was similar in genetic organisation to E. coli 
plasmid pEC355 (partial sequence) (FM244708), a region spanning 7 % of the 130 kb sequence encoding 
dfrA12-orfF-cmlA1-aadA1-qac-sul3 resistance genes. WebACT (www.webact.org) was used to make 
the alignments (1000 bp cut-off) and determine regions of similarity. 
 
Figure 5-8: Plasmid pI2-52TC IncX replication region. Plasmid pI2-52TC encoded a π replication 
protein (pir) previously identified in IncX plasmids including the archetypal R6K plasmid. This region of 
similarity (95-98 %) to pOU1114 also harboured toxin-antitoxin (stbE/D), partition protein (parA) and 
resolvase (tnpR) genes. WebACT (www.webact.org) was used to make the alignments (1000 bp cut-
off) and determine regions of similarity.  
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Table 5-4: Predicted open reading frames identified in pI2-52TC. 
 
Continued on the following page. 
Contig Function Start Stop Strand
1 transposase 198 2747 +
1 streptomycin phosphotransferase 2740 3513 +
1 Insertion Sequence Associated 5361 3790 -
1 orf, conserved hypothetical protein 5728 5381 -
1 Insertion Sequence Associated 6405 5728 -
1 putative transposase 6722 6405 -
1 hypothetical protein 6858 6983 +
1 FIG00638738: hypothetical protein 7476 7081 -
1 involved in conjugative DNA transfer 10291 7580 -
1 Nickel ABC transporter, periplasmic nickel-binding protein NikA (TC 3.A.1.5.3) 10635 10303 -
1 hypothetical protein 10762 10878 +
1 hypothetical protein 10868 11203 +
1 YdiA 12137 11289 -
1 hypothetical protein 12343 12179 -
1 hypothetical protein 12369 12482 +
1 hypothetical protein 12542 12682 +
1 FIG00642528: hypothetical protein 12716 12967 +
1 FIG00639209: hypothetical protein 13204 12998 -
1 Transposase 14141 13263 -
1 CcgAII protein 14602 14138 -
1 hypothetical protein 14639 14511 -
1 hypothetical protein 14590 14703 +
1 YDFB protein 14970 14704 -
1 FIG01046738: hypothetical protein 15498 15064 -
1 hypothetical protein 15710 15495 -
1 hypothetical protein 15736 15936 +
1 hypothetical protein 15981 16115 +
1 Antirestriction protein ArdA 17121 16231 -
1 hypothetical protein 17789 17193 -
1 PsiA protein 18505 17786 -
1 PsiB protein 18936 18502 -
1 FIG00638906: hypothetical protein 20955 18991 -
1 Putative cytoplasmic protein 21241 21008 -
1 Single-stranded DNA-binding protein 21826 21299 -
1 YchA 22458 22210 -
1 FIG00638431: hypothetical protein 22787 22596 -
1 FIG01047188: hypothetical protein 23206 22784 -
1 Putative antirestriction protein 23678 23253 -
1 hypothetical protein 23835 23975 +
1 hypothetical protein 24094 23927 -
1 hypothetical protein 24864 24094 -
1 hypothetical protein 25343 24909 -
1 putative cytoplasmic protein 25578 25357 -
1 Adenine-specific methyltransferase (EC 2.1.1.72) 26262 25579 -
1 hypothetical protein 26369 26494 +
1 FIG01048508: hypothetical protein 27549 26647 -
1 FIG00640646: hypothetical protein 27806 28216 +
1 Error-prone repair protein UmuD 28213 28650 +
1 Error-prone, lesion bypass DNA polymerase V (UmuC) 28650 29921 +
1 Chromosome (plasmid) partitioning protein ParA 30210 30743 +
1 hypothetical protein 30740 31042 +
1 hypothetical protein 31544 31380 -
1 FIG00641828: hypothetical protein 32899 31553 -
1 hypothetical protein 32977 33096 +
1 FIG00644632: hypothetical protein 33253 33855 +
1 FIG00643565: hypothetical protein 33872 34387 +
1 FIG00732908: hypothetical protein 34384 34653 +
1 stability (stb) locus of IncFII plasmid NR1; similar to SwissProt accession number P11907 35125 34844 -
1 FIG01069112: hypothetical protein 35506 35231 -
1 hypothetical protein 35790 35506 -
1 hypothetical protein 36345 36211 -
1 RepA1 37567 36695 -
1 hypothetical protein 37792 37604 -
1 IncI1 plasmid conjugative transfer NusG-type transcription antiterminator TraB 38270 38911 +
1 IncI1 plasmid conjugative transfer protein TraC 39052 39714 +
1 hypothetical protein 39981 40601 +
1 Inner membrane protein YqiK 40628 42322 +
1 hypothetical protein 42403 42645 +
1 hypothetical protein 43072 42941 -
1 hypothetical protein 43129 43245 +
1 IncI1 plasmid conjugative transfer protein PilL 43323 44393 +
1 IncI1 plasmid conjugative transfer protein PilM 44397 44834 +
1 IncI1 plasmid conjugative transfer lipoprotein PilN 44866 46485 +
1 IncI1 plasmid pilus assembly protein PilO 46506 47801 +
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Contig Function Start Stop Strand
1 IncI1 plasmid pilus assembly protein PilP 47791 48249 +
1 IncI1 plasmid conjugative transfer ATPase PilQ 48353 49861 +
1 IncI1 plasmid conjugative transfer inner membrane protein PilR 49863 50957 +
1 IncI1 plasmid conjugative transfer prepilin PilS 51019 51555 +
1 IncI1 plasmid conjugative transfer putative membrane protein PilT 51600 52085 +
1 Type-IV sectretion leader peptidase/N-methyltransferase 52101 52727 +
1 IncI1 plasmid conjugative transfer pilus-tip adhesin protein PilV 52745 54106 +
1 Cob(I)alamin adenosyltransferase (EC 2.5.1.17) 54351 54145 -
1 hypothetical protein 54340 54492 +
1 IncI1 plasmid conjugative transfer protein TraE 54579 55400 +
1 IncI1 plasmid conjugative transfer protein TraF 55502 56704 +
1 hypothetical protein 56813 56694 -
1 IncI1 plasmid conjugative transfer protein TraH 56808 57266 +
1 IncI1 plasmid conjugative transfer protein TraI 57263 58099 +
1 IncI1 plasmid conjugative transfer protein TraJ, related to pilus biogenesis/retracton protein 58083 59231 +
1 IncI1 plasmid conjugative transfer protein TraK 59228 59518 +
1 IncI1 plasmid conjugative transfer DNA primase 59582 63643 +
1 IncI1 plasmid conjugative transfer protein TraL 63660 64010 +
1 IncI1 plasmid conjugative transfer protein TraM 64022 64717 +
1 IncI1 plasmid conjugative transfer protein TraN 64728 65702 +
1 IncI1 plasmid conjugative transfer protein TraO 65706 67043 +
1 IncI1 plasmid conjugative transfer protein TraP 67040 67753 +
1 IncI1 plasmid conjugative transfer protein TraQ 67750 68280 +
1 IncI1 plasmid conjugative transfer protein TraR 68327 68725 +
1 IncI1 plasmid conjugative transfer protein TraS 68782 69033 +
1 IncI1 plasmid conjugative transfer protein TraT 69053 69766 +
1 FIG00644353: hypothetical protein 69995 69759 -
1 IncI1 plasmid conjugative transfer protein TraU 70061 73105 +
1 IncI1 plasmid conjugative transfer protein TraV 73105 73725 +
1 IncI1 plasmid conjugative transfer protein TraW 73683 74888 +
1 IncI1 plasmid conjugative transfer protein TraX 74885 75454 +
1 IncI1 plasmid conjugative transfer integral membrane protein TraY 75529 77688 +
1 surface exclusion protein 77776 78422 +
1 hypothetical protein 78528 78373 -
1 COG0568: DNA-directed RNA polymerase, sigma subunit (sigma70/sigma32) 78696 79595 +
1 COG0568: DNA-directed RNA polymerase, sigma subunit (sigma70/sigma32) 79774 80286 +
1 Protein pndA 80576 80424 -
1 hypothetical protein 80859 80740 -
1 FIG00642036: hypothetical protein 80828 81148 +
1 hypothetical protein 81236 81427 +
1 FIG00641173: hypothetical protein 81424 81807 +
1 FIG00643543: hypothetical protein 81811 82026 +
1 FIG00641946: hypothetical protein 82904 82224 -
1 putative nuclease 83007 83474 +
1 FIG00641806: hypothetical protein 83624 83800 +
1 hypothetical protein 84105 83863 -
1 hypothetical protein 84180 84365 +
1 hypothetical protein 84362 84490 +
1 hypothetical protein 84841 84695 -
1 TrbA 85179 86477 +
1 TrbB protein 86474 87598 +
1 FIG00640314: hypothetical protein 87579 89948 +
1 hypothetical protein 89995 90288 +
1 replication initiation protein 90360 90557 +
1 Dihydropteroate synthase (EC 2.5.1.15) 90745 91560 +
1 Aminoglycoside 3'-phosphotransferase (EC 2.7.1.95) 91621 92163 +
1 Dihydrofolate reductase (EC 1.5.1.3) 92169 92642 +
1 Aminoglycoside 3'-phosphotransferase (EC 2.7.1.95) 92747 92992 +
1 Beta-lactamase (EC 3.5.2.6) 94108 93248 -
1 Resolvase/integrase Bin 94848 94291 -
2 Streptomycin 3''-O-adenylyltransferase (EC 2.7.7.47) @ Spectinomycin 9-O-adenylyltransferase 436 654 +
2 Dihydrofolate reductase (EC 1.5.1.3) 651 1148 +
2 FIG01049527: hypothetical protein 1522 1397 -
2 Streptomycin 3''-O-adenylyltransferase (EC 2.7.7.47) @ Spectinomycin 9-O-adenylyltransferase 1568 2347 +
2 Chloramphenicol resistance protein 2609 3868 +
2 Streptomycin 3''-O-adenylyltransferase (EC 2.7.7.47) @ Spectinomycin 9-O-adenylyltransferase 3961 4752 +
2 Ethidium bromide-methyl viologen resistance protein EmrE 4922 5254 +
2 Transposase 6109 5501 -
2 Dihydropteroate synthase (EC 2.5.1.15) 7225 6368 -
2 hypothetical protein 7938 7693 -
2 short-chain dehydrogenase/reductase SDR 8839 7976 -
2 macrolide-efflux determinant 9239 8985 -
3 Resolvase 1088 444 -
3 Chromosome partitioning protein ParA 1469 2131 +
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3 unknown 2229 2510 +
3 hypothetical protein 2883 3017 +
3 DNA distortion protein 3 3864 3508 -
3 FIG01047678: hypothetical protein 4123 4001 -
3 FIG01047678: hypothetical protein 4447 4322 -
3 PI protein (Replication initiation protein) 5221 4487 -
3 hypothetical protein 5262 5492 +
3 FIG01046213: hypothetical protein 5640 5771 +
3 hypothetical protein 6141 6296 +
3 RelB/StbD replicon stabilization protein (antitoxin to RelE/StbE) 6557 6808 +
3 RelE/StbE replicon stabilization toxin 6798 7079 +
3 hypothetical protein 7125 7337 +
4 Mobile element protein 285 19 -
4 DNA-cytosine methyltransferase (EC 2.1.1.37) 385 1818 +
4 FIG01046921: hypothetical protein 2445 1852 -
4 IS5 transposase 3782 2802 -
4 Lipid A acylation protein PagP, palmitoyltransferase 3781 3915 +
4 Beta-lactamase (EC 3.5.2.6) 4083 4958 +
4 Tryptophan synthase beta chain like (EC 4.2.1.20) 5202 5005 -
4 FIG01046921: hypothetical protein 5950 5261 -
5 Relaxase /helicase 24 266 +
5 Transcriptional regulator, TetR family 975 298 -
5 Tetracycline efflux protein TetA 979 2253 +
5 Permease of the drug/metabolite transporter (DMT) superfamily 3169 2285 -
5 Amidases related to nicotinamidase 3699 3307 -
6 Integron integrase IntI1 33 512 +
6 Tn21 protein of unknown function Urf2 667 1065 +
6 Resolvase for Tn21 1191 1751 +
7 TnpA transposase 16 1752 +
8 Uncharacterized outer membrane usher protein yqiG precursor 17 1462 +
8 hypothetical protein 1462 1674 +
9 hypothetical protein 207 10 -
9 hypothetical protein 721 212 -
9 hypothetical protein 1220 909 -
9 hypothetical protein 1388 1558 +
11 aminoglycoside 3'-phosphotransferase 87 902 +
12 transposase 65 769 +
13 IS1 protein InsB 98 475 +
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5.3.3.2 Plasmid transfer, establishment and maintenance 
Like the pR3521 IncB plasmid, pI2-52TC encoded the type IV thin conjugative pili 
required for liquid mating (pilI, pilL- pilV) (Komano et al., 1990). Additional proteins 
involved in conjugation included 22 tra genes, trbABC and sogS/L to which SogS acts 
as a regulator for the SogL DNA primase that is involved in priming DNA during the 
synthesis of the transferred DNA strand during conjugation (Komano et al., 2000).  
 Other genes necessary for plasmid establishment in the recipient include ssb, psiB, nik 
(Althrope et al., 1999; Furaya and Komano, 1991; Shereda et al., 2007). Also encoded 
were surface exclusion genes excA (an analogue to exc of IncI), traT and traS, which 
function to reduce redundant transfer of same or closely related plasmid between cells 
(Furuya and Komano, 1994; Perumal et al., 1984). The plasmid encoded two types of 
post segregation killing systems stbE/stbD and pndC/pndA. 
5.3.3.3 Mobile genetic elements 
This plasmid harboured transposes associated with Tn172, Tn2-like, Tn3 and Tn21. 
Also identified were IS1 and IS5 mediated transposases and a truncated ISEcp1 
adjacent to the β-lactamase gene. In addition a class 1 integron associated integrase 
gene (intI1) was identified, closely associated with antimicrobial resistance genes 
dfrA12-aadA2-cmlA1-aadA1-qac-sul3. This genetic organisation was similar to plasmid 
pEC355 (partial sequence) (GenBank FM244708) (Fig. 5-6C), but similar genetic 
organisations have been previously identified in E. coli and Salmonella strains (Sunde 
et al., 2008). 
5.3.3.4 Drug resistance 
The two β-lactamase genes identified were blaTEM-1 and blaCTX-M-32. The blaTEM-1 gene 
was adjacent to a Tn3 associated transposase. Tn3 is frequently associated with 
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mobilisation of the blaTEM-1 gene (Partridge and Hall, 2005). The blaCTX-M-32 gene was 
not found in any of the plasmids similar to pI2-52TC i.e. pOU1114 and pR3521. This 
gene was identified adjacent to an IS5-associated transposase and a truncated ISEcp1 
element similar to a blaCTX-M-32 encoding region of an E. coli strain, ECO39 (GenBank 
EU921825) (Fig 5-9) (Lee et al., 2009). This structure is commonly found among 
blaCTX-M-32 harbouring plasmids (Cartelle et al., 2004; Vinue et al., 2009). 
Other drug resistance genes identified included aminoglycoside resistance genes aadA1, 
aadA2, aph, strB, chloramphenicol resistance genes cmlA, trimethoprim resistance 
genes dfrA12, dfrA14, sulphonamide resistance genes sul1, sul3, tetA, a quaternary 
ammonium compound resistance gene qac and a macrolide drug efflux gene mefE.  
 
Figure 5-9: A schematic diagram of the genetic organisation surrounding the blaCTX-M-32 gene. This 
ISEcp1- blaCTX-M-32 region was found to be similar (100 % homology) to a blaCTX-M-32 harbouring plasmid 
ECO39 (EU921825) from an E. coli strain. The arrows indicate the orientation of each of the genes 
identified. The ISEcp1-like element was disrupted by another insertion element IS5 upstream of the 
blaCTX-M-32 gene. 
5.3.3.5 Virulence associated genes 
Additional genes were identified that may confer an advantage and include the putative 
adhesion genes yqiJ and yqiJ, thought to be crucial in colonization of avian pathogenic 
E. coli (APEC) during infection (Antao et al., 2009). The plasmid also encoded umuDC 
and impABC UV-protection genes. The proteins mediate repair of error-prone DNA, 
thereby contributing to cell survival upon exposure to mutagens (Runyen-Janecky et al., 
1999). This may provide a selective advantage especially in environments where UV is 
the primary sterilising technique e.g. sterilising equipment and environment in 
hospitals. 
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5.3.3.6 Hypothesis of plasmid formation 
Plasmid pI2-52TC was found to have 67 % nucleotide identity with an IncB plasmid 
(p3521) encoding the Tra, Trb and Pil conjugative mechanisms. However the RepA 
replication protein encoded by pI2-52TC only had 45 % nucleotide identity to the repA 
gene of p3521 but was 99 % similar to the RepA gene of an IncZ plasmid pIE545 
(GenBank M93064), which is not included in the PBRT scheme (Praszkier et al., 1989). 
Praszkier and colleagues found the IncZ and IncB plasmid to be incompatible, thus 
indicating that these plasmids share the same replication mechanism using small counter 
transcript RNA molecules. The RNAI and RNAII sequence of IncB plasmids control 
the copy number of these plasmids by forming a stem-loop structure (Praszkier et al., 
1989). This region was found to be 97 % similar (nucleotide identity) to RNAI-RNAII 
and promoter regions of the IncB plasmid pMU720 (GenBank M28718) (Fig. 5-10).  
Alignment with these typical IncB plasmids, classified by their replication control 
mechanisms, strongly suggests the presence of an IncB plasmid scaffold in pI2-52TC. A 
second Pir mediated replication system was identified in pI2-52TC that is a protein 
previously identified amongst plasmids of the IncX family (Chu et al., 2008; Norman et 
al., 2008; Partridge et al., 2010). Three (sul2, strB and blaTEM-1) of the four additional 
resistance genes markers that were not identified in other plasmids of this farm were 
also identified in the IncB p3521 plasmid (see Fig 5-7B). The remainder of the 
resistance genes were found associated with an IntI1 integrase gene, characteristic of a 
class I integron. Thus the acquisition of the multiple antimicrobial resistance genes 
harboured within a class I integron to an IncB plasmid scaffold via an integrase 
mediated recombination event is proposed. 
The acquisition of the IncX replication region (pir and oriV sites) may have occurred 
via another transposition event resulting in the coexistence of two replicons.  
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Figure 5-10: Sequence alignment of the RNA I and RNA II region of the IncB minireplicon 
(pMU720: GeneBank M28718) and pI2-52TC using ClustalW (www.ebi.ac.uk). The RNA II 
(complement) is located at position 420-790, the RNA I; 569 -631, stem loop (shaded grey). The putative 
transcription initiator sites RNA II and RNA I at located at positions 420 and 423, and 629 and 622 
respectively. The symbols: “*”; identical,  “:” (colon) and “.” (dot/ fill stop) are conserved and 
semiconserved substitutions respectively. Adapted from Praszkeir et al., 1989. 
 
5.3.4 Analysis of pI2-53TF 
Two plasmids from the field isolate (I2-52) were both found to encode the blaCTX-M-32 
gene on a 40 kb transformant (pI2-52TF) and a 171 kb transconjugant (pI2-52TC) (see 
section 5.3.3 above). Analysis of the genetic composition pI2-53TF was thought to 
elucidate possible linkage of this ~ 40 kb plasmid with the 150 kb IncB pI2-52TC 
plasmid (see above section), which harbours the same resistance genes as pI2-53TF (see 
table 5-1).  
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5.3.4.1 Plasmid Scaffold 
Plasmid pI2-53TF, found to be untypeable by the PBRT scheme, was found to have 
52 % similarity to a 140 kb Salmonella enterica subsp. enterica serovar Choleraesuis 
pSC138 plasmid (GenBank AY509004) (Chiu et al., 2005; Chiu et al., 2011) (Fig 5-
11A). Plasmid pI2-53TF was also was found to be 47 % similar to a 35 kb Salmonella 
enterica subsp. enterica serovar Dublin plasmid pOU1114 (GenBank DQ115387) (Chu 
et al., 2008) (Fig. 5-11B). However, neither of these plasmids (pSC138 or pOU1114) 
was found to possess the blaCTX-M-32 gene, unlike pI2-53TF. The region harbouring the 
blaCTX-M-32 gene was found to be 100 % similar to an E. coli strain EC039 (GenBank 
EU921825) also identified in the IncB-IncX1 pI2-52TC plasmid from this farm. This 
plasmid harboured 56 predicted ORFs (see Table 5-5). 
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Figure 5-11: Plasmid pI2-53TF scaffold. Plasmid pI2-53TF was compared to the scaffold of two 
plasmids; pSC138 and pOU111 found to have 52 % and 47 % similarity respectively. Sequence 
comparisons were performed using WebACT (www.webact.org) sequence comparison tool, using a cut-
off of 1000 bp. A) IncI1-like plasmid pSC138 (AY509004) was found to have 46 % (18.5 kb) nucleotide 
identity to pI2-53TF. B) IncX1 35 kb plasmid pOU1114 (DQ115387) was found to have 17 % (6.6 kb) 
nucleotide identity to pI2-53TF.  
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Table 5-5: Predicted open reading frames identified in pI2-53TF. 
 
Contig Function Start Stop Strand
1 Dihydrofolate reductase (EC 1.5.1.3) 651 1148 +
1 FIG01049527: hypothetical protein 1522 1397 -
1 Streptomycin 3''-O-adenylyltransferase (EC 2.7.7.47) @ Spectinomycin 9-O-adenylyltransferase 1568 2347 +
1 Chloramphenicol resistance protein 2609 3868 +
1 Streptomycin 3''-O-adenylyltransferase (EC 2.7.7.47) @ Spectinomycin 9-O-adenylyltransferase 3961 4752 +
1 Ethidium bromide-methyl viologen resistance protein EmrE 4922 5254 +
1 Transposase 6109 5501 -
1 hypothetical protein 6156 6431 +
1 Dihydropteroate synthase (EC 2.5.1.15) 7225 6434 -
1 hypothetical protein 7564 7316 -
1 hypothetical protein 7939 7694 -
1 short-chain dehydrogenase/reductase SDR 8840 7977 -
1 short chain dehydrogenase 8969 8853 -
1 macrolide-efflux determinant 9240 8986 -
2 Resolvase 1306 662 -
2 Chromosome partitioning protein ParA 1687 2349 +
2 unknown 2447 2728 +
2 hypothetical protein 2753 3235 +
2 hypothetical protein 3268 3729 +
2 DNA distortion protein 3 4082 3726 -
2 FIG01047678: hypothetical protein 4482 4219 -
2 FIG01047678: hypothetical protein 4665 4540 -
2 PI protein (Replication initiation protein) 5439 4705 -
2 hypothetical protein 5480 5710 +
2 FIG01046213: hypothetical protein 5858 5989 +
2 hypothetical protein 6359 6514 +
2 RelB/StbD replicon stabilization protein (antitoxin to RelE/StbE) 6775 7026 +
2 RelE/StbE replicon stabilization toxin 7016 7297 +
3 Mobile element protein 285 19 -
3 DNA-cytosine methyltransferase (EC 2.1.1.37) 385 1818 +
3 FIG01046921: hypothetical protein 2445 1852 -
3 hypothetical protein 2744 2598 -
3 IS5 transposase 3782 2802 -
3 Lipid A acylation protein PagP, palmitoyltransferase 3781 3915 +
3 Beta-lactamase (EC 3.5.2.6) 4083 4958 +
3 Tryptophan synthase beta chain like (EC 4.2.1.20) 5274 5005 -
3 FIG01046921: hypothetical protein 5950 5261 -
3 transposase 6500 6306 -
4 Relaxase /helicase 24 266 +
4 Transcriptional regulator, TetR family 975 298 -
4 Tetracycline efflux protein TetA 1054 2253 +
4 Permease of the drug/metabolite transporter (DMT) superfamily 3169 2285 -
4 Amidases related to nicotinamidase 3699 3307 -
5 Resolvase for Tn21 2269 1709 -
5 Tn21 protein of unknown function Urf2 2745 2395 -
5 Integron integrase IntI1 3427 2948 -
6 hypothetical protein 207 10 -
6 hypothetical protein 721 212 -
6 hypothetical protein 1220 909 -
6 IncN plasmid KikA protein 1570 1256 -
7 TnpA transposase 17 1753 +
8 hypothetical protein 75 770 +
9 hypothetical protein 141 902 +
10 transposase 248 54 -
11 macrolide-efflux determinant 220 11 -
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5.3.4.2 Plasmid transfer, establishment and maintenance 
A π replication protein (encoded by pir) was identified, similar to pOU1114 (GenBank 
DQ115387), an IncX1 plasmid from E. coli, originally identified in the archetypal 
IncX2 plasmid R6K (Chu et al., 2008; Filutowicz et al., 1998).  
Plasmid pI2-53TF was found to be conjugative with a frequency of transfer rate of 
1.50x10-8. No conjugative systems typical of conjugative plasmids including IncX1 
plasmids (Pilx and Tax proteins) or the type IV conjugative pilus systems were 
identified (Chu et al., 2008; Norman et al., 2008; Nunez et al., 1997). A putative 
auxiliary conjugative protein TaxD was identified; however this gene had very weak 
homology; 36 % and 43 % to genes identified in pE001 (GenBank JF776874) and 
pOU1114 IncX plasmids (see Fig. 5-12) (Bielak et al., 2011; Chu et al., 2008). In 
addition, a putative IncN associated conjugative transfer protein KikA, lethal to 
Klebsiella oxytoca was identified (Holcik et al., 1996). As these plasmids were able to 
transfer by conjugation (see chapter 4), closure of this plasmid would enable the 
conjugative system to be elucidated. 
Plasmid partition gene parA and post-segregational killing genes stbE/stbD were 
identified, involved in plasmid maintenance ensuring stable inheritance of the plasmid 
(Funnel, 2005).  
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pE001           ATGACGTCATTGACGCCATTTTACGGCGTTTGCCCGGTAACCTACAGTCGGTTCTTATTG 60 
pOU1114         ------------------------------------------------------------ 
pI2-53TF        -----------TTAGCTTTTATATAAAAAAT-CAATGTTATCATTTGTCAG--------- 39 
                                                                             
 
pE001           GAGAATTTTATGAAATATCAGG-TGAGAGAGTTTATTAACGAAAAATATGCTAAGGCTGT 119 
pOU1114         ---------ATGAAATATCAGG-TGAGAGAGTTTATTAACGAAAAATATGCTAAGGCTGT 50 
pI2-53TF        ---------AAGATCAGCGAGGGTAATACATTCAAGAACCACAATATTTGTTCCTTCCAA 90 
                         *:**:.:.  *** *.* * * * :* :*.*..**:**:** *..  * .: 
 
pE001           TAATATTTTAAATGATAATCTTAAAGAAAACTACCATGTTTTTTATGGAGTAAGATTAAG 179 
pOU1114         TAATCTTTTAAAAGATAATCTTAAAGAAAACTACCATGTTTTTTATGGAGTACGATTAAG 110 
pI2-53TF        CAAACTGG-CATCAAGTATCTTATCGAAGCTGATAATCATCAT--TGGCTTGCGTT---G 144 
                 **:.*   .*: .* :******:.***..  * .** :* :*  ***. *..*:*   * 
 
pE001           TGAGATTCTTTTCCCTGCCAGTG--AGTATGGCTCTGATGCATTCTTTAAAGAGTTTGAA 237 
pOU1114         TGAGATTCTTTTTCCTGCCAGTG--AGTATGGCACTGATGCATTCTTTAAAGAGTTTGAA 168 
pI2-53TF        TGTTAAATCAAAGATTACCAATGGAAGTATTACACTGTTAATTAATTCAAACTCTTTAAA 204 
                **: *::  ::: . *.***.**  ***** .*:***:*..:*:.** *** : ***.** 
 
pE001           TCAATTAACAGTGTAATACTTCCAT-TAGTAATATTTGATTTTATAGACCGAAAGCCG-- 294 
pOU1114         TCAATTAACAGTGTAATACTTCCAT-TAGTAATCTTTGATTTAATACAACGCAAGCCA-- 225 
pI2-53TF        GAAAGCATCAGTGCCATACTCACTGGCTGGAAAAAGAATCTCAATTAATCTCACACCATA 264 
                 .**  *:***** .***** .*:   :* **:.: :.: * :**: * * .*..**.   
 
pE001           ATTATGGTTATCGGCTTCGATAAGATACCTGATGCCAGTTTGTTTGAAGGAACAAATATT 354 
pOU1114         ATGATGATTATCAGCTTCGATAAGATACTTGATGCCAGTTTGTTGGAAGGAACAAATATT 285 
pI2-53TF        AAAAACATGGTAGTTTTCTTTAAGGTTATCCTT--TAAAATATTAACAG--CCTTAGTAT 320 
                *: *: .* .*..  *** :****.*:.   :*   *.::*.** ..**  .*::* ::* 
 
pE001           GTGGTTCTTGAATGTACTACCCTCGCCGATCTTCTGACAAATGAT--AACATTTGTT--T 410 
pOU1114         GTGGTTCTTGAATGTACTACCCTCGCTGATCTTCTGACAAATGAT--AACATTGATT--C 341 
pI2-53TF        ATTTTTCGTTAATAAACTCTCTCACCTGATATTCCATAAAATTCTCCGACAAGAACCGAC 380 
                .*  *** * ***.:***. *  . * ***.*** .:.**** .*  .***:  .      
 
pE001           TTTATATAAAAGCTAA 426 
pOU1114         TTTATATAAAAGCTAA 357 
pI2-53TF        TGTAGGTCACCGGGCA 396 
                * ** .*.*..*  .* 
 
Figure 5-12: Base pair alignment of TaxD putative auxiliary conjugative protein found identified in 
pE001 (JF776874) and pOU1114 IncX plasmids. This gene only shared 36 % and 43 % homology to 
these genes respectively. The TaxD sequence of pOU1114 was 69 bp shorter than the taxD gene of 
pE001, another IncX plasmid. It is not known whether the differences in the sequences will impacts on 
the function of this protein. Key: “*”; identical,  “:” (colon) and “.” (dot/full stop) are conserved and 
semiconserved substitutions respectively. 
 
5.3.4.3 Mobile genetic elements 
A class 1 integron associated integrase gene (intI1) was identified in the same contig as 
several resistance determinants in similar arrangement to a sul3 harbouring class 1 
integron carried on an E. coli plasmid pEC355 (GenBank FM244708) (see Fig. 5-13A). 
This contig harboured integrase (intI), transposase (tnp), a putative oxidoreductase 
(orfB) and resistance genes in the following arrangement: intiI-dfrA12-orfF-cmlA1-
aadA1-qacH-tnp440-sul3-orfA-orfB (Fig. 5-13). A similar integron structure was also 
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observed in a type II designated integron with the structure intI-dfrA12-gcuF-cmlA1-
aadA1-qacH-tnp440-sul3, carried on an IncI1 plasmid pRYC301 (HQ875012) isolated 
from E. coli (Curiao et al., 2011). The gcuF gene of unknown function had a 100 % 
base pair similarity to orfF (unknown function) of pEC355 (see Fig. 5-14).  
The sul3 gene was adjacent to the IS440 associated transposase. This sul3-IS440 
platform may be involved in acquisition of the class I integron via an integrase mediated 
transposition event from a plasmid harbouring the multidrug resistance gene cassette, 
resulting in the acquisition of this integron onto an IncX plasmid backbone (Curiao et 
al., 2011). 
Tn21 associated resolvase (tnpR) and transposase (tnpA) was encoded on pI2-53TF. 
Tn21 has previously been identified in sul3 containing integrons of E. coli and 
Salmonella strains (Curiao et al., 2011; Sunde et al., 2008). Also identified were IS1, 
IS5, IS26 and Tn1721 associated transposases. The abundance of these MGEs increases 
the probability of both intra- and inter-molecular movement that may not require 
homology to a DNA sequence, although preference for particular base pair sequences 
have been reported (Craig, 1997). 
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Figure 5-13: Integron associated genes identified in a single contig of pI2-53TF. This genetic 
organisation of a sul3 containing integron was been observed in pEC355 (FM244708) in a class 1 
integron. A) The alignment of the pEC355 integron with pI2-53TF using WebACT (www.webact.org) 
using a 1000 bp cut-off. Schematic diagram B shows the five resistance genes (green boxes) identified in 
one contig on pI2-53TF, these were found in the same genetic organisation as in pEC355. 
 
gcuF            ATGTTTATTCAAACGGCATTTAGCTTTTCAGGCGTTATTCAGTGCCTGTTTTGCCTTTTT 60 
orfF            ATGTTTATTCAAACGGCATTTAGCTTTTCAGGCGTTATTCAGTGCCTGTTTTGCCTTTTT 60 
                ************************************************************ 
 
gcuF            TCCGGGCTTCGCCTGCATGGGCTGCGCAGGTTTTCAGTCTTTTTGGCCTCTAGCCCTTGC 120 
orfF            TCCGGGCTTCGCCTGCATGGGCTGCGCAGGTTTTCAGTCTTTTTGGCCTCTAGCCCTTGC 120 
                ************************************************************ 
 
gcuF            GTAGCAAGCGCAAGCAGCTATCGTTTTTGCAGTGCTGTGCCGCCTCGGTGGCGCAGCGTT 180 
orfF            GTAGCAAGCGCAAGCAGCTATCGTTTTTGCAGTGCTGTGCCGCCTCGGTGGCGCAGCGTT 180 
                ************************************************************ 
 
gcuF            TTTTCACGGTTAGCGCCCGTCGCCAAATTCAAGTTATCCGTTTTGGCTTCTGGTTCTAAC 240 
orfF            TTTTCACGGTTAGCGCCCGTCGCCAAATTCAAGTTATCCGTTTTGGCTTCTGGTTCTAAC 240 
                ************************************************************ 
 
gcuF            ATTTCGGTCAAGCCGACCCGCATTCTGCGGTCGGCTTACCTCGCCCGTTAG 291 
orfF            ATTTCGGTCAAGCCGACCCGCATTCTGCGGTCGGCTTACCTCGCCCGTTAG 291 
                *************************************************** 
 
Figure 5-14: Base pair alignment of integron associated gene gcuF (pRYC301, HQ875012) and orfF 
(pEC355, FM244708) encoding proteins of unknown functions. Alignments were performed using the 
ClustalW2 program (www.ebi.ac.uk), these genes were found to have 100 % similarity. Key: “*”; 
identical nucleotide base. 
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5.3.4.4 Drug resistance 
Plasmid pI2-53TF encodes multiple drug resistance region similar to the class I integron 
associated region of a partial sequence plasmid pEC355 (GenBank FM244708). 
Resistance genes included, aadA1, aadA2 (aminoglycoside), cmlA1 (chloramphenicol 
transporter), dfrA12 (trimethoprim), qacH (quaternary ammonium resistance), sul3 
(sulphonamide). Additional resistance genes identified included aphA1 
(aminoglycoside), a macrolide efflux determinant mefB, tetracycline resistant 
determinants tetA (efflux) and tetR (repressor), adjacent to a pecM gene; a member of 
the drug metabolite superfamily thought to export antioxidant compounds protecting the 
pathogen from host defences (Jack et al., 2001). 
The region harbouring the blaCTX-M-32 gene was found to be similar to an E. coli strain 
ECO39 (GenBank EU921825) (Fig. 5-15), with an ISEcp1 like element disrupted by 
another insertion element IS5, upstream of the blaCTX-M-32 gene (Cartelle et al., 2004; 
Fernandez et al., 2007; Lee et al., 2009). 
 
Figure 5-15: Genetic environment of blaCTX-M-32 in pI2-53TF. A) Alignment of pI2-53TF with ECO39 
(EU921825); a blaCTX-M-32 harbouring E. coli strain encoding an ISEcp1 disrupted by an IS5 insertion 
element upstream of the blaCTX-M-32 gene. B) Schematic diagram of the genetic organisation of this 
region, with arrows indicating the orientation of each of the genes identified. WebACT 
(www.webact.org) was used to make the alignments (1000 bp cut-off) and calculate similarity. 
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5.3.4.5 Hypothesis of plasmid formation 
Plasmid pI2-53TF was found to harbour elements of the IncX replication machinery, 
however this region only covered approximately 17 % of the plasmid genophore. The 
plasmid was found to harbour class I integron associated genes including the sul3 gene 
previously found on IncI1 plasmids. Interestingly these integron and the genes cassettes 
encompassed were previously identified on another plasmid from the same farm (pI2-
52TC, IncB). The difference in the genetic background of these two plasmids suggests 
the acquisition of these genes cassettes was mediated by an integrase dependent 
transposition mechanism into the IncX plasmid backbone. Sequence comparison of the 
smaller 40 kb plasmid pI2-53TF to the 150 kb pI2-52TC revealed a 93 % sequence 
identity between the two plasmids. This suggests for the latter plasmid, the acquisition 
of IncX1 blaCTX-M-15 onto an IncB plasmid backbone already encoding the blaTEM, strA 
and sul2 genes, genes not identified in pI2-53TF, resulting in the plasmid cointegrate 
pI2-52TC harbouring IncB-IncX1 replicons (see Fig. 5-16).  
 
Figure 5-16: Sequence comparison of two blaCTX-M-32 plasmid isolated from E. coli strain from the 
same farm. The smaller IncX1 plasmid (40 kb) pI2-53TF was found to have 93 % sequence identity to 
the larger IncB-IncX1 (~ 150 kb) plasmid pI2-52TC, suggesting a possible cointegration of an Inc1 and 
IncB plasmid forming the larger pI2-52TC. WebACT (www.webact.org) was used to make the 
alignments (1000 bp cut-off) and calculate similarity. 
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IncX plasmids have previously only been associated with blaCTX-M-15 and -14 plasmids. 
However, like these plasmids, pI2-53TF encodes an ISEcp1 element upstream of the 
blaCTX-M-32 gene. Plasmids harbouring the blaCTX-M-32 gene have been identified 
previously in IncN harbouring plasmids (Novais et al., 2007), but so far have not been 
identified in plasmids of the IncX group. This implicates the ISEcp1 element, a known 
mobilising agent for adjacent blaCTX-M genes, to be involved in the acquisition of the 
blaCTX-M-32 gene onto an IncX plasmid backbone by transposition or homologous 
recombination, or by a combination of both mechanisms, thus mobilizing ISEcp1-
blaCTX-M-32 as a transposed unit (Poirel et al., 2005; Zong et al., 2010). 
What is not clear about the pI2-53TF plasmid is the mechanism of conjugation. This 
plasmid was found to have conjugation frequencies of 1.50x10-8, which fell below the 
interquartile range when compared with the frequency of transfer rates of all the 
plasmids regardless of size and Inc type included in this study (mean = 2.28x10-4, 
standard deviation = 1.42x10-3, lower quartile = 1.66x10-8, upper quartile  = 1.16x10-5). 
However, no classical conjugative systems (pil, tax, tra or trb) were identified on this 
plasmid nor were any mobilisation proteins. That is not say that these systems were 
absent, but they might be encoded within the sequence not covered by the contigs and 
would require further investigation by gap closure. Although showing only 43 % 
homology, the identification of taxD gene, a putative auxiliary conjugative protein 
found on IncX plasmids (Bielak et al., 2011), may indicate the presence of a Tax 
mediated mobilising system. Another alternative could be that this plasmid may not 
have been conjugative at all, but could have been a result of spontaneous mutants of the 
donor strains conferring resistance to rifampicin. To eliminate this possibility a PFGE 
could be carried out on this and the donor strain.   
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5.4 Conclusion 
Sequence analysis of these plasmids identified multiple systems encoded within the 
plasmids to ensure efficient transfer including plasmid partitioning systems, addiction 
systems and extensive conjugative proteins in IncB, IncI1 and IncFIA-FIB-FII plasmids. 
In the case of the IncB plasmid (pI2-52TC), a second conjugative system, belonging to 
the IncX plasmid group (tax and pilx) was identified in addition to its replication control 
(pir and oriV). Co-integration of a large conjugative plasmid and a smaller mobilisation 
plasmid has previously been observed in Enterobacteriaciae (Olsen et al., 2004). The 
distinct plasmid systems identified in pI2-52 suggest possible co-integration of the IncX 
scaffold and the IncB plasmids. This is different from the IncFIA-FIB-FII (pI1-34TF) 
fusion plasmid, which form the plasmid scaffold and the abundant transposase genes 
identified appears to be the result of multiple independent transposition and 
recombination events resulting in a mosaic structure.  Common to all the plasmids were 
plasmid maintenance systems to ensure stable inheritance in the absence of selection. In 
some cases, genes thought to contribute to virulence were also identified. All these 
mechanisms; plasmid transfer (conjugation and mobilization), maintenance (plasmid, 
replication, multimer resolution and post-segregational killing systems), resistance and 
virulence determinants and even the ability to acquire multiple replicons; may provide a 
selective advantage to the host or the plasmid itself and cumulatively contribute to the 
general success of a plasmid with respect to spread and persistence.  
It is thought that plasmids impose a metabolic burden on the host, potentially because of 
the mechanisms in place to ensure plasmid maintenance, which could result in 
differential growth rates between the plasmid free and plasmid containing bacteria 
(Bennett, 2008; Dahlberg & Chao, 2003; De Gelder et al., 2007; Sengupta et al., 2011; 
Turner et al., 1998). In the next chapter, the impact of plasmid acquisition upon the host 
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will be investigated. Differential growth patterns between plasmid harbouring and 
plasmid free strains will be compared. In addition other the plasmid traits that may 
confer advantage will be investigated including; resistance genes in the context of the 
plasmid environment and the contribution of efflux systems to resistance.   
The plasmids described here display mosaic structures that do not resemble any one 
plasmid in the GenBank database. This may well indicate promiscuous re-assortment as 
a common phenomenon in plasmids that may aid the rapid dissemination of 
antimicrobial resistance genes and contribute to the persistence of resistance genes in 
commensal E. coli strains, thereby increasing reservoirs of multiple drug resistance 
genes. 
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6 RESULTS CHAPTER 6: Analysing plasmid impact on host fitness 
6.1 Introduction  
The acquisition of resistance determinants by horizontal gene transfer is thought to 
impart a fitness cost to the host in the absence of selection (Dahlberg and Chao, 2003). 
The cost is thought to be attributed to maintaining the plasmid in the host during 
replication and partitioning with every generation (Ebersbach and Gerdes, 2005). In 
addition, plasmid encoded determinants are thought to be contributors to the decreased 
fitness observed due to the expression of these determinants, which may inadvertently 
affect bacterial growth or other basic cellular functions (Dahlberg and Chao, 2003; 
Turner et al., 1998).  
The fitness impact on the host is thought to be alleviated by the strict control of plasmid 
copy number (Brantl, 2004). In addition, fitness trade-offs have been observed between 
the plasmid and host, whereby the rate of conjugation was shown to increase but at the 
expense of host fitness (Turner et al., 1998).  
In the absence of selection, plasmid maintenance systems ensure the stable inheritance 
of the plasmids and in the presence of selection, the plasmid harbouring genes confer an 
advantage e.g. plasmid encoding antimicrobial resistance genes will be positively 
selected in the presence of the said antimicrobial. Sometimes the success of the plasmid 
harbouring strain is due to its efficient clonal dissemination, for example in the case of 
the ST131 clones harbouring a CTX-M-15 β-lactamase (Peirano and Pitout, 2010). In 
some instances however, the prevalence of particular plasmids has been attributed to the 
plasmids themselves, loosely termed epidemic plasmids (Livermore et al., 2007). The 
rapid rise in CTX-M producing plasmids cannot be solely explained by the genetic 
platform these genes are harboured within i.e. the plasmids, as this enzyme confers 
resistance to the same class of antimicrobials as its ancestral predecessors: TEM and 
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SHV ESBLs, often encoded on similar plasmid backbones (Livermore et al., 2007; 
Rossolini et al., 2008). Previous studies have demonstrated the fitness advantage 
conferred between variants of the blaTEM enzymes; TEM-1, TEM-10 and TEM-12 in the 
presence of selection. The differences in the relative growth and susceptibility to ESBLs, 
was thought to be due to the efficiency of β-lactam hydrolysis (Mroczkowska et al., 
2008). Mroczckowska and colleagues proposed that the relative abundance of TEM-1 
producing strains was due to higher catalytic efficiencies of this variant over TEM-10 
and TEM-12 in the presence of ampicillin. As TEM-1 is the most common blaTEM allele, 
it was proposed that the global β-lactam based antibiotic consumption selected for this 
allele, resulting in higher frequencies of this allele amongst clinical populations of 
Gram-negative bacteria  (Mroczkowska et al., 2008). 
Novais et al., later proposed that the evolutionary trajectory of blaCTX-M diversification 
and consequently abundance of CTX-M variants was driven by the higher efficiency of 
cephalosporin inactivation by this enzyme, more frequently used in treatment (Novais et 
al., 2010). Here, Novais et al. reported the increase in minimum inhibitory 
concentration (MIC) values as a measure of fitness based on two assumptions; a) only 
organisms able to survive high concentrations of the antimicrobial will survive and b) 
where there is a concentration gradient established, such as in the human body, only 
those populations able to withstand higher concentrations of the drug will be selected 
(Baquero and Blazquez, 1997; Novais et al., 2010). 
In chapter 4, the different CTX-M variants: CTX-M-1, CTX-M-14, CTX-M-14b, CTX-
M-15 and CTX-M-32, displayed varying MIC values against ceftazidime.  To 
investigate the possible fitness advantage conferred by these CTX-M variants, enzyme 
kinetic studies were employed to determine the efficiency of β-lactam hydrolysis with 
respect to the plasmid system encoding blaCTX-M variants and any additional β-
lactamases encoded. Five representative plasmids from the total isolate set (n = 52) 
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were transformed into E. coli BL21 strains, two of which were sequenced (reported in 
chapter 5): pI1-34TF, a ~160 kb CTX-M-15 plasmid; and pI2-53TF, a ~44 kb CTX-M-
32 plasmid. In addition, three plasmids only found to encode one resistance gene were 
studied: pI1-33TF, CTX-M-15; and pI2-38TF, CTX-M-1 and finally, pI2-47TF; a ~44 
kb derivative of I2-47. This field strain (I2-47) harboured two blaCTX-M-14b encoding 
plasmids, one a transconjugant derivative approximately ~130 kb in size (pI2-47TC) 
and a second ~44 kb plasmid (pI2-47TF) transferred by transformation. The larger  
~130 kb plasmid was sequenced and revealed a possible cointegrate plasmid consisting 
of an IncI1 and IncX1 scaffold (refer to chapter 5).  To ensure single plasmids were 
transferred to the BL21 host, the plasmid DNA extracted from the donor field strain was 
used to transform the BL21 cells. Upon screening only the ~44 kb plasmid was 
transferred. This ~44 kb plasmid was used in subsequent phenotypic studies.  
Discussed in this chapter is the impact of plasmid acquisition to the host with respect to 
fitness. The above plasmids were assayed for difference in growth rates between the 
plasmid-free strain and strains harbouring the CTX-M plasmids in the presence and 
absence of selection, as a measure of fitness. In addition the impact of plasmid 
acquisition to host growth in limited carbon sources was tested using the Biolog™ 
phenotypic microarray.  The 160 kb large plasmid pI1-34TF, which was found to 
harbour >200 predicted open reading frames from sequencing was transformed into E. 
coli BL21 and the stability of the plasmid upon acquisition into a host was determined 
by maintenance of this strain on solid media by subculturing for 30 days. Growth 
differences between the plasmid-free and plasmid-harbouring strains were determined 
in 380 different metabolites using the phenotypic microarray. 
This plasmid was also found to encode multiple membrane proteins including ATP-
binding cassette (ABC) proteins, permeases and major facilitator (MFS) transporters. 
Both ABC and MFS families of transporters have been known to contribute to drug 
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resistance by indiscriminate or specific efflux of antimicrobial drugs (Mahamoud et al., 
2007; Piddock, 2006). The effect of these and other plasmid encoded drug transporters, 
to drug resistance was investigated by monitoring changes in MIC to β-lactams in the 
presence of the efflux pump inhibitor phenyl-arginine-β-napthylamide (PAβN). 
This chapter addresses the question as to what features of the plasmid ensure the 
success of the plasmid with respect to persistence and abundance within the Gram-
negative bacterial population observed in the clinical and veterinary setting, or if in fact 
the plasmid system as a whole entity including the genetic platform that the genes are 
encoded on may be a reason for the success of blaCTX-M harbouring plasmids, as 
suggested by Livermore et al., 2007.  
6.2 Results 
6.2.1 Growth kinetics 
The impact of plasmid acquisition on growth rates to the host was determined by 
monitoring the optical density (OD600) over a 24-hour period in defined minimal media 
(MM) with glucose as the sole carbon and energy source (see chapter 2, section 2.5.3). 
The initial assay measured the differences in growth rate between the plasmid 
harbouring strains and the plasmid free E. coli BL21 host strain. The differences in 
growth were given as a measure of the area under the curve (AUC) from 6 replicates. 
The AUC was used to measure the total growth of the plasmid harbouring strains over 
the 24-hour period (presumed stationary phase). This measurement was taken to 
account for the total growth change in the 24-hour period. The limitation of this method 
being, the initial growth rates, whilst in exponential phase may not be obvious after 
AUC after 24 hours is taken. 
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The AUC followed similar profiles as the apparent rates of growth and thus AUC values 
were used instead of rate constants to take into account total growth for the duration of 
the experiment.  
A non-paired student t-test was used to compare growth kinetics. 
 
6.2.1.1 Growth kinetics in the absence of selection 
The plasmid pI1-34TF harboured in BL21, was found to have significantly higher (p < 
0.001) total growth (measured by the AUC) than the plasmid free BL21 host strain in 
LB-broth (Fig. 6.1A). Host strains (BL21) harbouring plasmids pI2-38TF and pI2-47TF 
were found to have significantly lower (p < 0.001) growth compared to the plasmid free 
BL21 strains and no difference in growth was observed with BL21 strains harbouring 
pI1-33TF and pI2-53TF.  
When grown in defined minimal media (MM) no significant difference (p < 0.001) in 
growth was observed between the plasmid harbouring and plasmid free strains (Fig. 6-
1B). Here the growth of the strains show a biphasic pattern, indicating growth on 
minimal media may be limited approximately after 8 hours, probably due to exhaustion 
of the carbon source. 
To determine if plasmid introduction to ΔBL21KAMR; an AcrAB-MdtABC deficient 
mutant (RND deficient), had any effect on growth, measurements were taken in both 
LB-broth and MM. No significant differences (p < 0.001) in growth between the 
plasmid free and plasmid harbouring strains were seen in either growth medium (Fig. 6-
1C and D).  
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Figure 6-1: Growth of plasmid in host strains in the absence of selection in LB-broth and minimal media supplemented with 0.1 % glucose. (A) and (B) Growth kinetics of 
CTX-M producing plasmids harboured in BL21 in LB-broth and minimal media respectively. (C) and (D) Growth kinetics of CTX-M producing plasmids harboured in 
ΔBL21KAMR in LB-broth and minimal media respectively. Two biological replicates and three technical replicates were averaged to give the mean OD600 in the 24 hour period 
used to monitor the growth of the strains, measured in 15 minute intervals.   
    
Growth of BL21 strains in LB broth
5 10 15 20 25
-0.2
0.0
0.2
0.4
0.6
0.8
BL21_LB
pI1-33TF_LB
pI1-34TF_LB
pI2-38TF_LB
pI2-47TF_LB
pI2-53TF_LB
Time (Hours)
O
D
60
0
Growth of BL21 strains in minimal media
5 10 15 20 25
-0.2
0.0
0.2
0.4
0.6
BL21_MM
pI1-33TF_MM
pI1-34TF_MM
pI2-38TF_MM
pI2-47TF_MM
pI2-53TF_MM
Time (Hours)
O
D
60
0
Growth of ΔBL21KAMR strains in LB broth
5 10 15 20 25
-0.2
0.0
0.2
0.4
0.6
0.8
ΔBL21KAMR_LB
pI1-33TF_LB ΔBL21KAMR
pI1-34TF_LB ΔBL21KAMR
pI2-38TF_LB ΔBL21KAMR
pI2-47TF_LB ΔBL21KAMR
pI2-53TF_LB ΔBL21KAMR
O
D
6
0
0
Time (Hours)
Growth of ΔBL21KAMR strains in minimal media
5 10 15 20 25
-0.2
0.0
0.2
0.4
0.6
ΔBL21KAMR_MM
pI1-33TF_MM ΔBL21KAMR
pI1-34TF_MM ΔBL21KAMR
pI2-38TF_MM ΔBL21KAMR
pI2-47TF_MM ΔBL21KAMR
pI2-53TF_MM ΔBL21KAMR
Time (Hours)
O
D
60
0
A B 
C D
 211 
6.2.1.2 Growth kinetics is the presence of selection 
Defined media was used in determining the growth kinetics in the presence of selection. 
Cefotaxime and ceftazidime were chosen due to differences in MICs observed in 
previous experiments (see section chapter 4). 
The plasmids, harboured within BL21 background were grown in the presence of 
cefotaxime (1 mg/L) (Fig. 6-2A). Significantly (p < 0.001) faster growth was observed 
in strains harbouring pI1-33TF (CTX-M-15), pI2-47TF (CTX-M-14b) and pI2-53TF 
(CTX-M-32) plasmids compared to the plasmid free strain. When compared to the 
untreated strains (no cefotaxime) in MM, no significant differences (p < 0.001) in 
growth were observed in strains harbouring these plasmids. Strains harbouring pI1-
34TF (CTX-M-15) and pI1-38TF (CTX-M-1) had significantly lower growth rates than 
the untreated strains harbouring these plasmids. These results show differences in the 
two IncF plasmids producing the CTX-M-15 enzyme upon exposure to the antibiotic 
cefotaxime, despite these enzymes being regarded as the more efficient inactivators in 
MIC experiments in chapter 4 (section 4.2.8) that may suggest intrinsic differences in 
these plasmids independent of the CTX-M variant produced. 
 
Interestingly, pI1-34TF in the RND deficient background (ΔBL21KAMR) treated with 
cefotaxime grew better than the same plasmid harbored in the BL21 host, having 
significantly higher growth rates (p < 0.001) than the plasmid free strain (Fig. 6-2B). 
Strains harboring pI1-33TF, pI2-47TF and pI2-53TF grew at similar rates as when in 
the BL21 host. The strain harbouring pI2-38TF had no significant difference in growth 
compared to the plasmid free strain. These results suggests, that even in the absence of 
the AcrAB efflux system, strains harbouring the CTX-M plasmids are able to survive 
exposure to cefotaxime, possibly due to efficient drug inactivation by the enzymes or by 
other compensatory efflux systems or reduced porin expression in the host background. 
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Transcriptional studies and possibly the use of transposon directed insertion-site 
sequencing (TraDIS) could be employed to determine the genes upregulated and or 
essential for resistance to cefotaxime. 
A 
 
B 
       
Figure 6-2: Growth kinetics of CTX-M producing plasmids in the presence of cefotaxime (1 mg/L). 
(A) Depicts growth of plasmids harboured within E. coli BL21 strains and (B) is the growth of these 
plasmids in the ΔBL21KAMR RND deficient background. Two biological replicates and three technical 
replicates were averaged to give the mean OD600 in the 24 hour period used to monitor the growth of the 
strains, measured in 15 minute intervals.  
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Growth of the strains in the presence of 0.5 mg/L of ceftazidime was monitored (Fig. 6-
3A and B). The MIC for the host strains, BL21 and ΔBL21KAMR was < 0.5 mg/L. 
Strains were grown in minimal media supplemented with 0.5 mg/L ceftazidime to 
inhibit growth of the plasmid free strains. However, both the plasmid free control 
strains grew in the presence of ceftazidime, with no significant (p < 0.001) difference in 
growth compared to the plasmid bearing strains (see Fig. 6-3A and B).  
Moulin and colleagues found differences in growth of E. coli strains in different carbon 
sources in the presence of ceftazidime (Malouin et al., 1991). To determine if the 
growth of the control strains was due to the use of glucose (0.1 %) as a supplement in 
the defined media, the plasmid free strains and CTX-M-15 producing plasmid pI1-33TF, 
in the BL21 and ΔBL21KAMR background, were streaked on minimal agar plates 
supplemented with 1% (w/v) sodium succinate and ferric citrate (AbuOun 2009) and 
10 % (w/v) glutamate (Malouin et al., 1991). The plates were supplemented with 0.5, 1 
and 2 mg/L ceftazidime (above the MIC of the plasmid free host strains). Control plates 
contained LB-agar supplemented with 0.5, 1 and 2 mg//L ceftazidime. Both the plasmid 
free and plasmid harboring strains grew in the presence of all concentrations of 
ceftazidime in LB-agar. No growth was observed in the other two carbon sources (in 
minimal media) in all three concentrations of ceftazidime. Growth of the plasmid 
harboring strain (pI1-33TF; CTX-M-15) was only observed at the initial streaking point. 
The change in carbon source appears to recover efficacy of the drug and even limit the 
growth of the CTX-M plasmid. Future work will employ MIC experiments to 
investigate the effect of the different carbon sources on the efficacy of ceftazidime with 
different CTX-M producing plasmids to determine if the MICs observed using Iso-
sensitest agar (which contains glucose) has an effect on the efficacy of the drug.  
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Figure 6-3: Growth kinetics of CTX-M producing plasmids in the presence of ceftazidime (0.5 
mg/L) in BL21 (A) and BL21KAMR (B). Growth of both of the host strains in concentrations of 
ceftazidime above their pre-determined MICs deemed these results as inaccurate, requiring optimisation 
in different growth medium. Two biological replicates and three technical replicates were averaged to 
give the mean OD600 in the 24 hour period used to monitor the growth of the strains, measured in 15 
minute intervals. 
 
6.2.2 Plasmid stability in ageing colonies 
To investigate the fitness cost of plasmid acquisition to the host strain, a single plasmid 
(pI1-34TF; CTX-M-15) was selected for analysis because of the severe growth 
retardation when grown in the presence of cefotaxime in the BL21 host strain, the 
surprising recovery once introduced into the RND deficient strain (Fig. 6-1) and the 
large size (150 kb) with over 200 predicted ORFs identified by the RAST prediction 
annotation tool (rast.nmpdr.org) (see chapter 5). 
 
6.2.2.1 Plasmid stability in E. coli BL21 
Plasmid pI1-34TF was introduced into E. coli BL21 by transformation. The plasmid 
bearing and plasmid free (control) strains were maintained on solid LB-agar 
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supplemented with 0.2 % glucose and 3 mM CaCl2 for 30 cycles. Fresh BL21 host 
strain and the plasmid harbouring (pI1-34TF) BL21strain, were streaked on the plate to 
a single colony, this was defined as cycle 0. A cycle was defined as growth of a single 
colony after an overnight incubation, which is approximately 28 generations, totalling 
approximately 900 generations in 30 cycles (Andersson and Hughes, 1996). A single 
colony from the overnight plate was picked and streaked onto a fresh plate giving cycle 
1 strains. This was repeated a further 29 times to obtain 30 cycles. Picking a single 
colony is thought to provide an intense genetic drift due to lineages being generated 
through forceful bottleneck selection (Andersson and Hughes, 1996). The single colony 
picked for re-streaking was grown overnight in liquid media and frozen at -80 °C for 
subsequent phenotypic experiments. 
 
6.2.2.2 Growth kinetics between the plasmid free and plasmid bearing strain at 
cycle 0, 15 and 30 
To determine if plasmid acquisition and maintenance affects growth of the host over the 
30-cycle period, the plasmid free and plasmid (pI1-34TF) harbouring BL21 was 
monitored over a 24-hour period in minimal media supplemented with 0.2 % glucose 
(Fig. 6-4). No significant difference (p < 0.001) in growth between the cycles 0, 15 and 
30 (approximately 28, 420 and 840 generations respectively) was observed between the 
plasmid free and the plasmid bearing strain. However, what is interesting to note is the 
growth rate between the plasmid bearing strains increased with time (i.e. growth at 
cycle 30 > cycle 15 > cycle 0), the reverse of BL21, suggesting some form of adaptation 
of the plasmid bearing strains in accommodating the plasmid. 
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Figure 6-4: Graph showing the growth kinetics (measured at OD600) of the plasmid (BL21) and 
plasmid bearing (pI1-34TF) strain maintained on solid media for 0 cycles (28 generations), 15 (420 
generations) and 30 (840 generations) cycles. The strains were grown in defined minimal media 
containing glucose. Two biological replicates, each with three technical replicates were measured.  
 
6.2.3 Assessing the impact of plasmid acquisition and maintenance to host 
metabolism 
The plasmid harbouring strains and the control (plasmid free BL21) was assessed for 
differences in growth in 380 different metabolite sources using the Biolog™ phenotypic 
microarray. Metabolites tested included phosphorous and peptide nitrogen sources. The 
peptide nitrogen sources were selected because of the significant differences in growth 
observed between an E. coli 0157 harbouring a 92 kb F-like MDR plasmid; pO157 and 
the cured strains (Lim et al., 2010). The phosphorous compounds were selected because 
phosphorous is an important compound in numerous signal transduction pathways, 
which may affect downstream genes or pathways that may be involved in expression of 
resistance mechanisms (Wanner, 1996). 
The three cycles 0, 15 and 30, from the 30 cycle sustained growth on solid media were 
selected for phenotypic analysis. The experiment was run for 96 hours, with differences 
in growth represented at 26 (Fig. 6-5), 48 (Fig. 6-6) and 96 (Fig. 6-7) hours.  
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At 26 hours (Fig. 6-5), for cycle 0 (28 generations) bacteria, the plasmid bearing strain 
only utilised (1-2 fold) 4 of the 380 (1 %) metabolites tested. All were dipeptide 
compounds. In the cycle 15 passage strains (420 generations), the plasmid bearing strain 
grew better in phosphorous compounds (1-2 fold). The cycle 30 strains (840 
generations) utilised less phosphorous compounds than the plasmid free strain (up to 5 
fold). Interestingly, the plasmid harbouring strain in this older generation (30 cycles) 
utilised dipeptide compounds better than the cycle 0 and 15 passage. 
At 48 hours (Fig. 6-6), no difference was observed between BL21 and the plasmid 
bearing strain of cycle 0. However with the cycle 15 passage, the plasmid bearing strain 
did not utilise D-Manose-1-phospate as well as the plasmid free strains (3 fold less) also 
at the cycle 15 passage, but utilised the dipeptide compounds more (1-2 fold) than 
BL21-cycle 15 passaged strain. The cycle 30 passaged plasmid bearing strain utilised 
less phosphorous compounds (up to 4 fold less) but was able to utilize the dipeptide 
compounds 1-2 fold better than the plasmid free in the than BL21-cycle 30 passaged 
strain. 
At 96 hours (Fig. 6-7), the cycle 0 and 15 passaged strains utilized the similar amounts 
of compounds as the plasmid free strain, a reduction in respiration in only 0.3 % and 
1.6 % and an increase in 1.1 % and 2.4 % of the metabolites tested respectively. 
However the older generation (cycle 30) plasmid bearing strain utilized the 
phosphorous-based compounds up to 3 fold less than the plasmid free (cycle 30) 
passages strain. However, this cycle 30 passaged strain utilized the dipeptide 
compounds four times better than the plasmid free cycle 30 passaged strain. The 
differences in compound utilization at the 96 hour time point relative to the plasmid free 
BL21, may be skewed because other better utilized compounds may be provided by the 
break-down of dead cells, resulting in the reduced number of compounds affecting the 
plasmid harbouring strains. These results suggest that as the passages and therefore the 
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age of the strains increase, the plasmid harbouring strain is less able to utilise the same 
compounds as its plasmid free counterpart, but this phenotype is not reflected in the 
growth of the strains (Fig. 6-4). Further work could look at the growth by measuring 
changes in OD600 of the strains in compounds, which show variability in metabolite 
usage between the cycles. 
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Figure 6-5: Graph showing fold change differences in metabolite utilization relative to the plasmid free BL21 strain, using fold change cut-offs of ≥  1 or ≤  -1 for increased 
and decrease in growth respectively relative to BL21 after 26 hours of incubation. The area under the curve of the kinetic graphs were taken at each time interval for two 
biological replicates and the fold change relative to each of their respective negative controls; present on each of the 96 well phenotypic plates, was calculated. The differences in the 
fold change were calculated to compare differences in metabolite utilization between the plasmid harbouring and host (plasmid free) strains and Fold changes of the plasmid bearing 
strain (pI1-34TF) are shown in blue (cycle 0), red (cycle 15) and green (cycle 30) relative to the plasmid free host strains at the corresponding cycles.  
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Figure Error! No text of specified style in document.-1: Graph showing fold change differences in growth relative to the plasmid free BL21 strain, using fold change cut-offs 
of ≥  1 or ≤  -1 for increased and decrease in growth respectively relative to BL21 after 48 hours of incubation. The area under the curve of the kinetic graphs were taken at each 
time interval for two biological replicates and the fold change relative to each of their respective negative controls; present on each of the 96 well phenotypic plates, was calculated. 
The differences in the fold change were calculated to compare differences in metabolite utilization between the plasmid harbouring and host (plasmid free) strains and Fold changes 
of the plasmid bearing strain (pI1-34TF) are shown in blue (cycle 0), red (cycle 15) and green (cycle 30) relative to the plasmid free host strains at the corresponding cycles. 
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Figure Error! No text of specified style in document.-2: Graph showing fold change differences in growth relative to the plasmid free BL21 strain, using fold change cut-offs 
of ≥  1 or ≤  -1 for increased and decrease in growth respectively relative to BL21 after 96 hours of incubation. The area under the curve of the kinetic graphs were taken at each 
time interval for two biological replicates and the fold change relative to each of their respective negative controls; present on each of the 96 well phenotypic plates, was calculated. 
The differences in the fold change were calculated to compare differences in metabolite utilization between the plasmid harbouring and host (plasmid free) strains and Fold changes 
of the plasmid bearing strain (pI1-34TF) are shown in blue (cycle 0), red (cycle 15) and green (cycle 30) relative to the plasmid free host strains at the corresponding cycles. 
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6.2.4 Enzyme kinetics studies  
Kinetics measurements of purified CTX-M enzymes have previously been reported 
(Barthelemy et al., 1993; Bradford et al., 1998; Cartelle et al., 2004; Ishii et al., 1995; 
Kimura et al., 2004; Ma et al., 2002). To investigate the efficiency of the CTX-M 
producing plasmids, the plasmids were transformed into an E. coli BL21 strain. Crude 
cell extracts were used to determine the contribution of plasmid encoded β-lactamase 
genes i.e. CTX-M or additional TEM and OXA enzymes (see table 6-1).  
Characteristically, purified CTX-M-32 enzymes are the most efficient variant at 
hydrolysing ceftazidime between all the variants tested, followed by CTX-M-15, CTX-
M-1 and finally CTX-M-14(b) (Bonnet, 2004; Novais et al., 2010). Using crude lysates 
for the kinetic measurements would in theory take into account other plasmid 
characteristics which may affect the efficiency of β-lactam hydrolysis including 
additional β-lactamases and plasmid copy number, and as a consequence the relative 
expression levels of the β-lactamase enzyme. This measurement could therefore reflect 
the efficiency of the plasmid as an entity is deactivating β-lactamases. The plasmid free 
host strain was used as a control to measure any residual β-lactamase activity produced 
by the host. 
 
Table 6-1: Plasmids selected to determine the impact of plasmids to host fitness. 
The resistance gene profiles of the plasmids are also given. 
Plasmid Plasmid Size (kb) Antimicrobial resistance genes 
pI1-33TF 70 blaCTX-M-15 
pI1-34TF 150 aac6lb, aadA4, catA1, blaCTX-M-15, dfrA17, blaOXA-1, sul1, blaTEM-1 
pI2-38TF 44 blaCTX-M-1 
pI2-47TF 44 blaCTX-M-14b,  blaTEM-1 
pI2-53TF 44 aadA1, aadA2, cmlA1, blaCTX-M-32, dfrA12, sul3, tetA 
Gene targets: blaCTX-M, blaTEM and blaOXA; ESBLs, aadA and aac; aminogylcosides, cmlA1 and catA1; Chloramphenicols, dfrA12 
and dfrA17; trimethoprims, sul1 and sul3; sulphonamides, tetA; tetracyclines. 
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Steady state kinetics of the five plasmids was determined by monitoring the colour 
change of nitrocefin. Nitrocefin  (Fig. 6-8) is a chromogenic cephalosporin with a 
highly reactive β-lactam ring, readily hydrolyzed by all known β-lactamases produced 
by both Gram-negative and Gram-positive bacteria. It undergoes a distinctive colour 
change from yellow (λ=390 pH7.0) to red (λ=486nm pH 7.0) upon hydrolysis of the β-
lactam ring, consequently producing a colour change. This is thought to be a result of 
cleavage of the amide bond within the β-lactam ring in an already highly conjugated 
system (emitting the yellow colour) leading to further conjugation, thus producing the 
red colour, which can be measured spectrophotometrically (O’Callaghan, 1972; 39). 
The colour change is monitored in the 480-500 nm range (Herdberg, 1995; 39, 
Reifferscheid, 2006; 46). 
 
Figure 6-8: Chemical structures of broad spectrum (ampicillin), extended spectrum (cefotaxime 
and ceftazidime) and the colorimetric substrate used to measure β-lactam hydrolysis, nitrocefin. 
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6.2.4.1 Determining the protein concentration  
The protein content was measured using the BCA protein assay kit (Thermoscientific), 
using BSA as a standard (see table 6-2). BSA absorbance values corrected against the 
blank and known BSA protein concentrations (µg/ml) were plotted to give a standard 
curve (Fig. 6-9). The total protein [T.Prot] was calculated from the standard curve 
(polynomial; order 3) (table 6-3). Four of the plasmid harbouring strains had similar 
protein concentrations (approximately 200 µg/ml) compared to the plasmid free host 
(BL21). One plasmid pI2-53TF/BL21 had a slightly lower protein concentration at 
178.85 µg/ml. 
 
Table 6-2: Absorbance at λ=562 nm of BSA standards determine using the BCA 
assay. 
     
  Absorbance 
Dilution Concentration (µg/ml) Replicate 1 Replicate 2 Mean ABS Corrected 
A 2000 1.856 2.161 2.0085 1.861 
B 1500 1.899 2.02 1.9595 1.812 
C 1000 1.283 1.318 1.3005 1.153 
D 750 0.952 0.879 0.9155 0.768 
E 500 0.734 0.813 0.7735 0.626 
F 250 0.434 0.349 0.3915 0.244 
G 125 0.303 0.32 0.3115 0.164 
H 25 0.173 0.177 0.175 0.0275 
I (Blank) 0 0.153 0.142 0.1475 0 
 
The bovine serum albumin (BSA) protein standards were prepared according to the manufacturer’s instructions using an albumin 
standard (BSA). Protein measurements were made at 562 nm. The mean readings were subtracted from the blank (I) readings t give 
the ‘corrected’ readings, used to plot a graph (standard curve of absorbance at 562nm versus protein concentration (µg/ml).(below; 
Fig. 6-2). 
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Figure 6-9: BSA standard curve used to estimate total protein concentration of crude cell extracts 
[T.Prot]. The total protein [T.Prot] was calculated from the standard curve (polynomial; order 3). 
 
Table 6-3: Protein concentration of crude lysates 
     
Sample Replicate 1 Replicate 2 Mean ABS Concentration (µg/ml) 
pI1-33TF 0.199 0.208 0.2035 201.34 
pI1-34TF 0.202 0.205 0.2035 201.34 
pI2-38TF 0.211 0.21 0.2105 208.73 
pI2-47TF 0.205 0.201 0.203 200.81 
pI2-53TF 0.182 0.183 0.1825 178.85 
BL21 0.199 0.192 0.1955 192.83 
 
Equal volumes of the crude lysates were mixed with the bicinchonic acid (BCA; Pierce) to measure the absorbance, according to the 
manufacturer’s instructions. Protein concentrations [T Prot] were estimated from the standard curve generated from the BSA 
standards (Fig. 6-1).  
 
6.2.4.2 Enzyme activity 
The enzyme activity is the amount of substrate converted per unit of time under the 
given conditions. The β-lactamase activity (enzyme activity) of the crude extracts were 
measured as units of activity, where one Unit of β-lactamase is the amount of enzyme 
required to form 1 µmol of product per min in 1 ml of reaction. See chapter 2; section 
2.5.5.4 for details.  
Figure 6-11 shows the graph used to estimate the β-lactamase activity given as Units of 
enzyme per minute (Units min-1). Two plasmids, pI2-38TF and pI2-47TF reached 
y = 291.64x3 - 717.63x2 + 1315.3x - 39.061 
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saturation before measurement could begin (see Fig. 6-10). These two extracts were 
diluted 1 in 10 and measurements repeated. The β-lactamase activities are displayed in 
table 6-4. From this data, plasmid pI2-38TF (CTX-M-1) and pI2-47TF (CTX-M-14b) 
had the highest β-lactamase activity, followed by pI1-34TF (CTX-M-15), 16 times 
lower activity than pI2-38TF, pI2-53TF (CTX-M-32) with 20 times less activity than 
pI2-38TF (the highest activity of the plasmids tested) and finally pI1-33TF with 35 
times less activity compared to pI2-38TF. The host strain (with no plasmids) was also 
measured to obtain residual β-lactamase activity, found to have 540 times lower activity 
than pI2-38TF and 154 times lower than the least active of the plasmids; pI1-33TF. 
 
Figure 6-10: Measuring β-lactamase activity from crude extracts in the presence of 0.1 mM 
nitrocefin. Absorbance values were plotted against time (minutes). Rates (OD/min) were determined by 
the gradient of the linear portion of the non-linear regression. The rates (OD/min) were used to calculate 
the enzyme activity (Bisswanger 2004). *; pI2-38TF and pI2-47TF extracts were diluted 1in 10 to allow 
the measurements of initial rates. 
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Table 6-4: Calculating total enzyme activity in Units (µmol min-1). 
 
Plasmid OD/min 
Product 
converted (M) in 
100ul 
Product 
converted (M) in 
1ml 
Product 
converted 
(µM) in 1ml 
Enzyme activity  
(Units)a 
BL21b 0.005 4.57x10-7 4.57x10-6 0.46 4.57x10-4 
pI1-33TF 0.077 7.03x10-6 7.03x10-5 7.03 7.03x10-3 
pI1-34TF 0.1602 1.46x10-5 1.46x10-4 14.63 1.46x10-2 
*pI2-38TF 2.692 2.46x10-4 2.46x10-3 245.89 2.46x10-1 
*pI2-47TF 1.999 1.83x10-4 1.83x10-3 182.59 1.83x10-1 
pI2-53TF 0.1358 1.24x10-5 1.24x10-4 12.40 1.24x10-2 
*pI2-38TF and pI2-47TF extracts were diluted 1in 10 to allow the measurements of initial rates. The dilution factor was 
accounted for in calculating the units of enzyme. aEnzyme units are the amount of product in µmoles formed in one minute in 
1ml of a reaction with units (µmol min-1). 
bThe total enzyme activity for the plasmid free E. coli BL21, to which all test plasmids were transformed in.  
 
6.2.4.3 Calculating the specific enzyme activity 
The specific activity (µmol min-1 mg-1 or Units mg-1) (table 6-5) was calculated by 
dividing the enzyme activity (µmol min-1) by the amount of protein (mg). In the crude 
lysates a large percentage of the total protein [T.Prot] may not be the protein of interest. 
The purer the protein sample, the higher the proportion of [T.Prot] attributed to the 
enzyme. In a crude extract, the Units of activity remain the same as in the purified state 
of the same sample, but the protein content would decrease because of other protein 
contaminants, and consequently the specific activity attributed to the enzyme would be 
less. The specific enzyme activity of the BL21 host was subtracted from the specific 
activity of the CTX-M producing plasmids to discount the residual β-lactamase activity 
produced by the host strain. 
The CTX-M-1 and CTX-M-14b producing plasmids, pI2-38TF and pI2-47TF had the 
highest specific β-lactamase activities. Interestingly the CTX-M-32 producing plasmid, 
pI2-53 was found to have a higher specific activity compared to pI1-34TF; the CTX-M-
15 producing plasmid that had a higher enzyme activity, suggesting the CTX-M-32 
plasmid has a higher activity despite having a lower protein concentration. The lowest 
activity was observed with the CTX-M-15 producing plasmid, pI1-33TF. 
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Table 6-5: Calculating specific enzyme activity. 
Plasmid 
[T. Prot] 
(µg) 
[T. Prot] 
(mg) 
Enzyme activity 
(Units/ml)a 
Total specific activity  
(µmol min-1mg-1) 
 Specific activity  
(µmol min-1mg-1) 
BL21 7713 7.71 4.57x10-4 5.92x10-5 - 
pI1-33TF 8054 8.05 7.03x10-3 8.73x10-4 8.14x10-4 
pI1-34TF 8054 8.05 1.46x10-2 1.82x10-3 1.76x10-3 
pI2-38TF 8349 8.35 2.46x10-1 2.95x10-2 2.94x10-2 
pI2-47TF 8032 8.03 1.83x10-1 2.27x10-2 2.27x10-2 
pI2-53TF 7154 7.15 1.24x10-2 1.73x10-3 1.67x10-3 
 
a; Enzyme units are the amount of product in µmoles formed in one minute in 1ml of a reaction with units (µmol min-1). 
b;  The total enzyme activity for the plasmid free E. coli BL21, into which all test plasmids were transformed. The specific enzyme 
activity for the test plasmids was subtracted from the specific enzyme activity of plasmid free E. coli BL21 (residual β-lactamase 
activity).     
 
6.2.4.4 Determining the total enzyme concentration; [E]T 
The enzyme concentration (mol L-1) was calculated as described in section 2.5.5.5 
(chapter 2). The concentration of β-lactamase in CTX-M producing plasmids was 
similar averaging at 2.6x10-10 (see table 6-6), indicating that all the plasmids produce 
the same amount of enzyme. 
 
Table 6-6: Calculating [E]T. 
 
 
 
 
 
 
The total enzyme concentration [E]T (mol L-1) was calculated by dividing the total enzyme activity (µmol min-1), determine in 
section 6.1.5 of this chapter by the specific activity (µmol min-1 mg-1), determined in section 6.1.6. [E]T is the concentration of β-
lactamase enzyme in a 1 ml reaction. 
 
Plasmid [E] (mg ml-1) [E] (g L-1) MW (Da) [E]T (mol L-1) 
pI1-33TF 8.64 8.64x10-6 31143.60 2.77x10-10 
pI1-34TF 8.32 8.32x10-6 31143.60 2.67x10-10 
pI2-38TF 8.37 8.37x10-6 31245.69 2.68x10-10 
pI2-47TF 8.05 8.05x10-6 30979.38 2.60x10-10 
pI2-53TF 7.41 7.41x10-6 31187.66 2.37x10-10 
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6.2.4.5 Kinetic parameters 
The kinetic parameters of the crude extracts from CTX-M producing plasmids showed 
pI2-53TF (CTX-M-32) to have the lowest KM with 10.09 µM, followed by pI1-33TF 
(CTX-M-15); 14.46 µM, pI2-47TF (CTX-M14b); 20.05 µM and finally pI2-38TF 
(CTX-M-1) and pI1-34TF (CTX-M-15) with KM values of 38.67 µM and 38.81 µM 
respectively (Fig. 6-11 and table 6-7). An enzyme with a low KM achieves maximal 
catalytic efficiency at low substrate concentration and is considered to have a higher 
affinity for the substrate. Therefore by this definition, the CTX-32 producing plasmid 
has the highest affinity for nitrocefin and the enzyme to have the lowest affinity is the 
CTX-M-15 producing plasmid, pI1-34TF. This plasmid produces the same CTX-M 
variant as pI1-33TF, but these plasmids may sit on very different genetic platforms, 
which may explain the variation observed.  
Catalytic efficiencies (kCAT/KM ) of the five test plasmids showed the CTX-M-14b 
producing plasmid, pI2-47TF  to be the most efficient system with the highest kCAT/KM 
value, 211.63 µM-1s-1 (table 6-7). This was followed by CTX-M-32 pI2-53TF (103.09 
µM-1s-1), then CTX-M-1 pI2-38TF (97.45 µM-1s-1) then finally the CTX-M-15 
producing plasmids pI1-34TF (37.02 µM-1s-1) and pI1-33TF (28.59 µM-1s-1). Plasmids 
pI2-47TF, pI2-53TF and pI2-38TF were estimated to be approximately 44 kb in size by 
S1-nuclease PFGE. Given the relative sizes; 44 kb verses the 70-160 kb CTX-M-15 
plasmids, the two-fold drop of the enzyme efficiency between the 44 kb plasmids and 
the two larger IncF CTX-M-15 plasmids suggests a possible link with copy number; 
which is tightly regulated for IncF plasmids, and the enzyme efficiency. The lower 
enzyme efficiencies observed with the IncF CTX-M-15 plasmids might be due to lower 
plasmid copies of the CTX-M producing plasmid leading to lower gene expression and 
consequently lower enzymatic activities of these enzymes. 
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Figure 6-11: Double reciprocal (Lineweaver-Burke) plot used to determine KM and VMAX values 
using the intercept; X and Y intercepts respectively using the formula function in Microsoft excel. 
 
Table 6-7: Kinetic parameters of crude extracts from transformed E. coli BL21 
strains harbouring blaCTX-M variants. 
 
Genotype Plasmid KM (µM) VMAX (µM s-1) [E]T (µM) KCAT (s-1) KCAT/KM (µM-1/s-1) 
blaCTX-M-15 pI1-33TF 14.46 0.11 2.77x10-4 413.51 28.59 
blaCTX-M-15 pI1-34TF 38.81 0.38 2.67x10-4 1436.86 37.02 
blaCTX-M-1 pI2-38TF 38.67 1.01 2.68x10-4 3768.07 97.45 
blaCTX-M-14b pI2-47TF 20.05 1.10 2.60x10-4 4242.59 211.63 
blaCTX-M-32 pI2-53TF 10.09 0.25 2.37x10-4 1040.29 103.09 
 
The enzyme turnover or catalytic constant (KCAT) was calculated as a measure of the efficiency of the enzyme by dividing the VMAX 
by the total enzyme concentration [E]T. Catalytic efficiencies are given as KCAT/KM. 
 
 
. 
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6.2.5 Susceptibility of plasmid harboring blaCTX-M plasmid in a BL21 host 
PAβN was used to investigate the clinical relevance of using the EPIs in successfully 
inhibiting extrusion of β-lactams; which are transported via the AcrAB-TolC efflux 
system, the substrate for this EPI.  
The concentration at which PAβN (100 µg/ml) was used, was shown to effectively 
inhibit efflux in a dose dependent manner (Coldham et al., 2010). To eliminate toxicity 
related cell death, which may be associated with prolonged exposure to the inhibitor 
during susceptibility assays, a range of concentrations were used. The cells were 
incubated overnight in the presence of PAβN at 25, 50 and 100 µg/ml in the presence of 
ampicillin, cefotaxime or ceftazidime.  
For three of the plasmids, the decrease in MIC in the presence of increasing 
concentrations of PAβN was indirectly correlated. Plasmids, pI2-38TF and pI2-47TF 
and pI2-53TF showed up to a 2000 fold decrease in MIC in the presence of increasing 
concentrations of PAβN, making these strains susceptible to ampicillin (Fig. 6.12A). 
The CTX-M-15 producing plasmids pI1-33TF and pI1-34TF did not demonstrate a 
decrease in MIC in the presence of the EPI, maintaining MIC values of > 1024 mg/L 
(Fig. 6.12A).  
MICs against the cephalosporins cefotaxime (Fig. 6.12B) and ceftazidime (Fig. 6.12C) 
demonstrated a similar pattern with the three plasmids pI2-38TF, pI2-47TF and pI2-
53TF having over a 2000 fold decrease in MIC in the presence of 100 µg/ml PAβN. 
CTX-M-15 producing plasmids, pI1-33TF and pI1-34TF were found to only have two-
fold differences, in some cases resulting in an increase in MIC. Interestingly the MIC 
increased two fold for both plasmids in the presence of 25 µg/ml PAβN, however the 
MIC reduced two-fold in the presence of higher concentrations (50 and 100 µg/ml). 
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This suggests these two plasmids at low EPI concentrations have a decreased 
susceptibility to the EPI or may induce the expression of a different efflux system. 
 
 
 
Figure 6-12: Susceptibility to ampicillin, cefotaxime and ceftazidime in the presence of PAβN at 25, 
50 and 100µM. The white bars represent strain grown in the antibiotic but untreated with PAβN, the blue 
bars, in increasing blue intensity (light to dark blue) denote increasing concentrations of PAβN; 25 (light 
blue), 50 (medium blue) and 100µM (dark blue). A range of concentrations lower than that used to inhibit 
efflux (100 µg/ml) in the H33343 accumulation experiment were chosen to limit toxicity, however the 
bacterial cells were able grow in the presence of the highest concentration of PAβN used.  
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6.3 Discussion 
The effect of plasmid acquisition and maintenance for 840 bacterial generations, to host 
fitness was investigated. Differential growth patterns in defined media were measured 
in the presence of phosphorous, sulphur and peptide nitrogen sources.  
Plasmid pI1-34TF was selected for analysis of plasmid maintenance and its impact on 
host fitness using the Biolog phenotypic microarray. The size of the pI1-34TF (150 kb) 
made this an ideal candidate, because the size may impose a greater fitness cost to the 
host. Daily single colonies were picked, artificially forcing a genetic bottleneck of a 
random single cell, a process thought to limit mutations that may outcompete each other 
in a heterogeneous population, thereby decreasing the likelihood of bias estimates of the 
mutation rate (Andersson et al., 1996; Sniegowski et al., 2010; Stevens et al., 2011). 
 After passaging on plates for 30 cycles, the “aged” plasmid harboring strain was found 
to utilize phosphorous compounds less than the BL21 strain but interestingly 
metabolized some dipeptide nitrogen sources better. This reduction of phosphorous 
utilization compounds may be a result of the stress conditions of growing the plasmid 
on solid media for prolonged periods. In periods of stress, the RpoS; a stress inducible 
RNA polymerase (RNAP) σ factor or σS is produced. To confirm this hypothesis, RT-
PCR could be performed on selected genes of the RpoS regulon to assess the 
contribution to the phenotype observed. When complexed with RNAP, the holoenzyme 
induces expression of stress response genes including genes that control phosphate (Pi) 
transport and metabolism (Ruiz and Silhavy, 2003). The induction of RpoS during 
carbon and Pi limitation would result in activation of the pst regulon, that encodes 
proteins involved in Pi transport. Ruiz and colleagues found that in limited Pi rpoS 
translation and stability increase, resulting in increase Pi transport and metabolism. In 
the present study the abundance of Pi compounds may result in the opposite function, 
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that would decrease the translation of rpoS and consequently the expression of the Pst 
transport system, resulting in decreased utilization of phosphorous observed.  
 
To investigate the role of possible reduced growth rates as a result of acquiring the 
plasmid, direct competition experiments with the plasmid free and plasmid-harboring 
strains were performed. The results did not show any significant difference in growth 
between the two strains, suggesting no little or not cost to growth rate. 
 
Plasmid acquisition and maintenance is thought to impart a fitness cost due to the 
expression of genes encoded within it (Andersson and Hughes, 2010). During selection 
the plasmid confers some advantage (e.g. antibiotic resistance) enabling it to be retained 
in the host. It can be assumed due to its fitness cost that the plasmid should be lost, but 
rarely is this observed (Andersson and Hughes, 2010). In this chapter the in vitro effects 
of plasmid acquisition and maintenance with respect to β-lactamase enzyme kinetics, 
growth kinetics and metabolite usage in defined carbon sources were investigated.  
The CTX-M-14 producing plasmid was found to be the most enzymatically efficient 
plasmid system followed by the CTX-M group 1 plasmids, then CTX-M-32, CTX-M-1 
and the CTX-M-15 plasmids in descending order. Previously published studies report 
CTX-M group 1 enzymes to have higher enzymatic efficiencies than the group 9 
enzymes (Bonnet, 2004).  
In the results presented above the efficiency of the plasmid system was investigated, 
which includes the CTX-M enzymes in addition to other β-lactamases that may be 
encoded within the plasmid, as in pI1-34TF and pI2-47TF, which encoded TEM-1 and 
OXA-1 enzymes.  
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Evolutionary trajectories of the CTX-M group 1 enzymes published by Novais et al. put 
forward the hypothesis that the CTX-M-3 enzyme was likely to be the evolutionary 
predecessor of the group 1 enzymes (Novais et al., 2010). They then proposed the 
diversification of this group was a result of exposure to cefotaxime and ceftazidime. As 
a consequence higher MICs are observed for both antibiotics in later variants.  CTX-M-
1, -15 and -32, are thought to be derivatives of CTX-M-3 variant and are thought to be 
the more efficient inactivators of ceftazidime when compared to the group 9 enzymes 
(CTX-M-14 and -14b) because of a D240G amino acid substitution observed in CTX-
M-15 and -32 variants, thought to render the bulkier ceftazidime side chain more 
accessible to β-lactamase (Bonnet, 2004; Chen et al., 2005; Novais et al., 2010). 
In the kinetic measurements, nitrocefin, a narrow spectrum cephalosporin was used to 
measure the efficiency of β-lactam inactivation. In this instance the lowest efficiency 
was observed in plasmids producing CTX-M-15 (pI1-33TF and pI1-34TF). This was 
unexpected. These enzymes had higher affinities (low KM) but were found to be the 
least efficient compared to the other plasmids. Plasmid pI2-53TF producing CTX-M-32 
was found to the second most efficient enzyme after CTX-M-14b, with higher MIC 
values against cefotaxime. Previous studies have found CTX-M-14 enzymes to 
hydrolyze cefotaxime more efficiently than ceftazidime. The Ser237Ala amino acid 
substitution in CTX-M-14 variants is thought to contribute to the increased efficiency 
observed between cefotaxime and ceftazidime. The decreased steric hindrance and the 
formation of a hydrogen bond with the carboxylate functional group of cefotaxime is 
thought to bring the β–lactam ring into position for acylation (Ma et al., 2002). This 
difference between the CTX-M-14 (group 9) enzyme and the remaining group 1 
enzymes (CTX-M-1, 15 and 32) that lack this mutation may account for the higher 
tolerance to cefotaxime.   
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Subtle differences between the two CTX-M-15 producing plasmids were observed in in 
the enzyme kinetic measurements and the MIC. Lower susceptibility to ampicillin and 
ceftazidime was observed in pI1-33TF encoding just the CTX-M-15 β–lactamase (from 
DNA microarray data) compared to pI1-34TF encoding TEM-1 and OXA-1 in addition 
to CTX-M-15. Although TEM-1 and OXA-1 are poor substrates of ceftazidime and 
cefotaxime (Aubert et al., 2001), they are efficient inactivators of aminopenicillins and 
in the case of TEM-1 reported to be a more efficient than CTX-M at hydrolyzing 
aminopenicillins (Bonnet, 2004). This additional β-lactamse activity may have resulted 
in higher efficiency values for pI1-34TF compared to pI1-33TF, despite both plasmids 
encoding the same CTX-M variant.  
Previous studies have reported lower β-lactamase activities upon acquisition of an SHV 
encoding plasmid from K. pneumoniae to E. coli by conjugation, thought to be a result 
of a lower plasmid copy number in the new host (Xiang et al., 1997). Another later 
study also associated an increase in plasmidic CMY-2 expression and subsequent MIC 
values to increased plasmid copy number as a result of a point mutation in the IncI1 
plasmid replication control RNA antisense molecule (Kurpiel et al., 2012). This 
suggests that plasmid copy number may influence the overall kinetics of β-lactam 
hydrolysis as part of the plasmid maintenance mechanisms the plasmid copy number is 
tightly controlled, especially in large IncF plasmids such as pI1-34TF (~160 kb) and 
pI1-33TF in this study. As a result the amount of enzyme expressed may be lower in 
comparison to a smaller high copy plasmid harbouring the same resistance gene. As a 
consequence of lower expression, the amount of enzyme catalysing the hydrolysis of the 
β-lactam may be affected leading to lower efficiencies observed (Valenzuela et al., 
1996). By using the method of crude lysis to measure the kinetic parameters of the β-
lactamases expressed by the plasmid, variables such as plasmid copy number, β-lactam 
expression and multiple β-lactamases encoded on the same plasmid, which may all 
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influence the overall efficiency of β-lactam inactivation, and should be taken into 
account. The low efficiencies for the two CTX-M-15 enzymes possibly reflects this 
variability; an efficient enzyme in an inefficient plasmid system (large, low copy 
plasmid). To confirm this, real time PCR analysis and transcriptomics (RNAseq) could 
be performed to assess the levels of CTX-M expression should be performed to confirm 
whether the size and therefore the copy number of the plasmid influences β-lactamase 
expression. This experiment should also be repeated with a larger sample set with 
strains harbouring varying sizes of plasmids, to determine if the β-lactamase efficiency 
is affected by plasmid size.  It must be mentioned here the limitations of this assay is 
also the possible contamination of the lysate with inhibitory molecules or degrading 
enzymes that may alter kinetic data. An improvement of this assay would be to include 
protease inhibitors during the cell lysis stage. 
Other effectors of multidrug resistance include the active efflux of antimicrobial 
compounds. Plasmid sequence analysis identified multiple transport and membrane 
associated proteins were encoded in pI1-34TF and pI2-47TC. Based on this observation, 
the ability to extrude antimicrobials by diminishing host efflux by using EPIs was 
monitored by chages in MIC to amp, caz and ctx. In the presence of PAβN, complete 
susceptibility of some of these ESBL plasmid-harbouring strains to ampicillin was 
achieved.  
 
In conclusion, the effect of plasmid acquisition on the host depends on the variant of 
CTX-M encoded in addition to the plasmid genetic platform on which it is encoded 
(Bennett, 2008). For example, plasmid copy number, which may have effectors that 
result in increased tolerance to the drug by way of decreased efflux, or 
increased/decreased survival in carbon limiting sources. In addition, the plasmid 
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appears to have no effect or slightly increased fitness in non-aged colonies in the 
absence of selection in phosphate and dipeptide sources. Previous studies observed an 
increased in fitness upon plasmid acquisition, which may have implications in 
persistence of MDR plasmids (Enne et al., 2004; Michon et al., 2011). The aged 
colonies appeared to have a reduced fitness in the absence of selection, however these 
were grown on selected metabolites and do not necessarily reflect ‘natural’ 
environments i.e. a host strain that has evolved to accommodate multiple plasmids 
without a fitness burden or the ecosystem these strain may be surviving (the gastro-
intestinal tract) may have other metabolites abundances/shortages not tested in the 
phenotypic microarray. Using a BL21 lab adapted strain as a host, may however add 
some limitations to the interpretation of this data, as this strain has been passaged over a 
prolonged period and may have accumulated detrimental mutations that could affect the 
reduced metabolite usage. This experiment could be improved by using a field strain, 
naive to this plasmid and compare differences in metabolite usage upon acquiring the 
plasmid. 
 These results indicate the contribution of a multitude of factors: plasmid regulation; 
copy number and gene expression, encoded resistance genes and MDR efflux, are 
involved in persistence of antimicrobial resistance plasmids without impacting on host 
fitness unless grown under nutrient limiting conditions. 
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7 GENERAL DISCUSSION  
The increased isolation of CTX-M producing E. coli is of great concern to human and 
veterinary health (Li et al., 2007; Livermore et al., 2007; Rossolini et al., 2008). E. coli 
is one of the most common species isolated from clinical and veterinary samples, and 
dissemination of CTX-M producing strains is not limited to either setting, which 
impacts greatly on the epidemiology of the ESBL producing strains by increased 
incidences of E. coli harbouring the ESBL phenotype (Bradford, 2001; Brinas et al., 
2003; Bonnet, 2004; Li et al., 2007).  
The diverse nature of blaCTX-M encoding strains collected from both commensal and 
pathogenic E. coli species in the United Kingdom was demonstrated by PFGE analysis 
(see chapter 3), with all of the strains harbouring a MDR phenotype, however it must be 
said that these strains were initially screened for ESBL production and therefore may 
only be representative sample of ESBL producing strains and not the complete E. coli 
population that may have not harboured the ESBL containing plasmids. An interesting 
approach would have been to isolate E. coli strains from a single sampling (time or 
location) and subsequently screened for the resistance phenotype, accounting for the 
percentage of strains conferring the ESBL phenotype.  
All the isolates conferred a MDR phenotype and interestingly were found to belong to 
the avirulent commensal E. coli strains (A and B1 phylogroups) and virulent D and B2 
phylogroups (Chattaway et al., 2011; Sims and Kim, 2011). These results emphasise the 
potential of cattle to act as reservoirs of multi-drug resistant pathogenic E. coli strains, 
which may be easily passed to humans through the food chain. The presence of these 
MDR strains in food producing animals and domestic animals have previously been 
implicated in spread of E. coli clones between humans and animals (Johnson et al., 
2009). The global spread of a MDR E. coli clone ST131 O25:H4, is one such successful 
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clone (Coque et al., 2008; Nicholas-Chanoine et al., 2008). This UPEC strain is 
commonly associated with IncFII, IncFIA-FIB and IncI1 plasmids producing CTX-M-
15 (Woodford et al., 2009) and CTX-M-14 enzymes (Periano and Pitout, 2010). These 
two types of plasmids are known to be transmissible by conjugation. The association of 
blaCTX-M genes on conjugative plasmids is thought to have contributed to the 
dissemination of these plasmids (Naseer and Sundsfjord, 2011). Plasmid MLST studies 
on the IncI1 plasmids from the present study demonstrate the widespread nature of these 
plasmids, with some of the IncI1 plasmids reported in Belgium, France, Germany, The 
Netherlands, UK and the USA. Interestingly, these IncI1 STs have been isolated from E. 
coli and S. sonnei species from human sources indicating the potential of transfer of 
these plasmids between different bacterial species and between human and animals.  
The isolates in this study were found to harbour at least one plasmid encoding a 
minimum of one ESBL gene. These were limited to blaCTX-M group 1 and blaCTX-M 
group 9 variants, harboured amongst conjugative plasmids with IncF (IncFIA, FIB, FII), 
IncI1, IncN, IncB/O and IncX1 groups which were identified by replicon typing and 
plasmid sequencing for the IncX1 plasmid; although the latter has more recently been 
incorporated as part of a new subtyping system for the IncX plasmids (Johnson et al., 
2012). The plasmids represent known conjugative narrow (IncB/O, IncF, IncFIB and 
IncI) and broad (IncN) spectrum plasmids and are amongst those commonly found to be 
associated with large plasmids encoding multiple-antimicrobial resistance genes 
(Couturier et al., 1988; Boyd et al., 2004; Lavollay et al., 2006; Waters, 1999). 
These plasmids were found to be transmissible by conjugation in most cases after one 
hour incubation, resulting in the transfer of the MDR phenotype in plasmid sizes 
ranging from 28 to 100 kb. This transfer appeared to be irrespective of size with some 
of the 45 kb IncN plasmids having slower transfer rates than a 171 kb IncF plasmid (see 
Table 4-4). In the presence of selection, plasmids conferring a selective advantage i.e. 
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antimicrobial resistance will be maintained in the host. However in the absence of 
selection the plasmids were still maintained in the host. This was observed with the 
introduction of a 160 kb IncFIA-FIB-FII plasmid into an E. coli BL21 host. E. coli 
genomes vary in size, ranging from 4.6 Mb (E. coli K12) to 5.4 Mb (EHEC 0157:H7). It 
is estimated that E. coli genomes could potentially encode 4500 genes giving rise to 
approximately 4300 known polypeptides (http://ecocyc.org/ECOLI), therefore the effect 
of plasmid gene expression, in this case approximately 200 genes, may not impact 
greatly on the host. Sequencing (DNA and RNA-seq) of both the plasmids and the 
chromosome may give insight as to the origins of the phenotypes observed in the Biolog 
and growth kinetics assays. 
Plasmid sequencing revealed multiple plasmid maintenance systems were present to 
ensure stable inheritance of the plasmid in the absence of selection, which included 
multimer resolving systems (parA) and multiple post segregation killing systems 
(hok/mok, ccdB/ccdA, pemK/pemI), with one IncFIA-FIB-FII plasmid encoding at least 
four of these addiction systems, a feature commonly found in IncF plasmids encoding 
blaCTX-M (Mnif et al., 2010). These maintenance systems encoded within the plasmid 
may enable the 160 kb plasmid to be maintained over the 840 generations despite not 
having the compensatory rpoB mutations or observable phenotypes 
 
The establishment and maintenance of these plasmids in a new host that may be of a 
different bacterial genus would need to express the genes essential for plasmid 
replication and maintenance. In addition to plasmid based promoter sequences, all the 
plasmids identified in this study harboured ISEcp1 elements upstream of the CTX-M 
genes, a feature commonly associated with blaCTX-M genes (Poirel et al., 2003; Miriagou 
et al., 2006). ISEcp1 elements are part of the MGE superfamily that can mobilize the 
intervening gene (Mahillon et al., 1999; Poirel et al., 2003; Canton and Coque, 2006; 
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Miriagou et al., 2006; Novais et al., 2010). ISEcp1 elements not only contribute to their 
dissemination but have also been linked to driving expression of the genes downstream; 
a quality thought to be exploited when genetic transfer occurs between bacteria of 
differing species origin, where expression in the recipient species is low due to a weak 
promoter (Poirel et al., 2003), thereby increasing the potential of the plasmid to occupy 
a new niche. 
Sequence analysis of plasmids provided additional evidence of their mosaic nature, 
especially in the IncFIA-FIB-FII triple replicon plasmid. The presence of three 
replicons provided evidence of fusion of these three subgroups of IncF plasmid types, 
and comparisons of this plasmid with previously sequenced plasmids gave further 
evidence for genetic exchange, with similarities between 37-57 % observed with other 
IncF plasmids from human origin (see Fig. 5-1) (Perichon et al., 2008; Woodford et al., 
2009; Smet et al., 2010). The presence of multi-replicon plasmids may be advantageous 
if the host were to acquire another plasmid of the same Inc group. The replication could 
occur at another replication region enabling the plasmids to co-exist and as seen in the 
IncF plasmid reported in this thesis, HGT may occur, suggesting the ability to 
accommodate multiple plasmids of the same Inc group may result in variability 
enabling the exchange of genetic material from a larger pool of plasmids. 
The presence of mobile genetic elements such as, insertion elements; ISEcp1, IS26, IS1, 
integrons; intI1, intI2 and complex transposons Tn21 and Tn3, facilitate the capture of 
genetic material aiding the evolution of these plasmids and their dissemination. 
Previous studies have shown the common association of blaCTX-M variants with class 1 
and 2 integrons (Carattoli, 2001). These integrons are often found within transposons, 
which capture genes that confer resistance, namely to aminoglycosides (aadA), 
chloramphenicols (cmlA), sulphonamides (sul1) and trimethoprims (dfrA). The Tn21 
family of transposons have previously been associated with blaCTX-M genes, and are 
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thought to influence the spread of genes they encompass within integrons (Liebert et al., 
1999; Novais et al., 2006; Valverde et al., 2006). The identification of the Tn21 
transposon associated transposases and resolvases on all of the sequenced plasmids, 
pI2-53TF, pI2-47TC, pI2-52TC and pI1-34TF belonging to the IncX1, IncI1-X1, 
IncB/O and IncFIA-FIB-FII plasmid groups, indicates that this Tn21 element 
contributes to their multidrug phenotype and the high probability of its role in the 
spread of MDR. 
Plasmid sequencing of pI2-53TF revealed a) a backbone to be similar to IncI1 plasmid, 
b) acquired resistance gene cassettes commonly associated with a class I integrons, c) 
an IncX1 replication protein (pir) and d) the blaCTX-M-32 gene associated with the ISEcp1 
element (see Fig. 5-11). This plasmid was found to be approximately 35 kb in size by 
S1 nuclease PFGE and able to conjugate at frequencies of 1.50 x 10-8. In 2011, 
Partridge and colleagues published the first blaCTX-M-15 harbouring IncX1 plasmid 
pJIE143, which is 35 kb in size (Partridge et al., 2011). To date, this is the first CTX-M-
32 producing IncX1 plasmid identified. Due to the similar size and replication system as 
pJIE143, it could have been assumed that mutations in the CTX-M-15 genes resulting in 
the CTX-M-32 variant giving rise to pI1-53TF. The mutation may have been brought 
about from intense antibiotic selection pressure, as suggested by Novais et al., 2010. 
However, sequence comparison of these two plasmids revealed the only the CTX-M 
region encoding blaCTX-M gene and the ISEcp1 element upstream to show 98% 
similarity (see Fig 7-1). The 2% difference corresponds to the 11 base pair difference 
between the two CTX-M variants. Therefore it can be proposed that the blaCTX-M-32 gene 
on an IncX1 background was acquired via an ISEcp1 mediated transposition event by 
other plasmids such as IncN, commonly associated with this CTX-M variant (Diestra et 
al., 2009) or via a Asp240-Gly substitution of a CTX-M-1 variant (Cartelle et al., 2004).  
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Figure 7-1: Sequence alignment of pI2-53TF an IncX1 plasmid harbouring the blaCTX-M-32 variant 
and pJIE143 another IncX1 plasmid harbouring the blaCTX-M-1 variant. 
 
IncX1 plasmids have also been associated with blaCTX-M-1 and blaTEM-1 as a conintegrate 
with an IncHI1 plasmid (Dolejska et al., 2011; Literak et al., 2010). Another IncX1 
plasmid from S. enterica Dublin was also described as a cointegrate with an IncF 
plasmid (Chu et al., 2008). Like the two plasmids sequenced in this study; pI2-53TF 
(IncX1) and pI2-47TF (IncX1-IncI1proposed cointegrate), these IncX1 plasmids have 
the potential to transfer by conjugation independently (Partridge et al., 2011; Ong et al., 
2009) or as a cointegrate (Chu et al., 2008, Dolejska et al., 2011) thereby maximising 
the chance of persistence of in a population. 
Before a recently published typing system for the IncX plasmids (Johnson et al., 2012) 
that further subdivided the IncX group into four different subtypes, the initial typing 
system by PBRT only identified plasmids of the IncX2 subgroup (Carattoli et al., 2005; 
Johnson et al., 2012). When sized by plasmid profiling techniques previously, this 35 kb 
band migrated at the same rate as the genomic DNA contaminant, this coupled with the 
previous undetected IncX1 plasmids by PBRT suggests that there may be a gross 
underestimation of IncX1 plasmids during screening of strains harbouring blaCTX-M 
genes with the ability to independently mobilize in Enterobacteriaceae.  
pI2-53TF 
pJIE143 
ISEcp1-blaCTX-M-14b element 
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Consistent within all the sequenced plasmids in this study was the genetic variability 
between them and with other previously sequenced plasmids. It has been suggested that 
in order for a plasmid to be successful and persist in a population, it must retain the 
most efficient inheritance systems, low fitness burden and a high transfer rate (Sorensen 
et al., 2005). The adaptation of the plasmid by genetic exchange resulting in gene loss 
or gain can be advantageous in some cases to the host (Enne et al., 2005). One such 
advantage may be the acquisition of a more efficient CTX-M enzyme by mutation or 
lateral gene transfer; mediated by MGEs. The rapid rise in CTX-M enzymes in the 
bacterial population that quickly replaced TEM ESBLs may have been the result of a 
selective advantage offered by the more efficient enzyme; CTX-M at hydrolysing 3rd 
generation cephalosporins as their use in the clinical and veterinary setting began to 
increase (Bonnet, 2004; Livermore et al., 2007). However TEM-1 enzymes are still 
prevalent within the plasmid population and was present in nearly half the plasmids 
tested, all of which were also harbouring CTX-M variants (see chapter 4). However, 
noted is the selection bias these isolates present due to initial screening on chromagar 
media supplemented with 2 mg/L cefotaxime, which would consequently not select for 
isolates encoding TEM only, and therefore there may be an under-representation of 
TEM producing isolates in the isolates. The question arises that why, if a more efficient 
inactivator of the extended spectrum cephalosporins were present, would other β-
lactamase enzymes such as TEM-1 and OXA-1 persist?  The results of the plasmid 
enzyme kinetics revealed the most efficient systems to be plasmids producing CTX-M-
14 and CTX-M-1 enzymes, with CTX-M-15 producing plasmids being the least 
efficient. Previous enzyme kinetics studies of purified CTX-M β-lactamases using 
ceftazidime and cefotaxime substrates, report CTX-M-14 enzymes to have higher 
efficiencies at hydrolysing ceftazidime than the CTX-M-15 and CTX-M-1 variants 
(Barthelemy et al., 1992 1122; Dutour et al., 2002; Poirel et al., 2002 50). Although 
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those studies have reported differences in efficiencies (KCAT/KM) between the group 9 
(CTX-M-14) and group 1 (CTX-M-1 and -15) enzymes to be less than 1 fold. In this 
study, using nitrocefin as the substrate, a 6-fold difference was observed with the cell 
extracts of E. coli K12 harbouring plasmids encoding these derivatives (see Table 6-8). 
Enzyme efficiencies may be affected as a result of plasmid copy number, which when 
studied in plasmids used in recombinant gene expression, show a maintenance burden 
proportional to the plasmid size, thought to be a result of high replication and gene 
expression (Camps, 2010). By maintaining low copy numbers for the larger IncF 
plasmids (producing CTX-M-15), the burden of maintaining these plasmids may 
decrease but at the cost of gene expression and the opposite may be said for the other 
smaller ~44kb plasmid harbouring the CTX-M-1, -14b and -32 variants. This may in 
turn affect the efficiency of nitrocefin hydrolysis and result in the efficiencies observed. 
Differences were also observed when the plasmid harbouring strains were grown in the 
presence of cefotaxime. The largest CTX-M-15 producing plasmid (160 kb); pI1-34TF 
(in a BL21 host strain), experienced an extended lag phase prior to growth for the first 
20 hours, which in the absence of host efflux mechanisms (AcrAB and MdtABC) 
resulted in the recovery of growth to similar levels to another CTX-M-15 producing 
plasmid (pI1-33TF) after this time, suggesting the presence of the plasmid had some 
effect of host permeability (Fig. 6-2). This was reflected when MICs against cefotaxime, 
ceftazidime and ampicillin in BL21 strains harbouring these CTX-M-15 plasmids were 
unaffected upon treatment with the EPI, PAβN (Fig. 6-21). These results suggest that 
these two plasmids may not rely heavily on host efflux for decreased susceptibilities to 
these compounds as may be the case for the other CTX-M producing plasmids, but use 
the plasmid mediated β-lactamase enzyme to efficiently cleave the antimicrobial to a 
lower inhibitory concentration, enabling the bacteria to survive to a point when the drug 
concentration is negligible or has degraded. The half-life of cefotaxime is 
 247 
approximately 1 hour (Patel et al., 1995). The combined effect of degraded cefotaxime 
by natural or enzymatic processes may be a contributing factor to the survival of 
bacteria harbouring pI1-34TF-like plasmids. 
A proposed hypotheses for this stark difference in enzyme kinetics and the growth of 
bacteria harbouring these plasmids is the genetic platform in which the β-lactamase 
enzyme is encoded, includes: 1) the type of β-lactamase encoded; which will determine 
the efficiency of inactivation, 2) the copy number of the plasmid the enzymes are 
encoded on; which will subsequently determine the amount of genes expressed and 
subsequently proteins synthesised. This may in turn may affect the efficiency of the 
hydrolytic reaction and 3) any additional β-lactamases encoded on the plasmid such as 
TEM-1, which has been shown to have increased hydrolytic activity towards 
ceftazidime (Petrosino and Palzkill, 1996); or OXA-1, which confers resistance to β-
lactam inhibitors (Zhou et al., 1994). 
The dissemination and persistence of a plasmid in a population would be the 
contributing factor to its success, but is dependant on a complex interplay of multiple 
factors including the growth of the bacterium in the absence of selection, which would 
depend on plasmid encoded maintenance systems (partitioning, multimer resolution and 
post-segregation killing systems); and in the presence of selection the expression of 
antimicrobial resistance genes, adjacent to ISEcp1 elements that may function as 
promoters resulting in high level expression. In addition to these factors, other attributes 
that enable coexistence of the plasmid in the host such as the ability to transfer by 
conjugation, which may create an advantage by promoting cell-to-cell interaction, 
thereby increasing the chances of biofilm formation (Sorensen et al., 2005), 
compensatory mutations to alleviate fitness costs, copy number control mechanisms, 
and permeability alterations; which may serve as an advantage in the presence of 
antimicrobial selection and the constant genetic exchange that ensures the existence of a 
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well established plasmid harbouring all these features to exist and spread globally. One 
such example of plasmid-host harmony is the success of the UPEC O25:H4-ST131 E. 
coli strain harbouring a multidrug resistance IncF conjugative plasmid. With the ability 
for genetic exchange to readily occur, the genetic shift provided by this exchange could 
be the determining feature of a successful plasmid, resulting in the balance between 
selective advantage and fitness costs. This would suggest that the novel IncX1 plasmid 
identified in this study, harbouring the CTX-M-32 variant with the ability to conjugate, 
harbour several antimicrobial resistance genes and being relatively small in size, may be 
able to achieve an ideal symbiotic relationship with the host bacterium. Future studies 
could involve monitoring the spread this plasmid from its original isolate to a 
population naïve to this plasmid and determine the persistence of this IncX1 plasmid 
amongst bacteria already harbouring multiple MDR plasmids over a prolonged period.  
In conclusion, the work carried out in this thesis demonstrates the ability of these 
plasmids to exist in commensal bacteria in cattle, implicating them as natural reservoirs 
for resistant strains, with the ability to transmit these multidrug resistance determinants 
and persist in a host without imposing metabolic burden to the host and in some cases 
even increase fitness by conferring resistance to EPIs, which has implications in future 
treatment options that favour the development of EPIs in future treatment strategies 
(Lomovskaya et al., 2007). 
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APPENDIX 
 
 
Appendix A 
Please see attached table for a comprehensive view of the strains presented in this 
thesis. 
 
Appendix B 
The table below lists the primers used in this study. The primers are listed in the 5’ to 3’ 
direction. 
Primers used for E. coli phylogrouping 
Name Sequence Reference  
ChuA.1 F- GACGAACCAACGGTCAGGAT Clermont et al. (2000) 
ChuA.2  R- TGCCGCCAGTACCAAAGACA 
YjaA.1  F- TGAAGTGTCAGGAGACGCTG Clermont et al. (2000) 
YjaA.2  R- ATGGAGAATGCGTTCCTCAAC 
TspE4C2.1  F- GAGTAATGTCGGGGCATTCA Clermont et al. (2000) 
TspE4C2.2  R- CGCGCCAACAAAGTATTACG 
   
   
   DNA array PCR validation primers 
Name Sequence Reference  
qnr F- GATAAAGTTTTTCAGCAAGAGG Jacoby et al. (2003)  
R- ATCCAGATCGGCAAAGGTTA 
sul1 F- TCACCGAGGACTCCTTCTTC Randall et al. (2004) 
R- AATATCGGGATAGAGCGCAG 
sul2 F- GATATTCGCGGTTTTCCAGA R. Walker, unpublished 
R- CGAATTCTTGCGGTTTCTTT 
sul3 F- ACCGATAGTTTTTCCGATGG Batchelor et al. (2008) 
R- TGCGGAGATAATCTGCACCT 
tet(A) F- GCTACATCCTGCTTGCCTTC Ng et al. (1999) 
R- CATAGATCGCCGTGAAGAGG 
tet(B) F- TTGGTTAGGGGCAAGTTTTG Ng et al. (1999) 
R- GTAATGGGCCAATAACACCG 
tet(C) F- CTTGAGAGCCTTCAACCCAG Ng et al. (2001) 
R- ATGGTCGTCATCTACCTGCC 
tet(D) F- AAACCATTACGGCATTCTGC Ng et al. (2001) 
R- GACCGGATACACCATCCATC 
tet(E) F- AAACCACATCCTCCATACGC Ng et al. (2001) 
R- AAATAGGCCACAACCGTCAG 
tet(G) F- CCGGTCTTATGGGTGCTCTA Randall et al. (2004) 
R- CCAGAAGAACGAAGCCAGTC 
intI1 F- GGCATCCAAGCAGCAAG Goldstein et al. (2001) 
R- AAGCAGACTTGACCTGA 
intI2 F- TTATTGCTGGGATTAGGC Goldstein et al. (2001) 
R- ACGGCTACCCTCTGTTATC 
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aadA1-like F- TATCAGAGGTAGTTGGCGTCAT Standvang and Aarestrup. (2000) 
R- GTTCCATAGCGTTAAGGTTTCATT 
aadA2-like F- TGTTGGTTACTGTGGCCGTA Randall et al. (2004) 
R- GATCTCGCCTTTCACAAAGC 
aadA4-like F- CAATCCACCTGTTCGGATCT Batchelor et al. (2008) 
R- AGCAACGTCCTTAGGAGCAA 
blaPSE-1-like F- GCTTCGCAACTATGACTAC Randall et al. (2004) 
R- GTTCACCATCCAAGACTC 
cmlA1-like F- TGTCATTTACGGCATACTCG Guerra et al. (2003) 
R- ATCAGGCATCCCATTCCCAT 
catA1 F- CGCCTGATGAATGCTCATCCG Aarestrup et al. (2003) 
R- CCTGCCACTCATCGCAGTAC 
catIII F- CCTGGAACCGCAGAGAAC Arcangioli et al. ( 2000) 
R- CCTGCTGAAACTTTGCCA 
catB3-like F- GGTACGACTGGGCATCATCT Batchelor et al. (2008) 
R- TCGAGCCAATACTTGTGCAG 
floR F- GGAGCAGCTTGGTCTTCAAC Randall et al. (2004) 
R- AATGAATATCGCCTGCCATC 
dfrA1 F- GTGAAACTATCACTAATGG Naviaet al. (2003) 
R- TTAACCCTTTTGCCAGATTT 
dfrA7 F- CAGAAAATGGCGTAATCG Batchelor et al. (2008) 
R- TCAACGTGAACAGTAGACAAA 
dfr12 F- GGTG(G/C)GCAGAAGATTTTTCGC Naviaet al. (2003) 
R- TGGGAAGGCGTCACCCTC 
dfrA14 F- ATAGCTGCGAAAGCGAAAAA Batchelor et al. (2008) 
R- CCCTTTTTCCAAATTTGATAGC 
dfrA17 F- CAGAAAATGGCGTAATCG Batchelor et al. (2008) 
R- TCAACGTGAACAGTAGACAAA 
dfrA19 F- GCGATTTACGCGGATTTCTA Batchelor et al. (2008) 
R- CAAAGTGAATGCGCTCTTGA 
aac(3)-Ia F- TTGATCTTTTCGGTCGTGAGT Frana et al. (2001) 
R- TAAGCCGCGAGAGCGCCAACA 
aac(3)-IVa F- TCGGTCAGCTTCTCAACCTT Batchelor et al. (2008) 
R- ACCGACTGGACCTTCCTTCT 
aac(6')-Ib F- GTTACTGGCGAATGCATCACA Frana et al. (2001) 
R- TGTTTGAACCATGTACACGGC 
ant(2")-Ia F- GGGCGCGTCATGGAGGAGTT Steward et al. (2001) 
R- TATCGCGACCTGAAAGCGGC 
blaDHA-1 F- AACTTTCACAGGTGTGCTGGGT Perez-Perez and Hanson.(2002) 
R- CCGTACGCATACTGGCTTTGC 
blaACC F- AACAGCCTCAGCAGCCGGTTA Perez-Perez and Hanson.(2002) 
R- TTCGCCGCAATCATCCCTAGC 
blaMOX F- GCTGCTCAAGGAGCACAGGAT Perez-Perez and Hanson.(2002) 
R- CACATTGACATAGGTGTGGTGC 
blaCMY F- TGGCCAGAACTGACAGGCAAA Perez-Perez and Hanson.(2002) 
R- TTTCTCCTGAACGTGGCTGGC 
blaFOX F- AACATGGGGTATCAGGGAGAT Perez-Perez and Hanson.(2002) 
R- CAAAGCGCGTAACCGGATTGG 
blaSHV  F- CGGCCCCGCAGGATTGACT E. Pleydell, unpublished 
R- TCCCGGCGATTTGCTGATTTC 
blaTEM-1 F- TCGTGTCGCCCTTATTCCCTTTTT E. Pleydell et al. (2007) 
R- GCGGTTAGCTCCTTCGGTCCTC 
blaOXA-1 F- TTGATGCGGAAATAATAGAT E. Pleydell, unpublished 
R- TGCGGACACAAAAACATA 
blaOXA-2 F- TTCAAGCCAAAGGCACGATAG Walker et al. (2001) 
R- TCCGAGTTGACTGCCGGGTTG 
blaOXA-7 F- CGTGCTTTGTAAAAGTAGCAG Walker et al. (2001) 
R- CATGATTTTGGTGGGAATGG 
blaCTX-M-1 F- CGATGTGCAGTACCAGTAA Batchelor et al.(2005) 
R- TTAGTGACCAGAATCAGCGG 
blaCTX-M-2 F- CGATGTGCAGTACCAGTAA Batchelor et al.(2005) 
R- TTAGTGACCAGAATCAGCGG 
blaCTX-M-9 F- CGATGTGCAGTACCAGTAA Batchelor et al. (2005) 
R- TTAGTGACCAGAATCAGCGG 
blaOXA-9 F- CGTCGCTCACCATATCTCCC Batchelor et al. (2008)  
R- CCTCTCGTGCTTTAGACCCG 
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Amplification of gyrA/parC genes 
Name Sequence Reference 
qepA  F- AACTGCTTGAGCCCGTAGAT Kim et al. (2009) 
R- GTCTACGCCATGGACCTCAC 
gyrA F- AAATCTGCCCGTGTCGTTGGT Rodríguez-Martínez et al. (2006) 
R- GCCATACCTACGGCGATACC 
parC  F- CTGAATGCCAGCGCCAAATT Rodríguez-Martínez et al. (2006) 
R- GCGAACGATTTCGGATCGTC 
  
 
  
 
CTX-M universal primers  
Name Sequence  Reference  
CTX-M-uni F- CGATGTGCAGTACCAGTAA Batchelor et al. (2005) 
R- TTAGTGACCAGAATCAGCGG 
   
   Primers used for the amplification of CTX-M group 1 and 9 genes 
Name Sequence  Reference  
CTX-M-9 F- GTGACAAAGAGAGTGCAACGG Sabate et al. (2002) 
R- ATGATTCTCGCCGCTGAAGCC 
CTX-M-1 F- CCCATGGTTAAAAAATCACTGC Carattoli A. (2008) 
R- CAGCGCTTTTGCCGTCTAAG 
   
   Primers used for the amplification of CTX-M groups 
Name Sequence  Reference  
CTX-M-1 F- AAAAATCACTGCGCCAGTTC Woodford et al. (2006) 
R- AGCTTATTCATCGCCACGTT 
CTX-M-2 F- CGACGCTACCCCTGCTATT Woodford et al. (2006) 
R- CCAGCGTCAGATTTTTCAGG 
CTX-M-9 F- CAAAGAGAGTGCAACGGATG Woodford et al. (2006) 
R- ATTGGAAAGCGTTCATCACC 
  
 
   
   Primers usd for the amplification of ISEcp1 and adjacent blaCTX gene 
Name Sequence Reference 
ISEcp1F F- TGCTCTGTGGATAACTTGC Poirel et al. (2002) 
CTX-M-15 R- CCGTTTCCGCTATTACAAAC 
CTX-M-9 R- ATGATTCTCGCCGCTGAAGCC Sabate et al. (2002) 
   
   PCR primers fot the identification of plasmid incopatibility groups 
Name Sequence Reference 
FrepB  F- TGATCGTTTAAGGAATTTTG Carattoli et al. (2005) 
R- GAAGATCAGTCACACCATCC 
K/B  F- GCGGTCCGGAAAGCCAGAAAAC 
K  R- TCTTTCACGAGCCCGCCAAA 
B/O  R- TCTGCGTTCCGCCAAGTTCGA 
HI1  F- GGAGCGATGGATTACTTCAGTAC 
R- TGCCGTTCACCTCGTGAGTA 
HI2  F- TTTCTCCTGAGTCACCTGTTAACAC 
R- GGCTCACTACCGTTGTCATCCT 
I1  F- CGAAAGCCGGACGGCAGAA 
R- TCGTCGTTCCGCCAAGTTCGT 
X  F- AACCTTAGAGGCTATTTAAGTTGCTGAT 
R- TGAGAGTCAATTTTTATCTCATGTTTTAGC 
L/M F- GGATGAAAACTATCAGCATCTGAAG 
R- CTGCAGGGGCGATTCTTTAGG 
N  F- GTCTAACGAGCTTACCGAAG 
R- GTTTCAACTCTGCCAAGTTC 
FIA  F- CCATGCTGGTTCTAGAGAAGGTG 
R- GTATATCCTTACTGGCTTCCGCAG 
FIB  F- GGAGTTCTGACACACGATTTTCTG 
R- CTCCCGTCGCTTCAGGGCATT 
W  F- CCTAAGAACAACAAAGCCCCCG 
R- GGTGCGCGGCATAGAACCGT 
Y  F- AATTCAAACAACACTGTGCAGCCTG 
R- GCGAGAATGGACGATTACAAAACTTT 
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P  F- CTATGGCCCTGCAAACGCGCCAGAAA 
R- TCACGCGCCAGGGCGCAGCC 
FIC  F- GTGAACTGGCAGATGAGGAAGG 
R- TTCTCCTCGTCGCCAAACTAGAT 
A/C  F- GAGAACCAAAGACAAAGACCTGGA 
R- ACGACAAACCTGAATTGCCTCCTT 
T  F- TTGGCCTGTTTGTGCCTAAACCAT 
R- CGTTGATTACACTTAGCTTTGGAC 
FIIs  F- CTGTCGTAAGCTGATGGC 
R- CTCTGCCACAAACTTCAGC 
   
   Primers used for PCR amplification and sequencing of IncI1 plasmids 
Name Sequence Reference 
repI1  F- CGAAAGCCGGACGGCAGAA Garcia-Fernandez et al. (2008) 
R- TCGTCGTTCCGCCAAGTTCGT 
ardA F- ATGTCTGTTGTTGCACCTGC Garcia-Fernandez et al. (2008) 
R- TCACCGACGGAACACATGACC 
trbA  F- CGACAAATGCTTCCGGGGT Garcia-Fernandez et al. (2008) 
pndC  R- CGAATCCCTCACCATCCAG 
SogS  F- TTCCGGGGCGTAGACAATACT Garcia-Fernandez et al. (2008) 
R- AACAGTGATATGCCGTCGC 
pilL  F- CCATATGACCATCCAGTGCG Garcia-Fernandez et al. (2008) 
R- AACCACTATCTCGCCAGCAG 
 
 
 
 
 
 
 
 
 
 
 
 
